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Abstract
Colorectal cancer is one of the most clinically signiﬁcant types of cancer due to both
high incidence and mortality. Despite the well-established role of aberrant Wnt signalling
in initiation and progression of colorectal cancer, therapies that speciﬁcally target the
Wnt pathway are exceptionally limited. The development of such therapies is, in part,
restricted by the toxicity of Wnt signalling inhibition for adult tissue homeostasis. Given
this limitation, therapies that target downstream components and target genes of the
Wnt pathway are required to minimise potential toxicity.
The chromatin remodelling ATPase subunit Brg1 has been found to interact with
β-catenin and facilitate transcriptional program driven by the Wnt pathway. In this
thesis I aimed to explore Brg1’s potential as a therapeutic target in Wnt driven intestinal
tumourigenesis. To achieve this, I conditionally deleted Brg1 in the murine small intestinal
epithelium under normal physiological conditions and in the context of aberrant Wnt
signalling using a range of transgenic mouse models. Additionally, I investigated the
potential toxicity of Brg1 inhibition by analysing the eﬀects of Brg1 loss in a range of
epithelial tissues from the gastrointestinal tract and bladder.
The results presented in this thesis demonstrate that Brg1 deﬁciency impedes Wnt-
driven tumourigenesis in the murine small intestinal epithelium via attenuation of Wnt
signalling and the elimination of stem cell derived tumours, which have a higher tumouri-
genic potential. Additionally, Brg1 was found to play a major role in the maintenance
of normal small intestinal stem cell homeostasis, as loss of Brg1 in the small intestinal
epithelium resulted in ablation of the stem cell population. The impact of Brg1 deﬁciency
on homeostasis of other tissues of the gastrointestinal tract and bladder exhibited a re-
markable diversity, from induction of epithelial hyperplasia to very subtle alterations in
cell diﬀerentiation.
Overall, the results presented in this thesis portray Brg1 as a promising potential
therapeutic target in Wnt-driven neoplasia and suggest that speciﬁc targeting of the
Brg1/β-catenin interaction rather than the catalytic activity of Brg1 may help to avoid
any Wnt-independent toxicity of Brg1 inhibition.
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Chapter 1
General introduction
1.1 The Mammalian Small Intestine
1.1.1 General anatomy and functions of the gastrointestinal tract
The digestive tract in mammals forms a central part of the digestive system with speciﬁc
functions assigned to its diﬀerent parts. The major function of the digestive tract is to
enable the passage of consumed food, while it is being processed, digested and absorbed in
the form of the elementary nutrients. The largest part of the digestive tract is represented
by the gastrointestinal tract that consists of the stomach and the intestines. The stomach
serves as a temporary storage compartment for consumed food, where the latter is mixed
and subjected to the initial stages of digestion and undergoes limited absorption. Glands
embedded in the stomach epithelium secrete hydrochloric acid, a number of digestive
enzymes and mucus that protects the mucosa from damage by the hydrochloric acid and
digestive enzymes. Finally, the muscular layers embedding the stomach enable mixing
of its contents and facilitate propulsion of the partially digested food into the intestine
(Seeley et al., 2002).
The mammalian intestine is divided into two major parts - the small and large in-
testines. The small intestine, in turn, is divided into three regions: the duodenum, je-
junum and ileum. With the exception of two papillae that serve as entry points for the
bile and pancreatic ducts and the presence of Brunner’s glands in the submucosa of the
duodenum, all three regions of the small intestine share a similar organisation (Figure
1.1). The outermost layer of the intestine is represented by the connective tissue of the
serosa. Underneath the serosa, two layers of muscle (longitudinal and circular) surround
the submucosa composed of connective tissue containing blood vasculature and nerves.
Finally, the small intestinal mucosa is composed of a muscularis mucosae, a lamina pro-
pria and the simple columnar epithelium. The useful surface area of the human small
intestinal epithelium is increased about 600 fold via a number of modiﬁcations. Firstly,
both mucosa and submucosa are formed into circular folds perpendicular to the intestinal
axis. Secondly, the mucosa is organised in ﬁnger-like projections extending into the in-
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testinal lumen, termed villi. At the bottom of the villi, the epithelium forms pocket-like
invaginations into the lamina propria termed the crypts of Lieberku¨hn. Finally, the apical
membrane of the absorptive columnar epithelium covering the surface of the villi forms
multiple cytoplasmic protrusions called microvilli further increasing the epithelial surface
area. Progressing from the duodenum towards the ileum, the number of the circular folds
decreases as does the density and the size of the villi. The mucosa and submucosa of the
small intestine also contain numerous lymph nodes termed Peyer’s patches protecting the
intestine from microorganisms (Seeley et al., 2002).
In addition to the digestive enzymes produced by the pancreas, the small intestinal
epithelium secretes a number of enzymes that remain associated with the epithelial sur-
face, which aid the ﬁnal stages of digestion. The majority of the water, electrolytes and
nutrients present in the contents of the intestine are absorbed in the small intestine (pri-
marily in the duodenum and jejunum) while the rest is absorbed in the large intestine.
The large intestine is organised into four compartments: caecum, colon, rectum and anal
canal, the colon forming the major part of the large intestine. The colonic epithelium
diﬀers from the small intestinal mucosa in the absence of circular folds and villi. The
mucosa of the colon is organised into crypts similar to those found in the small intestine.
There is, however, a shift in the cell type abundance. While absorptive cells form the ma-
jor population of the small intestinal epithelium, the mucus secreting cells predominate
in the colon (Seeley et al., 2002).
1.1.2 Micro-architecture of the small intestinal epithelium
As mentioned in the previous section, the intestine is lined with a single sheet of columnar
epithelial cells. This sheet is organised into folds termed villi, which protrude into the gut
lumen; and crypts, pocket-like invaginations that extend into the underlying stromal tissue
(Figure 1.1). The crypts are occupied by dividing cells that originate from the stem cells
positioned at the crypt base. These actively proliferating cells form a transit amplifying
(TA) zone, where they undergo several rounds of cell division and the initial stages of
diﬀerentiation. Partially diﬀerentiated progenitor cells migrate towards the crypt-villus
junction, where they lose their proliferative capacity and terminally diﬀerentiate into
one of the mature cell types that occupy the villus surface (Cheng and Leblond, 1974a).
The terminally diﬀerentiated cells continue their migration towards the villus tip and
eventually undergo apoptosis or are sloughed oﬀ into the lumen, where they undergo
anoikis (Hall et al., 1994). As a result of the continuous migration towards the villus tip,
virtually all the mature cells in the small intestine are renewed every 5 days in humans
and every 3 days in mice (Marshman et al., 2002). The only diﬀerentiated cells that
escape this upward ﬂow are the Paneth cells that migrate towards the bottom of the
crypt (Cheng et al., 1969).
The majority of mature cells in the small intestinal epithelium belong to one of the
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Figure 1.1: Histology of the small intestinal epithelium. The outermost layer of the intestine is repre-
sented by the connective tissue of serosa. Underneath the serosa, two layers of muscle (longitudinal and
circular) surround the submucosa composed of connective tissue containing blood vasculature and nerves.
Finally, the small intestinal mucosa is composed of a muscularis mucosae, a lamina propria and the simple
columnar epithelium. The useful surface of the human small intestinal epithelium is increased greatly
due to formation of the ﬁnger-like projections extended into the lumen, termed villi. At the bottom of
the villi epithelium forms pocket-like invaginations into the lamina propria termed crypts of Lieberku¨hn.
four major cell types. Enterocytes or columnar cells represent the absorptive lineage,
while goblet, Paneth and enteroendocrine cells constitute the secretory lineages.
Enterocytes comprise more than 80% of all epithelial cells in the small intestine and
are actively renewed with an average turnover time of 3 days. They are positioned along
the top of the crypt and over the whole of the villus. The enterocytes are distinguished
by a lack of secretory granules and the presence of a tight array of microvilli on their
apical membrane that constitute a brush border (Cheng and Leblond, 1974a). The mem-
brane that forms the microvilli harbours numerous hydrolase enzymes that facilitate the
ﬁnal stages of digestion. Various channel proteins located in both the apical and basal
membranes of the enterocytes carry out transport of nutrients from the gut lumen into
the blood and lymphatic vasculature, while also transporting certain ions into the lumen
(Smith, 1985).
The most abundant members of the secretory lineages are the mucus secreting goblet
cells, although their relative numbers vary between diﬀerent regions of the small intestine.
Mature goblet cells are distributed among the enterocytes from mid-crypt to the villus tip
and are renewed at a rate similar to that of the enterocytes (Troughton and Trier, 1969).
Goblet cells are characterised by the presence of large mucus containing granules and
enlarged rough endoplasmic reticulum. The mucus produced by the goblet cells serves as
a lubricant for the passing food and protects the lining of the intestine from mechanical
Chapter 1. General introduction 5
abrasion, damage by acidic stomach contents and autodigestion by the digestive enzymes
(Cheng, 1974).
The Paneth cells represent the second most abundant cell type in the secretory lineage.
They diﬀer from all the other mature cell types in their downward migration, maintenance
of active Wnt signalling, and substantially slower turnover. Initial estimates of the Paneth
cell turnover rate based on labelling with [3H]thymidine have suggested a period of 18-
23 days (Cheng et al., 1969). Another study using a similar approach established that
label retaining Paneth cells persisted for at least 29 days (Troughton and Trier, 1969). A
recent study using an inducible enhanced yellow ﬂuorescent protein (EYFP) reporter has
indicated that the turnover rate of the Paneth cells may be as much as 57 days (Ireland
et al., 2005). The turnover rate of the Paneth cells, however, is likely to vary between
diﬀerent parts of the intestine. Morphologically, the Paneth cells are characterised by the
presence of a large number of apical secretory granules. These granules contain a number
of substances with antimicrobial activity. Among these are polypeptides targeted against
bacterial cell wall, such as lysozyme, defensins (cryptdins in mice) and phospholipase
A2. Other granule components, such as immunoglobulin IgA, pancreatitis-associated
protein and secretory leukocyte inhibitor may be involved in the modulation of the immune
response (Porter et al., 2002). The Paneth cells are therefore considered to play a crucial
role in the regulation of the intestinal microﬂora. A recent report has also suggested that
Paneth cells provide a niche for the intestinal stem cells (Sato et al., 2010). This particular
aspect of the Paneth cell physiology is described in greater detail in later sections.
Enteroendocrine cells represent less than 1% of terminally diﬀerentiated cells and com-
prise a family of at least 15 diﬀerent cell types. These cells diﬀer in the morphology of
their secretory granules, the nature of the principal secretory product and expression of
speciﬁc markers. The unifying feature of all the enteroendocrine cells is expression and se-
cretion of a range of polypeptide hormones. These include serotonine, secretin, substance
P, cholecystokinin, gastric inhibitory polypeptide and others (Ho¨cker and Wiedenmann,
1998).
In addition to the main cell types, two minor cell lineages are present in the small
intestinal epithelium. M (membranous or microfold) cells are encountered in the epithe-
lium adjacent to the Peyer’s patches. Their basolateral membrane forms invaginations
occupied by macrophages and T and B lymphocytes. M cells are able to internalise par-
ticles and microorganisms from the lumen by endo- or phagocytosis and transport them
across the epithelial border, where they are processed by the immune cells (Neutra et al.,
1996). Tuft cells (also known as brush, caveolated or ﬁbrillovesicular cells) are distributed
throughout organs of the gastrointestinal and respiratory tracts. They are characterised
by a goblet-shaped body, the presence of long and blunt microvilli on the apical membrane
and numerous vesicles in the apical cytoplasm. Although their role in the small intestine
is still undeﬁned, the abundance of the vesicles in the cytoplasm indicates that tuft cells
may be involved in the secretion or absorption of certain substances. Studies in other
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organs have also suggested that tuft cells may function as pressure or chemoreceptors,
however no direct synaptic contact between the tuft cells of the alimentary tract and
neurons have been detected (Sato, 2007).
1.1.3 The small intestine epithelial homeostasis
In order to ensure the proper maintenance and function of the intricate cellular archi-
tecture described in the previous section, a number of carefully coordinated processes
need to take place. Firstly, active but controlled proliferation ensures continuous renewal
of the epithelial sheet. Secondly, proliferation is conﬁned to the crypts, where actively
dividing cells are protected from exposure to the contents of the gut lumen. Thirdly,
migration of the newly produced cells up the crypt-villus axis further contributes to the
ﬂow and renewal of the epithelial layer. And ﬁnally, diﬀerentiation along various cell lin-
eages ensures the appropriate balance between cell types. All these processes are precisely
orchestrated by a mesh of signalling pathways including Hedgehog (Hh), platelet-derived
growth factor (PDGF), bone morphogenetic protein (BMP), transforming growth factor
β (TGFβ), Wnt and Notch (Figures 1.2 and 1.3). This section will brieﬂy describe each
of the pathways and the role they play in maintaining the intestinal homeostasis.
1.1.3.1 Epithelium-to-mesenchyme signalling: Hedgehog and PDGF path-
ways
The importance of the mesenchyme-epithelium interaction for the development and main-
tenance of the intestinal epithelium has been long established (Kedinger et al., 1986).
More recent studies have provided evidence that this interaction is to a large extent medi-
ated by the Hedgehog (Hh), PDGF and TGFβ/BMP signalling pathways. The ﬁrst two
pathways cover the epithelium-to-mesenchyme side of this interaction.
Hh signalling (Figure 1.2) was ﬁrst described in Drosophila melanogaster and has been
implicated in a variety of biological processes including development and maintenance of
tissue homeostasis, carcinogenesis and tissue repair (Katoh and Katoh, 2006). The Hh
pathway ligands in mammals are represented by three paralogues: Sonic hedgehog (Shh),
Indian hedgehog (Ihh) and Desert hedgehog (Dhh), the former two being expressed in
the intestinal epithelium. In the absence of Hh ligands the Patched (Ptch1 and Ptch2)
receptor inhibits transducer of the Hh signalling, the transmembrane receptor Smoothened
(Smo). Inactive Smo serves as an assembly core for a complex consisting of Costal-
2 (Cos-2) and fused (Fu). Cos-2 further binds to casein kinase 1α (CK1α), glycogen
synthase kinase-3β (GSK3β) and protein kinase A (PKA). This complex sequesters and
targets for proteasomal degradation Glioblastoma (Gli) transcription factors (Gli1, Gli2
and Gli3). In the gut full length Gli2 and Gli3 act as the major transducers of the Hh
pathway. At the same time, proteasomal degradation of Gli3 and (to a lesser extent)
Gli2 results in truncated proteins that are able to act as Hh suppressors. Binding of
Chapter 1. General introduction 7
F
ig
u
re
1.
2:
M
a
jo
r
si
g
n
a
ll
in
g
p
a
th
w
ay
s
g
ov
er
n
in
g
sm
a
ll
in
te
st
in
a
l
h
o
m
eo
st
a
si
s.
H
e
d
g
e
h
o
g
si
g
n
a
ll
in
g
:
U
n
b
ou
n
d
p
a
tc
h
ed
re
ce
p
to
r
(P
tc
h
)
in
h
ib
it
s
th
e
sm
o
o
th
en
ed
(S
m
o
)
si
g
n
a
l
tr
a
n
sd
u
ce
r
a
ll
ow
in
g
fo
rm
a
ti
o
n
of
C
o
s2
/
F
u
co
m
p
le
x
w
it
h
m
ic
ro
tu
b
u
le
s
(M
T
),
w
h
ic
h
b
in
d
s
G
li
tr
a
n
sc
ri
p
ti
o
n
fa
ct
o
r
se
q
u
es
te
ri
n
g
it
aw
ay
fr
o
m
th
e
n
u
cl
eu
s
an
d
ta
rg
et
in
g
it
s
d
eg
ra
d
a
ti
o
n
.
B
in
d
in
g
o
f
h
ed
g
eh
o
g
li
g
a
n
d
s
to
P
tc
h
re
le
a
se
s
it
s
in
h
ib
it
io
n
o
f
S
m
o
,
w
h
ic
h
in
tu
rn
a
ct
iv
a
te
s
S
T
K
3
6
.
S
u
p
p
re
ss
o
r
of
fu
se
d
(S
u
F
u
)
is
a
ct
iv
at
ed
p
re
v
en
ti
n
g
C
o
s2
/
F
u
co
n
ta
in
in
g
co
m
p
le
x
fr
o
m
b
ei
n
g
fo
rm
ed
.
F
u
ll
le
n
g
th
G
li
is
al
lo
w
ed
to
ac
cu
m
u
la
te
a
n
d
tr
a
n
sl
o
ca
te
to
th
e
n
u
cl
eu
s,
w
h
er
e
it
a
ct
iv
at
es
ta
rg
et
ge
n
e
ex
p
re
ss
io
n
.
T
G
F
β
/
B
M
P
si
g
n
a
ll
in
g
:
B
M
P
s
o
r
T
G
F
β
s
b
in
d
to
th
ei
r
co
g
n
a
te
ty
p
e
I/
II
re
ce
p
to
rs
re
su
lt
in
g
in
p
h
o
sp
h
o
ry
la
ti
o
n
o
f
th
e
ty
p
e
I
re
ce
p
to
r.
B
M
P
si
g
n
a
ls
a
re
tr
a
n
sd
u
ce
d
th
ro
u
g
h
S
M
A
D
1
/
5
/
8
,
T
G
F
β
s
th
ro
u
g
h
S
M
A
D
2
/
3
.
B
o
th
re
su
lt
in
a
ct
iv
at
io
n
o
f
S
M
A
D
4
,
w
h
ic
h
tr
a
n
sl
o
ca
te
s
to
th
e
n
u
cl
eu
s
a
n
d
in
te
ra
ct
s
w
it
h
co
-a
ct
iv
a
to
rs
an
d
co
-r
ep
re
ss
o
rs
to
m
o
d
u
la
te
tr
a
n
sc
ri
p
ti
o
n
o
f
ta
rg
et
g
en
es
.
W
n
t
si
g
n
a
ll
in
g
:
A
b
se
n
ce
o
f
W
n
t
li
g
a
n
d
al
lo
w
s
a
ss
em
b
ly
o
f
th
e
β
-c
a
te
n
in
d
es
tr
u
ct
io
n
co
m
p
le
x
co
m
p
ri
se
d
o
f
A
x
in
,
A
p
c
a
n
d
G
S
K
3β
,
w
h
ic
h
b
in
d
s
β
-c
a
te
n
in
a
n
d
m
ed
ia
te
s
it
s
p
h
o
sp
h
o
ry
la
ti
o
n
a
n
d
p
ro
te
a
so
m
a
l
d
eg
ra
d
a
ti
o
n
.
B
in
d
in
g
o
f
W
n
t
li
g
a
n
d
to
F
ri
zz
le
d
re
ce
p
to
r
an
d
L
R
P
5
/
6
co
-r
ec
ep
to
r
re
su
lt
s
in
a
ct
iv
a
ti
o
n
o
f
D
is
h
ev
el
le
d
(D
sh
)
a
n
d
p
h
o
sp
h
o
ry
la
ti
o
n
o
f
L
R
P
,
w
h
ic
h
in
h
ib
it
re
cr
u
it
s
A
x
in
to
th
e
re
ce
p
to
r
th
u
s
m
ed
ia
ti
n
g
d
is
a
ss
em
b
ly
of
β
-c
a
te
n
in
d
es
tr
u
ct
io
n
co
m
p
le
x
a
ll
ow
in
g
a
cc
u
m
u
la
ti
o
n
a
n
d
tr
a
n
sl
o
ca
ti
o
n
o
f
β
-c
a
te
n
in
to
th
e
n
u
cl
eu
s
w
h
er
e
it
b
in
d
s
T
C
F
/
L
E
F
tr
a
n
sc
ri
p
ti
o
n
fa
ct
o
rs
an
d
a
ct
iv
at
es
ex
p
re
ss
io
n
of
W
n
t
ta
rg
et
g
en
es
.
N
o
tc
h
si
g
n
a
ll
in
g
:
B
in
d
in
g
o
f
n
o
tc
h
re
ce
p
to
r
b
y
ce
ll
su
rf
a
ce
li
g
a
n
d
s
o
f
th
e
D
el
ta
/
J
a
g
g
ed
fa
m
il
y
st
im
u
la
te
s
cl
ea
va
g
e
o
f
th
e
n
o
tc
h
re
ce
p
to
r
b
y
T
A
C
E
an
d
γ
-s
ec
re
ta
se
.
C
le
av
a
g
e
b
y
γ
-s
ec
re
ta
se
re
le
a
se
s
th
e
n
o
tc
h
in
tr
a
ce
ll
u
la
r
d
o
m
a
in
(N
IC
D
),
w
h
ic
h
tr
a
n
sl
o
ca
te
s
to
th
e
n
u
cl
eu
s
an
d
a
ct
s
w
it
h
th
e
tr
a
n
sc
ri
p
ti
o
n
fa
ct
o
r
C
S
L
to
ac
ti
va
te
ex
p
re
ss
io
n
o
f
ta
rg
et
g
en
es
.
Chapter 1. General introduction 8
Hh ligands to the Ptch receptor releases inhibition of Smo and prevents formation of
the Gli destruction complex. Stabilisation of Gli results in its nuclear accumulation and
activation of downstream Hh targets (reviewed in Katoh and Katoh, 2006; Lees et al.,
2005; van den Brink, 2007).
In the developing murine small intestine, Shh and Ihh are expressed throughout the
epithelium. But, in time, with villus morphogenesis their expression becomes progressively
conﬁned to the intervillus regions and, at later stages, to the crypts. At the same time,
expression of the Hh receptors Ptch1 and Ptch2, and the Hh eﬀectors Gli2 and Gli3,
is limited to the underlying stromal cells. The loss of either Shh or Ihh results in gross
abnormalities in the epithelial development of the gut (Ramalho-Santos et al., 2000). Loss
of Ihh results in perinatal death and is paralleled by reduced proliferation in the crypt
region. Ihh−/− mice have also been shown to display a reduction in the enteroendocrine
cell markers implying a role for Ihh in cell diﬀerentiation. Loss of Shh, while still causing
early post-natal lethality, led to an opposite phenotype. Shh−/− mice exhibited overgrown
villi in the duodenum suggesting an increase in proliferation (Ramalho-Santos et al.,
2000). Despite the overlapping expression of Ihh and Shh, these observations suggested
distinct roles for diﬀerent Hh ligands in the small intestine. In order to explore the
combined role of both Hh ligands in adult intestinal homeostasis, Madison et al. (2005)
speciﬁcally blocked Hh signalling in the intestine by overexpression of the Hh inhibitor
Hhip in a tissue-speciﬁc manner. High expression level of Hhip resulted in a highly
proliferative intestinal epithelium with complete abolition of villi. Lower levels of Hh
pathway inhibition have been found to produce a milder phenotype, which, nevertheless,
was characterised by development of abnormal branched villi with sites of ectopic Wnt
activation and proliferation. The model proposed by Madison and colleagues suggested
that Shh and Ihh are released in the crypt region and act as paracrine signals for the
smooth muscle cells and subepithelial myoﬁbroblasts, which, in turn, inhibit proliferation
in the villus epithelium (Madison et al., 2005).
Another pathway that facilitates the ﬂow of signals from epithelium to mesenchyme is
the PDGF pathway. Four PDGF ligands (PDGF-A, PDGF-B, PDGF-C and PDGF-D)
bind to two related receptor tyrosine kinases, PDGFR-α and PDGFR-β, that trans-
mit the signal to a number of signal transduction pathways, including signal transducer
and activator of transcription (STAT), Mitogen-activated protein kinase (MAPK), phos-
phatidylinositol 3-kinase (PI3K/Akt) and others (reviewed in Andrae et al,. 2008). Loss
of PDGF-A in murine small intestine has been shown to result in reduction of villus den-
sity as well as abnormal villus spacing and morphology (Karlsson et al., 2000). A model
proposed to explain the abnormal villus development suggested that PDGF-A expression
by epithelial cells (ﬁrst ubiquitous, then restricted to intervillus regions) drives prolif-
eration and prevents premature diﬀerentiation of PDGFR-α positive mesenchymal cells.
These cells form so called villus clusters that give rise to fully-formed villi by inducing
epithelial folding and blocking the epithelial proliferation in the fold. The loss of PDGF-A
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in this scenario leads to the depletion of undiﬀerentiated self-renewing PDGFR-α positive
mesenchymal cells and failure to initiate villus clusters, ultimately resulting in fewer, more
spaced out villi (Karlsson et al., 2000).
1.1.3.2 Mesenchyme-to-epithelium signalling: TGF-β and BMP pathways
TGF-β signalling (Figure 1.2) regulates a plethora of biological processes such as embryo-
genesis, wound healing, cell proliferation and diﬀerentiation (Shi and Massague´, 2003).
The TGF-β family of cytokine molecules is represented by the TGF-β/Activin/Nodal
and bone morphogenetic protein (BMP) subfamilies. Both subfamilies of ligands initiate
signalling by binding to type I and II receptor serine/threonine kinases. The resulting colo-
calisation of the two receptors allows phosphorylation of the type I receptor by the type
II receptor. This initiates a signalling cascade via phosphorylation of Mothers Against
Decapentaplegic (Smad) proteins. The eight Smad family proteins can be divided into
three functional classes: the receptor-regulated (R-Smads: Smad1, 2, 3, 5, and 8); the
co-mediator (Co-Smad: Smad4); and the inhibitory (I-Smads: Smad6 and 7). Activated
type I receptors phosphorylate the R-Smads, which upon activation assemble into het-
eromeric complexes with Co-Smad. The activated complexes are then translocated to the
nucleus, where they regulate expression of the respective target genes. I-Smads compete
with R-Smads for receptor binding and Co-Smad thus inhibiting the pathway (reviewed
in Shi and Massague´, 2003)
In the intestine, BMP2 and BMP4 ligands are expressed in the mesenchyme, being
positively regulated by the Hh pathway (Madison et al., 2005). At the same time, the
BMP pathway receptor, Bmpr1a, is expressed in the epithelial cells (Karlsson et al., 2000).
Notably, the inhibitor of BMP signalling, Noggin, is expressed in the submucosa around
the crypt region, thus blocking BMP signals from mesenchyme in this region (He et al.,
2004b). Conversely, epithelial cells of the villi have been shown to display elevated levels
of phospho-Smad1, 5 and 8, indicating active BMP signalling (Haramis et al., 2004). Both
conditional deletion of Bmpr1a and overexpression of Noggin in mouse intestine resulted
in excessive development of aberrant crypt-like structures. Whereas Noggin overexpress-
ing mice developed ectopic crypt structures on the sides of villi (Haramis et al., 2004),
loss of Bmpr1a resulted in increased crypt density in the aﬀected areas (He et al., 2004b).
Both models developed polyps that were characterised by an expanded proliferative com-
partment. These observations demonstrate that BMP signalling inhibits ectopic crypt
formation and restricts proliferation to the crypt region due to the Noggin availability.
Taken together, the patterns of Hh and BMP signalling provide a model that attempts
to explain the crypt-villus self-organisation (Figure 1.3). Hh signalling released by epithe-
lial cells acts upon the underlying mesenchyme, which, in turn, releases BMP ligands.
The presence of Noggin in the intervillus region protects crypt from the BMP-mediated
inhibition of cellular proliferation. At the same time, BMP signals released by the stroma
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underlying the villus epithelium inhibit proliferation and ectopic crypt formation there.
Figure 1.3: Interplay of signalling pathways in maintenance of small intestinal homeostasis. A network
of signalling pathways is required to establish and maintain homeostasis of the small intestinal epithelium.
High levels of Wnt and Notch signalling in the crypt region maintain the undiﬀerentiated state of intestinal
stem and progenitor cells. As cells migrate towards the crypt opening along decreasing gradient of
Wnt and Notch signals, progenitor cells loose their proliferative capacity and undergo diﬀerentiation.
Expression of Hedgehog ligands by epithelial cells activates hedgehog pathway in surrounding stroma
and, in turn, activates expression of BMP ligands. Activation of BMP signalling in epithelial cells of
the villus prevents cell proliferation in this region. At the same time expression of the BMP antagonist
Noggin in the crypt region protects proliferating crypt cells from inhibition by BMP signals.
1.1.3.3 Epithelium-to-epithelium signalling: the Wnt pathway
The Wnt pathway (Figure 1.2) is conserved throughout the animal kingdom from cnidar-
ians through insects and worms to mammals. It plays a crucial role in body patterning
and axis formation during development. Importantly, Wnt signalling is also involved in
maintenance of adult tissues, and abnormalities in its function are linked to numerous
pathological conditions (reviewed in Clevers, 2006).
Wnts are a family of cysteine-rich glycoproteins whose biological activity requires
palmitoylation of a conserved cysteine residue during their production and secretion
(Willert et al., 2003). Once released into the extracellular space, Wnts can activate their
target cells via interaction with a family of Frizzled (Fz) transmembrane proteins (Bhanot
et al., 1996). For the activation of the canonical Wnt pathway in vertebrates, Fzs need to
cooperate with single-span transmembrane protein LRP5 or LRP6 (Pinson et al., 2000;
Tamai et al., 2000). The β-catenin protein is a key player in the canonical Wnt pathway
and in the absence of Wnt activation, the pool of free β-catenin is sequestered in the
cytoplasm by the so-called destruction complex. The tumour suppressor proteins APC
and Axin form the scaﬀold of this complex and bind free β-catenin enabling its phospho-
rylation by CK1 at the Ser45 residue (Amit et al., 2002; Liu et al., 2002). Subsequently,
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β-catenin is further phosphorylated by GSK3β (Rubinfeld et al., 1996) and recognized
by the E3 ubiquitin ligase β-TrCP, which triggers the ubiquitination of β-catenin and its
subsequent degradation by proteasomes (Hart et al., 1999).
Binding of Wnts to Fz and LRP5/6 leads to the phosphorylation of the cytoplasmic
domain of LRP5/6, which, along with the Fz-bound Dishevelled protein, recruits the Axin
protein to the plasma membrane. Axin depletion from the cytoplasm disrupts the integrity
of the destruction complex, thus increasing the cytoplasmic pool of free β-catenin (Tamai
et al., 2004). Stabilized β-catenin is then translocated to the nucleus, where it binds to
members of the Tcf transcription factor family (Waterman, 2002). In a Wnt-inactive cell,
Tcf proteins are associated with general transcriptional repressors, such as Groucho, and
repress the expression of Tcf-responsive genes (Roose et al., 1998). On the activation of
Wnt signalling, β-catenin binding to Tcf proteins displaces Groucho (Daniels and Weis,
2005) and recruits a number of transcriptional coactivators such as BRG1 and the histone
acetylase CBP to the Tcf target sites (Barker et al., 2001; Hecht et al., 2000).
Wnt signalling maintains crypt cell proliferation Numerous lines of evidence have
suggested that in the intestinal epithelium Wnt signalling plays a pivotal role in main-
taining proliferation, so that pathway inhibition reduces the proliferative compartment,
while pathway activation expands it. The importance of the Wnt pathway in the main-
tenance of the crypt region is highlighted by the expression pattern of its components.
Expression of the canonical Wnt pathway ligands (Wnt3, Wnt6 and Wnt9b) and receptors
(Fz5, 7 and LRP5, 6) is conﬁned to the proliferative epithelial crypt cells. At the same
time, a number of Wnt ligands (Wnt-2b, Wnt-4, Wnt-5a, and Wnt-5b) are expressed
in the villus mesenchyme. These ligands induce non-canonical Wnt signalling, which is
considered to have an inhibitory eﬀect on the canonical Wnt pathway. Accordingly, Fz4
and 6 are known to mediate non-canonical Wnt signal transduction and are expressed in
diﬀerentiated epithelial cells of the villus (Gregorieﬀ et al., 2005).
The Wnt pathway inhibition by inactivation of its major downstream eﬀector, Tcf4,
have been demonstrated to result in complete abolition of proliferation in the intervillus
region of the developing gut (Korinek et al., 1998). Similarly, inducible loss of β-catenin in
the adult intestine leads to ablation of cell proliferation, dramatic crypt loss and intestinal
failure (Fevr et al., 2007). Conditional Wnt signalling inhibition by overexpression of a
Wnt inhibitor Dickkopf 1 (Dkk1) results in a similar phenotype involving depletion of the
proliferative compartment, crypt loss and architectural abnormalities, such as reduction
in villus size and numbers (Kuhnert et al., 2004; Pinto et al., 2003). Finally, conditional
inactivation of a downstream Wnt target c-Myc slows down the cell cycle in the prolif-
erating crypt cells. This leads to gradual elimination of c-Myc deﬁcient crypts and their
repopulation with crypts retaining c-Myc expression (Muncan et al., 2006)
Conversely, aberrant activation of the Wnt pathway by either loss of the Wnt pathway
negative regulator Apc or by overexpression of a dominant stable form of β-catenin have
Chapter 1. General introduction 12
been shown to induce expansion of the proliferative compartment and enlargement of
crypts (Harada et al., 1999; Sansom et al., 2004). The same studies have shown that Wnt
signalling activation impairs cell migration along the crypt-villus axis, indicating increased
cell aﬃnity to the proliferative compartment. Notably, whilst pan-epithelial Apc loss
activates Wnt signalling in both crypt and villus cells, it does not induce proliferation in
the villus, suggesting that other signals are required for the Wnt signalling manifestation
(Andreu et al., 2005).
Wnt signalling guides progenitor cells towards the secretory lineage Apart
from its function in maintaining proliferation, Wnt signalling has been implicated in the
determination of cell fate choices. The most explicit evidence for this comes from Paneth
cell diﬀerentiation. Unlike other diﬀerentiated cells, Paneth cells remain at the bottom
of the crypt and display signs of active Wnt signalling (such as nuclear β-catenin). Wnt
signalling in Paneth cells has been implicated in the commitment to Paneth cell fate by
driving the expression of Paneth cell-speciﬁc genes (Andreu et al., 2005; van Es et al.,
2005a). The inﬂuence of the Wnt pathway on the other cell lineages is less straightforward.
Wnt signalling inhibition by Dkk1 overexpression resulted in loss of all the secretory cell
lineages without aﬀecting enterocyte diﬀerentiation (Pinto et al., 2003). Surprisingly,
aberrant activation of Wnt signalling yielded a similar phenotype. Thus, loss of Apc
function has been reported to result in general failure to diﬀerentiate as evident by the loss
of all but Paneth cell diﬀerentiation markers (Andreu et al., 2005; Sansom et al., 2004).
Together these data suggest that Wnt signalling plays three major roles: maintaining
cell proliferation, preventing cell diﬀerentiation and directing cells towards the secretory
lineage.
Wnt signalling controls cell segregation via the Eph/ephrin system One more
function of the Wnt pathway in intestinal homeostasis is spatial segregation of distinct
cellular populations. This function is mediated by the expression pattern of the tyrosine
kinase guidance receptors EphB2 and EphB3 and their ligand ephrin B1. Wnt signalling
stimulates expression of the EphB receptors, while inhibiting ephrin B1 expression. In
the intestine of neonatal mice EphB2 and EphB3 are co-expressed in the cells of inter-
villus pockets, while ephrin B1 expression is largely limited to the villus cells. In adult
intestine EphB3 expression is restricted to the Paneth cells, while EphB2 is expressed in
proliferating cells with a decreasing gradient towards the crypt-villus junction. Ephrins
B1 and B2 are highly expressed around the crypt-villus junction with a gradual decrease
towards the bottom of the crypt in a counter-gradient to EphB2. Loss of either of the
EphB receptors has no major eﬀects on intestinal homeostasis, although EphB3 loss does
result in mislocalisation of the Paneth cells. The simultaneous loss of EphB2 and EphB3
still allows for near normal development and maturation of the intestinal epithelium, but
leads to disruption of the boundaries between cellular compartments and intermingling
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of proliferating and post-mitotic diﬀerentiated cells (Batlle et al., 2002).
1.1.3.4 Cell-to-cell lateral inhibition: Notch/Delta pathway
The Notch receptors and their respective ligands are represented by a number of trans-
membrane proteins that mediate cell-to-cell signal transduction between adjacent cells.
The Notch pathway controls a range of biological processes including apoptosis, prolif-
eration, spatial patterning and cell fate determination (Artavanis-Tsakonas et al., 1999).
The Notch signalling cascade is initiated after a receptor and a ligand on the surface of the
two neighbouring cells come into contact (Figure 1.2). As a result of this receptor-ligand
interaction the Notch receptor undergoes two successive proteolytic cleavage events. The
ﬁrst cleavage occurs in the extracellular domain and is mediated by the tumour necrosis
factor-α-converting enzyme (TACE) metalloprotease. The second cleavage takes place
within the trans-membrane domain and is carried out by a large protein complex termed
γ-secretase. The second cleavage releases the Notch intracellular domain (NICD). NICD
is translocated to the nucleus, where it binds to the Notch downstream transcription fac-
tor CSL (also known as CBF1 in humans and RBP-J in mice). Binding of NICD to CSL
displaces co-repressors and recruits co-activators that facilitate transcription of the target
genes. One of the best characterised Notch downstream eﬀectors is the hairy enhancer
of split (Hes) family of transcriptional repressors that, in turn, regulate expression of a
number of target genes (reviewed in Wilson and Radtke, 2006).
In the adult intestine expression of the Notch pathway receptors and ligands is mainly
conﬁned to the epithelial cells of the crypt region and, to a lesser extent, the mesenchyme
(Schro¨der and Gossler, 2002). The expression of the Notch downstream target, Hes1, is
also limited to the crypt compartment, indicating Notch activation in this cell population
(van Es et al., 2005b). Conditional inactivation of CSL in the murine intestine results in
the dramatic loss of proliferating crypt cells and their conversion into post-mitotic goblet
cells. A similar eﬀect is achieved by blocking Notch signalling with γ-secretase inhibitors
(van Es et al., 2005b). A milder inhibition of the Notch pathway by inactivation of the
downstream eﬀector Hes1 causes excessive diﬀerentiation of enteroendocrine and goblet
cells at the expense of enterocytes (Jensen et al., 2000). It appears, therefore, that
secretory cell fate is a default choice in the absence of Notch signalling.
Excessive activation of Notch signalling by expression of a dominant active form of
NICD impairs diﬀerentiation of all the cell lineages, while expanding the proliferative
compartment (Fre et al., 2005). Notably, the loss of the transcription factor Mouse atonal
homologue 1 (Math1), negatively regulated by Hes1, depletes intestinal epithelium of the
secretory cell lineages without aﬀecting enterocyte diﬀerentiation (Yang et al., 2001). To-
gether, these observations suggest two primary functions of Notch signalling in intestinal
homeostasis: maintenance of the crypt progenitors in the undiﬀerentiated state and deter-
mination of the cell fate towards the absorptive lineage. The second function is likely to
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be mediated by lateral inhibition. It has been shown that cells committed to the secretory
lineage express Notch ligands (Crosnier et al., 2005). These cells, therefore, are able to
induce Notch signalling in their neighbours and prevent their commitment towards the
secretory lineage via Math1 inhibition.
1.1.4 The small intestinal stem cell
The intestinal epithelium is one of the fastest renewing tissues in the mammalian organism.
With the exception of the Paneth cells, all major types of terminally diﬀerentiated cells
in the small intestinal epithelium are replaced with new cells in a matter of days. The
constant renewal of the epithelial sheet is sustained due to the activity of the intestinal
stem cell. The stem cells are deﬁned as those cells able to proliferate and self-renew for
an unlimited period of time, while generating diverse diﬀerentiated progeny speciﬁc to
the given tissue (Potten and Loeﬄer, 1990). Considering the central role the stem cells
play in epithelial homeostasis, knowledge of intestinal stem cell function and regulation
is crucial for our understanding of the normal and pathological processes in the intestinal
epithelium.
1.1.4.1 Intestinal stem cell identity and location
The major obstacle in intestinal stem cell research is the lack of deﬁnitive markers that
would allow identiﬁcation of the stem cell within the crypt. The exact location of the
intestinal stem cell has been disputed over decades (Figure 1.4). A number of recent
ﬁndings have at last provided functional evidence of stem cell identity, although this has
not yet brought the discussion to resolution. This section will discuss the historic views
on the stem cell position within the crypt as well as recent advances in the quest for
intestinal stem cell markers.
Initial insights into the position of the intestinal stem cell were based on the obser-
vation that the proliferative compartment is bound at the bottom by non-proliferating
Paneth cells. Downward migration of Paneth cells creates two migration counter-gradients
that seemingly originate at the bottom of the migratory column, immediately above the
Paneth cells, suggesting it is a likely location for the crypt stem cell (Cairnie et al., 1965).
Positioning of the intestinal stem cell immediately above the Paneth cells has been sup-
ported by a number of DNA labelling experiments. The rationale for these experiments
comes from the observation that at least in some tissues relative quiescence is a deﬁnitive
characteristic of the stem cell in contrast to its actively proliferating progeny. If an ex-
panding stem cell population is exposed to a DNA labelling agent, the stem cells are able
to incorporate and retain the label due to their low proliferation rate. Conversely, active
proliferation of the progenitor cells ensures that the label is rapidly diluted and lost. The
label-retaining cells (LRCs) can therefore be used to highlight the position of the stem
cell and are well characterised in the stem cells of the hair follicle bulge (Cotsarellis et al.,
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Figure 1.4: Schematic diagram of the small intestinal crypt and candidate locations of the intestinal
stem cell. Actively proliferating transit amplifying (TA) zone of the crypt is bound at the bottom by
non-cycling Paneth cells. The small intestinal stem cell has been proposed to sit right above Paneth
cells (+4 stem cell) or wedged between them (CBC cell). Some evidence suggest that both population
can coexist within a crypt. Orange boxes contain the list of proposed stem cell markers for each of the
candidate locations. Paneth and mesenchymal cells are proposed to constitute the stem cell niche.
1990) and bone marrow (Cheng et al., 2000), as well as in muscle satellite cells (Boldrin
et al., 2010).
Labelling of the intestinal epithelium with tritiated thymidine (3HTdR) has identiﬁed
a population of slowly cycling cells at position +4, immediately above the Paneth cells.
These cells cycled on average once a day, i.e. at half the rate of the rest of the proliferating
crypt cells, and were therefore proposed as putative stem cells (Potten et al., 1974).
When the label was administered at the time of stem cell expansion, such as during
post-irradiation crypt regeneration, the +4 cells were able to retain the label for at least
one week post labelling (Potten et al., 1978). Taking into account the 24 hour cell cycle
of the +4 cells, they are expected to undergo 8 cell divisions in a week resulting in
dilution and loss of the label. The long-term label retention of the +4 cells therefore
required an explanation alternative to a merely slower cell cycle. Such an explanation
has been proposed by Cairns (1975), who suggested that stem cells may use selective
segregation of the parental template and daughter DNA strands to avoid acquisition of
mutations during DNA replication. Post-irradiation labelling of the intestinal epithelium
with 3HTdR followed by bromodeoxyuridine (BrdU) administration 8 days later has been
shown to generate a population of double-labelled cells displaying both 3HTdR and BrdU
label (Potten et al., 2002). Of the two DNA strands in a double-labelled cell the template
DNA strand contained 3HTdR, while the daughter strand incorporated BrdU. All the
double-labelled cells lost BrdU labelling on day 3 after BrdU exposure, while retaining
3HTdR label for at least an extra week. A two day period required for the elimination
of the double-labelled cells is consistent with the cell division rate of the +4 cells as two
divisions would be necessary to eliminate the freshly synthesised BrdU-labelled strand
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(Potten et al., 2002).
Consistent with selective segregation of the template and daughter DNA strands is
sensitivity of the +4 cells to extremely low levels of ionising radiation. Even minimal
damage to the template DNA strand has been shown to result in altruistic apoptosis
rather than an attempt to repair the damage (Potten, 1977). Lost stem cells are then
replaced either by clonal expansion of undamaged stem cells or by more repair-proﬁcient
progenitor cells retaining a stem-cell potential. Indeed, it has been suggested that every
crypt contains a hierarchy of cells able to regenerate a crypt after radioactive damage
(i.e. clonogenic cells). The ﬁrst tier of this hierarchy is represented by the true stem cells
highly sensitive to ionising radiation. The second tier contains the immediate progeny of
the stem cells and is more resistant to radioactive damage, while the immediate progeny of
the second tier cells forms the third, most radioresistant, tier of clonogenic cells (Potten,
1998).
Although the view that the small intestinal stem cell is located at the +4 position
has prevailed for decades, an alternative location for the intestinal stem cell was proposed
in the same year as for the +4 position. The undiﬀerentiated proliferative crypt-base
columnar (CBC) cells intercalated between the Paneth cells at the very bottom of the
crypt have been found to be radiosensitive and display signs of active phagocytosis (Cheng
and Leblond, 1974b). Upon administration of 3HTdR occasional CBC cells underwent
radiation-induced apoptosis and were subsequently phagocytosed by neighbouring CBC
cells. Phagosomes containing radioactively labelled nuclei were then used as a marker for
tracing the progeny of the CBC cells. 3HTdR containing phagosomes eventually became
present in all four mature cell types suggesting that CBC cells have the potential to
produce all the diﬀerentiated cell types of the intestinal epithelium and are therefore
likely candidates for the intestinal stem cell (Cheng and Leblond, 1974b). The proposed
role for CBC cells as the intestinal stem cell has been further supported by a number of
clonal analysis experiments that suggested the presence of the stem cell zone between cell
positions 1-4 at the crypt base (Bjerknes and Cheng, 1981). This alternative candidate
location for the intestinal stem cell, however, has been largely overlooked until recently.
An ability to reliably identify the intestinal stem cell would substantially aid in un-
derstanding normal intestinal homeostasis and pathogenic processes, such as a disruption
of normal homeostasis. It comes as no surprise, therefore, that many eﬀorts have been
directed at establishing molecular markers that would distinguish the stem cell from other
cells in the crypt (for a list of proposed markers and cells marked by them see Figure 1.4).
Early attempts to identify such markers were based on the presumed location of the stem
cell and were therefore looking for proteins exclusively expressed in the stem-cell zone.
One of the earliest intestinal stem cell markers to be suggested is an RNA-binding protein
Musashi-1. It has been found to be expressed at high levels in developing and regenerating
crypts as well as in intestinal adenomas of ApcMIN mice, all of which are likely to contain
expanded stem cell populations. Musashi-1 expression, however, has been reported in
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both +4 and CBC cells as well as in early progenitor cells and therefore cannot be used
as an exclusive marker for the intestinal stem cell (Potten et al., 2003).
The inactive (phosphorylated) phosphatase and tensin homologue (Pten) protein has
been suggested as another position-based stem cell marker. He et al. (2004b) observed
co-staining of position +4 BrdU-retaining cells with P-Pten in the intestinal crypts. Con-
sistent with Pten inactivation these cells displayed active PI3K/Akt signalling as well as
nuclear localisation of β-catenin indicating active Wnt signalling (He et al., 2004b). These
observations, however, have been questioned by Bjerknes and Cheng (2005) who demon-
strated that P-Pten staining was not exclusive to +4 cells and was indeed encountered
throughout the crypt-villus axis, although at a lower frequency than at the bottom of the
crypt. They also observed consistent co-staining of P-Pten with Chromogranin A, which
is a speciﬁc marker of enteroendocrine cells (Bjerknes and Cheng, 2005).
Similarly, the microtubule-associated kinase doublecortin and CaM kinase-like-1 (Dcamkl-
1) protein has been proposed to mark the intestinal stem cell based on its ability to stain
individual cells around position +4 (May et al., 2008). Dcamkl-1 has also been shown
to mark a very small population of non-proliferating cells in intestinal adenomas from
ApcMIN mice, suggesting that Dcamkl-1 marks a quiescent stem cell (May et al., 2008).
While May et al. did not assess the proliferative state of Dcamkl-1 positive cells in normal
tissue, a later study failed to detect any proliferating Dcamkl-1 positive cells irrespective
of their position along the crypt-villus axis (Gerbe et al., 2009). Additionally, a number
of characteristics have undermined the role of Dcamkl-1 as a classic stem cell marker.
Dcamkl-1 positive cells are frequently detected among the villus cells, they are resistant
to ionising radiation and do not seem to drive post-irradiation crypt regeneration (May et
al., 2008). It has also been demonstrated that all Dcamkl-1 positive cells in the intestinal
epithelium express molecular markers of tuft cells, such as cyclooxygenase 1 and 2, and
thus mark post-mitotic diﬀerentiated tuft cells rather than quiescent stem cells (Gerbe et
al., 2009).
All the proposed markers mentioned so far deﬁne the stem cell according to its pro-
posed topographical location along the crypt-villus axis. These studies, however do not
provide any functional evidence of the ‘stemness’ of these cells, namely, the ability to
self-renew or give rise to the mature epithelial cell lineages. Such evidence has at last
been provided by two studies using transgenic techniques (Barker et al., 2007; Sangiorgi
and Capecci, 2008). Barker et al. reported that a Wnt target gene, leucine-rich-repeat-
containing G-protein-coupled receptor 5 (Lgr5), is selectively expressed in rare cells in
a range of tissues. In the tissues of the gastrointestinal tract (stomach, small and large
intestines) Lgr5 expression is conﬁned to the crypt base. In the small intestine Lgr5 ex-
pression speciﬁcally marks the CBC cells. Using an inducible Cre-recombinase transgene
expressed under the control of the Lgr5 promoter and the LacZ reporter allele, Barker
and colleagues demonstrated that Lgr5 expressing (Lgr5+) CBC cells are capable of pro-
ducing all the mature intestinal cell types and clones generated by these CBC cells persist
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in the intestinal epithelium for at least 60 days (Barker et al., 2007). Lgr5+ cells, thus,
fulﬁl both prerequisites of stem cells, namely pluripotency and long-term self-renewal,
establishing CBC cells as true intestinal stem cells. Two additional stem cell markers
have been proposed based on their co-expression with Lgr5. Achaete scute-like 2 (Ascl2)
and Olfactomedin-4 (Olfm4) have been found exclusively expressed in Lgr5+ CBC cells,
but not in Paneth or transit amplifying cells (van der Flier et al., 2009).
Although Barker et al. convincingly demonstrated the stem cell nature of CBC cells, a
study by Sangiorgi and Capecci (2008) has provided functional evidence that the polycomb
group protein Bmi1 (a polycomb group ring ﬁnger oncogene) also marks true stem cells,
but is mainly expressed in position +4 cells, thus introducing an extra degree of complexity
into the debate over the intestinal stem cell identity. Activation of the reporter allele in
Bmi1 expressing (Bmi1+) cells has established that Bmi1+ cells are able to form long-
lasting cell clones that include all the diﬀerentiated cell lineages. Additionally, stem cell
ablation via selective expression of diphtheria toxin in Bmi1+ cells resulted in a rapid
crypt loss (Sangiorgi and Capecci, 2008).
While the position of Bmi1+ cells was the main feature that distinguished them from
Lgr5+ cells, a number of other distinct characteristics have been observed. While Lgr5+
cells are ubiquitous throughout the alimentary tract, Bmi1 expression has been detected
only in the ﬁrst 20 cm of the small intestine, indicating that Lgr5 is a more universal stem
cell marker, which is consistent with its expression in the putative stem cell zones of other
tissues (Barker et al., 2007). It has been claimed that Bmi1+ cells proliferate at a slower
rate than CBC cells (Sangiorgi and Capecci, 2008). This claim has been widely used
to propose that Bmi1+ and Lgr5+ cells represent two distinct stem cell populations with
Bmi1+ cells comprising a quiescent or slow cycling population and Lgr5+ cells representing
active stem cells. Coexistence of such populations has been described in other tissues such
as hair follicle and bone marrow (reviewed in Li and Clevers, 2010).
Interestingly, while Lgr5+ CBC cells have been described as actively proliferating,
initial estimations of their cell cycle suggested that they divide once a day (Barker et al.,
2007). More accurate assessment of the Lgr5+ cell proliferation rate has demonstrated
that they cycle every 21.5 hours, nearly at half the rate of transit-amplifying cells, which
divide every 12 hours (Schepers et al., 2011). The 21.5 hour long cell cycle of Lgr5+ cells
is strikingly similar to the 24 hour cell division rate of the classic +4 LRC described by
Potten et al. (1974), a fact widely overlooked in the literature. On the other hand, no
deliberate assessment of the proliferation kinetics of Bmi1+ cells has been performed. The
claim that Bmi1+ cells are slow cycling is loosely based on the observation that following
activation of the yellow ﬂuorescent protein (YFP) reporter in Bmi1+ cells, occasional
doublets of YFP expressing cells are detected as late as 5 days after induction, placing
the length of the cell cycle in the order of several days (Sangiorgi and Capecci, 2008).
However, essentially identical experiments in the same study using a LacZ reporter have
revealed relatively large LacZ positive clones as early as day 2 after induction, indicating
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a much faster cell cycle. Another argument in favour of a slower proliferation rate for
Bmi1+ cells is the longer time required for the reporter expressing progeny of Bmi1+
cells to expand and populate the crypt, compared to the progeny of Lgr5+ cells. This
discrepancy, however, could be explained by the higher abundance of the Lgr5+ cells
compared to Bmi1+ cells as evident from expression studies (Barker et al., 2007; Sangiorgi
and Capecci, 2008). In view of these observations, and the absence of a careful assessment
of the Bmi1+ cell proliferation rate, the claims that Bmi1+ cells divide less frequently than
Lgr5+ cells appear to be unsubstantiated.
Notably, it is generally assumed that since Bmi1 is mainly expressed around the +4
position, Bmi1+ cells equate to the classic LRC stem cell. However, no study to date
has explicitly shown if Bmi1+ cells are capable of long-term label retention and whether
they selectively segregate the template DNA strand. At the same time, it has been
demonstrated that Lgr5+ cells segregate their chromosomes at random (Schepers et al.,
2011) consistent with the lack of asymmetric division in the CBC cells (Snippert et al.,
2010).
A strong argument against Bmi1 expression marking a distinct population of the
quiescent stem cells comes from the stem cell ablation experiment. Cre recombinase-
mediated induction of diphtheria toxin expression in Bmi1+ cells results in the rapid
loss of intestinal epithelium and animal death within 2-3 days after induction, while a
lower dose induction protocol aids animal survival, but still causes extensive crypt loss
(Sangiorgi and Capecci, 2008). Notably, the low dosage protocol has been reported to
induce reporter gene recombination in 10% of the crypts in the ﬁrst 10 cm of the duodenum
and gradually decreases along the length of the small intestine. Although the exact
frequency of recombination induced by the high dosage protocol has not been speciﬁed,
it has been said to be similar to that induced by the low dosage protocol (Sangiorgi and
Capecci, 2008). With these observations in mind, it is rather remarkable that expression
of diphtheria toxin in a quiescent stem cell population in approximately 10% of the crypts
is able to cause such a rapid and severe crypt ablation. If Bmi1 was indeed expressed
in ‘quiescent’ stem cells, the ‘active’ stem cell population would be expected to maintain
normal intestinal homeostasis at least for some time.
Remarkably, a very recent report has attempted to revise the ‘reserve stem cell’ hy-
pothesis using the reciprocal approach of controlled ablation of the Lrg5+ cells. Tian
et al. (2011) placed a diphtheria toxin receptor transgene under the control of the Lgr5
promoter thus conferring diphtheria toxin (DT) sensitivity to Lgr5+ cells. DT treatment
of mice carrying this knock-in transgene was found to ablate Lgr5+ cells as determined by
the loss of the transgene-controlled reporter and Lgr5 mRNA. The loss of Lgr5 expression
in the small intestinal epithelium was accompanied by an apparent loss of CBC cells on
electron microphotographs of the crypt bases. To the authors’ surprise, the ablation of
Lgr5+ cells had no major impact on epithelial architecture and homeostasis for as long
as 10 days of DT treatment with the exception of increased apoptosis at the crypt base
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for the duration of the treatment. Notably, the frequency of Bmi1+ cells was found to
increase substantially upon ablation of Lgr5+ cells. Additionally, lineage tracing experi-
ments detected an expansion of the intestinal crypts populated by descendants of Bmi1+
cells upon ablation of Lgr5+ cells. Together, these observations were used by authors to
suggest that Bmi1+ cells are mobilised upon loss of Lgr5+ cells and are able to give rise to
all small intestinal cell lineages bypassing the intermediate Lgr5+ state. Finally, lineage
tracing with a Bmi1-driven reporter allele was used to demonstrate that Bmi1+ cells are
able to give rise to Lgr5+ cells under physiological conditions and upon cessation of DT
treatment (Tian et al., 2011).
While the report by Tian et al. provides strong evidence in favour of Bmi1+ cells
being able to contribute to intestinal homeostasis in the absence of Lgr5+ cells and give
rise to Lgr5+ cells both under physiological conditions and following Lgr5+ cell ablation,
the methodology used has an innate vulnerability that may undermine the conclusions.
Additionally, the authors make a number of unsubstantiated claims, that would require
additional experiments to conﬁrm their validity. Firstly, the ablation of Lgr5+ cells using
DT treatment depends on the penetrance and levels of transgene expression. It is possible,
therefore, that a fraction of Lgr5+ cells fail to express the transgene or express it at levels
insuﬃcient to cause cell death. Importantly, analysis of GFP knock-in expression revealed
that Lgr5 is expressed in a decreasing gradient along the crypt-villus axis rather than in an
on-oﬀ pattern (Sato et al., 2009). Tian et al., attempted to address the possibility of rare
Lgr5+ cells persisting in largely Lgr5 deﬁcient epithelium by using an inducible reporter
allele activated by Cre recombinase expression from the same knock-in transgene as the
DT receptor. When no reporter expression was detected upon Cre recombinase induction
in DT treated small intestine, the authors claimed that all the Lgr5+ cells had been elim-
inated and intestinal homeostasis was sustained due to the activity of the ‘reserve’ stem
cell. This approach is, however, innately vulnerable as it equates ‘Lgr5 expressing cells’
with ‘transgene expressing cells’. Additionally, as this experiment required the manipula-
tion of both Lgr5 alleles and hence compromised animal survival, it had to be carried out
in an artiﬁcial setting by transplanting pieces of embryonic small intestine under the kid-
ney capsule of immunocompromised mice. While this transplanted intestine formed the
crypt-villus architecture and resembled early postnatal epithelium, its homeostasis could
diﬀer from that of intact epithelial tissue. It is, therefore, still possible that a population
of low-level Lgr5+ cells contributes to the maintenance of intestinal homeostasis in the
absence of high-level Lgr5+ cells. This notion is supported by the observation that after 6
days of lineage tracing in DT treated gut, only a third of the crypts were fully populated
with descendants of Bmi1+ cells (Tian et al., 2011).
Based on the ability of Bmi1+ cells to mobilise and contribute to intestinal homeostasis,
Tian et al. claimed that Lgr5+ and Bmi1+ cells represent distinct stem cell populations.
The key point in such a claim is a deﬁnition of what makes two cell populations distinct.
The ﬁrst deﬁnition can be based on the expression of molecular markers, such as Bmi1 or
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Lgr5 themselves. However, Tian et al., reported a clear overlap between Bmi1 and Lgr5
expression as double-labelled cells are detected under physiological conditions between
positions 1 and 6, consistent with the original report by Sangiorgi and Capecci (2008).
Although Tian et al. did not explicitly state the frequency of such double-labelled cells,
analysis of their quantitative data suggests that about 21% of Bmi1+ cells also expressed
Lgr5. While the proportion of Lgr5+ cells expressing Bmi1 is likely to be lower, due to
the overall higher number of Lgr5+ cells per crypt, it is clear that Lgr5+ and Bmi1+
cells cannot be regarded as distinct population based on the expression of these molecular
markers. The second deﬁnition of distinct cell populations could rely on the cell morphol-
ogy. Although no thorough morphological analysis of Lgr5+ and Bmi1+ cells has been
conducted, the former have been strongly associated with a narrow spindle-like shape
and an elongated nucleus – a morphology characteristic of the CBC cell. Visual analy-
sis of Bmi1+ cells can distinguish two morphotypes loosely correlated to their location
within the crypt. Bmi1+ cells at the bottom of the crypt appear to have a CBC cell-like
morphology, while cells higher in the crypt are characterised by a larger and more round
nucleus (Sangiorgi and Capecci, 2008; Tian et al., 2011). Consistent with this observation,
ﬂuorescence-activated cell sorting (FACS) analysis of intestinal crypt cells distinguished
two morphologically distinct populations: the ‘main’ population consisting of larger cells
was largely represented by transit amplifying cells, while the ‘small’ population was rep-
resented by smaller CBC cells. Notably, while Lgr5 expression was strictly conﬁned to
‘small’ cells, Bmi1 was expressed in both populations (Montgomery et al., 2011). There-
fore, based on morphology, Bmi1+ cells not only overlap with CBC cells, but appear to
comprise two morphologically distinct populations. Finally, physiological properties can
be used to deﬁne the stem cell populations. One such property relevant to this dispute is
the rate of proliferation. While Tian et al. explicitly state that Bmi1+ cell quiescence is
yet to be demonstrated, they repeatedly imply that Bmi1+ cells are cycling slower than
Lgr5+ cells. However, since no careful analysis of cell cycle kinetics of Bmi1+ cells has
been performed to date, this parameter cannot be used to identify Lgr5+ and Bmi1+
cells as two distinct populations. Given the possible deﬁnitions of distinct cell popula-
tions, even if Lgr5+ and Bmi1+ cells form diﬀerent populations, these are more likely to
represent a continuum rather that distinct populations. Based on the lineage tracing of
Bmi1+ cells’ descendants and Lgr5 expression in a fraction of these descendants, Tian et
al. arrived at the conclusion that Bmi1+ cells give rise to Lgr5+ cells under physiological
conditions. Based on this conclusion, the authors went on to speculate that Bmi1+ cells
take an upstream position in the stem cell hierarchy in relation to Lgr5+ cells. However,
the observations that led the authors to conclude a Bmi1+ origin for Lgr5+ cells could
be interpreted in a number of ways. For example, 24 hours after the activation of the
inducible reporter gene using a Bmi1-driven Cre recombinase, Tian et al. observed single
cells expressing the reporter. These cells were postulated to be Bmi1+ cells before their
ﬁrst division since labelling. As mentioned above, 21% of these reporter expressing cells
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were also found to express Lgr5. Since these Bmi1+ cells had not undergone a division,
they represent an overlapping population of Bmi1 and Lgr5 expressing cells and cannot be
regarded as Lgr5+ cells that originated from Bmi1+ cells, but rather as a cell population
that expresses both markers. Somewhat hastily the authors then stated that the number
of the double-labelled cells increased two-fold by 48 hours after reporter activation and
concluded that Bmi1+ cells can give rise to Lgr5+ cells under normal physiological con-
ditions. However, the two-fold increase in the number of double-labelled cells is readily
explained by the 21.5 hour cell cycle of Lgr5+ cells (Schepers et al., 2011). This notion is
consistent with the images provided in the paper that show pairs of double-labelled cells,
suggesting that the observed increase in double-labelled cells is due to normal proliferation
of the Lgr5+ cell population. Therefore, what these observations appear to suggest is the
existence of a cell population that expresses both stem cell markers and proliferates at a
rate comparable to that of Lgr5+ cells. Indeed, if Bmi1+ cells truly ‘gave rise’ to Lgr5+
cells (i.e. underwent a cell division with one daughter cell retaining reporter-only staining
and the second daughter cell acquiring Lgr5 expression and becoming a double-labelled
cell) a rather diﬀerent picture is expected. In such a scenario no double-labelled cells
would be observed at 24 hours after induction of reporter expression. The ﬁrst double-
labelled cells would appear at 48 hours after induction and ideally would be found in pairs
comprised of one reporter-expressing and one double-labelled cell.
Finally, even if one accepts the authors’ reasoning that Bmi1+ cells can give rise to
Lgr5+ cells, a reciprocal experiment demonstrating that Lgr5+ cells are unable to give rise
to Bmi1+ cells is required to support the claim that Bmi1+ cells are upstream of Lgr5+ cells
in the stem cell hierarchy. Without such an experiment an equipotent possibility remains
that a two-way ﬂow exists between these two populations. Such a possibility is favoured
by the presence of a substantial intermediate population expressing both markers.
Taking all these caveats into consideration, Bmi1 is unlikely to speciﬁcally mark a
population of quiescent stem cells distinct from Lgr5+ cells. It seems more reasonable
to conclude that Bmi1 is expressed in, but not limited to, a subset of Lgr5+ cells in the
proximal section of the small intestine. However, this does not rule out the existence of
the quiescent intestinal stem cell altogether. Notably, a recent report identiﬁed a rare
population of murine intestinal cells characterised by the expression of mouse telomerase
reverse transcriptase (mTert) (Montgomery et al., 2011). These cells were found to be
largely quiescent as 90-95% of mTert+ cells failed to exhibit expression of the prolifera-
tion marker Ki67. The progeny of mTert+ cells were able to populate the whole crypt
over an extended period of time and gave rise to all the intestinal cell lineages. While
the descendants of mTert+ cells were found among Lgr5+ cells, whether Lgr5+ cells can
contribute to the pool of mTert+ cells was not explored (Montgomery et al., 2011). It,
therefore, remains unclear, whether mTert+ cells represent a ‘master’ stem cell popula-
tion or whether the two populations exist in a dynamic equilibrium with each population
contributing to the other.
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Notably, mTert and Lgr5 expression in the crypt intestinal cell populations was found
to be mutually exclusive. mTert expression was absent from Lgr5 expressing CBC cells,
and vice versa no Lgr5 expression was detected in the mTert+ population. Conversely,
Bmi1 expression was detected in both of these cellular populations, as well as in cells
lacking expression of either of these markers (Montgomery et al., 2011). Bmi1, therefore,
appears to mark a diverse population of intestinal cells likely to comprise both ‘active’
and ‘reserve’ stem cells as well as some undeﬁned cell population. Thus, designation of
Bmi1 as a ‘speciﬁc’ stem cell marker should be used with caution.
A number of reports have also proposed a hematopoietic stem cell marker CD133
(Prominin 1 (Prom1) in mice) as a molecular marker for the intestinal stem cell (Snippert
et al., 2009; Zhu et al., 2009). Targeting a reporter gene to the Prom1 locus has indeed
demonstrated that Prom1 expression in the small intestine is mainly conﬁned to the
CBC cells that are able to give rise to all mature cell lineages (Zhu et al., 2009). However,
Snippert et al. (2009) have reported a broader expression of Prom1 and a rapid elimination
of reporter labelled cells from the intestinal epithelium. They, therefore, concluded that
Prom1 expression marks a population of cells mainly composed of early progenitor and,
to a much lesser extent, of stem cells (Snippert et al., 2009).
1.1.4.2 Dynamics and homeostasis of the small intestinal stem cell
While a certain degree of controversy remains over which of the newly discovered stem
cell markers identify the ‘true’ stem cell population, and what being a ‘true’ stem cell
population entails, these markers represent powerful tools that enable investigation of
many aspects of stem cell biology.
One of the central questions in the intestinal stem cell biology is the number of active
stem cells in the crypt. The classic model postulates that the annulus of cells at position
+4 contains 16 cells, 4-6 of which are proposed to be the stem cells. Mathematical
modelling of the crypt dynamics has further suggested that a steady state crypt contains
between 4 and 16 stem cells, while their number can increase up to 30-40 per crypt in
response to damage (reviewed in Potten et al., 2009). Consistent with these estimations,
Snippert et al. have calculated that the crypt base contains between 12 and 16 Lgr5+
cells (Snippert et al., 2010).
The presence of more than 1 stem cell per crypt raises the question of their equipotency.
The use of chimeric mice from strains diﬀerentially expressing binding sites for lectin has
demonstrated that while crypts of neonatal mice were composed of cells derived from both
parental strains, the crypts of mice older than 2 weeks were monoclonal (Schmidt et al.,
1988). These results were consistent with a number of other studies exploiting various
approaches that concluded that crypts of adult mice are derived from a single ‘founder’
cell (Ponder et al., 1985; Winton et al., 1988). A number of reports exploiting mutagenesis
to randomly interrupt otherwise uniform expression of a reporter gene have demonstrated
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mosaic reporter expression in crypts shortly after mutagenesis. Long-term observations
of such crypts have revealed a gradual increase in the number of uniformly expressing
(or not expressing) crypts coincident with the loss of mosaic crypts, a process termed
‘monoclonal conversion’ (Park et al., 1995; Williams et al., 1992; Winton et al., 1988).
These observations raise the possibility of a single ‘master’ stem cell producing the rest of
the stem cells. In this scenario, if the inactivating mutation occurs in the ‘master’ stem
cell the whole crypt eventually becomes mutant. Conversely, mutations in the shorter-
lived ‘slave’ stem cells are eventually lost, returning the crypt to the uniform expression of
the intact reporter. An alternative model has proposed the existence of several equipotent
stem cells that stochastically undergo symmetric division, which could equally explain the
observed return to monoclonality (Loeﬄer et al., 1997). Symmetric division gives rise to
either two new stem cells or two partially committed progenitors. However, asymmetric
divisions are postulated to predominate in the intestinal stem cell population, with the
daughter cells adopting divergent fates (i.e. one stem and one committed progenitor)
(Scoville et al., 2008).
Two recent studies have demonstrated that, contrary to the widespread conﬁdence in
prevalence of asymmetric stem cell division, the majority of intestinal stem cell divisions
occur in a symmetric fashion thus creating a steady-state asymmetry on the populational
level. Lopez-Garcia et al. (2010) and Snippert et al. (2010) have conducted mathemat-
ical analyses of long-term lineage tracing of recombination events resulting in reporter
gene activation. The observed patterns of clonal expansion and monoclonal conversion
are consistent with the existence of equipotent stem cell populations predominantly un-
dergoing symmetric divisions. In this scenario, stem cell loss due to production of two
committed progenitor cells is compensated by symmetrical divisions generating two stem
cells. As a result, monoclonal conversion is achieved due to neutral competition between
the existing stem cells rather than expansion of the ‘master’ stem cell (Lopez-Garcia et
al., 2010; Snippert et al., 2010). While both groups have stated that their conclusions do
not disprove the existence of a hypothetical quiescent ‘master’ stem cell, its activity does
not seem to have a substantial inﬂuence on the steady-state homeostasis of the crypt stem
cell population. Notably, while Snippert et al. have used Lgr5-driven Cre recombinase to
activate the reporter gene, Lopez-Garcia et al. have employed the AhCreER recombinase,
which is expressed in wider stem and progenitor cell populations. The similarity between
the two models derived from these experimental approaches implies that even if Lgr5+
cells are not the only stem cells in the crypt, they represent the major driving force behind
the crypt repopulation.
The prevalence of symmetric divisions within the stem cell population has challenged
another common view. It has been generally agreed that certain mechanisms are re-
quired to protect the stem cell DNA from the inevitable errors during replication and
environment-induced mutagenesis. Two such mechanisms have been observed in other
stem cell systems. The ﬁrst mechanism involves a very slowly cycling stem cell, which
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produces actively proliferating progeny. The stem cell thus undergoes a limited num-
ber of cell divisions during the lifetime of an organism and in that way is protected
from replication-induced mutagenesis. Such a mechanism has been reported in the bone
marrow (Cheng et al., 2000). An alternative mechanism ﬁrst proposed by Cairns (1975)
involves an asymmetric division and retention of the ‘immortal’ DNA strand by the newly
formed stem cell. In this way, the original DNA template is maintained unchanged in the
stem cell and thus prevents the accumulation of the errors produced during replication
(Cairns, 1975). Such a system has been proposed in a number of tissues including mam-
mary epithelium, brain and muscle (Karpowicz et al., 2005; Shinin et al., 2006; Smith,
2005). As mentioned earlier, label retaining cells have been observed in the small intesti-
nal epithelium, where they have been demonstrated to segregate their parental and newly
synthesised DNA strands (Potten et al., 2002). However, in view of the lack of asym-
metric stem cell division reported recently, it is unlikely that retention of the ‘immortal’
DNA strand takes place, at least in the majority of the intestinal stem cells. Consistent
with this, Schepers et al. (2011) have reported that Lgr5 expressing CBC cells segregate
chromosomes between the daughter cells at random. Additionally, a recent report has
provided conclusive evidence that both CBC cells and position +4 cells (deﬁned as the
ﬁrst cell just above Paneth cells) segregate their chromosomes randomly (Escobar et al.,
2011). Moreover, post-irradiation DNA label retention in this study has demonstrated
that the only crypt cells retaining high levels of the label at day 9 post labelling were
represented by the mature cell types. Conversely, CBC and position +4 cells displayed
heavily diluted label at day 9 that was completely lost by day 18 post labelling (Escobar
et al., 2011). Intestinal stem cells or at least the majority of them, therefore, represent
an unusual stem cell population. They are relatively fast-cycling, predominantly undergo
symmetric divisions and segregate their chromosomes at random. Yet, the stem cell pop-
ulation persists for the lifetime of an organism, undergoing 700-1000 cell divisions, while
demonstrating reasonably low mutability (Scheppers et al., 2011). Therefore in the cur-
rent absence of evidence in favour of a quiescent ‘master’ stem cell new mechanisms are
necessary to explain the protection of the stem cell genome integrity.
In addition to the lack of deﬁnitive stem cell markers, the absence of a deﬁned in
vitro system to culture intestinal crypts has hindered the progress in understanding the
pathways involved in intestinal stem cell homeostasis. A number of attempts to develop
such a system have provided insights into the factors and pathways required for stem
cell maintenance. These insights have been consolidated by Sato et al. (2009), who
generated an in vitro system capable of supporting the development and long-term growth
of intestinal organoids composed of crypt and villus-like domains encompassing a central
lumen. This system makes use of laminin-rich matrigel media to avoid detachment-
induced apoptosis (anoikis) and contains the Wnt agonist R-spondin, epidermal growth
factor (EGF), the Notch ligand Jagged and the BMP antagonist Noggin (Sato et al.,
2009). The components of this system therefore deﬁne the requirements for the intestinal
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stem cell niche. In order to sustain the long-term growth of the epithelium the intestinal
stem cells require the presence of the laminin-containing basal membrane, activated Wnt
and Notch pathways, activation of the EGF receptor and inhibition of BMP signalling.
Notably, the named components are suﬃcient to support the development of the crypt-
villus organoids from a single Lgr5 expressing cell further supporting the signiﬁcance of
Lgr5 as a marker of the functional stem cell (Sato et al., 2009).
The mesenchymal tissue underlying the epithelial sheet has been proposed to provide
a cellular niche for the intestinal stem cell (reviewed in Shaker and Rubin, 2010). In
terms of the particular signals required for intestinal stem cell function, mesenchymal
cells contribute some of the basal membrane components, such as collagen IV, laminin
and nidogen, providing structural support and the base for cell adhesion (Paulsson, 1992).
Additionally, stromal cells adjacent to the crypt base have been shown to express BMP
antagonists such as Noggin, Gremlin and Chordin thus creating a permissive environment
for stem cell proliferation (Haramis et al., 2004; Kosinski et al., 2007).
In addition to the suggested role of mesenchymal cells in creating the stem cell per-
missive environment, it has been demonstrated that within the crypt the stem cell niche
is provided by the Paneth cells. Along with the production of antimicrobial substances,
Paneth cells have been found to express the Wnt ligands Wnt3 and Wnt11, the EGF
receptor ligands Egf and Tgfα as well as the Notch ligand Dll4 (Sato et al., 2010). Signals
generated by the Paneth cells thus complement the signals provided by the mesenchyme
to generate an environment capable of supporting the intestinal stem cell as outlined
earlier. Of note, Lgr5 expressing cells have been found to position themselves so that to
maximise their contact area with Paneth cells (Sato et al., 2010). Consistent with the re-
quirement for the signals provided by Paneth cells for stem cell maintenance, Paneth cell
ablation via conditional inactivation of the Sox9 gene has been shown to result in crypt
loss coincidental with the expected Paneth cell turnover rate (Sato et al., 2010). Notably,
while single Lgr5 expressing cells are able to produce crypt-villus organoids in culture,
this happens with a frequency of about 7%. Conversely, heterotypic doublets consisting
of one Lgr5 expressing cell and one Paneth cell give rise to intestinal organoids with 60%
eﬃciency (Snippert et al., 2010). The improved plating eﬃciency of stem cell - Paneth
cell tandems could be explained by the Paneth cell-mediated secretion of the Wnt ligands.
Consistent with this hypothesis, the presence of the Wnt agonist R-spondin in the culture
media only seems able to amplify the pre-existing Wnt response induced by Wnt ligands
provided by the Paneth cells. Despite the ubiquitous presence of R-spondin, active Wnt
signalling has been found to be conﬁned to the crypt base of the cultured organoids, as
assessed by Wnt reporter expression. Conversely, addition of Wnt3 ligand to the media
has been shown to induce the organoid-wide expression of the Wnt reporter, coincidental
with expansion of the proliferative compartment and the loss of diﬀerentiated cell types
(Sato et al., 2010).
Finally, in vitro culture of the intestinal organoids has highlighted a requirement for
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Notch signalling in intestinal stem cell homeostasis (Sato et al., 2010). As mentioned in
the previous section, suppression of Notch signalling using γ-secretase inhibitors has been
shown to abolish cell proliferation and induce diﬀerentiation along the secretory lineage
(van Es et al., 2005b). Conversely, expression of constitutively active Notch1 receptor
has been reported to induce a dramatic increase in cell proliferation, while suppressing
cell diﬀerentiation (Fre et al., 2005). However, expression of constitutively active Notch1
receptor in the intestinal epithelium lacking Tcf4 was unable to rescue ablation of the
proliferative compartment caused by a dearth of Wnt signalling (Fre et al., 2009). It
appears, therefore, that a combination of Wnt and Notch signals is required to maintain
cell proliferation in the crypt. Notably, activated Wnt signalling has been reported to
induce Notch signalling as judged by the increased expression levels of the Notch target
gene Hes1 in intestinal adenomas (van Es et al., 2005b). Conversely, neither blocking nor
activation of Notch signalling seems to aﬀect the extent of Wnt pathway activation (Fre
et al., 2005; van Es et al., 2005b). Together, these observations suggest a model (Figure
1.3), where high levels of Wnt signalling at the bottom of the crypt induce expression
of Notch pathway components. By a yet unknown mechanism, some cells express Notch
ligands and thus escape Notch activation. These cells impose lateral inhibition on their
neighbours by activating Notch signalling and maintaining their proliferation. As cells
migrate up the crypt and down the Wnt ligand gradient, they lose their proliferative
potential and diﬀerentiate into one of the mature cell types. Those cells that escape
Notch activation diﬀerentiate along the secretory lineage, while the cells with activated
Notch signalling diﬀerentiate into enterocytes (reviewed in Crosnier et al., 2006).
1.2 Colorectal cancer
1.2.1 Incidence and environmental risk factors
Colorectal cancer (CRC) is the third most common cancer in UK (excluding non-melanoma
skin cancer). CRC is more common in men than women, and its incidence has remained
relatively unchanged during the last decade. Although the 10-year survival rate has im-
proved nearly two-fold in the past 40 years, CRC still is the second most common cause of
cancer-related mortality after lung cancer (Cancer Research UK). Environmental factors
suggested to increase the risk of developing CRC include diet rich in red and processed
meat (Norat et al., 2000) and poor in natural ﬁbres (Park et al., 2005), lack of physical
activity (Wolin et al., 2011), obesity (Moghaddam et al., 2007), smoking (Liang et al.,
2009) and alcohol consumption (Fedirko et al., 2011).
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1.2.2 Genetic predisposition to CRC
It is estimated that 20-25% of all CRC cases have a familial hereditary origin, while 5-10%
of all cases are inherited with a mendelian ratio, indicating an autosomal dominant na-
ture of the mutation (Lynch and de la Chapelle, 2003). Hereditary syndromes conferring
susceptibility to CRC development have provided invaluable insights into the causes and
natural history of CRC. Hereditary CRC syndromes are classiﬁed into two major cate-
gories depending on the presence of intestinal polyps. Polyposis syndromes are, in turn
subdivided into adenomatous and hamartomatous polyposis based on the predominant
tissue within the polyps.
1.2.2.1 Familial adenomatous polyposis (FAP)
The individuals diagnosed with FAP develop hundreds to thousands of ﬂorid colonic
adenomas at an early age, predominantly composed of epithelial cells. By the mean age
of 40 years high adenoma burden results in the development of adenocarcinoma in nearly
100% of cases. Tumours from such patients are commonly characterised by aneuploidy
and chromosomal instability. They typically carry mutations in a range of important
oncogenes and tumour suppressors such as APC, KRAS and P53 (reviewed in Lynch and
de la Chapelle, 2003). In 1991 Groden and colleagues discovered that mutations in APC
(adenomatous polyposis coli) gene are implicated in the development of FAP (Groden et
al., 1991). Additionally, APC has been found to be mutated in 80% of early adenomas in
sporadic cases of CRC (Nagase and Nakamura, 1993). The position of the mutation within
the APC gene is known to aﬀect the manifestation of the syndrome. While mutations in
the second half of the last APC exone result in typical FAP symptoms, mutations earlier
in the gene, or in the most 5’ region, manifest as attenuated FAP (AFAP) characterised
by fewer and more proximal adenomas as well as a delayed adenoma formation (reviewed
in Sancho et al., 2004).
1.2.2.2 Hamartomatous polyposis syndromes
Hamartomatous polyposis syndromes are a group of four syndromes characterised by hy-
perplasia of otherwise normal tissue with predominant stromal component. This group
includes the juvenile polyposis syndrome (JPS), the Peutz-Jeghers syndrome (PJS), the
Bannayan-Ruvalcaba-Riley syndrome and Cowden’s disease (de la Chapelle, 2004). The
latter two syndromes are both linked to mutations within the PTEN gene and display a
substantial symptomatic overlap, suggesting that they might represent diﬀerent manifes-
tations of the same syndrome (Eng and Ji, 2003). Notably, although these two syndromes
have been shown to result in malignant carcinoma in a limited number of cases, gastroin-
testinal lesions developing in the patients are predominantly benign in nature and the
involvement of these syndromes in development of advanced CRC is yet to be conclu-
sively demonstrated (Merg and Howe, 2004). The other two syndromes (PJS and JPS),
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despite their low incidence, confer a substantial risk of colorectal cancer (de la Chapelle,
2004).
JPS patients develop between 50 and 200 polyps predominantly in rectosigmoid region
of the colon. The polyps in JPS patients diﬀer from ﬂorid FAP polyps in a spherical
morphology with smooth surface. Histologically, JPS polyps consist of mucous cysts
surrounded by stromal tissue with obvious chronic inﬂammation response (Rashid et al.,
2000). The mutations most commonly associated with JPS have been found to occur in
SMAD4 (Howe et al., 1998) and BMPR1A (Howe et al., 2001) genes.
Individuals with PJS develop benign hamartomatous polyps in the gastrointestinal
tract, which are characterised by cystically dilated glands with a prominent presence of
mucus overproducing Goblet cells (Tomlinson and Houlston, 1997). 50% of PJS cases are
linked to a mutation in the LKB1 gene (Lim et al., 2003).
1.2.2.3 Hereditary nonpolyposis colorectal cancer
Hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome accounts for
2.5-5% of all CRC depending on the deﬁnition (de la Chapelle, 2004). This syndrome is
characterised by the development of CRC in the absence of marked intestinal polyposis
with a relatively late onset (Hampel et al., 2005). A distinctive feature of HNPCC tumours
is microsatellite instability (as opposed to chromosomal instability in FAP) (Thibodeau
et al., 1993). Consistent with this, HNPCC is strongly associated with mutations in mis-
match repair (MMR) genes such asMLH1, MSH2, MSH6, PMS1 and PMS2 with the ﬁrst
two genes accounting for 90% of all mutations in HNPCC cases. Microsatellite instability
caused by deﬁciency in MMR is then thought to accelerate the rate of mutagenesis.
These three groups of hereditary syndromes predisposing to colorectal cancer exem-
plify defects in diﬀerent functional groups of genes as deﬁned by Kinsler and Vogelstein
(1998), namely ‘gatekeeper’, ‘landscaper’ and ‘caretaker’ genes. Malfunction of the gate-
keeper genes, such as APC, results in large number of benign polyps. As a result of their
abundance, some polyps progress to malignant cancer with nearly 100% penetrance. In
contrast to this, polyps in individuals with defects in caretaker genes (for instance, MMR
system genes) arise at a rate comparable to general population. However, due to the accel-
erated rate of tumourigenesis, these polyps are more likely to progress towards advanced
stages. Finally, defects in the landscaper genes leading to hamartomatous polyposis dis-
rupt the physiological microenvironment of epithelial cells thus creating permissive state
for cancer development (Kinzler and Vogelstein, 1998).
1.2.3 Major signalling pathways involved in CRC
Although familial cases of CRCs account only for about 20% of all cases, mutations in the
pathways implicated in the hereditary syndromes leading to CRC are commonly detected
in sporadic cases of CRC. Research into the causes of CRC-related syndromes, as well as
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mutational analysis of sporadic CRCs, has therefore provided insights into the signalling
pathways involved in initiation and progression of CRC (reviewed in Sancho et al., 2004).
1.2.3.1 Wnt signalling
Characterisation of the mutations within the APC gene in patients with FAP has provided
an early link between the Wnt pathway and CRC (Groden et al., 1991). As described ear-
lier in this chapter, APC is a central component of the destruction complex that targets
cytoplasmic β-catenin for proteasomal degradation (Figure 1.2). Loss of APC therefore
results in an inability to control cytoplasmic levels of β-catenin and, as a result, up-
regulation of the canonical Wnt pathway target genes (reviewed in Giles et al., 2003).
Although FAP represents a small proportion of all CRC cases, APC mutations are de-
tected in 80% of CRC cases (Nagase and Nakamura, 1993). Additionally, mutations in
β-catenin that render it resistant to proteasomal degradation have been observed in 10%
of CRC (Morin et al., 1997). Remarkably, mutations in β-catenin and APC appear to be
mutually exclusive suggesting complementarity of Wnt activating mutations. However, β-
catenin activating mutations are more common in small adenomas and under-represented
in invasive carcinomas, indicating that APC might have other tumour suppressor roles in
addition to β-catenin degradation (Samowitz et al., 1999). Interestingly, although other
Wnt pathway components, such as AXIN and certain WNT ligands, have been found
mutated or misregulated in other cancers, the role of these mutations in CRC appears to
be insigniﬁcant (reviewed in Giles et al., 2003). Notably, mutations leading to aberrant
activation of the Wnt pathway are the only genetic aberrations observed in early pre-
malignant stages of CRC such as aberrant crypt foci and early adenomas (Powell et al.,
1992). This suggests that aberrant activation of Wnt signalling is an early event in CRC
natural history.
A number of animal models targeting Wnt pathway components have been generated
in order to recapitulate FAP symptoms and CRC development in a controlled environ-
ment (reviewed in Heyer et al., 1999). An N-ethyl-N-nitrosourea (ENU) screen by Su et
al. (1992) yielded the ﬁrst mouse model of the intestinal carcinogenesis, termed Multiple
Intestinal Neoplasia (MIN). These mice have been found to carry a nonsense-mutation
in codon 850 of Apc resulting in a truncated protein. Mice heterozygous for the ApcMIN
allele have a shortened lifespan and develop numerous adenomas across the gastrointesti-
nal tract (Su et al., 1992). Similarly, mice with a heterozygous truncating mutation in
codon 716 of Apc gene (Apc∆716) developed multiple intestinal adenomas (Oshima et al.,
1995). Somewhat in contrast to these two studies, mice with a mutation at codon 1638
of Apc gene (Apc1638N) developed far fewer intestinal tumours, which were nonetheless
capable of progressing towards carcinoma (Fodde et al., 1994). These mice also displayed
a range of extra-intestinal phenotypes similar to those found in FAP patients. The obser-
vation that distinct mutations in the murine Apc gene manifest in diﬀerent ways reﬂects
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the heterogeneity of the symptoms observed in FAP patients. Deletion of exon 3 of β-
catenin resulting in dominant stable form of the protein has also been reported to cause
an intestinal neoplasia phenotype similar to the one observed in Apc∆716 mice (Harada
et al., 1999). Notably, mutational analysis of adenomas arising in Apc1638N mice have
demonstrated that the only mutation consistently present across the majority of tumours
is the loss of the intact Apc allele, further supporting the idea that aberrant activation
of the Wnt pathway is suﬃcient to initiate CRC (Smits et al., 1997). It should be noted,
however, that while in mouse models mutation of the intact Apc allele usually results
in complete inactivation of Apc tumour suppressor activity, in human cancers selection
favours mutations that retain residual β-catenin degradation activity of APC. This rela-
tionship between APC mutations and the level of Wnt activation has been formulated into
the ‘just-right’ model, which postulates that an ‘optimal’ level of Wnt signal is required
for tumour development with both ‘too-low’ and ‘too-high’ levels of signalling conferring
selective disadvantage (reviewed in Fodde et al., 2001).
Notably, all mouse models based on Apc inactivation predominantly develop tumours
in the small intestine. This is in contrast to the pattern of intestinal tumourigenesis in
humans, where the majority of cancer arise in the large intestine. Additionally, large
numbers of polyps arising in these models and extra-intestinal manifestations results in
a drastically reduced animal lifespan thus limiting the time available for cancer progres-
sion. As a result, only very few adenomas progress to carcinoma stage and virtually no
metastatic spread is detected in these animals (Heyer et al., 1999). Generation of a condi-
tional Apc allele, whose truncation is induced by the expression of the Cre-recombinase,
has made it feasible to overcome these limitations by conﬁning Apc loss to a speciﬁc tis-
sue and even to a particular region or cell type within the gastrointestinal tract (Shibata
et al., 1997). Indeed, expression of the Cre-recombinase under the control of the CDX2
promoter elements along with a conditional Apc allele resulted in preferential adenoma
and carcinoma development in the colon and distal small intestine (Hinoi et al., 2007).
1.2.3.2 RAS-RAF-MAPK signalling
Another signalling pathway, whose components are commonly found to be mutated in
CRC is the RAS-RAF-MAPK pathway. The Rat Sarcoma viral oncogene homology (RAS)
family is represented by Harvey (H-RAS), Kirsten (K-RAS) and neuroblastoma (N-RAS)
members. RAS proteins are a group of small G-proteins that are activated by various
extracellular stimuli and act as GDP/GTP controlled switches. RAS proteins assume
active or inactive states, when bound by GTP or GDP respectively. The GTP-bound
active form of RAS is continuously converted to the inactive state via dephosphorylation
of GTP to GDP by GTPase Activating Proteins (GAPs). Return to the active state is
promoted by Guanine nucleotide Exchange Factors (GEFs) that facilitate exchange of
GDP for GTP. Once bound by GTP, the active form of RAS is able to phosphorylate one
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of the many downstream eﬀectors. The most characterised pathway downstream of RAS
involves sequential signal transduction between RAF, MEK and mitogen-activated pro-
tein kinases (MAPK). Phosphorylated MAPK kinases are translocated into the nucleus,
where they activate a range of transcription factors resulting in predominantly mitogenic
response (reviewed in Malumbres and Barbacid, 2003).
Mutations resulting in constitutively activated K-RAS have been found to occur in
over one third of all CRCs (Bos et al., 1987). Additionally, activating mutations in the
B-RAF gene have been found in 20% of CRC with functional K-RAS (Rajagopalan et
al., 2002). Mutations in either K-RAS or B-RAF are predominantly found in tumours
larger than 1 cm and are rare in smaller lesions (Vogelstein et al., 1988). This observation
suggests that aberrant activation of RAS-RAF-MAPK pathway is more likely to be ac-
quired at later stages of CRC genesis rather than at initiation (Rajagopalan et al., 2002).
This notion of K-RAS and B-RAF mutations as drivers of cancer progression have been
supported by a number of animal models. Early studies of transgenic expression of onco-
genic forms of k-Ras in postmitotic villus as well as proliferating crypt cells has revealed
no increase in tumourigenesis (Coopersmith et al., 1997; Kim et al., 1993). In contrast, a
report from Janssen et al. (2002) has shown that transgenic expression of oncogenic k-Ras
under the control of Villin promoter in murine intestine resulted in a limited number of
tumours ranging from ACF to invasive adenocarcinomas (Janssen et al., 2002). However,
expression of a k-Ras oncogene from the Villin promoter results not only in activation of
k-Ras, but also its over-expression. Expression of a k-Ras oncogene from the endogenous
promoter would, therefore, represent a more genuine model of k-Ras activation. Indeed,
expression of an oncogenic k-Ras at endogenous locus has failed to alter normal home-
ostasis of the intestinal epithelium (Guerra et al., 2003). However, conditional expression
of the same oncogenic form of k-Ras in the context of heterozygous Apc loss accelerated
Wnt-driven tumourigenesis and conferred more invasive phenotype compared to tumours
with native k-Ras (Sansom et al., 2006). Together, these observations further support
the notion that aberrant activation of RAS-RAF-MAPK pathway plays a crucial role in
progression of pre-existing tumours.
1.2.3.3 TGFβ and BMP signalling
As described earlier, TGFβ and BMP ligands are both members of a larger family of
TGFβ cytokines. Although TGFβ and BMP ligands diﬀer in the receptor aﬃnities and
preferential activation of receptor regulated R-SMAD proteins, they share the same sig-
nal transduction machinery in the form of the SMAD4 eﬀector protein (Shi and Mas-
sague´, 2003). BMP and TGFβ signalling, therefore, exert a similar anti-proliferative,
pro-apoptotic and pro-diﬀerentiation eﬀect on the target tissue (Waite and Eng, 2003).
Consistent with this, mutations in the BMP receptor BMPR1A and SMAD4 have been
implicated in Juvenile polyposis syndrome associated with increased risk of CRC (Chow
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and Macrae, 2005). Additionally, TGFβ mutations are frequently acquired in the course
of adenoma-carcinoma progression (Fearon and Vogelstein, 1990). The most commonly
inactivated component of TGFβ in CRC is the TGFβ receptor type II (TGFβR2) (Grady
et al., 1999; Markowitz et al., 1995). SMAD proteins 2 and 4 have also been found to
be mutated in 6% and 16% of colon carcinomas respectively (Eppert et al., 1996; Takagi
et al., 1996). A number of mouse models targeting components of TGFβ pathway failed
to detect an increase in colon neoplasia (reviewed in Dunker and Krieglstein, 2000). The
SMAD4 protein represents an exception to this rule as mice with heterozygous loss of
SMAD4 have been reported to develop duodenal polyps not dissimilar to polyps in hu-
man JPS (Takaku et al., 1999). Similarly, overexpression of the BMP inhibitor Noggin
resulted in development of polyps similar to those found in JPS patients (Haramis et al.,
2004). Notably, heterozygous loss of SMAD4 and homozygous deletion of TGFβ1 have
been reported to accelerate progression of pre-existing lesions towards advanced carci-
noma (Engle et al., 1999; Takaku et al., 1998). Taken together, these studies indicate
that abrogation of TGFβ and BMP signalling is essential for CRC progression. This idea
is consistent with the observation that TGFβR2 mutations are mainly observed in cancers
at or after the adenoma/carcinoma transition stage (Markowitz et al., 1995). Remarkably,
TGFβ signalling has been reported to have an opposite role in advanced cancer as TGFβ
activation has been shown to contribute to metastatic disease (reviewed in Roberts and
Wakeﬁeld, 2003).
1.2.4 The genetic model of cancer progression
Analysis of the genetic alterations present at various stages of the CRC has revealed
a number of commonly recurring mutations. Based on these observations, Fearon and
Vogelstein (1990) proposed a model of cancer progression from benign adenoma to carci-
noma and, ﬁnally, metastatic disease. This model postulates that gradual accumulation
of genetic aberrations in a range of tumour suppressor and oncogene genes is required
for cancer to progress towards a malignant disease. Although alterations in speciﬁc genes
are more likely to be found at particular stages, their progressive accumulation is what
is required for disease progression, rather than particular chronological order. Neverthe-
less, the model proposed by Fearon and Vogelstein had suggested a likely sequence of the
events based on the likelihood of the genetic alterations. As described earlier, aberrant
activation of the Wnt pathway (most frequently due to loss of APC tumour suppressor) is
commonly seen as a pivotal event in CRC initiation. Further acquisition of an activating
mutation in the RAS oncogene is viewed as the next common step enabling progression
to later stages of adenoma. Loss of the long arm of chromosome 18 is also frequently ob-
served towards more advanced stages of adenoma development. This has been associated
with the loss of candidate tumour suppressor gene Deleted in colorectal cancer (DCC)
located on 18q (Fearon et al., 1990). Later studies have also implicated the TGFβ and
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BMP pathways eﬀectors SMAD2 and SMAD4 as likely tumour suppressors mapped to
chromosome 18q (Eppert et al., 1996; Thiagalingam et al., 1996). Finally, Fearon and Vo-
gelstein proposed the loss of short arm of chromosome 17, which contains the TP53 locus
encoding p53 tumour suppressor, as a ﬁnal step required for cancer progression towards
malignant disease (Fearon and Vogelstein, 1990). Indeed, p53 has been found mutated
in nearly 50% of colorectal cancers (reviewed in Iacopetta 2003). Consistent with the
model proposed by Fearon and Vogelstein, expression of the mutant form of p53 has been
reported in nearly 50% of carcinomas, while in less than 10% of adenomas, supporting
the loss of p53 function as a late event in adenoma-to-carcinoma progression (Purdie et
al., 1991).
Curiously, even considering the simpliﬁed model proposed by Fearon and Vogelstein,
for CRC to arise and progress to a malignant disease would require an accumulation of at
least seven independent genetic alterations (loss of both copies of three tumour suppressors
and an oncogene activation). Based on the mutation rate in normal tissue, this amount
of mutations is unlikely to be achieved during the lifetime of an individual (Kinzler and
Vogelstein, 1996). However, a mechanism exists that allows cancers to overcome this
limitation. In particular, CRCs initiated by APC loss are characterised by ‘chromosomal
instability’ (CIN) that drastically increases the level of chromosomal rearrangements and
thus accelerates accumulation of the genetic alterations needed for cancer progression.
Moreover, chromosomal instability in these tumours has been directly linked to the loss
of APC function (reviewed in Fodde et al., 2001).
An alternative pathway for cancer progression accounting for nearly 15% of CRC cases
is exempliﬁed by cancers developed in HNPCC, where microsatellite instability (MIN) due
to the defects in mismatch repair system results in mutation rate two to three fold higher
that in wild type cells and, as a result, accelerated cancer evolution (Jass et al., 2002).
Remarkably, although mutations in MIN cancers aﬀect a set of genes distinct from those
in CIN cancer, they tend to target the same four major signalling pathways, namely,
Wnt/β-catenin, RAS-RAF-MAPK, TGFβ and p53 further highlighting the importance
of these pathways in CRC pathogenesis (reviewed in Laurent-Puig et al, 1999).
1.2.5 Cancer stem cell concept and the intestinal stem cell as a
cell of origin in CRC
The concept of a cancer stem cell has become increasingly popular over the past ﬁve
decades (reviewed in Reya et al., 2001; Wicha et al., 2006). This concept has two major
implications. The ﬁrst is the notion that tumours are comprised of heterogeneous cell
populations with varying ability to initiate new tumours (clonogenicity). The second
implication stems from the hypothesis that cancers arise from cells with stem cell like
properties. These two implications are causing a paradigm shift in a number of aspects
of cancer biology such as models of carcinogenesis, early cancer detection and prevention,
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therapeutic target discovery, drug resistance, metastasis and others (Wicha et al., 2006).
A range of cancer stem cell targeting strategies speciﬁc for colorectal cancer have been
reviewed by de Sousa et al. (2011)
The notion that cancer cells have a limited capacity to form colonies in the host en-
vironment was ﬁrst reported in a number of studies using mouse myeloma cells. It has
been demonstrated that only a minor fraction of isolated leukaemic cells are able to form
colonies both in vitro and in vivo (Bruce and van der Gaag, 1963; Park et al., 1971). Two
alternative explanations were proposed to account for the limited clonogenicity of the
leukaemic cells. Either cancer cells in their totality had overall low clonogenic capacity,
or a particular small subset of cells was enriched for cancer-initiating cells with the rest of
the cells in cancer being non-clonogenic. This duality has been to some extent resolved by
Bonnet and Dick (1997). Using human acute myeloid leukaemia (AML) cells, Bonnet and
Dick demonstrated that, when transplanted in non-obese diabetic/severe combined im-
munodeﬁciency disease (NOD/SCID) mice, AML cells expressing the cell surface marker
CD34 but not CD38 (CD34+CD38− cells) were the only cell population able to induce
AML (Bonnet and Dick, 1997). Although widely accepted in blood cancers, the idea of
cancer stem cell in solid cancers is more controversial (reviewed in Hill, 2006). Cancer cells
of CRC has proven to be as elusive as from any other solid cancer, if not more so. A num-
ber of studies using transplantation of deﬁned populations of CRC cells into NOD/SCID
mice have suggested a limited number of cell surface markers alleged to identify cancer
stem cells. One of the ﬁrst markers proposed to deﬁne the cancer stem cell population in
CRC was CD133 (also known as Prominin 1). Cells expressing CD133 have been found
to be 200-fold enriched for cancer initiating cells compared to the CD133− population
(O’Brien et al., 2007; Ricci-Vitiani et al., 2007). A similar study by Dalerba et al. (2007)
has shown that high expression levels of epithelial cell adhesion molecule (EpCAM) as
well as expression of cell surface marker CD44 deﬁne a subpopulation of cells with high
ability to initiate tumours morphologically comparable to the original lesion (Dalerba et
al., 2007). A number of other colorectal cancer stem cell markers such as CD166, CD29,
CD24 and Lgr5 have been suggested, based on their expression in spheroid cultures de-
rived from CD133+ cells (Vermeulen et al., 2008). These results, however, should be
taken with caution, especially in the light of the recent study by Shmelkov et al. (2008).
Shmelkov et al. have observed wide-spread expression of CD133 in human and mouse
metastatic colon cancers, undermining its candidacy as a marker for rare cancer stem
cells. Moreover, CD133− cells from metastatic colon cancer have been found to possess
equal if not greater tumourigenic capacity than CD133+ cells (Shmelkov et al., 2008).
Although CRC stem cell surface markers such as CD44, CD166 and others are unlikely
to be essential for cancer cell survival and therefore may not represent valuable therapeutic
targets, with advances in our understanding of such markers in CRC they may provide a
useful tool in developing therapies that would selectively target this cell population.
The second implication of the cancer stem cell concept is that cancers arise from
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a particular population of cells with the stem cell-like properties. A number of char-
acteristics make normal tissue stem cells particularly favourable targets for malignant
transformation. In fast regenerating tissues, such as intestinal epithelium diﬀerentiated
cells are replace in a matter of several days. Unlike diﬀerentiated sells, adult stem cells
are retained in the tissue over longer periods of time, which theoretically enables them to
accumulate the mutations required for neoplastic transformation. Furthermore, somatic
stem cells are capable of self-renewal, have activated anti-apoptotic pathways, are respon-
sive to growth signals and express telomerase - hallmarks commonly shared by cancer
cells (Wicha et al., 2006). A study by Barker et al. (2009) has made a strong case in
favour of a stem cell origin of CRC. Using a Cre recombinase expressed in Lgr5 positive
cells Barker et al. have demonstrated that selective induction of Apc loss in the small
intestinal stem cells resulted in rapid development of macroscopic adenomas. Conversely,
Apc deﬁcient lesions originating from transit amplifying cells displayed impeded growth
and rarely progressed beyond the microadenoma stage (Barker et al., 2009). A recent
study by Merlos-Suarez et al. (2011) have reported that a gene expression signature of
normal intestinal stem cells is shared by a subpopulation of CRC cells. This subpop-
ulation has been shown to initiate tumour growth in immunodeﬁcient mice with high
frequency. Additionally, cells with this gene expression signature has been shown to be
enriched in recurrent and metastatic CRCs (Merlos-Suarez et al., 2011). Together, these
observations further support the relevance of the cancer stem cell concept in CRC and
could potentially lead to the development of cancer stem cell targeted therapies.
1.2.6 The Wnt pathway as a therapeutic target in CRC
1.2.6.1 Conventional therapies in CRC treatment
The exact treatment plan for CRC patients in UK is normally devised by a multidisci-
plinary team of specialists including surgeons, oncologist, histopathologist, radiologist and
others. The treatment plan is based on the range of factors such as stage and location of
the tumour as well as ﬁtness of the patient (NICE guidelines, 2004). Invasive surgery to
remove the tumour is undertaken in approximately 80% of cases and is the primary option
in CRC management. Although not used routinely, pre-operative radiotherapy in a small
number of cases has been shown to substantially reduce the risk of local recurrence. How-
ever, its use is limited by radiotherapy-related adverse eﬀects. Adjuvant chemotherapy
is recommended in invasive cancers that have spread to local lymph nodes. In cases of
advanced cancer with metastatic spread surgical removal of the primary tumour may be
recommended to alleviate symptoms such as bowel obstruction or substantial rectal bleed-
ing as well as palliative chemotherapy. In a limited number of cases metastatic spread to
the liver is also managed by surgical resection of the liver (NICE guidelines, 2004).
The standard chemotherapy for CRC involves six month intravenous treatment with 5’-
ﬂuorouracil and folinic acid (FUFA) (NICE guidelines, 2004). Two other drugs commonly
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used in treatment of advanced CRC are topoisomerase I inhibitor Irinotecan and platinum-
based alkylating agent Oxaliplatin (Cancer Research UK). General cytotoxicity caused
by these drugs during the treatment is often accompanied by substantial side eﬀects. A
number of novel therapies targeting speciﬁc signalling pathways are being introduced in
an attempt to reduce the oﬀ-target side eﬀects. Examples of such drugs approved for
CRC treatment include a monoclonal antibody against epidermal growth factor receptor
(EGFR), Cetuximab, and an EGFR tyrosine kinase domain inhibitor, Geﬁtinib (Cancer
Research UK).
1.2.6.2 Wnt signalling as a therapeutic target
Despite the Wnt pathway being aberrantly activated in 90% of CRC cases, therapies
targeting the Wnt pathway remain very limited (Gehrke et al., 2009). A number of
factors contribute to the lack of the Wnt targeting therapies, such as potentially high
toxicity and the complexity of pathway regulatory mechanisms. At the same time, the
modular nature of the Wnt pathway provides multiple points of intervention to alter the
level of signalling. Wnt signalling, therefore, may be potentially modulated at many
levels, such as ligand expression, processing and secretion, ligand binding to the receptor
complex, β-catenin degradation, formation of the nuclear complex between β-catenin and
transcription factors as well as expression of downstream Wnt targets.
Although Wnt activation in the majority of CRCs is due to defects in the mecha-
nisms regulating β-catenin degradation, a number of studies have also observed elevated
levels of Wnt ligand expression in CRC cell lines (Baﬁco et al,. 2004; Gregorieﬀ et al.,
2005; Holcombe et al., 2002). The use of a monoclonal antibody against WNT-1 has
been demonstrated to induce an apoptotic response in CRC cells even in the presence
of downstream mutations in APC or β-catenin (He et al., 2004a). Further, soluble Wnt
inhibitors such as secreted frizzled-related proteins (SFRPs) capable of binding Wnt lig-
ands and preventing their interaction with the receptor complex have been found to be
epigenetically silenced in a range of CRC cells and primary tumours. Notably, restoration
of SFRP function in CRC cells with mutations in either APC or β-catenin have been
found to attenuate Wnt signalling and inhibit colony formation (Suzuki et al., 2004). An-
other Wnt inhibitor family of proteins Dikkopf (DKK) has been found silenced in CRC
cells and primary cancers. Over-expression of DKK in CRC cells even with mutations in
APC and β-catenin has been demonstrated to suppress Wnt signalling and impair colony
formation (Sato et al., 2007). It should be noted, however, that the above studies used
endogenous expression of the Wnt inhibitors. It is unclear, therefore, if treatment with
exogenous inhibitors would yield comparable results.
A number of approaches targeting the components of the Wnt receptor complex, such
as Frizzled and Dishevelled proteins, have been found eﬀective in suppressing tumourige-
nesis in a range of cancer cell lines of various tissue origin (Fujii et al., 2007; Merle et al.,
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2004; Nagayama et al., 2005). However, despite increased expression of Frizzled receptors
in colon tumours (Holcombe et al., 2002), no studies have yet demonstrated the feasibility
of targeting Wnt receptor components in CRC.
Reﬂecting diﬀerent mechanisms that lead to β-catenin accumulation (i.e. stabilising
mutations in βcatenin or loss-of-function mutations in the components of the destruction
complex) therapeutic approaches at the level of β-catenin turnover complex may either
target the oncogenic form of β-catenin or aim to restore the function of the β-catenin
destruction complex. Both approaches present a signiﬁcant challenge. In the case of
stabilised β-catenin a number of ‘proof of concept’ studies have demonstrated that selec-
tive deletion of stabilised β-catenin in CRC cells can suppress clonal growth (Kim et al.,
2002). However, even more interestingly, some cell lines have been found to have lost their
reliance on Wnt signalling. In these cells targeting the stabilised β-catenin was successful
in suppressing the Wnt pathway, but appeared to have no eﬀect on the cell ability to
grow and form tumours in mouse xenografts (Chan et al., 2002; Kim et al., 2002). This
observation raises a concern that advanced cancers may overcome their requirement for
the activated Wnt signalling by acquisition of additional mutations.
Restoration of functionality to the β-catenin turnover complex is logistically challeng-
ing, especially in vivo, due to the ‘loss of function’ nature of the mutations involved. This
approach, therefore, would require introduction of a functional protein into cancer cells.
A study by Arenas et al. (1996) has provided an indication that this approach might
prove feasible in vivo as liposome-mediated delivery of an Apc-expressing construct sup-
pressed tumour incidence in ApcMIN mice (Arenas et al., 1996). An alternative approach
to restoration of the β-catenin turnover complex activity has been recently discovered that
bypasses the need for the introduction of the functional version of Apc. Two groups have
independently discovered a number of compounds that inhibit Tankyrase, a poly-ADP-
ribose polymerase that facilitated ubiquitin-mediated degradation of Axin. Inhibition of
Tankyrase by the given compounds results in stabilisation of Axin and the turnover com-
plex thus promoting β-catenin degradation even in cells with APC mutations (Chen et
al., 2009; Huang et al., 2009).
Glycogen synthase kinase 3 (GSK3) represents yet another potential target for the reg-
ulation of oncogenic β-catenin. Activation of GSK3β by diﬀerentiation-inducing factors
(DIFs) from Dictyostelium discoideum has been found to inhibit expression of the Wnt
target gene Cyclin D1 and suppress proliferation in a number of CRC cell lines including
those bearing activating mutations in β-catenin (Takahashi-Yanaga and Sasaguri 2009).
A number of alternative pathways of β-catenin degradation have been proposed as
therapeutic targets in Wnt-driven neoplasia. Chemically induced expression of Siah1, a
ubiquitin-ligase binding protein, has been shown to promote β-catenin degradation in a
GSK3β-independent manner and suppress proliferation of CRC cells bearing an oncogenic
form of β-catenin (Park et al., 2006). It should be noted, however, that Siah1 mediated
degradation still relies on functional APC and thus is unlikely to be eﬀective in APC
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deﬁcient cancers. Conversely, a small molecule compound Murrayafoline A has been
found to facilitate proteasomal degradation of β-catenin independent of GSK3β and APC
activity. Murrayafoline A has been found to be eﬀective in suppressing Wnt target gene
expression and proliferation of a number of CRC cell lines regardless of their APC status
(Choi et al., 2010).
In order to initiate transcription, the β-catenin/TCF complex interacts with a number
of transcriptional co-activators, such an acetyletransferases p300 and CBP (CREB bind-
ing protein). Targeting the interactions between β-catenin and TCF as well as various
co-activators and co-repressors may prove an attractive therapeutic approach for Wnt
signalling suppression. An obvious beneﬁt of targeting the Wnt pathway at such a late
stage is that it would allow modulation of the pathway even in the presence of upstream
APC and β-catenin mutations. A number of small-molecule compounds targeting β-
catenin/TCF interaction have been demonstrated to repress Wnt target genes and induce
apoptosis in CRC cells (Leproucelet et al., 2004). Similarly, the ﬂavonoid quercetin has
been shown to repress Wnt target genes by disrupting the interaction between β-catenin
and TCF. As a result, quercetin suppresses cell proliferation and promotes apoptosis in
CRC cells in a dose-dependent manner (Shan et al., 2009). Accordingly, quercetin has
been previously shown to reduce the number of chemically induced aberrant crypt foci in
rats (Matsukawa et al., 1997). A small molecule compound that disrupts interaction be-
tween CBP and β-catenin has been shown to induce apoptosis in CRC cells and suppress
polyp formation in ApcMIN mice (Emami et al., 2004).
Downstream Wnt target genes represent attractive therapeutic targets for the same
reasons that apply to the β-catenin/TCF nuclear complex. Targeting genes commonly up-
regulated in Wnt driven neoplasia may provide a tool to manipulate oncogenic eﬀects of
aberrant activation of the pathway rather than the pathway itself, thus reducing toxicity
and bypassing the upstream mutations. Concurrent inactivation of the Wnt target gene
c-Myc and Apc in transgenic mice has been found to attenuate the intestinal eﬀects of Apc
loss, such as increased proliferation and disruption of cell migration and diﬀerentiation
(Sansom et al., 2007b). Furthermore, antisense morpholino oligomer targeted against c-
Myc has been found eﬀective in suppressing the growth of lung and prostate cancer cells in
mouse xenografts, while being well tolerated by healthy individuals (Iversen et al., 2003;
Sekhon et al., 2008). Adenomas from ApcMIN mice have been demonstrated to express
high levels of matricellular protein Sparc, suggesting its Wnt-induced expression. In line
with this observation, Sparc deﬁciency in ApcMIN mice greatly reduced polyp formation,
most likely due to enhanced cell migration in normal small intestinal mucosa (Sansom et
al,. 2007a).
Advances in our understanding of the intestinal stem cell biology may lead to the
development of novel therapies targeted at the CRC stem cells. Wnt target genes proposed
as the intestinal stem cell markers, such as LGR5 and ASCL2 have been found expressed
in a fraction of cells in CRC, suggesting a possible overlap between normal and cancer
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stem cell marker genes (Becker et al., 2008; Jubb et al., 2006). Notably, ASCL2 knock-
down has been shown to induce cell cycle arrest in ASCL2 expressing CRC cells lines
(Jubb et al., 2006).
Epigenetic silencing of negative Wnt signalling regulators due to promoter hyperme-
thylation has been demonstrated to contribute towards aberrant activation of the Wnt
pathway. Particularly, a number of soluble Wnt inhibitors, such as DKKs, SFRPs or
WIF, have been shown to be epigenetically silenced in a range of cancers (See Ewan and
Dale (2008) for a summary). The use of DNA-methylation inhibitors may, therefore, have
a therapeutic beneﬁt in Wnt driven neoplasms. It should be noted, however, that the
comprehensive eﬀect of such a therapy is likely to aﬀect cellular processes beyond the
Wnt pathway. For instance, activation of silenced tumour suppressors may enhance the
anti-oncogenic eﬀect of Wnt signalling suppression.
Inhibition of the DNA methyl transferases (DNMTs) is a common approach used
in the reversion of aberrant DNA methylation. However, the use of DNMT inhibitors is
primarily restricted to blood cancers due to poor bioavailability in solid tumours (reviewed
in Sharma et al. 2010). Gene silencing caused by promoter methylation is mediated
by a group of methyl-DNA binding domain (MBD) proteins. These proteins bind to
methylated CpGs and recruit a range of proteins, such as histone methyl transferases and
histone deacetylases, which, in turn, establish repressive histone signature (reviewed in
Klose and Bird, 2006). Constitutive deletion of some MBD proteins (Mbd2 and Kaiso) in
ApcMIN mice have been shown to extend animal survival and suppress tumour formation
and growth (Prokhortchouk et al. 2006; Sansom et al., 2003). Of importance, mice
deﬁcient for Mbd2 or Kaiso showed no serious abnormalities, which makes MBD proteins
favourable potential therapeutic targets.
1.2.7 Use of mouse models in development of novel therapies
One of the obstacles slowing the development of therapies targeting Wnt signalling is the
lack of appropriate models for the drug target discovery, validation and testing. Over
the decades various human CRC cell lines have served as a platform for target validation
and drug testing. In order to assess the validity of a protein as a therapeutic target
or the eﬃciency of a drug, a number of cellular characteristics are examined in the re-
sponse to drug administration. These include cell proliferation, apoptosis, clonal survival,
anchorage-independent growth and the ability to form tumours when transplanted into
immunodeﬁcient mice. These approaches, however, suﬀer from a range of shortcomings.
Some of the CRC cell lines were isolated decades ago and maintained in culture ever
since. Considering the high inherent mutation rate and genomic instability in cancer
cells, it is likely that these cell lines have acquired numerous mutations and chromosome
rearrangements and only remotely resemble the original cancers they were isolated from.
Additionally, in vitro conditions lack a range of factors that cancer cells are exposed to
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in vivo. A cocktail of growth factors, interactions with stromal cells and extracellular
matrix all can aﬀect cancer cell survival and modulate the eﬀects of the treatment and
should be taken into account during testing of novel therapies. This is considered to be
of particular importance for cancer stem cells (Watt and Driskell, 2010)
While transplantation of cancer cells into immunodeﬁcient mice addresses some of
the limitations of the in vitro conditions, it is not suﬃcient to recapitulated the native
microenvironment of the cancer. The standard xenotransplantation procedure involves
CRC cells being injected subcutaneously into mouse ﬂanks. While this might, to some
extent, model the process of metastatic spread, the interactions between the xenograft
and surrounding tissue are likely to diﬀer signiﬁcantly from those observed between a
primary tumour and its microenvironment in the tissue of origin. Physiological processes,
such as angiogenesis, immune response and secretion of the growth regulating factors by
the stromal cells play a crucial role in cancer survival. Due to these factors, naturally
arising tumours are likely to have a number of advantages over a xenograft in terms of
modelling the tumour response. This is particularly relevant when transplanting human
cancer cells into mice as mouse tissue may lack the whole range of factors needed for
human cell survival (Kelly et al., 2007). As a result, xenotransplanted cells may be more
susceptible to the anti-cancer therapy and their extensive use as a testing platform may
account for a high failure rate of novel anti-cancer drugs at the transition between animal
and human studies (Olive et al., 2009).
The combination of these factors highlights the need for the models that would faith-
fully recapitulate the microenvironment and evolution of human cancer in animal models.
Despite clear diﬀerences in physiology and genetics, mice represent an ideal organism to
model human neoplasia due to well establishes transgenic approaches and their relatively
short reproductive period. A good genetic model of mouse colorectal carcinogenesis should
reproducibly generate tumours within a short time frame, which are able to progress
through all the stages of carcinoma development to metastatic disease and recapitulate
the evolutionary history of human neoplasia in terms of the accumulated mutations.
A number of mouse models that make use of germline mutations in Apc gene have
been described earlier in this chapter. While the ApcMIN mouse in particular has made
an invaluable contribution to our understanding of CRC initiation and development, a
substantial diﬀerences exist between carcinogenesis in ApcMIN and human intestine. The
major diﬀerences concern the tumour distribution and extent of progression to advanced
stages (reviewed in Heyer et al., 1999). In response to these diﬀerenced more advanced
models combining mutations in diﬀerent genes are being constantly generated in order to
‘humanise’ mouse cancer.
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1.2.7.1 Constitutive transgenesis
Generation of targeted deletion of hypoxanthine-guanosine phosphoribosyl transferase
(HPRT) in 1987 marked the beginning of targeted transgenesis technology in mice (Kuehn
et al., 1987). Numerous mouse models of constitutive gene deletion have been generated
since in order to model various conditions and study gene function in vivo. While con-
stitutive transgenesis has provided many insights into the physiological role of numerous
genes, it has also revealed a number of intrinsic limitations associated with constitutive
gene loss.
The ﬁrst limitation is concerned with the absolute requirement of many genes for
normal embryonic development. As a result, constitutive loss or activation of an important
developmental regulator is likely to prevent the study of its function in adult tissues. This
is particularly relevant in cancer, where many tumour suppressors and oncogenes are vital
for normal development. The second limitation is associated with pan-organism loss of the
targeted gene. This makes it diﬃcult to study the eﬀects of gene loss in a particular tissue
if the gene inactivation causes severe complications elsewhere in the organism. Finally,
targeting a gene in all cells of the organism is likely to mask the eﬀects of gene loss in
speciﬁc cell types as well as aﬀect the interaction between diﬀerent cell types.
1.2.7.2 Conditional transgenesis
In order to overcome the limitations imposed by constitutive transgenesis, a number of
conditional transgenic approaches have been developed, which allow more intricate control
over gene manipulation. The simplest case of conditional transgenesis is exempliﬁed by the
use of tissue-speciﬁc promoters to drive the expression of a gene of interest. This provides
spatial control over the gene expression and circumvents the ‘side eﬀects’ outside the
target tissue. Understandably, this approach is mainly restricted to gene overexpression
and, therefore, has a limited value for loss-of-function studies. Moreover, in the majority
of cases simply expressing a gene in a tissue-speciﬁc manner does not provide temporal
control and thus does not overcome possible developmental eﬀects. In relation to models
of CRC, this approach can be exempliﬁed by expression of the oncogenic form of K-Ras in
the murine intestinal epithelium under control of Villin promoter (Janssen et al., 2002).
To achieve temporal control over gene loss or activation, a switching mechanism is
required that would allow voluntary alteration of gene expression status. A number of
systems have been designed to provide such a mechanism. Among the most successful
conditional transgenesis systems are Cre-loxP (Causes recombination (Cre) - Locus of
crossover of bacteriophage P1 (loxP)), TetO (tetracycline operator) and Flp-Frt (Flp-Flp
recognition target). The basis of all these systems lies in two principal elements: the
inducible ‘eﬀector’ and the targeted gene. In the case of the Cre-loxP system the eﬀec-
tor component is represented by Cre recombinase. Cre is a DNA recombinase able to
speciﬁcally recognise 34 bp long nucleotide sequences from bacteriophage P1 and facil-
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itate recombination between them (Sternberg and Hamilton, 1981). Depending on the
loxP sites orientation, recombination results in either inversion or excision of the DNA
fragment enclosed between the sites. When loxP sites are placed unidirectionally so that
they ﬂank a crucial part of a gene or a whole gene, Cre recombinase expression would re-
sult in excision of that locus eﬀectively rendering the gene inactive. The Cre-loxP system
can equally be used to express constitutively activated oncogenes. To this end, a tran-
scription terminating stop-cassette ﬂanked by loxP sites is inserted before the gene, whose
expression needs to be induced. When needed, Cre recombinase mediated excision of the
loxP ﬂanked region eliminates the stop cassette and allows gene expression to resume.
Two main approaches are commonly exploited to control Cre recombinase activity.
Transcriptional control makes use of inducible promoters, while post-translational ap-
proaches mainly rely on ligand-mediated activation of the pre-existent recombinase. Of
the transcriptionally inducible Cre-recombinases used in the intestinal epithelium, AhCre
recombinase is arguably one of the most commonly utilised. It exploits regulatory ele-
ments of the rat cytochrome P4501A1 gene (Cyp1A1 ). Under normal physiological condi-
tions Cyp1A1 is transcriptionally silent. Interaction of certain lipophilic xenobiotics (e.g.
β-naphthoﬂavone) with the cytoplasmic aryl hydrocarbon receptor results in transloca-
tion of the latter to the nucleus, binding to Cyp1A1 promoter and Cyp1A1 transcription
initiation (Ireland et al., 2004).
AhCre recombinase expression is limited to a ﬁnite number of epithelial tissues and
thus confers a degree of tissue speciﬁcity. However, in order to make this approach
applicable to a large number of tissues would require ﬁnding an inducible gene-expression
system for every tissue of interest. On the other hand, post-translational activation of Cre
recombinase activity allows the combination of tissue-speciﬁcity with inducibility. The
most common approach to post-translational regulation of Cre recombinase is the use of
a fusion protein between the recombinase and mutated ligand binding domain of human
oestrogen receptor (ER) that selectively binds to the oestrogen antagonist tamoxifen, but
not endogenous oestrogen (Feil et al., 1997). In the absence of tamoxifen, the fusion
Cre-ER protein is sequestered in the cytoplasm preventing it from accessing loxP sites.
Tamoxifen binding to the ER domain of the fusion protein reveals a nuclear localisation
signal and permits Cre recombinase transport to nucleus, where it can recognise and
recombine the loxP sites. Expression of the Cre-ER fusion protein under the control of
a tissue speciﬁc promoter thus provides a means of tissue-speciﬁc inducible deletion or
activation of a given targeted gene. As an example of post-translational Cre recombinase
regulation, expression of the Cre-ER recombinase protein from the Villin locus has been
shown to controllably drive recombination in the intestinal epithelium (el Marjou et al.,
2004).
Finally, a combination of transcriptional and post-translational approached creates
an opportunity for more stringent control over the Cre recombinase regulation. The
use of the Cre-ER fusion protein expressed from Cyp1A1 promoter overcomes undesired
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expression of AhCre recombinase during embryonic development. The resulting AhCreER
recombinase requires two ligands, β-naphthoﬂavone and tamoxifen, for its activation and
thus provides a tighter regulatory mechanism (Kemp et al,. 2004).
The mechanism of action of the Flp/FRT recombination system derived from Sac-
charomyces cerevisiae is, in essence, very similar to Cre-loxP system (Dymecki, 1996).
Since wild type Flp is characterised by a substantial thermolability and limited activity
at 37 ◦C, an enhanced Flp variant termed Flpe has been created to increase the recombi-
nation eﬃciency in mice (Buchholz et al., 1998).
One of the disadvantages of both the Cre/loxP and Flp/FRT systems is the irreversible
nature of the genetic alterations driven by the excision of the targeted region. This
limitation has been to some extent resolved in Tetracycline-controlled gene expression
systems. Based on the Tet repressor protein from Escherichia coli, Bujard and colleagues
have designed Tet-On and Tet-Oﬀ expression systems that induce or suppress a targeted
gene expression respectively in response to administration of the tetracycline derivative
doxycycline (Gossen and Bujard, 1992; Gossen et al., 1995).
The availability of the various conditional transgenesis systems creates a potential
for the development of the ‘multi-stage’ models with several levels of gene manipulation.
The ﬁrst stage of such a model would involve ‘cancer initiating’ mutations (Apc, β-
catenin, K-RAS, p53, etc) being triggered by Cre recombinase. At the second stage a
‘therapeutic’ gene would be depleted or activated via Tet-regulated system. Combined
with new developments in CRC mouse models such an approach may be particularly
useful in assessment of the therapeutic potential of novel targets in advanced tumours.
Implementation of such a model, however, would require reliable activity of the stage-two
targeting system within malignant tissue.
1.3 Brg1 as a therapeutic target candidate for Wnt-
driven tumourigenesis
DNA comprising the genome of eukaryotic cells is tightly packaged into chromatin in
order to be accommodated within the relatively small boundaries of the nucleus. The
basic unit of chromatin is represented by a nucleosome core comprised of DNA wrapped
around the octamer of histone proteins. Nucleosomal organisation of chromatin poses
substantial challenges for processes that require access to DNA, such as transcription
and DNA repair. At the same time, control over the ‘chromatin barrier’ provides diverse
mechanisms for the regulation of the aforementioned processes. Chromatin remodelling
complexes capable of shifting and displacing nucleosomes constitute one of these mecha-
nisms. Chromatin remodelling activity thus maintains chromatin in a dynamic state and
aids in the interpretation of the variety of inter- and intracellular cues, both normal and
neoplastic (For the extensive review of chromatin remodelling complexes see de la Serna
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et al., 2006; Roberts and Orkin, 2004; Workman and Kingston, 1998). This section will
describe the chromatin remodelling factor BRG1 and its role in mammalian development
and tumourigenesis.
1.3.1 Discovery and functional redundancy between paralogues
Brahma related gene 1 (BRG1, also known as SWI/SNF related, matrix associated,
actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4 )) is one of
the two mutually exclusive ATPase subunits characteristic of the SWItch/Sucrose Non-
Fermentable (SWI/SNF) class of chromatin remodelling complexes in mammals. Human
BRG1 and its paralogue human Brahma (BRM) have been independently discovered based
on the sequence similarity to their homologues in yeast (SWI2/SNF2) and Drosophila
(Brahma) (Khavari et al., 1993; Muchardt and Yaniv, 1993). BRG1 and hBRM have
been found to share domain structure with their yeast and Drosophila homologues, in-
cluding acetyl-lysine binding bromodomain and DNA unwinding helicase motiﬀs (Chiba et
al., 1994). Both BRG1 and hBRM have been reported to be enzymatically active and pro-
tein complexes containing either of the subunits are capable of remodelling nucleosomes
in vitro (Phelan et al., 1999). However, a number of studies have reported substantial
diﬀerences in the expression patterns and function of BRG1 and hBRM, suggesting a lack
of functional redundancy between the two ATPases. Analysis of expression patterns has
revealed that hBRM is predominantly expressed in tissues with low proliferation rates
such as liver, brain, ﬁbromuscular and endothelial cells. Conversely, BRG1 expression
has been found to be mainly conﬁned to tissues with high cell turnover, such as epithelial
tissues of the gastrointestinal tract, skin, etc. (Reisman et al., 2005). Functional diﬀer-
ences between BRG1 and hBRM have been highlighted by the eﬀects of the respective
constitutive knock-out mouse models. hBRM null mice have been reported to be viable
and fertile, albeit displaying increased cell proliferation (Reyes et al., 1998). Conversely,
BRG1 homozygous null embryos have been found to die in utero prior to implantation,
while heterozygous knock-outs often display exencephaly and are predisposed to tumouri-
genesis (Bultman et al., 2000). Furthermore, BRG1 and hBRM have been reported to
exhibit antagonistic roles in some processes, for instance osteoblast diﬀerentiation (Flow-
ers et al., 2009). This functional diversity is likely to be facilitated by interactions with
distinct non-overlapping protein populations. Indeed, both BRG1 and hBRM have been
found to contain unique domains not present in the other paralogue that could allow pref-
erential interaction with distinct classes of transcription factors (Kadam and Emerson,
2003).
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1.3.2 Physiological functions of BRG1
1.3.2.1 BRG1 protein-protein interactions
Since the SWI/SNF chromatin remodelling complex does not possess an intrinsic DNA
binding ability, its recruitment to DNA is accomplished via interaction with transcrip-
tion factors (Kwon and Wagner, 2007). While BRG1 has no DNA binding ability ei-
ther, its bromodomain enables BRG1 recruitment to acetylated lysines on histone tails.
BRG1, therefore, may serve as an interpreter of the chromatin epigenetic signature for the
SWI/SNF complex (Shen et al., 2007). Due to its role as a recruitment platform, BRG1
has been found to mediate the interaction of the SWI/SNF complex with a number of
nuclear receptors. Among those are the oestrogen receptor (Chiba et al., 1994), glucocor-
ticoid receptor (Trotter et al., 2008), androgen receptor (Link et al., 2005), retinoid acid
receptor (Dilworth et al., 2000), peroxisome proliferator-activated receptor γ (Debril et
al., 2004) and vitamin D3 receptor (Kitagawa et al., 2003).
In addition to SWI/SNF complex, BRG1 and BRG1-associated factors (BAFs) have
been found to participate in other complexes with activities as diverse as transcriptional
control, DNA replication, recombination and repair. Examples of BRG1 and BAFs con-
taining complexes include WINAC (WSTF including nucleosome assembly complex) in-
volved in nuclear receptor mediated transcription regulation and chromatin assembly
after DNA replication (Belandia and Parker, 2003); the NUMAC complex (nucleoso-
mal methylation activation complex) containing the histone methylating enzyme CARM1
(coactivator-associated arginine methyltransferase-1) (Xu et al,. 2006); and the NCoR-
1 complex (Nuclear receptor corepressors-1) containing histone deacetylase 3 (HDAC3)
and the transcriptional corepressor KAP-1 (Krab associated protein 1) (Underhill et al.,
2000). For an extensive list of BRG1 mediated protein interactions and their respective
eﬀect on transcription see Trotter and Archer, 2008.
1.3.3 The role of BRG1 in mammalian development
Taking into account the vast network of protein interactions involving BRG1, it is hardly
surprising that BRG1 has been implicated in the regulation of various physiological pro-
cesses. Early developmental failure of Brg1 deﬁcient mice indicates an essential role played
by Brg1 during the very early stages of embryonic development (Bultman et al., 2000).
The earliest developmental event that has been found to require Brg1 is zygotic genome ac-
tivation – reprogramming of the transcriptional signatures upon zygote formation, which
is crucial for establishment of totipotency and development initiation (Bultman et al.,
2006). The ﬁrst cell-fate decision event in mammalian development occurs at the blas-
tocyst stage. Cells located within the blastocyst termed inner cell mass (ICM) cells are
destined to become the proper embryo, while external cells give rise to the trophecto-
derm that produces the embryonic portion of placenta. The segregation between ICM
Chapter 1. General introduction 47
and trophectoderm is controlled by the activity of two transcription factors: Oct4 and
Cdx2. During the segregation event, Oct4 transcription becomes limited to ICM, while
Cdx2 becomes exclusively expressed in trophectoderm (Nichols et al., 1998; Strumpf et
al., 2005). Transcriptional repression of Oct4 in trophectoderm has been shown to be
mediated by Cdx2 and require Brg1, thus implicating Brg1 in ICM-trophectoderm diﬀer-
entiation (Wang et al., 2010). The ICM cells from a mouse embryo can be successfully
maintained in culture and re-introduced into a new blastocyst contributing to all three
germ layers of the resulting chimaera embryo (Evans and Kaufman, 1981). These pluripo-
tent cells have been termed embryonic stem (ES) cells and have had an immense impact on
the understanding of early stages of embryonic development and generation of transgenic
techniques. The ability of ES cells to maintain pluripotency and self-renewal has been
largely attributed to the activity of two key transcription factors: Nanog and Oct4 (Cham-
bers et al., 2003; Nichols et al., 1998). Of these, Nanog has been demonstrated to directly
interact with Brg1 in mouse ES cells (Liang et al., 2008). This interaction has been proven
to be functional as Brg1 has been found to co-localise with both Nanog and Oct4 as well
as Sox2, Stat3 and Smad1 at the promoters of their target genes and thus contribute
to regulation of ES cell pluripotency and self-renewal (Ho et al., 2009). Furthermore,
Brg1 has also been demonstrated to occupy promoters of these transcriptional regulators
(Oct4, Sox2, Nanog, Sall4 and others) and regulate their expression both in ES cells and
in the blastocyst (Kidder et al., 2009). Taken together, these observations suggest that
Brg1 plays a crucial role in the maintenance of ES cell self-renewal and pluripotency by
regulating expression of key transcriptional regulators and their respective target genes.
In addition to its role in ES cell physiology, Brg1 has been implicated in various pro-
cesses at later stages of embryonic development, mainly in aiding diﬀerentiation along
various cell lineages. Indeed, the components of the SWI/SNF remodelling complex have
been found to participate in the majority of diﬀerentiation events examined (de la Serna
et al., 2006). The developmental processes that have been found to require Brg1 in-
clude skeletal and cardiac muscle diﬀerentiation (Hang et al., 2010; Ohkawa et al,. 2006;
Stankunas et al., 2008), active albumin expression during liver development (Inayoshi et
al., 2006), erythropoesis (Bultman et al,. 2005; Griﬃn et al., 2008; Xu et al., 2006), T-cell
diﬀerentiation and activation (Chi et al., 2003; De et al., 2011), vascular remodelling of
the yolk sac (Griﬃn et al., 2008), limb patterning and keratinocyte diﬀerentiation (Indra
et al., 2005). Brg1 has also been found involved in maintenance and diﬀerentiation of
certain somatic stem cells including neural (Matsumoto et al., 2006) and mesenchymal
stem cells (Alessio et al., 2010; Napolitano et al., 2007).
1.3.4 The role of BRG1 as a tumour suppressor
Consistent with its importance for precise regulation of various cellular processes, mal-
function of BRG1 has also been implicated in a number of pathological conditions, par-
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ticularly in neoplasia. BRG1 is widely considered to act as a tumour suppressor in a
range of tissues. BRG1 is located within 19p13.2 locus, which it shares with another tu-
mour suppressor, LKB1, and which is frequently lost in certain cancers (Rodriguez-Nieto
and Sanchez-Cespedes, 2009). A number of studies have reported BRG1 mutations in
numerous human cancer cell lines as well as in primary and metastatic cancers (Becker
et al., 2009; Reisman et al., 2003; Wong et al., 2000). In lung cancer BRG1 mutations
have been detected in nearly a quarter of the screened cell lines making it the ﬁfth most
common mutation in non-small cell lung cancer (NSCLC) cell lines (Medina et al., 2008).
Despite the apparently low incidence of BRG1 mutations in primary lung cancers (Medina
et al., 2004) analysis of BRG1 expression in primary NSCLCs has detected loss of BRG1
expression in nearly 30% of tumours (Fukoka et al., 2004; Reisman et al., 2003). This
discrepancy has been rectiﬁed using ultra-deep pyrosequencing, a more sensitive sequenc-
ing technique able to detect under-represented mutations. The pyrosequencing analysis
of a panel of primary lung cancers has now detected biallelic BRG1 inactivation in a
substantial portion of tumours (Rodriguez-Nieto et al., 2011).
A number of mouse models have also suggested that Brg1 may act as a tumour suppres-
sor. Heterozygous constitutive Brg1 knock-out mice have been shown to be susceptible to
tumourigenesis in the mammary gland epithelium (Bultman et al., 2007). Notably, mam-
mary gland tumours that arise in mice with heterozygous Brg1 loss have been found to
retain expression of the remaining functional copy of Brg1. This observation suggests that
the oncogenic eﬀects of Brg1 loss are likely to be due to Brg1 haploinsuﬃciency rather
that loss of heterozygousity (Bultman et al., 2007). Consistent with this observation,
conditional inactivation of a single Brg1 allele has been reported to promote chemically
induced lung carcinogenesis in mice. At the same time, no increase in the number of
tumours has been observed in mice with both Brg1 alleles inactivated. Conversely, inac-
tivation of both Brg1 alleles after tumour initiation has been shown to result in increased
tumour burden (Glaros et al., 2008). Together with frequent biallelic loss of BRG1 in
human lung cancers, these observations indicate that partial and complete loss of Brg1
may have diﬀerent eﬀects at various stages of tumour initiation and progression.
Interestingly, another member of the SWI/SNF complex (SNF5/INI1) has been found
to act as a tumour suppressor. The gene encoding the SNF5/INI1 subunit has been found
to undergo biallelic inactivation in human malignant rhabdoid tumours (MRT) and less
frequently in other cancers (Roberts and Orkin, 2004). Similarly to Brg1−/− animals,
Snf5−/− null mice die in utero due to early developmental failure, while mice with het-
erozygous loss of Snf5 are prone to tumourigenesis. However, despite being components
of the same complex the tumours arising in these two models exhibit very distinct pheno-
types. Snf5+/− mice have been found to develop multiple tumours that resemble human
MRTs (Roberts et al., 2000). These tumours develop more rapidly and are more aggressive
compared to mammary tumours from Brg+/− animals. Even more curiously, MRT-like
tumours in Snf5+/− mice display loss of the functional copy in the malignant tissue and
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thus arise via loss-of-heterozygousity (LOH). These observations represent a peculiar case
that genetic aberrations within components of the same regulatory system may give rise
not only to morphologically distinct tumour types, but also lead to tumourigenesis via
diﬀerent paths (i.e. single-hit (haploinsuﬃciency) and two-hit (LOH)).
A number of mechanisms have been suggested to account for the apparent tumour
suppressor role of BRG1. One of the putative mechanisms has been proposed to rely on
the interaction between BRG1 and the retinoblastoma protein (pRB) repressive complex.
BRG1 activity has been found to be essential for pRB complex ability to repress the func-
tion of the E2F1 transcription factor (Trouche et al., 1997). An alternative pRB-mediated
mechanism of BRG1 tumour suppressor function has been proposed that involves the Cdk
inhibitor p21 (also known as CIP1 or WAF). BRG1 has been demonstrated to up-regulate
p21 expression, which, in turn, leads to hypophosphorylation of pRB and repression of
E2F1 activity (Kang et al., 2004). Although the majority of mutations targeting BRG1
result in abrogated expression, a range of cell lines have been found to bear point mu-
tations in BRG1 leading to single amino acid substitutions. Functional analysis of such
mutations has revealed that mutant BRG1 subunits are still capable of interacting with
other members of the chromatin remodelling complex and can bind to the promoters of
at least some target genes. However, cells bearing mutant BRG1 have been found to be
unable to respond to RB-mediated cell cycle arrest, indicating BRG1 failure to facilitate
RB-driven transcription (Bartlett et al., 2011).
The interaction of BRG1 with the known tumour suppressor BRCA1 has been sug-
gested as another putative mechanism of BRG1 mediated tumour suppression. BRCA1
has been found to co-purify with the SWI/SNF chromatin remodelling complex via di-
rect interaction with BRG1. Furthermore, BRCA1 activity as a transcriptional regulator
has been shown to rely on this interaction as BRG1 and BRCA1 mutations disrupting
this interaction result in an inability of BRCA1 to stimulate p53-dependent transcrip-
tion (Bochar et al., 2000). In addition to regulation of BRCA1 mediated p53-dependent
transcription, BRG1 has been shown to directly interact with p53. Overexpression of a
dominant negative form of BRG1 protein has been found to result in repression of p53
mediated transcription and an inhibition of p53’s ability to induce apoptosis and cell
growth arrest (Lee et al., 2002). This picture, however, has been complicated by a con-
trasting study suggesting an opposing role of BRG1 in p53 regulation as BRG1 has been
found to cooperate with the histone acetyl transferase protein, CBP, to destabilise p53
by promoting poly-ubiquitination of the latter (Naidu et al., 2009).
Transcriptional regulation by the SWI/SNF complexes involves both stimulation and
repression of gene expression. In line with this, BRG1 has been shown to repress tran-
scription of the c-Fos oncogene, with this repression being abrogated by an inactivating
mutation in the ATPase domain of BRG1 (Murphy et al., 1999).
This relatively simple portrayal of BRG1 as a bona ﬁde tumour suppressor is com-
plicated by a number of studies reporting positive correlations between increased BRG1
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expression and more advanced, invasive disease in melanoma and prostate cancer (Lin
et al., 2010; Saladi et al., 2007; Sun et al., 2007). The requirement of BRG1 for trans-
activation of the Wnt pathway target genes described in the following section further
contributes to the complexity of the involvement of BRG1 in tumourigenesis.
1.3.5 BRG1 as a mediator of the Wnt pathway - the oncogenic
face of BRG1
In contrast to the evidence from the animal models and cancer cell line studies implicating
BRG1 as a tumour suppressor in cancers as varied as melanoma, mammary and lung,
BRG1 has been found to facilitate activation of the Wnt pathway in CRC cell lines.
Further, yeast two-hybrid screening for proteins interacting with β-catenin has detected
an interaction between BRG1 and β-catenin, which was conﬁrmed by co-puriﬁcation
experiments (Barker et al., 2001). Upon the discovery of the β-catenin-BRG1 interaction
Barker et al. conducted a series of experiments to examine the possibility of BRG1
being recruited to TCF target genes and contributing to Wnt mediated transcriptional
activation. Reintroduction of functional BRG1 into BRG1 deﬁcient cell lines, along with
simultaneous activation of the Wnt pathway, has been found to double the level of TCF-
reporter gene expression compared to the Wnt pathway activation in BRG1 deﬁcient
controls. The described increase in reporter gene activity has been shown to require the
optimal TCF-recognition site sequence, suggesting that TCF binding to its target site is
essential for the recruitment of the β-catenin-BRG1 complex. Additionally, overexpression
of a dominant negative form of BRG1 in colon carcinoma cell lines has been demonstrated
to inhibit both TCF reporter gene and endogenous Wnt target genes expression.
Two independent reports have demonstrated that Brg1 positively regulates expression
of two Wnt target genes, CD44 and Cyclin D1. Ectopic BRG1 expression in BRG1 deﬁ-
cient cell lines derived from cervical carcinoma and adenocarcinoma has been observed to
restore CD44 expression otherwise suppressed in those cells (Strobeck et al., 2001). High
levels of BRG1 expression have also been found to positively correlate with expression of
the Wnt target gene Cyclin D1 in human CRC samples. Positive regulation of Cyclin D1
expression has been proposed to rely on BRG1 mediated suppression of tumour suppres-
sor phosphatase and tensin homolog (PTEN) and subsequent activation of PI3K-AKT
signalling (Watanabe et al., 2010). It should be noted, however, that explicit interaction
between BRG1 and Wnt signalling has not been explored in these studies, although it can-
not be ruled out. As a more direct indication of BRG1-Wnt pathway interaction, BRG1
has been found to cooperate with telomerase reverse transcriptase (TERT), a component
of the telomerase complex, at the promoter regions of Wnt target genes and activates
Wnt-dependent reporters, both in cultured cells and in vivo (Park et al,. 2009). Finally,
the Wnt target gene c-MYC has been found to interact with BRG1 and rely on this
interaction for trans-activation of its transcriptional targets (Cheng et al,. 1999).
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1.4 Aims and objectives
The main objective of this thesis is to explore the possibility of epigenetic modulation
of the Wnt pathway and its potential therapeutic beneﬁts. This objective is based on
the pivotal role of the Wnt pathway in the intestinal physiology and pathophysiology as
well as an apparent requirement of a chromatin remodelling ATPase subunit BRG1 for
execution of the Wnt pathway transcriptional programme. Numerous lines of research
have proposed aberrant activation of Wnt signalling as a key initiation step in intestinal
tumourigenesis. The previously published study by Barker et al. (2001) have reported
suppression of Wnt target genes upon inhibition of BRG1 function in CRC cell lines. This
project thus aims to further explore the possibility of epigenetic therapy of Wnt-driven
neoplasia in mouse models of CRC using conditional transgenesis.
Brg1 loss and haploinsuﬃciency have been implicated in tumourigenesis in a range of
tissues, which could potentially undermine its use as a therapeutic target. In order to
investigate potential contraindications of targeting Brg1, the eﬀects of heterozygous and
homozygous Brg1 loss will be studied in the context of normal small intestinal epithelium
as a tissue of choice for modelling Wnt-driven intestinal neoplasia in mice. To achieve this
objective Brg1 will be conditionally inactivated using a selection of Cre recombinases. This
work is described in Chapter 3. Additionally, the consequences of Brg1 haploinsuﬃciency
and loss of function will be analysed in a range of other tissues both within and outside
of the gastrointestinal tract. This part of the project is outlined in Chapter 4.
In order to address any potential therapeutic advantage of epigenetic modulation of
Wnt signalling by Brg1 loss, Brg1 deﬁciency will also be placed in the context of aberrant
Wnt signalling by conditional inactivation of the Apc gene. The outcomes of Brg1 loss in
the context of Wnt-driven neoplasia will be characterised in the small intestinal epithelium
as well as a range of other epithelial tissues. These studies are presented in Chapters 5
and 6.
Chapter 2
Materials and Methods
2.1 Experimental animals
All animal experiments were carried out in accordance with UK Home Oﬃce regulations,
under valid personal and project licenses.
2.1.1 Transgenic constructs and animals used in the project
A number of transgenic mouse lines were used in this project. These include mice bearing
tissue-speciﬁc inducible transgenes driving expression of a Cre recombinase as well as loxP
targeted native alleles and reporter constructs. Mice bearing the Tg(Cyp1a1-cre)1Dwi
transgene (abbreviated here as AhCre), which can be induced by β-naphthoﬂavone treat-
ment in a range of tissues including the intestinal epithelium, stomach and bladder, were
generated by Ireland et al. (2004). The Tg(Cyp1a1-cre/ESR1)1Dwi transgene (abbre-
viated here as AhCreER), expresses a fusion protein in which Cre recombinase and a
mutated oestrogen receptor are fused and thus provides additional control over Cre re-
combinase activation (Kemp et al., 2004). The Tg(Vil-cre/ESR1)23Syr transgene (fur-
ther abbreviated as VillinCre) expresses a tamoxifen-dependent Cre recombinase-ER fu-
sion protein under the transcriptional control of the Villin1 promoter (el Marjou et al.,
2004). Mice bearing Lgr5-EGFP-IRES-creERT2 knock-in transgene (further abbreviated
as Lgr5CreER) expressed from Lgr5 locus were provided by Owen Sansom (Barker et
al., 2007). The targeted Brg1 allele bearing loxP sites ﬂanking exons 2 and 3 (Figure
2.1a) was provided by Pierre Chambon (Sumi-Ichinose et al., 1997). The targeted Apc
transgene with loxP sites positioned within the introns surrounding exon 14 (Figure 2.1b)
was generated by Shibata et al., (1997).
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Figure 2.1: Schematic representation of the loxP targeted alleles and primer positions. (a) Two loxP
sites are placed in Brg1 gene so that they ﬂank exons 2 and 3. Primers speciﬁc to regions either side of
the second loxP site (GenFw-GenRev) enable PCR detection of the animal genotype. Primers speciﬁc
to regions upstream of the ﬁrst loxP site and downstream of the second site (RecFw-RecRev) allow for
PCR-mediated detection of recombination events (Sumi-Ichinose et al., 1997). (b) Two loxP sites are
placed either side of exon 14 of Apc gene. Primers speciﬁc to regions either side of the ﬁrst loxP site
(GenFw-GenRev) enable PCR-mediated detection of the transgene in the animal genome (Shibata et al.,
1997).
2.1.2 Animal husbandry
2.1.2.1 Colony maintenance
Mice were housed in a standard facility and had access to the Harlan standard diet
(Scientiﬁc Diet Services, RM3(E)) and water ad libitum.
2.1.2.2 Breeding
All mice were maintained on a mixed background. Adult animals (6 weeks and older) of
known genotype were mainly bred in trios (one male with two females). Pups were left
with their mothers until capable of feeding independently. They were weaned on average
at four weeks of age.
2.1.2.3 Identiﬁcation, ear and tail biopsies
At the time of weaning animals were sexed and separated. Ear clipping was employed
for animal identiﬁcation. The resulting ear pinna was used for DNA extraction and
genotyping (described below). When required surgical biopsy of 3–5 mm of the tail tip
was taken under local anaesthetics.
2.1.3 Experimental Procedures
Unless otherwise speciﬁed, animals were aged to at least 10 weeks before being subjected
to any experimental procedures. Intraperitoneal injections were performed using 1 ml
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syringe (BD Plastipak) and 25G needle (BD Microlance 3)
2.1.3.1 Injection of β-naphthoﬂavone
Expression of the AhCre recombinase was induced by administration of β-naphthoﬂavone
(bNF, Sigma) in corn oil (Sigma). Powdered bNF to a concentration of 10 mg/ml was
added to corn oil in an amber bottle in order to protect bNF from light exposure. The
solution was heated to 80 ◦C and stirred vigorously to aid complete dissolution of bNF.
Aliquots of bNF solution were frozen and stored at −20 ◦C until required. Prior to injec-
tion, aliquots were thawed, heated to 80 ◦C and kept at that temperature until immedi-
ately before injection to prevent bNF precipitation out of the solution. bNF was injected
intraperitoneally (IP) at a dose of 80 mg of bNF per kg of body weight. This dose was
repeated thrice with 8 hour interval between injections (4 injections in total). During a
single course of injections solution was kept in darkness at 4 ◦C and then any remaining
solution was discarded.
2.1.3.2 Injection of Tamoxifen
Animals expressing the VillinCre or Lgr5CreER transgenes were induced by administra-
tion of Tamoxifen (Sigma) in corn oil. Powdered Tamoxifen was added to corn oil in an
amber bottle to ﬁnal concentration of 10 mg/ml. The solution was heated to 80 ◦C with
regular shaking to aid Tamoxifen dissolution. Once completely dissolved, the Tamoxifen
solution was aliquoted and stored at −20 ◦C. Prior to injection the solution was thawed,
heated to 80 ◦C and kept at this temperature until immediately before injection. Two dis-
tinct induction protocols were used to induce VillinCre+ animals. The low-dose protocol
involved a single IP injection of 40 mg/kg Tamoxifen. The high-dose protocol involved
four daily IP injections at a dose of 80 mg/kg. Lgr5CreER+ animals received an initial
dose of 120 mg/kg followed by three daily injections at a dose of 80 mg/kg. After the
injection, the solution was re-frozen and re-used no more than 3 times to avoid Tamoxifen
degradation.
2.1.3.3 Combined injection of bNF and Tamoxifen
Mice bearing the AhCreER transgene were induced by combined bNF and Tamoxifen
treatment to induce both recombinase expression and activity. Powdered bNF and Ta-
moxifen were added to corn oil in an amber bottle to the ﬁnal concentration of 10 mg/ml
and heated to 80 ◦C with vigorous stirring until complete dissolution. Once dissolved
the solution was aliquoted and stored at −20 ◦C. The recombinase was induced by ﬁve
bi-daily IP injections of combined bNF+Tamoxifen solution at a dose of 80 mg/kg, unless
stated otherwise.
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2.1.3.4 Injection of 5’-bromo-2-deoxyuridine
Where speciﬁed, animals were administered 0.25 ml of 10 mg/ml 5’-Bromo-2-deoxyuridine
(BrdU, Amersham Biosciences) either 2 or 24 hours prior to dissection in order to label
cells in S-phase of the cell cycle.
2.1.3.5 Whole body γ-irradiation
For the assay of clonogenic repopulation of the intestinal epithelium mice were subjected
to whole body gamma irradiation. Animals were restrained using a small well ventilated
Perspex chamber. An eﬀective dose of 15 Gy of γ-irradiation was administered by ex-
posure to a Caesium-137 source delivering 2.1 Gy per minute (IBL437C irradiator, RPS
Services).
2.1.4 PCR Genotyping
Mice were genotyped by PCR using DNA extracted from ear or tail biopsies at weaning age
(four weeks) and conﬁrmed at death. Unless provided by earlier publications, all primers
used were designed using Primer3 software at http://fokker.wi.mit.edu/primer3/input.htm,
checked for speciﬁcity using BLAST engine against Ensembl database (http://www.ensembl.-
org/Multi/blastview) and synthesised by Sigma Genosys.
2.1.4.1 DNA puriﬁcation (Puregene method)
Ear or tail biopsy was placed in a 1.5 ml eppendorf tube and stored at −20 ◦C until
analysis. For DNA isolation 250 µl of Cell Lysis Solution (Gentra) and 5 µl of 20 mg/ml
Proteinase K (Roche) were added to the tissue and incubated overnight at 37 ◦C with
agitation. The next day the contents of the tubes were cooled to room temperature,
mixed with 100 µl of Protein Precipitation Solution (Gentra) and centrifuged at 13000
rpm in a microcentrifuge for 10 min. The supernatant was recovered and mixed with 250
µl of isopropanol in a fresh 1.5 ml eppendorf tube and centrifuged at 13000 rpm for 15
min. The supernatant was carefully discarded, and the tubes were left to air-dry for 1
hour. The DNA was then dissolved in 250 µl of PCR-grade water (Sigma) and 2.5 µl of
the resulting solution was used in PCR reactions.
2.1.4.2 Generic protocol for PCR genotyping
PCR reactions were carried out in thin-wall 96-well plates or in thin-wall 0.2 ml strip tubes
(Greiner Bio-One) and run using either PTC-100 Peltier (MJ Research), Techne Flexi-
gene (Krackeler Scientiﬁc) or GS1 (G-Storm) thermal cycler. Pipetting of the reagents
and DNA samples was carried out using ﬁltered pipette tips to avoid aerosol contami-
nation. 2.5 µl of crude genomic DNA extract was loaded into wells using multi-channel
pipette. The master-mix containing the remaining components of the reaction (distilled
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water, GOTaq 5X PCR buﬀer (Promega), 25 mM Magnesium Chloride (Promega), 25
mM dNTPs (Bioline), Primers (Sigma-Genosys) and either GOTaq (Promega) or Dream-
Taq (Fermentas) DNA Polymerase) was prepared according to Table 2.1. 47.5 µl of the
appropriate master-mix were added to each well. 96-well plates were sealed with alu-
minium foil tape, while strip-tubes were closed with appropriate caps (Greiner Bio-One).
The tubes were gently tapped to dislodge air bubbles and ensure the mixture was at the
bottom of the well. Reactions were run using cycle conditions outlined in Table 2.1.
The primer sequences used for genotyping of the particular transgenes and the size of
respective products are provided in Table 2.2.
2.1.4.3 Visualisation of PCR products
After completion of PCR reactions the products were visualised by agarose gel elec-
trophoresis. The reactions using colourless 5X PCR buﬀer (Promega) were mixed with
5µl of DNA loading dye (50% Glycerol (Sigma), 50% distilled water, 0.1% (w/v) Bro-
mophenol Blue (Sigma)). All samples and an appropriate marker (e.g. 100 bp ladder
(Promega)) were loaded onto 2% agarose gel (4 g agarose (Eurogentech), 200 ml 1X Tris-
Borate-EDTA (TBE) buﬀer (Sigma), 10 µl of 10 mg/ml ethidium bromide (Sigma) or
10µl Safeview (NBS Biologicals)). The products of Ah-Responder PCR were analysed
using 4% agarose gel. Gels were run in 1X TBE buﬀer at 120 V for 30 minutes. Products
were visualised in UV light using GelDoc apparatus (BioRad).
2.2 Tissue harvesting and processing
2.2.1 Tissue harvesting
Following a schedule 1 approved method of culling (cervical dislocation), animals were
dissected using a micro-dissection kit. The fur was sprayed with 70% ethanol and an
incision made along the mid-line of the abdomen, through both, skin and peritoneal wall.
Unless otherwise speciﬁed the following protocol of harvesting the small intestinal (SI)
tissue was adhered to. The small intestine between stomach and caecum was isolated and
ﬂushed with ice cold 1X PBS (Invitrogen) using 60 ml syringe (BD Plastipak). The ﬁrst
8 cm of the SI were ’swiss-rolled’ (intestine was opened longitudinally, spread on a ﬂat
surface with the epithelium facing up, rolled from end to end using forceps and secured
by piercing it with a 23G syringe needle (BD Microlance)). The following 8 cm were
cut into four 2 cm pieces and bundled together with surgical microtape. Epithelial and
stromal cells from the following 8 cm were separated from muscle wall by scraping with
the blunt edge of a scalpel. The scraped oﬀ tissue was divided into two equal parts, and
used for RNA (section 2.5.1) and protein (section 2.6.1) isolation. The following 8 cm
were cut into three equal pieces and bundled with surgical microtape. The rest of the
SI was ’swiss-rolled’. The stomach was cut open and ﬂushed with running tap water. It
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was then folded along the border separating glandular and forestomach sections and ﬁxed
with surgical microtape. The pyloric junction including 5 mm of pyloric stomach and ﬁrst
5 mm of duodenum was cut open, folded along the border between the stomach and small
intestine and ﬁxed with surgical microtape. The large intestine between the caecum and
the rectum was ﬂushed with ice cold 1X PBS (Invitrogen) and ’swiss-rolled’.
In addition to the gastrointestinal tract tissues, samples of the following tissues were
harvested from mice bearing particular transgenes: -AhCre and AhCreER: liver, pancreas,
kidney, bladder, spleen; - VillinCre: kidney.
2.2.2 Tissue ﬁxation
Once collected, tissue samples were immersed in ice cold formalin (4% neutral buﬀered
formaldehyde in saline, Sigma) and incubated for 12–24 hours at 4 ◦C. After initial
ﬁxation, samples were either processed straight away as described below or transferred
into ice cold 70% ethanol and stored at 4 ◦C until processing.
Fixation method used for the gut wholemount and β-galactosidase staining is described
in section 2.2.5.1.
2.2.3 Tissue processing for light microscopy
2.2.3.1 Tissue dehydration
Tissue samples were arranged in histocasettes and processed using an automatic processor
(Leica TP1050). Samples were dehydrated in increasing concentrations of ethanol (70%
for 1 hour, 95% for 1 hour, 100% 2 x 1 hour 30 min, 100% for 2 hours), Xylene 2 x 1 hour
and paraﬃn 1 x 1 hour and 2 x 2 hours. After dehydration, samples were embedded in
paraﬃn wax.
2.2.3.2 Tissue sectioning
A microtome (Leica RM2135) was used to cut 5 µm thick sections from paraﬃn blocks.
Sections were then ﬂoated onto slides coated with poly-L-lysine (PLL) and baked at 58 ◦C
for 24 hours.
2.2.4 Tissue preservation for RNA, DNA or protein extraction
Tissues intended for RNA or protein extraction were removed and frozen as quickly as
possible to avoid RNA and protein degradation, respectively.
2.2.4.1 For RNA extraction
Gut scrapes from the small intestinal epithelium were placed in a screw-cap tubes con-
taining 1.4 mm ceramic beads (Lysing Matrix D tubes, MP biomedical) and 1 ml of Trizol
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reagent (Invitrogen). Tubes were shaken brieﬂy to mix the tissue with Trizol and snap
frozen by immersion in liquid Nitrogen (LN2). Tissues were removed from (LN2) and
stored at −20 ◦C.
The bladder urothelium tissue was physically separated from the muscle wall (see
section 2.2.6.3), placed in a screw-cap tube with ceramic beads and 0.5 ml of Trizol
reagent, snap frozen in (LN2) and stored at −20 ◦C (see above).
2.2.4.2 For protein extraction
Gut scrapes of the small intestinal epithelium were transferred into 1.5 ml eppendorf tube
and quickly immersed and snap frozen by immersion in (LN2). Tissues were removed
from (LN2) at convenience and stored at −80 ◦C until needed.
2.2.4.3 For DNA extraction
Small samples were removed from tissues intended for DNA extraction. These samples
were placed in 1.5 ml eppendorf tube and stored at −20 ◦C until DNA extraction (typically
within 2 weeks).
2.2.5 Staining of tissue wholemounts
2.2.5.1 LacZ staining of the small intestine wholemount
Speciﬁc regions of whole small intestine were removed and ﬂushed with ice cold 1X PBS
(Invitrogen) and ice cold X-Gal ﬁxative solution (2% formaldehyde (Sigma), 0.1% glu-
taraldehyde (Sigma) in 1X PBS). Approximately 7 cm long sections of the small intestine
were placed on a set paraﬃn wax in 15 cm plastic Petri dish (paraﬃn wax (Sigma), with
10% mineral oil (Sigma)). The intestine then was cut open, spread with epithelial side
facing up and pinned down using entomological pins (Watkins & Doncaster). The tissue
was then ﬁxed in the X-Gal ﬁxative for at least 1 hour at room temperature, washed in
1X PBS and incubated in demucifying solution (10% glycerol (Sigma), 0.01 M Tris-HCl
(pH 8.2), 20% ethanol (Fisher Scientiﬁc), 0.9% NaCl, 0.003% (w/v) Dithiothreitol (DTT,
Sigma)) for 1 hour. The plate was ﬂooded with 1X PBS and any adhering mucin was
washed oﬀ the tissue using a plastic Pasteur pipette. The wholemounts were stained using
X-Gal staining solution: 1 mM MgCl2 (Sigma), 3 mM potassium ferricyanide (Sigma),
3 mM potassium ferrocyanide (Sigma) in 1X PBS. The solution was stored in a tin foil-
wrapped bottle at −20 ◦C and stock X-Gal solution (5% in DMF, Promega) 0.02% was
added immediately prior to staining. The intestines were incubated with the staining
solution overnight or until the suﬃcient level of staining was achieved. If necessary,
fresh solution was added after overnight incubation and incubated for further 4-6 hours.
Once stained, tissues were washed with 1X PBS and ﬁxed with formalin to avoid further
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staining. When required, formalin-ﬁxed intestines were ‘swiss-rolled’ and processed for
histology as described earlier (section 2.2.3).
Stained wholemounts were illuminated with Leica CLS50X light source and visually
analysed under Olympus SZX12 low-magniﬁcation stereo microscope. Where needed,
pictures were taken with Olympus C4040ZOOM 4.1 Megapixel digital camera.
2.2.6 Isolation of epithelium enriched cell populations
2.2.6.1 Isolation of the intestinal epithelial cells using Weiser solution
The protocol was adapted from (Flint et al., 1991). The ﬁrst 15 cm of the small intestine
from the stomach was ﬂushed with ice cold 1X PBS (Invitrogen), opened longitudinally
and placed in 50 ml falcon tube (Greiner Bio-One) containing 15 ml of freshly prepared
ice cold modiﬁed Weiser chelating solution (5.56 mM disodium hydrogen orthophosphate
(Sigma), 8 mM potassium dihydrogen orthophosphate (Sigma), 96 mM sodium chloride
(Sigma), 1.5 mM potassium chloride (Sigma), 27 mM tri-Sodium citrate (Sigma), 0.5
mM dithiothreitol (DTT, Sigma), 1.5% sucrose (Sigma), 1% D-sorbitol (Sigma), 6.07 mM
EDTA (Sigma), 4 mM EGTA (Sigma), pH 7.3). The intestine was washed in three changes
of ice cold Weiser solution by gentle shaking. After the washes, the tube containing 15 ml
of Weiser solution was attached to the vortex mixer and shaken at the lowest setting for
15 min. The tube was then shaken vigorously by hand and the solution was transferred
into a fresh tube. Fresh 15 ml of Weiser solution was added to the tube containing the
intestine and the shaking steps were repeated. Two 15 ml fractions were joined together
and the intestine was discarded. 30 ml of Weiser solution containing the epithelial cells
were centrifuged at 1500-2000 rpm for 5 min. The resulting pellet was resuspended in
20 ml of ice cold 1X PBS and centrifuged. The wash in 1X PBS was repeated twice,
the pellet was resuspended in 3 ml of 1X PBS and aliquoted into three 1.5 ml eppendorf
tubes. The tubes were centrifuged using a mini-centrifuge for 1 minute. The supernatant
was removed, the pellet was snap-frozen in LN2 and stored at −80 ◦C until needed.
2.2.6.2 Epithelial enrichment by gut scraping
In order to enrich the small intestinal tissue sample for epithelium, epithelial and stromal
cells were physically separated from the muscle wall. The small intestine was dissected
as described earlier (section 2.2.1). The fragment of small intestine intended for RNA
and protein extraction was opened longitudinally and spread on a ﬂat surface luminal
side facing up. The intestinal mucosa was then gently scraped oﬀ the muscle wall using
the blunt edge of a scalpel. The scraped material was divided into two equal parts and
transferred into 1.5 ml eppendorf tube for protein extraction or screw-cap tube with
ceramic beads and 1 ml of Trizol reagent (Invitrogen) for RNA extraction (see sections
2.5.1 and 2.6.1).
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2.2.6.3 Isolation of bladder urothelium
In order to obtain an epithelium enriched sample of bladder urothelium, the epithelial
sheet was physically separated from the bladder muscle wall. The bladder was isolated
from the genitourinary tract and an incision was made into the bladder wall with surgical
spring scissors. The epithelial sheet was then pulled from the muscle wall using two
microdissection forceps. The bladder urothelium was then preserved for RNA extraction
as described in section 2.5.1.
2.3 Histological analysis
2.3.1 Haematoxylin and Eosin (H&E staining of tissue sections)
Slides containing tissue sections were dewaxed and rehydrated as described in section 2.4.
Slides were stained for 5 min in Mayer’s Haemalum (R. A. Lamb), washed in running
tap water for further 5 min followed by 5 min staining in 1% aqueous Eosin (R.A. Lamb)
solution. Eosin was washed oﬀ by two 15 second washes in water. Stained sections were
dehydrated and mounted as described in section 2.4.
2.3.2 Quantitative histological analysis of H&E stained sections
Histological quantiﬁcation of the tissue sections was carried out using an Olympus BX41
light microscope. Where appropriate, microphotographs were taken with a Colorview III
camera (5 megapixel, Soft Imaging Systems) aided with AnalySIS software (v3.2, Build
831, Soft Imaging Systems) or Moticam 5000 camera (5 megpixel, Motic Instruments)
aided with Motic Images Advanced software (v.3.2, Motic China Group). Quantitative
and statistical analysis of histological parameters was carried out as described in section
2.7.
2.3.2.1 Scoring of crypt length
Crypt length was scored by counting the number of cells from the base of the crypt to the
crypt-villus junction. Scoring was carried out for 50 half-crypts per section and average
of 50 crypts were scored per mouse.
2.3.2.2 Scoring of villus length
To score villus length, the total number of cells from the crypt bottom to the villus tip were
counted on 50 half crypt-villus axes per slide. The average villus length was calculated as
average total crypt-villus length minus average crypt length for each mouse.
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2.3.2.3 Scoring of Mitotic index
Mitotic ﬁgures were scored on H&E stained sections based on their morphological appear-
ance. Number of mitotic ﬁgures was counted in 50 half-crypts per slide. Mitotic index
was calculated as average number of mitotic ﬁgures per half-crypt for each mouse.
2.3.2.4 Scoring of Apoptotic index
Apoptotic bodies were scored based on their characteristic appearance on H&E stained
sections. The number of apoptotic bodies was counted in 50 half-crypts per slide. The
apoptotic index was calculated as average number of apoptotic bodies per half-crypt for
each mouse. Where appropriate the position of apoptotic bodies in the crypt was also
scored to assess the distribution of apoptosis within the crypt. The positions were scored
from the crypt base, the bottom-most cell being the cell #1. The positional data from all
the mice of the same genotype were pooled together and analysed as described in section
2.7.
2.3.3 Use of speciﬁc stains for quantiﬁcation of histological traits
2.3.3.1 Grimelius staining
Grimelius staining was used to identify argyrophilic enteroendocrine cells. All glassware
used for the staining was rinsed thoroughly with ultrapure double-distilled (dd) H2O
prior to use. Tissue sections were dewaxed and rehydrated as described in section 2.4.
1% (w/v) silver nitrate (Sigma) was dissolved in Acetate buﬀer (0.02 M acetic acid (Fisher
Scientiﬁc), 0.02 M sodium acetate (Sigma) in ddH2O) and heated to 65
◦C on a water bath
in a coplin jar. Once slides were placed in preheated solution, the coplin jar was sealed,
wrapped in tin foil and incubated at 65 ◦C for 3 hours. Slides were then transferred to
reducing solution (0.04 M sodium sulphite (Fisher Scientiﬁc), 0.1 hydroquinone (Sigma)
in ddH2O) preheated to 45
◦C and incubated for 5 minutes or until the tissue developed
yellow coulour. Stained slides were dehydrated and mounted as described in section 2.4.
Stained sections were examined and the number of enteroendocrine cells were scored
in 50 half crypt-villus axes per mouse. The average number of enteroendocrine cells per
half crypt-villus axis was calculated for each mouse and analysed as described in section
2.7.
2.3.3.2 Staining with Alcian Blue
Alcian Blue staining was used to identify mucin-containing goblet cells. Tissue sections
were dewaxed and rehydrated as described in section 2.4. Slides were immersed in Alcian
Blue staining solution (1% (w/v) Alcian Blue (Sigma), in 3% (v/v) acetic acid (Fisher
Scientiﬁc)) for 30 seconds followed by washing in running water for 5 minutes. Slides were
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then counterstained with 0.1% Nuclear fast red (Sigma) for 5 min. Slides were washed in
running water for 5 min and then dehydrated and mounted as described in section 2.4.
Stained sections were examined and the number of goblet cells were scored in 50 half
crypt-villus axes per mouse. The average number of goblet cells per half crypt-villus axis
was calculated for each mouse and analysed as described in section 2.7.
2.3.3.3 Alkaline phosphatase staining
Staining for brush border-speciﬁc Alkaline phosphatase was used as a marker of mature
enterocytes. Tissue sections were dewaxed and rehydrated as described in section 2.4.
Slides were placed in a humidiﬁed chamber, tissue sections were overlaid with Fast Red
substrate (DAKO) and incubated for 20 min at room temperature. Slides were washed in
dH2O and counterstained in Mayer’s Haemalum for 30 seconds followed by a 5 min wash
in running water. Slides were then mounted using glycerol (Sigma).
The intensity of the staining and thickness of the brush border were visually analysed
using light microscopy.
2.3.3.4 Lysozyme staining
Immunohistochemistry with an anti-lysozyme antibody (see section 2.4) was used to iden-
tify Paneth cells. Both Paneth cell number and position was scored. Paneth cell quantity
was scored as the number of lysozyme positive cells in 50 half-crypts per section. The
average number of Paneth cells per half-crypt was calculated for each mouse and anal-
ysed as described in section 2.7. Paneth cell position was counted from the bottom of the
crypt, the bottom-most cell being #1. Paneth cell positions from all the mice of the same
genotype were pooled together and analysed as described in section 2.7.
2.3.3.5 Ki67 staining
Immunohistochemistry with an anti-Ki67 antibody (see section 2.4) was used to identify
proliferating cells as a supplement to the Mitotic index score. Both Ki67 cell number and
position was scored to assess the size and distribution of the proliferative compartment
of the crypt. The number of proliferating cells was scored as the number of Ki67 positive
cells in 50 half-crypts per slide. The average number of Ki67 positive cells per half-crypt
was calculated for each mouse and analysed as described in section 2.7. Ki67 positive
cell positions were counted from the bottom of the crypt, the bottom-most cell being
#1. Ki67 cell positions from all the mice of the same genotype were pooled together and
analysed as described in section 2.7.
2.3.3.6 Cleaved Caspase-3 staining
Immunostaining with cleaved caspase-3 antibody (see section 2.4) was used to conﬁrm the
morphology-based Apoptotic index. The number of Caspase-3 positive cells was scored
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in 50 half-crypts per slide. The average number of apoptotic cells per half-crypt was
calculated for each mouse and analysed as described in section 2.7. Where appropriate the
position of Caspase-3 positive cells was also scored to assess the distribution of apoptosis
within the crypt. The positions were scored from the crypt base, the bottom-most cell
being cell #1. The positional data from all the mice of the same genotype were pooled
together and analysed as described in section 2.7.
2.3.3.7 BrdU staining
Tissue samples harvested from mice injected with BrdU at 2 or 24 hours prior to dissection
were stained with a BrdU antibody as described in section 2.4. The number and position
of BrdU positive cells at 2 and 24 hours post labelling were used to assess proliferation
activity and cell migration respectively. The number of BrdU positive cells was scored in
50 half-crypts per slide. The average number of BrdU positive cells per half-crypt was
calculated for each mouse and analysed as described in section 2.7. The position of BrdU
labelled cells was counted from the bottom of the crypt, the bottom-most cell being #1.
Cell positions from all the mice of the same genotype were pooled together and analysed
as described in section 2.7.
2.4 Immunohistochemistry (IHC)
All IHC was carried out according to the generic protocol outlined below. Speciﬁc con-
ditions and modiﬁcations for particular antibodies are provided in Table 2.3. Unless
otherwise speciﬁed, all incubation steps were carried out at room temperature (approxi-
mately 22 ◦C) in humidiﬁed chamber to avoid drying out of the sections. To contain the
applied solutions to the tissue, slides were gently dried around the tissue section with tis-
sue paper and the area surrounding the tissue was circled with a water-resistant ImmEdge
pen (Vector Labs) typically before endogenous peroxidase block or serum block stage.
2.4.1 Generic immunohistochemistry protocol
2.4.1.1 Dewaxing and rehydration of tissue sections
Tissue sections were dewaxed by two 5 min washes in xylene (Fisher Scientiﬁc) followed
by rehydration washes in decreasing concentrations of ethanol (Fisher Scientiﬁc): two 3
min washes in 100%, one 3 min wash in 95% and one 3 min wash in 70% ethanol. Slides
were then transferred into dH2O and washed for 5 min.
2.4.1.2 Antigen retrieval
Antigen retrieval was achieved by heating slides in a boiling water bath or microwave
in either 1X citrate buﬀer (LabVision) or custom citrate buﬀer (10 mM Sodium Citrate
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(Sigma), pH 6.0). For water bath incubation slides were immersed in preheated buﬀer
in a Coplin jar (R. A. Lamb) and incubated at 99 ◦C for the time speciﬁed in Table 2.3
(typically 20 min). For microwave antigen retrieval, citrate buﬀer was placed in either
a plastic container or a plastic pressure cooker and preheated in domestic microwav at
high power (850 W) for 5 min. Slides held in a plastic slide rack were then immersed in
preheated buﬀer and heated according to conditions speciﬁed in Table 2.3. Slides were
kept in citrate buﬀer and allowed to cool at room temperature for 30–60 min followed by 5
min wash in dH2O. Slides were then washed in washing buﬀer (either 1X PBS (Invitrogen)
or 1X TBS (Sigma) in dH2O with 0.1% (v/v) TWEEN-20 (Sigma) as speciﬁed in Table
2.3).
2.4.1.3 Endogenous peroxidase activity block
Activity of endogenous peroxidases was blocked by incubating tissue sections with hy-
drogen peroxide. Either 30% hydrogen peroxide (Sigma) diluted in dH2O to appropriate
concentration or a commercial peroxidase blocking solution (Envision+ Kit, DAKO) were
used. The appropriate hydrogen peroxide concentrations and incubation times for spe-
ciﬁc antibodies are provided is Table 2.3. When using commercial peroxidase block, the
tissue was circled with water-resistant pen, placed in a slide chamber and enough solution
was applied to cover the tissue. When using hydrogen peroxide from the stock solution,
slides were placed in a Coplin jar containing enough solution to cover the tissue. After
incubation with the peroxidase blocking solution, slides were brieﬂy rinsed in dH2O and
washed 3 x 5 min in washing buﬀer.
2.4.1.4 Non-speciﬁc antibody binding block
To diminish non-speciﬁc antibody binding, tissue sections were treated either with normal
serum (DAKO) or BSA (Sigma) diluted to an appropriate concentration in washing buﬀer.
The speciﬁc blocking agent, concentrations and incubation times for particular antibodies
are outlined in Table 2.3. Typically, the serum used for blocking was derived from the
species, in which the secondary antibody was raised (i.e. if a secondary antibody was
raised in rabbit, normal rabbit serum was used to block non-speciﬁc binding). If not
already done, the tissue containing area was circled with a water-resistant pen, slides
were overlaid with 200 µl of blocking solution and incubated for the time speciﬁed.
2.4.1.5 Primary antibody treatment
Following incubation, blocking solution was removed and 200 µl of primary antibody
diluted in blocking solution was applied without washing of sides. The dilutions and
incubation times used with speciﬁc antibodies are outlined in Table 2.3. After incubation
with an antibody, the slides were washed 3 x 5 min in washing buﬀer.
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2.4.1.6 Secondary antibody treatment
The slides were transferred to the slide chamber and enough secondary antibody was
applied to cover the tissue. When signal ampliﬁcation step was required by the protocol,
an appropriate biotinylated secondary antibody (DAKO) was diluted 1:200 in blocking
solution. Otherwise, an appropriate Horseradish peroxidase (HRP) conjugated secondary
antibody (Envision+ Kit, DAKO) was used undiluted. Appropriate secondary antibodies
and incubation times for speciﬁc primary antibodies are provided in Table 2.3. After
incubation, slides were washed 3 x 5 min in washing buﬀer.
2.4.1.7 Signal ampliﬁcation
In instances, when anti-mouse or anti-rabbit Envision+ kits (DAKO) could not be used, a
signal ampliﬁcation step was introduced into the protocol. Avidin-Biotin Complex reagent
(Vectastain ABC kit, Vector labs) was prepared according to manufacturer’s instructions
30 min prior to use and stored at room temperature. Tissue sections were covered with
200 µl of ABC reagent and incubated for 30 min at room temperature, followed by 3 x 5
min washes in washing buﬀer.
2.4.1.8 Signal visualisation with 3.3’-diaminobenzidine (DAB)
Antibody binding was visualised by colourimetric detection with 3,3’-diaminobenzidine
(DAB). Tissue sections were covered with 200 µl of DAB solution (2 drops of DAB chro-
mogen mixed with 1 ml of DAB substrate (Envision+ Kit, DAKO)). Slides were incubated
for 5–10 min or until a suﬃcient level of staining was attained followed by a 5 min wash
in dH2O.
2.4.1.9 Counterstaining, dehydration and mounting
Tissue sections were counterstained in Mayers Haemalum (R. A. Lamb) for 30 sec and
washed in running tap water for 5 min. Slides were then dehydrated by consecutive washes
in increasing concentrations of ethanol (1 x 3 min 70%, 1 x 3 min in 95%, 2 x 3 min in
100%) and 2 x 5 min washes in xylene. Coverslips were mounted over dehydrated sections
using DPX mounting medium (R. A. Lamb).
2.5 Gene Expression Analysis
Due care was taken during procedures involving RNA extraction and handling to ensure
that all plastic and glass-ware was RNAse free. All solutions were made using RNAse free
water (Sigma) or water treated with Diethyl pyrocarbonate (DEPC, Sigma). Working
surfaces and pipettes were sprayed with RNaseZAP (Sigma). Sterile ﬁlter-tips were used
to carry out the procedures.
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2.5.1 RNA extraction from tissue samples
2.5.1.1 Homogenisation of tissue samples
Tissue samples were removed from storage and placed in screw-cap tubes containing
1 ml Trizol reagent (Invitrogen) and 1.4 mm ceramic beads (Lysing matrix D tubes,
MP Biomedical), unless this was done at the time of dissection. Samples were then
homogenised using Precellys24 homogeniser (Bertin Technologies) at 6500 RPM for 2 x
45 second cycles. Tubes were centrifuged at 11000 x g for 10 min at 4 ◦C to pellet the
beads and tissue debris.
2.5.1.2 RNA extraction
Supernatant was transferred into fresh 1.5 ml eppendorf tubes containing 200 µl of chlo-
roform (Fisher Scientiﬁc). Tubes were then shaken vigorously by hand for 30 seconds and
allowed to stand at room temperature for 3 min. Tubes were centrifuged at 11000 x g for
15 min at 4 ◦C. The top, aqueous, phase (approximately 400 µl) containing RNA was re-
moved and transferred into fresh 1.5 ml eppendorf tubes containing 400 µl of isopropanol.
Tubes were gently inverted until well mixed.
2.5.1.3 RNA puriﬁcation and DNAse treatment
RNA puriﬁcation was performed using the RNeasy mini kit (Qiagen) according to the
manufacturer’s instructions. All centrifugation steps were performed at 11000 x g in a
refrigerated bench top centrifuge cooled to 4 ◦C. The mix from the previous step was
transferred into puriﬁcation columns placed in a collection tubes. Columns were cen-
trifuged for 30 seconds and the ﬂow-through was discarded. On-column DNAse treatment
from illustra triplePrep Kit (GE Healthcare) was used to remove DNA contamination ac-
cording to the manufacturer’s instructions. 100 µl of DNAse treatment solution (70 µl
RNAse-free dH2O, 20 µl DNAse buﬀer, 10 µl DNAse I) was pipetted onto columns and
allowed to stand for 10 min at room temperature. After DNAse treatment, columns were
centrifuged for 30 seconds and the ﬂow-through was discarded. Columns were washed by
adding 500 µl of RPE wash buﬀer (RNeasy kit, Qiagen) and centrifuging for 30 seconds.
The ﬂow-through was discarded and the wash was repeated, followed by 2 min centrifu-
gation. The ﬂow-through was discarded and columns were centrifuged once again for 1
min to remove the remnants of the buﬀer from columns. To elute RNA, columns were
placed into fresh 1.5 ml eppendorf tubes, 100 µl of RNAse-free dH2O was pipetted onto
columns and allowed to stand for 3 min at 4 ◦C. Eluate containing RNA was collected
by centrifuging columns for 1 min and immediately placed on ice. The concentration and
purity of RNA was assessed using NanoDrop 1000 (Thermo Scientiﬁc). RNA samples
were stored at −80 ◦C until needed.
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2.5.1.4 Determination of RNA quality
The quality of the extracted RNA was analysed using denaturing agarose gel electrophore-
sis as described in Qiagen Bench Guide (Qiagen). RNA samples containing 2 µg of RNA
were mixed with the appropriate amount of RNA 5X loading buﬀer (0.25% Bromophenol
blue (Sigma), 4 mM EDTA (Sigma), 0.9 M formaldehyde (Sigma), 20% glycerol (Sigma),
30.1 % formamide (Sigma), 4X FA gel buﬀer (see below)), incubated at 65 ◦C for 3–5 min
and quenched on ice. Samples were then loaded onto a denaturing gel (1% agarose (Eu-
rogentech), in 1X FA gel buﬀer (20 mM 3-(N-Morpholino)propanesulfonic acid (MOPS,
Sigma), 5 mM sodium acetate (Sigma), 1 mM EDTA (Sigma), 0.22 M formaldehyde
(Sigma), 0.1 µg/ml Ethidium bromide (Sigma) in dH2O)). The gel was run in FA gel run-
ning buﬀer (20 mM 3-(N-Morpholino)propanesulfonic acid (MOPS, Sigma), 5 mM sodium
acetate (Sigma), 1 mM EDTA (Sigma), 0.25 M formaldehyde (Sigma) in dH2O) at 50 V
for 1 hour. RNA was then visualised under UV light on a GelDoc (BioRad). Assessment
of RNA quality was based on the sharpness of 18S and 28S ribosomal RNA bands.
2.5.2 Preparation of cDNA for quantitative analysis
cDNA synthesis was performed as described by Untergasser A. cDNA synthesis using su-
perscript II http://www.untergasser.de/lab/protocols/cdna synthesis superscript ii v1 0.
htm using Superscript II RNAse H reverse transcriptase kit (Invitrogen). 1 µg of RNA
was mixed with 5 µl of 100 ng/µl random hexamers (Promega), and made up to 20 µl
with DNAse free dH2O (Sigma). The mix was then incubated at 70
◦C for 10 min, 25 ◦C
for 10 min and held at 4 ◦C long enough to add 20 µl of enzyme mix (8 µl 5X First Strand
Buﬀer, 4 µl 0.1 M DTT, 0.8 µl 25 mM dNTPs (Bioline), 1 µl Superscript II enzyme, 6.2
µl RNAse-free dH2O) per reaction. The reaction mix was then incubated at 25
◦C for 10
min, 37 ◦C for 45 min, 42 ◦C for 45 min, 70 ◦C for 15 and stored at 4 ◦C. 160 µl of DNAse
free dH2O was added to 40 µl of reaction mix and 2 µl of the resulting cDNA was used
per reaction in quantitative RT-PCR. Negative control cDNA samples were synthesised
in the same manner but without addition of Superscript II enzyme to the enzyme mix.
2.5.3 Quantitative real-time PCR analysis
2.5.3.1 Primer design for qRT-PCR
Primers for qRT-PCR analysis (unless previously published) were designed using Primer3
software at http://fokker.wi.mit.edu/primer3/input.htm, checked for mispriming using
BLAST engine against Ensembl database (http://www.ensembl.org/Multi/blastview) and
synthesised by Sigma Genosys. A number of conditions were considered when designing
primers. Primers were designed to reside across exon boundaries to avoid ampliﬁcation of
genomic DNA. Primers were to yield a PCR product of 100–200 bp in size and to have an
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annealing temperature close to 60 ◦C. The primer sequences used are speciﬁed in Table
2.4.
Table 2.4: Primer sequences used for quantitative RT-PCR analysis
Gene Forward Primer Reverse Primer
E-cadherin CAGATGATGATACCCGGGACAA GGAGCCACATCATTTCGAGTCA
β-catenin AGTCCTTTATGAATGGGAGCAA TCTGAGCCCTAGTCATTGCATA
β-actin TGTTACCAACTGGGACGACA GGGGTGTTGAAGGTCTCAAA
CD44 ATCGCGGTCAATAGTAGGAGAA AAATGCACCATTTCCTGAGACT
C-myc CTAGTGCTGCATGAGGAGACAC GTAGTTGTGCTGGTGAGTGGAG
Cyclin D1 ACGATTTCATCGAACACTTCCT GGTCACACTTGATGACTCTGGA
Axin2 GCAGCTCAGCAAAAAGGGAAAT TACATGGGGAGCACTGTCTCGT
2.5.3.2 qRT-PCR reaction set-up
All reactions were run on StepOnePlus real-time PCR system supplemented with StepOne
software v2.1 (Applied Biosystems). All reactions were run in a minimum of three tech-
nical and three biological replicates. Samples devoid of cDNA served as negative controls
to test for contamination with genomic DNA. A housekeeping gene (typically β-actin)
was used in each run as a reference gene.
Reactions were run using either DyNAmo HS SYBR Green qPCR kit (Finnzymes)
according to the manufacturer’s instructions or a home-made SYBR Green Master Mix
(for 100 reactions: 400 µl 5X GOTaq Flexi buﬀer (Promega), 200 µl 25 mM Magnesium
Chloride (Promega), 20 µl 25 mM dNTPs (Bioline), 20 µl SYBR Green solution (2 µl of
stock 10000X SYBR Green (Molecular probes) made up in 1320 µl of DMSO (Sigma)),
40 µl 50X ROX dye (Finnzymes), 1068 µl DNAse-free dH2O (Sigma), 12 µl GOTaq poly-
merase (Promega)). qRT-PCR reactions for the intestinal stem cell markers (Lgr5 and
Ascl2) were performed using TaqMan assay (Applied Biosystems) following the manu-
facturer’s instructions and using custom designed TaqMan probes (Applied Biosystems).
Forward and reverse primers (100 mM) were mixed in equal quantities and diluted to 10
mM concentration. 0.4 µl of the resulting 10 mM primer mix was then used per reaction.
For all reactions 2 µl of cDNA was loaded into a thin wall 96-well PCR plate (Applied
Biosystems). 18 µl of Master Mix containing appropriate primers or TaqMan probes were
added to cDNA samples and plates were sealed with optically clear sealing ﬁlm (Applied
Biosystems). All SYBR Green reactions were run using the same cycling conditions: 95 ◦C
for 10 min followed by 40 cycles (95 ◦C for 15 seconds, 60 ◦C for 30 seconds, 72 ◦C for 30
seconds), To ensure that a single product was ampliﬁed by the primer set, a melting curve
was run after cycling from 60 ◦C to 95 ◦C with a 0.5 ◦C increment. TaqMan reactions were
run using the following conditions 50 ◦C for 2 min, 95 ◦C for 10 min followed by 40 cycles
(95 ◦C for 15 seconds, 60 ◦C for 1 min).
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2.5.3.3 Analysis of qRT-PCR data
Data from the samples with reproducible cycle time (Ct) values and a single peak melting
curve (when applicable) were analysed using the 2∆∆Ct method (Livak and Schmittgen,
2001). ∆Ct values were calculated using Ct value of the reference gene from the same sam-
ple. Average ∆Ct values were calculated for all control samples and ∆∆Ct value for each
individual sample was calculated in reference to the average ‘control’ ∆Ct. Average ∆∆Ct
values were calculated for samples from each biological group and the Mann-Whitney U
test was used to test for signiﬁcant diﬀerences between means. The average ∆∆Ct from
each biological group was transformed into fold change using formula 2∆∆Ct .
2.5.4 PCR analysis of genomic recombination
2.5.4.1 DNA extraction for recombined PCR
Tissue samples for DNA extraction were collected at the time of dissection and DNA was
isolated in the same manner as from ear and tail biopsies (section 2.1.4.1). In instances,
where fresh tissue was unavailable, DNA was extracted from paraﬃn embedded tissue.
Slides containing tissue sections were dewaxed and rehydrated as for immunohistochem-
istry (section 2.4). Sections were then brieﬂy counterstained in Mayer’s Haemalum (R. A.
Lamb) to aid tissue visualisation and washed in running tap water for 5 min. Required
tissue was then scraped oﬀ from the slides and placed in 1.5 ml eppendorf tube followed
by the previously described DNA extraction procedure (section 2.1.4.1). At the ﬁnal step,
the DNA pellet was resuspended in 100 µl and stored at 4 ◦C until needed.
2.5.4.2 Brg1 recombined PCR
Primers for Brg1 recombined PCR were designed using Primer3 software at http://fokker.-
wi.mit.edu/primer3/input.htm, checked for mispriming using the BLAST search engine
against Ensembl mouse database (http://www.ensembl.org/Multi/blastview) and syn-
thesised by Sigma Genosys. Primers speciﬁc for recombination product (see Table 2.2)
ampliﬁed a product of 529 bp from a DNA template that underwent recombination be-
tween loxP sites. The unrecombined template would yield a product of 2723 bp that
could not be ampliﬁed under the reaction conditions (40 seconds ampliﬁcation time). A
parallel PCR reaction with primers used for Brg1 genotyping was carried out to ascertain
DNA presence in samples and conﬁrm the animal genotype. The PCR reaction was set
up and run under the conditions outlined in Table 2.1. PCR products were visualised as
described in section 2.1.4.3.
2.5.5 In situ hybridisation
In situ hybridisation was used to examine the expression of the intestinal stem cell marker
Olfm4. This technique utilised digoxigenin (DIG) labelled anti-sense RNA probes (ribo-
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Table 2.5: Reaction constituents for DIG labelling
Component Volume
RNase Free H2O 12 µl
Transcription Buﬀer (10X) (Roche) 2 µl
DIG RNA Labelling mix (Roche) 2 µl
RNasin (Promega) 1 µl
T7 RNA Polymerase (Roche) 2 µl
DNA (1 µg/µl) 1 µl
probes) complementary to Olfm4 mRNA sequence. Probe binding was detected using
an anti-digoxigenin alkaline phosphatase-conjugated antibody by development of purple
staining. The probe for Olfm4, cloned in a pBluescript II SK+ vector, was provided by
Hans Clever’s group (Hubrecht Institute, Netherlands). All glassware used in the protocol
was heat-treated by baking at 200 ◦C overnight and RNAse-free (Sigma) or DEPC treated
dH2O was used to prepare all solutions.
2.5.5.1 Probe synthesis
The Olfm4 probe was synthesised by linearisation of plasmid DNA, RNA polymerase
reaction from the T7 promoter and DIG labelling. 30 µg of plasmid DNA was linearised
by restriction digest with NotI restriction enzyme (NEB) according to manufacturer’s
instructions. The restriction digest was carried out overnight at the appropriate tem-
perature, and 5 µl of reaction was run on an agarose gel alongside undigested vector to
conﬁrm complete linearisation. Linearised DNA was then puriﬁed using DNA puriﬁca-
tion columns (Qiagen). DNA concentration of the puriﬁed plasmid was determined using
NanoDrop 1000 (Thermo Scientiﬁc), and adjusted to 1 µg/µl using 10 mM Tris (pH 8.0)
as required. The linearised plasmid DNA was used as a template for the transcription
of DIG-labelled riboprobes using T7 RNA polymerase (Roche). The components of the
riboprobe-labelling reaction are outlined in Table 2.5.
The labelling reaction was carried out for 2 hours at 37 ◦C, followed by DNA template
digestion by incubation with 20 units of DNaseI (Ambion) for 15 minutes at 37 ◦C. Ri-
boprobes were puriﬁed using the RNeasy Mini kit (Qiagen) according to manufacturer’s
instructions. Probes were eluted with 100 µl of RNAse-free H2O and divided into 10 µl
aliquots, which were transferred to storage at -80 ◦C.
2.5.5.2 Probe hybridisation
Slides were dewaxed in 2 x 10 min changes of xylene, and rehydrated by 1 min washes in
ethanol of decreasing concentration: 2 x 100%, 95%, 85%, 75%, 50% and 30%. Slides were
incubated in 1X saline for 5 min followed by 5 min wash in 1X PBS. Endogenous alkaline
phosphatase activity was blocked by a 30 min incubation in 6% hydrogen peroxide (in 1X
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PBS) at room temperature. Slides were washed 2 x 5 min in 1X PBS, ﬁxed in ice cold
4% PFA (Sigma) (in 1X PBS) for 20 minutes followed by 2 x 5 min washes in 1X PBS.
Slides were incubated in Proteinase K (Roche) (20 µg/ml Proteinase K, 50 mM Tris, 5
mM EDTA in dH2O) for 5 min at room temperature, washed for 5 min in 1X PBS, post-
ﬁxed in 4% PFA for 5 minutes followed by 2 min wash in DEPC treated H2O. To reduce
non-speciﬁc probe binding, slides were incubated with acetic anhydride (0.01 M acetic
anhydride (Sigma), in 0.1 M triethanolamine hydrochloride (Sigma)), for 10 min at room
temperature. Slides were then consecutively washed in 1X PBS and 1X saline for 5 min at
room temperature. Slides were rehydrated through 1 min washes in 30%, 50%, 70%, 85%,
95% and 2 x 100% EtOH solutions (70% ethanol wash was carried out for 5 min to prevent
salt precipitation). Slides were air dried for 30 minutes and transferred into sealable boxes
lined with tissue paper saturated in moisture buﬀer (5X saline sodium citrate (SSC) buﬀer
(Sigma), 50% (v/v) formamide (Sigma) in dH2O). The probe was heated at 80
◦C for 3
minutes, and quenched on ice, and hybridisation buﬀer (5X SSC, 50% formamide, 1%
SDS, 0.05 mg/ml heparin (Sigma), 0.05 mg/ml calf liver tRNA (Merck) in dH2O) was
thawed at 80 ◦C. Adequate amounts of probe and hybridisation buﬀer were mixed (1 µl
probe per 100 µl hybridisation buﬀer per slide), and applied to slides. A piece of paraﬁlm
was placed on top of the slide to prevent probe mixture evaporation. The box was sealed
with electrical tape and incubated at 65 ◦C overnight in a water bath.
2.5.5.3 Post-hybridisation treatment
Slides were removed from the box and incubated in pre-warmed 5X SSC buﬀer at 65 ◦C
for 30 minutes. Slides were then washed 2 x 30 min in solution I (50% formamide, 5X
SSC, 1% (v/v) SDS (Sigma)) pre-warmed to 65 ◦C followed by 3 x 10 min washes in
solution II (0.5 M NaCl (Sigma), 0.01 Tris pH 7.5 (Sigma), 0.1% TWEEN-20 (Sigma))
at room temperature. Unhybridised probe was digested by a 45 min incubation with
RNase A (Roche) (0.02 mg/ml in solution II) at 37 ◦C, followed by a 10 min wash in
solution II at room temperature. Slides were washed 2 x 30 min in solution III (50%
formamide, 5X SSC) preheated to 65 ◦C. Slides were washed 2 x 10 min in PBS/T (0.1%
TWEEN-20 in 1X PBS) and pre-blocked in 10% heat-inactivated sheep serum (DAKO) in
PBS/T for 3 hours, covered with a piece of paraﬁlm to prevent drying up of the solution.
Anti-DIG alkaline phosphatase conjugated antibody (Roche) was pre-absorbed in 1% heat
inactivated sheep serum in PBS/T containing 6 mg/ml small intestine tissue powder for 3
hours at 4 ◦C and diluted to a ﬁnal concentration of 1:2000 in 1% sheep serum in PBS/T.
Slides were washed in PBS/T for 5 min, overlaid with 100 µl of antibody solution, covered
with a piece of paraﬁlm, and incubated overnight at 4 ◦C.
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2.5.5.4 Signal detection
Slides were washed in PBS/T for 5 min, followed by 2 x 5 min and subsequent 3 x
30 min washes in PBS/T. Slides were preconditioned in 3 x 5 min washes of NTMT
(0.1 M sodium chloride, 0.1 M Tris pH 9.5, 0.05 M magnesium chloride (Sigma), 0.1%
TWEEN-20) containing 2 mM Levamisole (Sigma). Slides were completely covered with
BM Purple substrate (Roche), sealed in a dark box and incubated at room temperature
until the desired level of signal was developed. Slides were then washed in PBS/T for
10 min, followed by a 30 min wash in dH2O, and counterstained by immersion in Eosin
Y Solution (Sigma) for up to 10 seconds. Excess eosin was washed oﬀ under running
tap water and slides were air dried for 30 min. Slides were washed brieﬂy in xylene and
mounted in DPX mounting media (R. A. Lamb).
2.6 Quantitative Protein Analysis
2.6.1 Protein extraction from tissue samples
Epithelium enriched tissue samples were removed from storage at -80 ◦C and placed on ice.
200 µl of cell lysis buﬀer (20 mM Tris-HCl pH 8.0,, 2 mM EDTA pH 8.0, 0.5% (v/v) NP-40
(Sigma)) containing protease inhibitors (complete mini protease inhibitor cocktail tablets
(Roche)) and phosphatase inhibitors (25 mM sodium β-glycerophosphate, (Calbiochem),
100 mM sodium ﬂuoride (Sigma), 20 nM Calyculin A from Discodermia calyx (Sigma),
10 mM sodium pyrophosphate (Sigma)) were added to the pellet and mixed by pipetting
until the pellet was thawed. Cells were sheared by passing through a syringe needle
(23G) at least 20 times. Tubes containing lysate were then centrifuged in a refrigerated
centrifuge (Legend Micro 17R, Thermo Scientiﬁc) at 9500 x g for 10 min at 4 ◦C to remove
residual insolubles. The supernatant was aliquoted into 0.5 ml tubes, snap frozen in LN2
and stored at -80 ◦C until needed.
2.6.2 Quantiﬁcation of protein concentration
The protein concentration in the samples was determined using the Pierce BCA (Bicin-
choninic acid) kit (Thermo Scientiﬁc). Serial dilutions of BSA (from 5 µg/ml to 25 µg/ml)
in 1X PBS (Invitrogen) were prepared along with serial dilutions of protein extract sam-
ples (1:100, 1:200 and 1:400 in 1X PBS) and blank solutions containing 1X PBS. All
solutions were loaded in duplicates onto 96-well microtitre plate. BCA kit reagents A
and B were mixed in 50:1 ratio. 100 µl of the mix was added to each well and mixed
by pipetting. The plate was then sealed with aluminium foil tape (Greiner Bio-One) and
incubated at 37 ◦C for 1 hour or at room temperature overnight. Plates were read at 590
nm on a microplate reader (BioTek). A standard curve was generated using serial dilu-
tions of BSA and respective protein concentrations in extracted samples were calculated.
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Protein concentration was equalised between samples with cell lysis buﬀer.
2.6.3 Western-blotting analysis
2.6.3.1 Protein sample preparation
Samples were removed from storage at -80 ◦C, placed on ice and allowed to defrost. An
aliquot of the protein extract containing 30 µg of protein was transferred into a fresh 1.5
ml eppendorf and made up to 25 µl with Laemmi buﬀer (0.125 M Tris-HCl pH 6.8, 4%
(w/v) sodium dodecyl sulphate (SDS, Sigma), 40% (v/v) glycerol (Sigma), 0.1% (w/v)
Bromophenol Blue (Sigma), 6% β-mercaptoethanol (Sigma), in ddH2O). Proteins were
denatured by heating samples at 95 ◦C for 5–10 min and quenching on ice just prior to
loading.
2.6.3.2 Casting of polyacrylamide gels
Polyacrylamide gels were set in Mini-Potean III (Bio-Rad) gel casting apparatus with
1.5 mm spacers. Solutions for resolving (10%) and stacking (5%) gels were prepared
according to Table 2.6, but without addition of TEMED. Casting plates were thoroughly
cleaned before use with ddH2O and 70% ethanol. Resolving gel solution was mixed with
the appropriate amount of TEMED and poured into the casting immediately leaving
approximately 1.5 cm from the top of the prospective gel. Resolving solution was overlaid
with 500 µl of ddH2O. After the gel had set the water was drained onto tissue paper. The
stacking solution was then mixed with an appropriate amount of TEMED and poured
into the casting followed by inserting a 10-well comb. After the stacking gel had set, the
plates containing the gels were removed from the casting apparatus, combs were removed
and the wells were rinsed with ddH2O.
Table 2.6: Solutions used for quantitative protein analysis
5% stacking polyacryalmide gel (2 gels) 10% resolving polyacrylamide gel (2 gels)
6.9ml Ultrapure double deionised H2O 6.8ml Ultrapure double deionised H2O
1.7ml 30% acrylamide/bisacrylamide (Sigma) 8.4ml 30% acrylamide/bisacrylamide (Sigma)
1.3ml 1M Tris-HCl pH6.8 9.4ml 1M Tris-HCl pH8.8
100µll 10% [w/v] SDS (Sigma) 250µll 10% [w/v] SDS (Sigma)
66µll 25% [w/v] Ammonium persulphate
(Sigma)
72µll 25% [w/v] Ammonium persulphate
(Sigma)
13.2µll N,N,N,N-tetramethylethylenediamine
(TEMED, Sigma)
13.2µll N,N,N,N-tetramethylethylenediamine
(TEMED, Sigma)
5X Running buﬀer (1L) 1X Transfer buﬀer (1L)
950ml deionised H2O 800ml deionised H2O
15.1g Tris base (Sigma) 200ml Methanol (Fisher)
94g Glycine (Sigma) 2.9g Tris base (Sigma)
50ml 10% [w/v] SDS (Sigma) 14.5g Glycine (Sigma)
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2.6.3.3 Protein separation by SDS-PAGE
Gels were assembled in the Mini-Protean III (Bio-Rad) electrophoresis tank and ﬁlled
with a suﬃcient amount of SDS-PAGE running buﬀer (see Table 2.6). Protein sam-
ples were loaded into the wells, along with full-range Rainbow molecular weight marker
(Amersham). Gels were run at 120V until the dye front reached the end of the gel.
2.6.3.4 Protein transfer to nitrocellulose membrane
After electrophoresis completion the gels were removed from the plates and immersed in
Transfer buﬀer (see Table 2.6). Amersham Hybond-ECL nitrocellulose membrane (GE
Healthcare) was soaked in transfer buﬀer prior to use. The nitrocellulose membrane was
placed on top of the polyacrylamide gel and sandwiched between two sheets of 3MM
blotting paper (Whatman) and sponge, each pre-soaked in transfer buﬀer. This assembly
was then placed into a wet electroblotting system (Flowgen Biosciences). The blotting
tank was ﬁtted with blots so that the current runs through gel towards the ﬁlter, ﬁlled
with transfer buﬀer and placed in a polystyrene box containing ice. The transfer was run
at 100 V for 1 hour.
Table 2.7: Antibody-speciﬁc conditions for Western blotting analysis
Primary
Antibody
Manufacturer Primary antibody
conditions
Secondary antibody
conditions
Anti-Active-
β-Catenin
Millipore
#05-665
1:2000 in 5% milk in
TBS/T, O/N at 4 ◦C
HRP-conjugated anti-mouse
(GE Healthcare) 1:3000 in
5% milk in TBS/T, 1 h at RT
Anti-β-actin Sigma
#A5316
1:5000 in 5% milk in
TBS/T, 1 h at RT
HRP-conjugated anti-mouse
(GE Healthcare) 1:2000 in
5% milk in TBS/T, 1 h at RT
Key: TBS/T Tris buﬀered saline with 0.1% Tween 20, RT room temperature, O/N
overnight
2.6.3.5 Generic protocol for membrane probing
Once the transfer was completed, membranes were removed from the blots and washed
brieﬂy in TBS/T. To prevent non-speciﬁc binding of antibodies, the membranes were
blocked in 5% skimmed milk powder in TBS/T with agitation for 1 hour at room tem-
perature. Membranes were incubated with agitation in blocking solution containing the
appropriate dilution of primary antibodies under conditions speciﬁed in Table 2.7. Mem-
branes were then washed in TBS/T 3 x 10 min. Secondary HRP-conjugated antibody was
diluted to the appropriate concentration with blocking solution and applied to the mem-
branes with agitation according to Table 2.7 followed by 3 x 10 min washes in TBS/T.
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Appropriate amount of ECL reagent kit (Amersham) was used to develop membranes ac-
cording to manufacturer’s instructions. After incubation, ECL reagent was drained from
membranes, which were then wrapped in cling ﬁlm prior to signal detection.
2.6.3.6 Signal detection
Chemiluminescent signal generated by antibody-conjugated HRP processing of ECL reagent
was detected by radiograph exposure. X-ray ﬁlm (FujiFilm Super RX blue background)
was exposed to blots in the darkness for various lengths of time to obtain clear images.
Exposed ﬁlm was processed on an automatic X-ray ﬁlm processor (Xograph Compact
X4). Processed ﬁlms were aligned with the original blot and the positions of molecular
weight markers were marked on the ﬁlm to identify target proteins.
2.7 Quantitative and statistical analysis of data
2.7.1 Quantitative analysis of histological parameters
Quantitative analysis of tissue sections was carried out using an Olympus BX41 light
microscope. Sample IDs were covered on all slides before scoring to avoid possible bias.
Areas to be quantiﬁed were carefully selected to ensure that they belong to approximately
the same region of the intestine and are free of sectioning artefacts. Quantiﬁable traits,
such as crypt and villus length, mitosis and apoptosis levels, number of diﬀerentiated
cells of particular types, etc. were scored on appropriately stained tissue sections. A
minimum of 50 half-crypt or half-crypt-villus axes were stained per mouse and at least 3
diﬀerent animals per genotype were examined to allow for statistical analysis. Individual
‘crypt’ scores were averaged to generate a ‘mouse’ score. And scored from all mice of the
same genotype were used to calculate average ‘group’ value as well as standard deviation.
Average ‘group’ values were plotted as histograms with error bars representing standard
deviation within each group. MS Excel 2003 was primarily used for graphical representa-
tion of the data. Individual ‘mouse’ values were also used to test for signiﬁcant diﬀerence
between means as described below. For all tests, the use of one- or two-tailed test was
decided on a case-by-case basis, depending on the appropriate null hypothesis.
2.7.2 Comparison of means
Quantitative data was ﬁrst tested for normal distribution using normal plot of residuals
and Anderson-Darling test in Minitab statistical analysis software (version 15.1.30.0).
Normally distributed data (Anderson-Darling test p≥0.05) was then tested for signiﬁcant
diﬀerence between means using One-Way ANOVA using SPSS sowtware (version 16.0.2).
If data from more than two groups were compared, One-Way ANOVA test was used to
establish the diﬀerence across all the groups and Post-Hoc Tukey’s test was subsequently
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employed to perform pair-wise comparisons between groups. These tests were carried out
using SPSS software. A signiﬁcant diﬀerence between means was accepted, when p value
was equal or less than 0.05.
Non-normally distributed data (Anderson-Darling test p≤0.05) was tested for signif-
icant diﬀerence between means using Mann-Whitney U test. The test was performed in
SPSS software. A signiﬁcant diﬀerence between means was accepted, when p value was
equal or less than 0.05.
2.7.3 Comparison of medians
Measured (as opposed to scored) parameters, such as tumour size and position, were
tested for signiﬁcant diﬀerence between medians rather than means. Mood’s Median Test
was performed on such datasets using Minitab software. A signiﬁcant diﬀerence between
medians was accepted, when p value was equal or less than 0.05.
2.7.4 Kolmogorov-Smirnov Z test
Kolmogorov-Smirnov Z test was used to test for the signiﬁcant diﬀerence in distribution
between two data sets. To assess the distribution of speciﬁc cells (i.e. BrdU positive,
Ki67 positive, Caspase-3 positive, apoptotic or Paneth cells) the positions of positive cells
were recorded using a following method. Each half-crypt was represented as a column of
numbers in a spreadsheet with positive cells recorded as 1 and negative cells recorded as 0.
Counting was started from the crypt-base so that the row in the column corresponded to
cell position on the crypt-villus axis. This was repeated for 50 half-crypts per mouse. The
sum of all 1 and 0 in any given row (at any given position) in every mouse was calculated
and sums of all the mice of the same genotype were pooled together. These intermediate
data sets were used to build graphs of cumulative frequency of positive cells using SPSS
16.0.2.
To test for the diﬀerence in distribution between the biological groups, the intermediate
data set was transformed using a custom-written KST (Kolmogorov-Smirnov Transforma-
tion) program (http://bio.bsu.by/t/temp/holik/KST/). KST was used to transform the
number of instances of cells at a given position in a sequence of numbers corresponding to
this position. For instance, number 43 in row 7 of the intermediate data set would mean
that out of all half-crypts in all the mice of a given genotype, 43 half-crypts contained a
positive cell at position 7. After transformations with KST, number 43 in row 7 would be
represented by 43 instances of number 7 and so on. Transformed data sets for each mouse
were then subjected to Kolmogorov-Smirnov Z test using SPSS software. The two-tailed
test was used throughout and statistically signiﬁcant diﬀerence between distributions was
accepted, when p value was less or equal 0.05.
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2.7.5 Kaplan-Meier survival analysis
Survival analysis and generation of survival curves was performed using the Kaplan-Meier
method with the aid of MedCalc software (version 8.2.1.0). Statistical signiﬁcance between
survival time of diﬀerent experimental cohorts was assessed using the Log-Rank method.
Diﬀerences in survival probability were accepted as signiﬁcant, when p value was less or
equal 0.05.
Chapter 3
Investigating the eﬀects of Brg1 loss
in the small intestinal epithelium
3.1 Introduction
Brg1 has been implicated in a diverse range of physiological and pathological processes
at both the cellular and organismic levels consistent with its involvement in mediation
of various signalling pathways (Trotter and Archer, 2008). Of particular interest is the
involvement of Brg1 in mediation of the Wnt signalling pathway. As has been previously
mentioned, a number of studies have implicated Brg1 in the trans-activation of Wnt
pathway target genes in both physiological and pathological environments (Barker et al.,
2001; Griﬃn et al., 2008; Park et al., 2009). The observation that suppression of Brg1
function impaired the expression of Wnt target genes in colorectal cancer cells (Barker
et al., 2001) positions Brg1 as a potential therapeutic target for Wnt driven neoplasia.
However, there is a concern that targeting Brg1 may have adverse eﬀects, particularly
in tissues that rely on Wnt signalling to maintain homeostasis. The small intestinal
epithelium has long been known to require Wnt signalling for its maintenance (Korinek
et al., 1998). More speciﬁcally, the intestinal stem cells have been shown to depend
on active Wnt signalling for their self-renewal (Fevr et al., 2007). The small intestinal
epithelium, therefore, represents a suitable tissue to analyse the eﬀects of Brg1 loss in
a cellular environment reliant on Wnt signalling for its homeostasis. Furthermore, the
murine small intestinal epithelium is commonly used as a model tissue to study human
CRC (reviewed in Heyer et al., 1999). It, therefore, appears appropriate to investigate
the consequences of Brg1 deﬁciency in the normal small intestinal epithelium in order to
explore its suitability as a potential therapeutic target for the Wnt-driven neoplasia.
Conversely, Brg1 loss (Becker et al., 2009; Reisman et al., 2003; Wong et al., 2000)
and haploinsuﬃciency (Bultman et al., 2007, Glaros et al., 2008) have been suggested to
contribute to tumourigenesis in a range of tissues. Targeting Brg1, therefore, may have a
potential oncogenic eﬀect and thus undermine the value of Brg1 as a therapeutic target
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in cancer.
This chapter aims to characterise the eﬀects of Brg1 deﬁciency and haploinsuﬃciency
in the small intestinal epithelium using a range of conditional transgenic approaches.
3.2 Results
3.2.1 Generation of small intestinal speciﬁc conditional Brg1
knock-out models
In order to investigate the eﬀects of Brg1 loss in the small intestinal epithelium, I exploited
Cre recombinase conditional knock-out system using targeted Brg1 alleles with loxP sites
ﬂanking exones 2 and 3 (Figure 2.1a, Sumi-Ichinose et al., 1997). Recombination between
the loxP sites within Brg1 alleles was achieved using a number of diﬀerent Cre recombi-
nases with distinct expression patterns and means of regulation. Initially, animals carrying
loxP targeted Brg1 alleles were intercrossed with mice bearing the Tg(Cyp1a1-cre)1Dwi
transgene (abbreviated here as AhCre) (Ireland et al., 2004). AhCre recombinase is ex-
pressed under control of an Aryl hydrocarbon (Ah) promoter element derived from the
rat cytochrome P4501A1 gene, which is induced by intraperitoneal administration of
beta-naphthoﬂavone in a range of tissues, such as intestinal epithelium, liver, pancreas
and others (Ireland et al., 2004). In the small intestinal epithelium the expression of the
AhCre recombinase is conﬁned to the bottom of the crypt, where it is primarily expressed
in the stem cell and early progenitor cell populations (Figure 3.1b). Expression of AhCre
recombinase in the small intestinal epithelium was conﬁrmed using the Gt(ROSA)26Sor
(further referred to as LacZ ) reporter allele to drive expression of β-galactosidase gene
upon Cre recombinase mediated removal of a loxP ﬂanked stop-cassette (Soriano, 1999).
Positive staining for β-galactosidase activity was detected in nearly 100% of the small
intestinal epithelium upon induction of AhCre recombinase (Figure 3.1a).
Unfortunately, due to oﬀ-target-tissue expression of AhCre recombinase during em-
bryonic development loxP targeted Brg1 alleles conferred embryonic lethality. In order
to overcome undesirable consequences of oﬀ-target AhCre recombinase expression, I em-
ployed Tg(Cyp1a1-cre/ESR1)1Dwi transgene (abbreviated here as AhCreER) (Kemp et
al., 2004). While AhCreER recombinase shares the expression pattern with AhCre (Fig-
ure 3.1b), the synthesised protein is sequestered in the cytoplasm due to the presence of
a modiﬁed hormone-binding domain of the oestrogen receptor (ER). AhCreER recombi-
nase therefore requires additional activation with tamoxifen, binding to which allows the
recombinase to be translocated to nucleus, where it is able to facilitate recombination
between the loxP sites. Introduction of the oestrogen receptor domain therefore provides
additional level of control over the recombinase activity. Staining for β-galactosidase
activity revealed that tighter regulation of the recombinase activity resulted in a lower
recombination frequency in the small intestine of AhCreER+LacZ+ mice compared to
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Figure 3.1: Comparative assessment of Cre recombinase eﬃciency in the small intestinal epithelium.
(a) Analysis of Cre recombinase eﬃciency was conducted using the ROSA26R/LacZ transgene preceded
by the loxP targeted PGK-Neo-STOP cassette. Induction of Cre recombinase activity results in PGK-
Neo-STOP cassette excision and expression of the LacZ gene. Expression of the latter can be visualised
by staining tissues of interest with X-gal substrate. Animals carrying the ROSA26R/LacZ reporter and
Cre recombinase were induced using diﬀerent induction protocols dependent on Cre recombinase present
(VillinCreER recombinase was induced using low-dose protocol). Cre− mice induced with respective
induction methods were used as negative controls. Mice were aged for between 15 and 30 days, when they
were dissected and the third 8 cm region of the small intestinal epithelium was harvested and stained with
X-gal. Analysis of LacZ expression in AhCreER+/LacZ mice revealed rare blue crypt-villus structures
at variable frequencies. LacZ staining of AhCre+/LacZ intestine displayed near 100% eﬃciency of
recombination. Intestine of V illinCre+/LacZ mice induced with the low-dose protocol, revealed LacZ
positive staining in approximately 50% of crypt-villus structures. No LacZ positive staining was detected
in Cre− animals. (b-c) Schematic representation of diﬀerences between recombination patterns induced
by AhCreER and VillinCre recombinases in the small intestinal epithelium. (b) AhCreER recombinase
drives recombination of targeted alleles in stem and early progenitor cells, progeny of which then can
populate the rest of the crypt and an associated villus (c) VillinCre recombinase drives recombination
of the targeted alleles in all epithelial cells of the small intestinal epithelium thus causing simultaneous
gene deletion in all cell populations.
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AhCre+LacZ+ animals (Figure 3.1a).
In order to obtain a further increase in the recombination eﬃciency, while avoiding oﬀ-
target recombination, I also interbred mice harbouring targeted Brg1 alleles with animals
expressing Cre recombinase under the control of Villin1 promoter (Vil1 ) (el Marjou et al.,
2004). Tg(Vil-cre/ESR1)23Syr transgene (further abbreviated as VillinCre) is expressed
along the entire length of the small and large intestine and its nuclear activity is induced
by intraperitoneal administration of tamoxifen. In contrast to AhCre and AhCreER
recombinases, VillinCre recombinase is expressed in all the cells comprising the intestinal
epithelium, both in the crypt and villus (Figure 3.1c). LacZ staining of the small intestinal
epithelium from V illinCre+LacZ+ mice induced with the low-dose protocol (2.1.3.2)
demonstrated eﬃcient recombination in more then 50% of small intestinal crypts (Figure
3.1). At the same time, high-dose induction protocol was able to drive near 100% eﬃcient
recombination in the small intestine of V illinCre+LacZ+ mice (not shown).
3.2.2 Brg1 loss under the control of AhCre recombinase results
in embryonic lethality
I initially attempted to delete Brg1 under the control of AhCre recombinase. However,
animals carrying both Brg1 loxP targeted alleles and the AhCre recombinase transgene
(AhCre+Brgfl/fl) were signiﬁcantly under-represented at weaning age (Chi-square test,
p<0.01). In order to investigate the disproportionately low numbers of AhCre+Brgfl/fl
animals at this time point I assessed the relative frequency of AhCre+Brgfl/fl genotype
at diﬀerent stages of development. Genotyping of 38 embryos at E19.5 failed to detect
any embryos with the AhCre+Brgfl/fl genotype (expected frequency 25%). This indi-
cated that oﬀ-target expression of AhCre recombinase could cause embryonic lethality of
AhCre+Brgfl/fl mice. Genotyping of 20 embryos at E15.5 demonstrated that AhCre+-
Brgfl/fl mice were present at the expected frequency, suggesting that AhCre+Brgfl/fl
animals died in utero between E15.5 and E19.5. Histological inspection of paraﬃn embed-
ded embryos at E15.5 revealed that AhCre+Brgfl/fl embryos were consistently smaller
in size and underdeveloped compared to AhCre−Brgfl/fl littermates (Figure 3.2a). Since
embryonic lethality was most likely caused by the loss of Brg1 in tissues with non-speciﬁc
expression of AhCre recombinase, I stained paraﬃn embedded sections of the embryos
at day E15.5 with antibodies against Brg1. The staining revealed areas of Brg1 loss
in regions of the choroid plexus, hind limb and tail (Figure 3.2b, white arrowheads)
of AhCre+Brgfl/fl embryos, while Brg1 was ubiquitously expressed in control embryos
(Figure 3.2a and b). Although this observation conﬁrmed alternative sights of Brg1 loss
during embryonic development, the limited pattern of Brg1 loss failed to explain in utero
lethality. It is plausible, however, that Brg1 deﬁcient cells are rapidly eliminated and that
the areas of Brg1 loss detected in E15 AhCre+Brgfl/fl embryos represent only those Brg1
deﬁcient cells with a slower elimination rate.
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Figure 3.2: AhCre recombinase drives oﬀ-target Brg1 loss during embryonic development. Pregnant
dams were dissected at day 16 after discovery of the plug. Embryos were harvested, ﬁxed in ice cold for-
malin and processed for histological analysis. (a) Left panels: Visual inspection of H&E stained sections
of AhCre+Brgfl/fl embryos at day E15.5 revealed a consistently smaller size, delayed development and
dilated cerebral ventricles compared to AhCre− controls. Right panels: Immunostaining of embryo sec-
tions with Brg1 antibody revealed ubiquitous Brg1 expression. (b, c) Closer inspection of Brg1 stained
sections of embryos at day E15.5 revealed loss of Brg1 expression in the vicinity of the choroid plexus
(b) and hind limb (c). Error bars represent 500 µm (a, c), 100 µm (b).
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3.2.3 AhCre+Brg+/fl mice are viable and not prone to intestinal
tumourigenesis
WhileAhCre+Brgfl/fl mice died in utero, heterozygousAhCre+Brg+/fl pups were present
at the expected ratio at the time of weaning and were viable and fertile. Mice with het-
erozygous loss of Brg1 have been reported to be prone to mammary and lung tumourigen-
esis (Bultman et al., 2007; Glaros et al., 2008). Notably, tumours developing in those mice
retained a functional copy of Brg1, indicating that Brg1 haploinsuﬃciency rather than
loss of heterozygousity contributed to tumourigenesis. In order to investigate the eﬀects of
Brg1 haploinsuﬃciency on intestinal tumourigenesis a cohort of AhCre+Brg+/fl (n=10)
animals was aged along with AhCre+Brg+/+ controls (n=9). Mice from both groups
were induced with four intraperitoneal injections of 80 mg/kg β-naphthoﬂavone at 8 hour
intervals and regularly inspected for signs of intestinal tumourigenesis. All mice were
sacriﬁced at 600 days post induction (PI) or earlier if found to display signs of ill health.
To conﬁrm that the targeted Brg1 allele was deleted upon activation of the AhCre recom-
binase, DNA was extracted from the small intestinal samples of AhCre+Brg+/fl mice.
Recombined PCR performed on the intestinal samples revealed the presence of the re-
combinant product as late as day 600 PI (Figure 3.3), indicating long-term retention of
the Brg1 heterozygous cells in the small intestinal epithelium.
Figure 3.3: Brg1 heterozygous cells are retained in AhCre expressing tissues over a long time. A PCR
reaction designed to detect the product of recombination of loxP sites in the targeted Brg1 allele was
carried out using DNA extracted from formalin ﬁxed tissue sections of AhCre+Brg+/fl and AhCre+-
Brg+/+ mice at day 600 PI. At least two mice per group were genotyped. Primers used for routine
genotyping were used as a positive control to test for the presence of DNA in the sample and to conﬁrm
the genotype of the animal (407 bp and 500 bp products are ampliﬁed from the wild type and targeted Brg1
alleles respectively, top section). Recombination-speciﬁc product (529 bp, bottom panel) was detected in
all tissues from AhCre+Brg+/fl mice with the exception of the bladder urothelium. No recombination-
speciﬁc product was detected in any of the DNA samples extracted from AhCre+Brg+/+ animals.
Survival analysis of AhCre+Brg+/fl (n=10) and control (n=9) animals demonstrated
no signiﬁcant diﬀerence between the cohorts (Figure 3.4, p=0.097 Log-Rank test, n≥9).
Notably, AhCre+Brg+/fl mice that became ill and had to be sacriﬁced prior to 600 days
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PI displayed no symptoms of intestinal tumourigenesis, such as pale feet, loss of weight or
faecal blood. Coincidentally, macro- and microscopic examination of the small intestine
from the animals with heterozygous Brg1 loss did not detect any signs of tumourigenesis.
Figure 3.4: Heterozygous loss oﬀ Brg1 does not impair animal survival. Cohorts of AhCre+Brg+/fl
(n=10) and AhCre+Brg+/+ mice (n=9) were induced with an appropriate protocol and aged for 600
days or until developed signs of ill health. Survival data was presented as a Kaplan-Meyer plot. No
signiﬁcant diﬀerence in survival probability was observed between the cohorts (Log-Rank test p=0.097,
n≥9)
3.2.4 AhCreER recombinase drives mosaic loss of Brg1 in AhCreER+-
Brgfl/fl mice
In order to overcome the embryonic lethality of Brg1 deﬁcient animals caused by oﬀ-target
expression of AhCre recombinase animals bearing targeted Brg1 alleles were intercrossed
with mice bearing AhCreER recombinase. The resulting AhCreER+Brgfl/fl mice were
viable and fertile.
To inactivate Brg1 in the small intestine under the control of AhCreER recombi-
nase, a cohort of AhCreER+Brgfl/fl mice along with AhCreER−Brgfl/fl controls were
induced by ﬁve intraperitoneal bi-daily injections of 80 mg/kg β-naphthoﬂavone and ta-
moxifen. Immunohistochemical analysis of Brg1 expression in the intestinal epithelium
of AhCreER+Brgfl/fl mice detected Brg1 deﬁcient cells as early as day 3 PI (Figure
3.5, black arrowheads). Consistent with the expression pattern of AhCreER recombinase,
Brg1 deﬁcient cells were mainly detected within the crypts or at the bottom of villi. Re-
ﬂecting the low frequency of AhCreER recombinase activation, Brg1 loss in the small
intestinal epithelium was mosaic with the majority of Brg1 negative cells found in small
clusters rather than populating full crypts (Figure 3.5, black arrowheads).
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Figure 3.5: AhCreER recombinase drives mosaic loss of Brg1 in the small intestinal epithelium.
AhCreER+Brgfl/fl mice along with AhCreER−Brgfl/fl controls were induced with an appropriate
protocol and dissected at day 3 PI. Immunohistochemical analysis of Brg1 expression revealed mosaic
loss of Brg1 in the small intestinal epithelium of AhCreER+Brgfl/fl mice (black arrowheads). No ex-
tensive areas of Brg1 loss were detected in the small intestine of control mice. Scale bars represent 100
µm.
3.2.5 Brg1 deﬁcient cells are repopulated with wild type cells
in AhCreER+Brgfl/fl mice
To analyse long-term fate of Brg1 deﬁcient cells in the small intestinal epithelium, AhCreER+-
Brgfl/fl mice and AhCreER−Brgfl/fl controls were dissected at various time points after
induction. Sections of the small intestine taken from these mice were stained with Brg1
antibody and inspected for the presence of Brg1 deﬁcient cells. Quantiﬁcation of the
crypts retaining Brg1 deﬁcient cells revealed a steady decrease in the frequency of such
crypts with time (Figure 3.6a and b). By day 15 PI the majority of Brg1 deﬁcient
cells were eliminated and replaced with cells retaining intact Brg1 alleles (Figure 3.6a).
Immunohistochemical analysis of Brg1 expression in the small intestinal epithelium of
AhCreER+Brgfl/fl mice 35 days PI failed to detect any Brg1 deﬁcient cells indicating
that the epithelium was entirely repopulated with wild type cells.
3.2.6 AhCreER recombinase drives recombination in the stem
cell compartment
Gradual elimination of Brg1 deﬁcient cells could be explained by Brg1 loss being limited
to short-lived progenitor cells as opposed to the stem cells. If AhCreER recombinase
activity induces Brg1 loss only in progenitor cells, such as those residing in the TA zone,
eventual exhaustion of the proliferative potential of Brg1 deﬁcient cells would cause their
migration towards the villus tip and gradual disappearance. Conversely, if AhCreER
drives loss of Brg1 in the stem cell compartment, Brg1 deﬁcient cells are expected to
Chapter 3. The eﬀects of Brg1 loss in the small intestinal epithelium 89
Figure 3.6: Brg1 deﬁcient cells are repopulated with wild type cells in AhCreER+Brgfl/fl small intes-
tine. AhCreER+Brgfl/fl mice were induced with an appropriate protocol and dissected at days 3, 5 , 7,
10 and 15 PI. Small intestinal samples harvested at each time point were subjected to immunohistochem-
ical analysis of Brg1 expression. The number of crypts with more than 5 Brg1 deﬁcient cells (b, black
arrowheads) was scored per total number of crypts. Both quantitative (a) and visual (b) analysis of Brg1
expression revealed a gradual decrease in the number of Brg1 deﬁcient crypts, which almost completely
disappeared by day 15 PI. A minimum of 3 mice per time point was analysed. Scale bars represent 100
µm.
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persist in the small intestinal epithelium over an extended period of time. Although
AhCreER recombinase has been previously reported to drive recombination of loxP tar-
geted alleles in intestinal stem cells (Kemp et al., 2004), diﬀerences in genetic background
of the animals could aﬀect its eﬃciency. I, therefore, aimed to validate whether the
present induction protocol induced AhCreER recombinase activity in the intestinal stem
cell population. In order to trace recombination events, I employed the LacZ reporter al-
lele expressing β-galactosidase gene from ROSA26 locus (Soriano, 1999). Presence of loxP
ﬂanked STOP-cassette upstream of β-galactosidase sequence facilitates Cre-recombinase
mediated activation of the reporter expression. AhCreER+LacZ+Brg+/+ animals were
induced with ﬁve bi-daily intraperitoneal injections of 80 mg/kg β-naphthoﬂavone and
tamoxifen and the small intestines were harvested 30 days later. Consistent with previous
reports (Kemp et al., 2004), staining for β-galactosidase activity revealed the presence
of positively stained crypts in the small intestine of AhCreER+, LacZ,Brg+/+ animals
albeit at low frequency (Figure 3.7). This observation suggested that elimination of Brg1
deﬁcient cells was not due to lack of recombination in the stem cell compartment.
Figure 3.7: AhCreER recombinase drives recombination in the stem cell compartment.
AhCreER+LacZ+Brg+/+ were induced with an appropriate protocol along with AhCreER− controls.
Animals were aged for 30 days PI, at which point the small intestinal tissue was harvested and stained
with X-gal substrate in order to visualise expression of the LacZ reporter. Analysis of X-gal staining
revealed LacZ positive crypts in the small intestinal epithelium of AhCreER+LacZ+Brg+/+ mice, con-
ﬁrming recombination event in long-term surviving stem cells. Frequency of LacZ positive crypts, however
was low and highly variable between diﬀerent animals as well as between diﬀerent sections of the small
intestinal epithelium. No LacZ positive crypts were observed in the small intestine of control AhCreER−
animals.
3.2.7 Low-dose induction of VillinCre recombinase drives par-
tial loss of Brg1 and subsequent repopulation with wild
type cells
While tighter regulation of AhCreER recombinase activity overcame embryonic lethality,
the low frequency of Brg1 loss made it impossible to analyse the mechanism behind
elimination of Brg1 deﬁcient cells in AhCreER+Brgfl/fl intestine. To avoid non-speciﬁc
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recombinase expression while maintaining high levels of recombination I intercrossed mice
carrying targeted Brg1 alleles with mice expressing VillinCre recombinase. The resulting
V illinCre+Brgfl/fl mice were viable and fertile.
In order to recapitulate elimination of Brg1 deﬁcient cells observed in AhCreER+-
Brgfl/fl epithelium, Brg1 loss was induced in V illinCre+Brgfl/fl mice at low frequency
by single intraperitoneal injection of 40 mg/kg tamoxifen. Small intestine samples were
harvested 5 and 30 days PI. Immunohistochemical analysis of Brg1 expression at day 5 PI
revealed mosaic loss of Brg1 with clusters of Brg1 deﬁcient cells detected both in the crypts
and villi of the small intestine of V illinCre+Brgfl/fl mice (Figure 3.8). However, by
day 30 PI the small intestinal epithelium of V illinCre+Brgfl/fl mice was predominantly
composed of Brg1 positive cells, once again indicating strong selective pressure against
Brg1 deﬁcient cells (Figure 3.8). The only cells retaining Brg1 deﬁcient status at 30 days
PI were Paneth cells, consistent with their low turnover rate (Figure 3.8, inset).
Figure 3.8: Low-dose induction of VillinCre recombinase drives partial loss of Brg1, which are subse-
quently repopulated with wild type cells V illinCre+Brgfl/fl were induced with the low-dose protocol
along with Cre− controls and the small intestine samples were harvested at 5 and 30 days PI. Immuno-
histochemical analysis of Brg1 expression revealed a mosaic pattern of Brg1 loss in the small intestine
of V illinCre+Brgfl/fl mice at day 5 PI. Brg1 deﬁcient cells, however, were largely eliminated from
V illinCre+Brgfl/fl small intestine at day 30 PI. The only Brg1 deﬁcient cells present at day 30 PI were
represented by the Paneth cells (inset, white arrowheads) intercalated between Brg1 positive CBC cells
(inset, black arrowheads). No extensive clusters of Brg1 deﬁcient cells were detected in the small intestine
of control mice at any time point.
To indirectly conﬁrm the selective pressure against Brg1 deﬁcient cells I used the LacZ
reporter allele to trace recombination events through the expression of β-galactosidase.
Mice carrying VillinCre, LacZ and either two wild type or two targeted Brg1 alleles were
induced with a low-dose protocol and the small intestine was harvested 30 days after
induction. Staining for β-galactosidase activity revealed a substantial number of LacZ
positive crypt-villus units (approximately 65%) in animals bearing intact Brg1 alleles, in-
dicating that induction using the low-dose protocol was suﬃcient to cause recombination
in a substantial proportion of the intestinal stem cells (Figure 3.9, middle panel). How-
ever, consistent with the apparent selection against Brg1 deﬁcient cells, the number of
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LacZ positive crypt-villus units was reduced in the intestine of V illinCre+LacZ+Brgfl/fl
mice approximately ﬁve-fold compared to V illinCre+LacZ+Brg+/+ intestines (Figure
3.9, right panel), suggesting that a large proportion of stem cells that had undergone
deletion of Brg1 were subsequently eliminated and replaced with wild type counterparts.
This observation implies incompatibility of Brg1 loss with long-term stem cell retention
in the small intestinal epithelium.
Figure 3.9: Brg1 deﬁcient cells are repopulated with wild type cells in the small intestinal epithelium of
V illinCre+Brgfl/fl mice. The LacZ reporter was used to indirectly conﬁrm elimination of Brg1 deﬁcient
cells from the small intestinal epithelium. V illinCre+LacZ+Brgfl/fl mice were induced with the low-
dose protocol along with positive V illinCre+LacZ+Brg+/+ and negative Cre− controls. Mice were
dissected at day 30 PI and LacZ expression was visualised in the whole mounted small intestine by staining
with X-gal substrate. LacZ expression was observed in approximately 50% of crypt-villus structures in
V illinCre+Brg+/+ intestine indicating eﬀective recombination in the stem cell compartment. Positive
crypts were largely lost in the small intestine of V illinCre+Brgfl/fl mice indicating negative selection
against retention of Brg1 deﬁcient stem cells. No LacZ expression was observed in the small intestine of
Cre− control mice.
3.2.8 High-dose induction of VillinCre recombinase drives com-
plete loss of Brg1
In order to dissect the mechanism behind elimination of Brg1 deﬁcient cells and fur-
ther investigate the immediate eﬀects of Brg1 loss on small intestinal homeostasis, I
attempted to drive complete loss of Brg1 in the intestinal epithelium. Cohorts of experi-
mental V illinCre+Brgfl/fl and control V illinCre−Brgfl/fl animals were induced with 4
daily intraperitoneal injections of tamoxifen. Animals were sacriﬁced and small intestines
harvested at 4 days PI. At the time of dissection, the intestinal morphology was indistin-
guishable between control and experimental animals. Immunohistochemical analysis of
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Brg1 expression at 4 days PI revealed near complete loss of Brg1 in the epithelial compart-
ment of the small intestine of V illinCre+Brgfl/fl mice (Figure 3.10). Brg1 expression was
however retained in the stromal compartment, consistent with the expression pattern of
VillinCre recombinase (el Marjou et al., 2004). Microscopic examination of H&E-stained
sections of the small intestine revealed no diﬀerence in histological appearance between
animals from control and experimental cohorts. Gross intestinal architecture appeared
indistinguishable between the two cohorts (Figure 3.10).
Figure 3.10: High-dose induction of VillinCre recombinase drives complete loss of Brg1. V illinCre+-
Brgfl/fl mice were induced with high-dose protocol along with Cre− controls. Analysis of H&E stained
small intestinal sections revealed no gross diﬀerences in epithelial morphology between Brg1 control and
Brg1 deﬁcient epithelium at day 4 PI (top panels). Immunohistochemical analysis of Brg1 expression
revealed near complete loss of Brg1 expression in the small intestinal epithelium of V illinCre+Brgfl/fl
mice at day 4 PI (bottom panels). Scale bars represent 200 µm.
3.2.9 Brg1 loss has mild immediate eﬀects on small intestinal
homeostasis
Although Brg1 deﬁcient epithelium did not display obvious morphological abnormalities,
quantitative analysis of histological and functional parameters of the intestinal epithelium
revealed a number of subtle diﬀerences between Brg1 deﬁcient and control animals. The
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results of quantitative analysis of histological parameters in control and V illinCre+-
Brgfl/fl animals are collated in Table 3.1.
Table 3.1: Quantitative analysis of the eﬀects of Brg1 loss on the small intestinal histology
Parameter Cohort Mean SD p Value
Crypt Length (cells)
Control 27.48 1.86
0.570
Brg1 KO 28.13 1.78
Villus Length (cells)
Control 76.11 3.26
0.003
Brg1 KO 67.31 3.82
Apoptosis per
half-crypt
Control 0.14 0.09
0.005
Brg1 KO 0.41 0.14
Caspase positive cells
per half-crypt
Control 0.11 0.04
0.073
Brg1 KO 0.29 0.16
Mitosis per half-crypt
Control 0.25 0.05
0.054
Brg1 KO 0.34 0.08
Ki67 positive cells per
half-crypt
Control 17.28 4.28
0.475
Brg1 KO 15.29 2.98
BrdU positive cells
per half-crypt
Control 8.41 0.90
0.038
Brg1 KO 9.77 0.61
Small intestinal tissue samples from V illinCreER− (marked here as Control) and
V illinCreER+Brgfl/fl (marked here as Brg1 KO) mice were collected at day 4 PI. Histologi-
cal parameters, such as crypt and villus length, apoptosis, proliferation and BrdU incorporation were
quiantiﬁed and compared between the two cohorts.
Crypt and villus lengths were scored on H&E stained sections as the average num-
ber of cells (± standard deviation) between the crypt base and the crypt-villus junction
and between the crypt-villus junction and the tip of the villus respectively. Crypt size
was found to be unaltered in control versus Brg1 deﬁcient epithelium (27.48±1.86 and
27.13±1.78, p=0.57, n≥5, Figure 3.11a). Conversely, quantiﬁcation of the villus length
detected a small decrease in the villus size of V illinCre+Brgfl/fl mice (76.11±3.26 and
67.31±3.82, p=0.003, n≥5, Figure 3.11b).
Apoptosis and mitosis levels were scored on H&E stained sections as the average
number (± standard deviation) of apoptotic bodies and mitotic ﬁgures per half-crypt
respectively. Quantiﬁcation of apoptotic bodies within the crypts revealed a statisti-
cally signiﬁcant elevation of apoptosis levels in Brg1 deﬁcient intestine (0.14±0.09 and
0.41±0.14, p=0.005, n≥5, Figure 3.11c). This observation, however, was not conﬁrmed
by scoring of cleaved Caspase-3 positive cells as no signiﬁcant diﬀerence was detected
between the control and experimental animals (0.11±0.04 and 0.29±0.16, p=0.073, n=4,
Figure 3.11c).
Scoring of mitotic ﬁgures revealed no diﬀerence in mitosis levels in control versus ex-
perimental animals (0.25±0.05 and 0.34±0.08, p=0.054, n≥5, Figure 3.11e). In order to
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Figure 3.11: Histological analysis of the eﬀects of short-term Brg1 deﬁciency in the small intestinal
epithelium. Control Cre− and experimental V illinCre+Brgfl/fl mice were induced with the high-dose
protocol and samples of the small intestinal epithelium were harvested at day 4 PI. (a-f) Histological
parameters such as crypt length (a), villus length (b), apoptosis ((c), left panel) and mitosis (e) were
scored on H&E stained sections from control (white bars) and V illinCre+Brgfl/fl (grey bars) small
intestines. The average number of BrdU (d), cleaved Caspase3 ((c), right panel) and Ki67 (f) positive
cells was scored on respective immunostained sections. Error bars represent standard deviation. Aster-
isks mark histological parameters, which displayed a statistically signiﬁcant diﬀerence (p value <0.05)
between the groups. Exact values, standard deviations, respective p values and number of animals anal-
ysed are provided in Table 3.1; (g) Cumulative frequency analysis revealed no diﬀerence in positional
distribution of Ki67 positive cells between control and experimental animals (Kolmogorov-Smirnov Z test
p=0.676, n=4); (h) Immunohistochemical analysis of Ki67 expression revealed no gross changes between
proliferative compartments of control and V illinCre+Brgfl/fl small intestines. Scale bars represent 100
µm.
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validate mitosis levels obtained from quantiﬁcation of mitotic ﬁgures, sections of the Brg1
deﬁcient and control intestine were stained with the cell proliferation marker Ki67. Quan-
tiﬁcation of the cells stained positive for Ki67 detected no change in the average number of
proliferating cells per half-crypt in control versus Brg1 deﬁcient samples (17.28±4.28 and
15.29±2.98, p=0.475, n=4, Figure 3.11f). Additionally, distribution of the Ki67 positive
cells was analysed in order to assess the shape of the proliferative compartment. Anal-
ysis of the cumulative frequency of Ki67 positive cells in the crypt showed no diﬀerence
in distribution of proliferating cells (Kolmogorov-Smirnov Z test p=0.676, n=4, Figure
3.11g and h).
Finally, the number of cells in S-phase of the cell cycle was estimated using the DNA la-
belling agent BrdU. V illinCre+Brgfl/fl and control mice were treated with BrdU reagent
2 hours prior to dissection. Small intestinal sections from treated mice were then stained
with antibodies against BrdU. In contrast to proliferation levels derived from quantiﬁ-
cation of mitotic ﬁgures and Ki67 expression, analysis of BrdU incorporation 2 hours
post labelling demonstrated a signiﬁcant increase in the average number of BrdU positive
cells per half-crypt in V illinCre+Brgfl/fl mice (8.41±0.9 and 9.77±0.61, p=0.038, n≥4,
Figure 3.11d).
Overall, quantitative analysis of the morphological and functional parameters of the
small intestinal epithelium demonstrated that Brg1 loss had a mild eﬀect on small intesti-
nal homeostasis slightly decreasing villus length, apoptosis levels and cell entry into the
S-phase of the cell cycle.
3.2.10 Brg1 loss impairs migration of the intestinal epithelium
In order to analyse the eﬀects of Brg1 loss on epithelial cell migration a BrdU pulse-
chase experiment was carried out. Cohorts of V illinCre+Brgfl/fl and control animals
(n≥3) were treated with BrdU reagent on day 4 PI. One group of mice from both cohorts
was then dissected 2 hours after BrdU administration to assess the number of cells in
S-phase. Another group of mice was left for 24 hours after BrdU administration and
dissected at day 5 PI to assess cell migration. In order to quantify migratory ability of
the epithelial cells in Brg1 deﬁcient and control intestine, I scored positions of the BrdU-
labelled cells and analysed their cumulative frequency, Positional quantiﬁcation of BrdU
positive cells 2 hours after labelling detected BrdU labelling to be mainly restricted to
the crypt, consistent with the location of the proliferative compartment (median position
10.5 cells for experimental and control animals, Figure 3.12a).
Despite identical median position of BrdU positive cells, distributional analysis of
BrdU-incorporation 2 hours post labelling revealed a signiﬁcant diﬀerence in distribution
of BrdU positive cells between control and experimental animals (Kolmogorov-Smirnov Z
test p=0.005, n≥4, Figure 3.12a). The frequency of BrdU-labelled cells in Brg1 deﬁcient
epithelium was increased towards the top of the crypt (Figure 3.12a). On contrary, Brg1
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Figure 3.12: Short-term Brg1 deﬁciency expands the population of BrdU positive cells and impairs cell
migration (a) Cumulative frequency analysis of BrdU immunostaining 2 hours post labelling revealed
a signiﬁcant diﬀerence in distribution of BrdU positive cells between V illinCre+Brgfl/fl and control
animals at day 4 PI (Kolmogorov-Smirnov Z test p=0.005, n≥4). While the median position of BrdU
positive cells was unaﬀected, Brg1 deﬁcient epithelium displayed an expansion of BrdU positive cells
towards the top of the crypt. Although less pronounced, a lack of BrdU positive cells was also observed at
the crypt base of V illinCre+Brgfl/fl mice. (b) Cumulative frequency analysis of BrdU immunostaining
24 hours post labelling revealed a signiﬁcantly impaired cell migration in the small intestinal epithelium of
V illinCre+Brgfl/fl (median migration distance 24.54 cells) compared to control mice (median migration
distance 30.39 cells) over a 22 hours period between days 4 and 5 PI (Kolmogorov-Smirnov Z test p<0.001,
n ≥3). (c) A similar pattern of impaired cell migration in the small intestine of V illinCre+Brgfl/fl
mice was observed when migration of BrdU positive cells was traced between days 3 and 4 PI.
deﬁcient epithelium displayed a marked reduction in number of BrdU-labelled cells to-
wards the crypt base, suggesting a decrease in proliferative activity in this region (Figure
3.12a).
Immunohistochemical analysis of BrdU incorporation 24 hours post labelling revealed
the extent of migration of the BrdU-labelled cells in both control and experimental an-
imals. Cumulative frequency analysis of BrdU-labelled cells 24 hours post labelling re-
vealed a signiﬁcantly impaired migratory ability of the Brg1 deﬁcient epithelium (Figure
3.12b). Median migration distance of BrdU-labelled cells in Brg1 deﬁcient epithelium was
found to be 24.54 cells compared to 30.39 cells in control mice (Kolmogorov-Smirnov Z
test p<0.001, n ≥3). Analysis of cell migration between day 3 and 4 PI revealed a similar
pattern of impaired cell migration in the small intestinal epithelium of V illinCre+Brgfl/fl
mice (Figure 3.12c).
3.2.11 Brg1 loss aﬀects diﬀerentiation of the certain cell types
The signalling networks that control intestinal homeostasis tightly regulate both, cell pro-
liferation and diﬀerentiation. Therefore, to further characterise the eﬀects of Brg1 loss on
small intestinal homeostasis I carried out quantitative analysis of the major diﬀerentiated
cell types present in the small intestinal epithelium in Brg1 deﬁcient and control mice at
day 4 PI (Figures 3.13 and 3.14. The results of quantitative analysis of diﬀerentiated cells
in control and V illinCre+Brgfl/fl animals are collated in Table 3.2.
Chapter 3. The eﬀects of Brg1 loss in the small intestinal epithelium 98
Table 3.2: Quantitative analysis of Brg1 deﬁciency eﬀects on cell diﬀerentiation in the
small intestinal epithelium
Parameter Cohort Mean SD p Value
Goblet cells per
half-crypt
Control 4.85 0.85
0.212
Brg1 KO 3.74 1.34
Enteroendocrine cells
per half-crypt
Control 0.76 0.09
0.005
Brg1 KO 0.49 0.09
Paneth cells per
half-crypt
Control 1.13 0.31
0.416
Brg1 KO 1.37 0.47
Small intestinal tissue samples from V illinCreER− (marked here as Control), and V illinCreER+-
Brg+/+ (marked here as Brg1 KO) mice were collected at day 4 PI. Cell type-speciﬁc stains were used
to detect major cell types of the small intestinal epithelium. Frequency of Goblet, Enteroendoctine and
Paneth cells was quantiﬁed and compared between the two cohorts.
The majority of the cells in the villus are represented by the only member of the
absorptive lineage - enterocytes. In order to investigate the state of the enterocytes in the
Brg1 deﬁcient epithelium I carried out speciﬁc staining for alkaline phosphatase, which
marks the brush border of the enterocytes. A consistent decrease in staining was observed
among Brg1 deﬁcient mice compared to the intestines of control mice (Figure 3.13a).
The second most abundant cell type in the small intestinal epithelium are Goblet
cells. To assess changes in Goblet cell diﬀerentiation upon Brg1 loss, Alcian blue staining
was carried out on small intestinal sections from experimental and control animals (Fig-
ure 3.13b). Scoring of the cells stained with Alcian blue showed no diﬀerence between
control and experimental animals (4.85±0.85 and 3.74±1.34 Goblet cells per half-crypt
respectively, p=0.212, n=4, Figure 3.14b).
Enteroendocrine cells represent another secretory cell lineage of the small intestinal
epithelium. Grimelius staining was carried out to assess the frequency of enteroendocrine
cells in the Brg1 deﬁcient epithelium (Figure 3.13d). Quantiﬁcation of the positively
stained cells revealed signiﬁcantly reduced number of enteroendocrine cells per half-crypt
in Brg1 deﬁcient intestine compared to control animals (0.76±0.09 and 0.49±0.09 in
control and Brg1 deﬁcient intestine respectively, p=0.005, n=4, Figure 3.14b).
The last member of the secretory cell lineage is represented by Paneth cells. Lysozyme
expression was used as a marker to measure the frequency of this cell type (Figure 3.13c).
Scoring of lysozyme positive cells showed no diﬀerence in the Paneth cell numbers be-
tween control and experimental animals (1.13±0.31 and 1.37±0.47, p=0.416, n=4, Figure
3.14c). Since localisation of the Paneth cells within the crypt is tightly regulated by the
Eph/Ephrin system, it serves as a sensitive indicator of the Wnt pathway deregulation. I
therefore analysed the position of the lysozyme positive cells. The analysis of cumulative
frequency of the Paneth cells revealed no diﬀerence between the Brg1 deﬁcient and control
intestine (Figure 3.14d, Kolmogorov-Smirnov Z test p=0.7, n=4).
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Figure 3.13: Qualitative analysis of cell diﬀerentiation upon loss of Brg1 within the small intestine.
Small intestinal sections of V illinCre+Brgfl/fl and Cre− control animals at day 4 PI were subjected
to cell type-speciﬁc stains to visualise Enterocytes (a), Goblet cells (b), Paneth cells (c) and Enteroen-
docrine cells (d). Alkaline phosphatase staining revealed a substantially diminished brush border in the
small intestine of V illinCre+Brgfl/fl mice (a). No gross changes were observed in diﬀerentiation of se-
cretory cell lineages upon Brg1 loss (b-d). Lysozyme staining revealed normal localisation of the Paneth
cells at the crypt base (c). Arrows mark positive cells for each staining method. Scale bars represent 100
µm.
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Figure 3.14: Quantitative analysis of cell diﬀerentiation upon loss of Brg1 within the small intestine.
(a-c) The average number of Goblet (a), Enteroendocrine (b) and Paneth (c), cells per half-crypt and
associated villus was scored in the small intestine of control (white bars) and V illinCre+Brgfl/fl (grey
bars) animals at day 4 PI. No signiﬁcant diﬀerence was observed in the numbers of Goblet (a) and Paneth
(c) cells between control and experimental mice. Quantiﬁcation of cells stained positive with Grimelius
staining revealed a signiﬁcant decrease in the number of Enteroendocrine cells in V illinCre+Brgfl/fl
small intestine (b); (d) Cumulative frequency analysis of Paneth cell distribution revealed no signiﬁcant
diﬀerence between control and V illinCre+Brgfl/fl mice. Error bars represent standard deviation. Exact
values, standard deviations, respective p values and number of animals analysed are provided in Table
3.2.
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3.2.12 Brg1 loss leads to rapid disruption of intestinal architec-
ture
In order to investigate the long-term eﬀects of complete Brg1 loss in the small intestine
I attempted to age a cohort of V illinCre+Brgfl/fl mice induced with the high dose
protocol. Surprisingly, considering the relatively mild eﬀects of Brg1 loss at day 4 PI,
V illinCre+Brgfl/fl mice displayed severe symptoms of ill health by day 8 PI and had to be
sacriﬁced. Histological analysis of the H&E stained sections of the small intestine revealed
a slightly perturbed crypt-villus architecture as early as day 5 PI (Figure 3.15a). These
mild alterations to epithelial architecture progressed to severe crypt loss and complete
abrogation of the normal intestinal morphology by day 8 PI (Figure 3.15a). Notably,
occasional crypts retaining Brg1 expression were present in the disrupted epithelium at
day 8 after induction. These crypts were commonly seen to undergo crypt ﬁssion, a process
characteristic of regenerating intestinal epithelium after exposure to ionising radiation
(Figure 3.15b).
Figure 3.15: Long-term Brg1 loss in the small intestinal epithelium results in crypt ablation.
V illinCre+Brgfl/fl and control Cre− mice were induced with the high-dose protocol and small in-
testinal samples were collected at various time points. (a) Histological analysis of H&E-stained sections
of the small intestine of V illinCre+Brgfl/fl mice at day 5 PI detected a partial loss of crypt-villus dif-
ferentiation. This was followed by severe crypt loss by day 8 PI; (b) Immunohistochemical analysis of
Brg1 expression in the small intestinal epithelium detected rare Brg1 positive crypts in predominantly
Brg1 deﬁcient deteriorating epithelium. Brg1 positive crypts had an enlarged appearance and were often
found to be undergoing crypt ﬁssion. Scale bars represent 200 µm.
3.2.13 Brg1 loss depletes the proliferative compartment
The intestinal epithelium of V illinCre+Brgfl/fl mice at day 5 PI was characterised by
distinctly shortened villi and disappearance of clear crypt-villus junctions (Figure 3.15a).
These eﬀects are likely to be caused by impaired proliferation in the crypt. To examine
this possibility I analysed the quantity and position of proliferating cells as assessed by
expression of Ki67 marker Figure 3.16a. Scoring of Ki67 positive cells at day 5 PI revealed
signiﬁcantly reduced numbers of proliferating cells in Brg1 deﬁcient epithelium compared
to control animals. The average number (± standard deviation) of Ki67 positive cells
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per half-crypt in control versus Brg1 deﬁcient epithelium was 8.84±1.61 and 15.23±1.48
respectively (p=0.03, n≥3, Figure 3.16b). Cumulative frequency analysis of Ki67 posi-
tive cell distribution revealed a signiﬁcant contraction of the proliferative region in Brg1
deﬁcient intestine (Figure 3.16c, Kolmogorov-Smirnov Z test p<0.001, n≥3).
Figure 3.16: Long-term Brg1 loss results in reduction of proliferative compartment. V illinCre+-
Brgfl/fl and control Cre− mice were induced with the high-dose protocol and small intestinal samples
were collected at day 5 PI. (a) Immunohistochemical analysis of Ki67 expression revealed a loss of Ki67
expressing cells in the small intestinal epithelium of V illinCre+Brgfl/fl mice. Scale bars represent
100 µm. (b) Quantiﬁcation of Ki67 stained sections revealed a signiﬁcantly reduced number of Ki67
positive cells in the small intestinal epithelium of V illinCre+Brgfl/fl mice (grey bar) compared to control
(white bar) animals (p=0.03, n≥3). (c) Cumulative frequency analysis of Ki67 positive cells revealed
a signiﬁcantly contracted proliferative compartment in the small intestinal epithelium of V illinCre+-
Brgfl/fl mice (Kolmogorov-Smirnov Z test p<0.001, n≥3).
3.2.14 Crypt ablation in Brg1 deﬁcient epithelium is not caused
by failure of the cell-adhesion machinery
Loss of the proteins involved in the formation of cell-to-cell adhesions has been shown to
disrupt epithelial architecture of the small intestine (Schneider et al., 2010). I therefore
assessed whether Brg1 loss aﬀected the expression levels of proteins involved in cell-to-cell
adhesion, such as β-catenin and E-cadherin. mRNA was extracted from small intestine
epithelial samples of V illinCre+Brgfl/fl and control mice at day 4 PI. qRT-PCR anal-
ysis of mRNA levels of β-catenin and E-cadherin did not reveal signiﬁcant changes in
their expression between experimental and control animals (Figure 3.17a, p>0.05, n≥3).
Immunohistochemical analysis of E-cadherin expression at day 4 PI revealed no consis-
tent diﬀerence between wild type and Brg1 deﬁcient epithelium (Figure 3.17b). Notably,
immunostaining for E-cadherin at day 8 PI demonstrated that even in heavily disrupted
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epithelium, E-cadherin was expressed at substantial levels and remained conﬁned to the
cellular membrane (Figure 3.17b). Together, these observations indicated that loss of
the epithelial architecture in Brg1 deﬁcient intestine was unlikely to be attributed to
cell-to-cell adhesion failure.
Figure 3.17: Brg1 loss in the small intestinal epithelium does not impair cell-to-cell adhesion machinery.
(a) Quantitative RT-PCR expression analysis of cell-to-cell adhesion genes β-catenin and E-cadherin re-
vealed no signiﬁcant diﬀerence between the small intestinal epithelium of V illinCre+Brgfl/fl (grey bars)
and control (white bars) mice at day 4 after high-dose induction (p>0.05, n≥3). (b) Immunohistochem-
ical analysis of E-cadherin expression in the small intestinal epithelium revealed no diﬀerence between
V illinCre+Brgfl/fl and control mice at day 4 PI. Analysis of E-cadherin expression in the small intes-
tine of V illinCre+Brgfl/fl mice at day 8 PI showed strong membrane-speciﬁc staining, despite severely
disrupted intestinal architecture. Scale bars represent 100 µm.
3.2.15 Brg1 loss compromises intestinal stem cell function
Delayed depletion of the proliferative compartment leading to severely perturbed epithelial
architecture implied that Brg1 could act as a regulator of intestinal stem cell maintenance.
In order to explore this hypothesis a series of experiments was conducted to test whether
Brg1 loss resulted in depletion of the stem cell population.
To assess the eﬀects of Brg1 loss on the small intestinal stem cell population, I exam-
ined the expression levels of the intestinal stem cell markers Ascl2 and Lgr5. Total mRNA
was extracted from the intestinal epithelium of V illinCre+Brgfl/fl and control mice at
day 4 PI and used for qRT-PCR. Expression analysis of Ascl2 and Lgr5 revealed signif-
icantly reduced expression levels of these genes in Brg1 deﬁcient epithelium (7.31- and
4.77-fold downregulation for Ascl and Lgr5 respectuvely, p=0.015, n=4, Figure 3.18a).
Since Lgr5 and Ascl2 have been found to be Wnt target genes (Barker et al., 2007; Jubb
et al., 2006), it may be argued that their reduced expression levels upon Brg1 loss are
merely a result of attenuated Wnt signalling rather than an indicator of the stem cell
depletion. In order to overcome this disadvantage of using Lgr5 and Ascl2 as stem cell
markers, expression levels of Olfm4, a Wnt-independent stem cell marker (van der Flier et
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al., 2009), were analysed. In situ hybridisation using an anti-Olfm4 probe revealed strong
staining around the crypt base of the control epithelium (Figure 3.18b)1. Conversely, in-
testinal epithelium from V illinCre+Brgfl/fl mice harvested at day 4 PI displayed nearly
complete loss of Olfm4 expression (Figure 3.18b).
Figure 3.18: Brg1 loss in the small intestinal epithelium depletes the stem cell population. (a) Quan-
titative RT-PCR analysis of the small intestinal epithelium 4 days after high-dose induction revealed
signiﬁcantly reduced expression levels of the intestinal stem cell markers Ascl2 and Lgr5 in the small
intestinal epithelium of V illinCre+Brgfl/fl mice (grey bar) compared to control (white bar) animals
(for both genes p=0.015, n=4). (b) In situ hybridisation analysis of the stem cell marker Olfm4 in the
small intestine of V illinCre+Brgfl/fl and control mice at day 4 PI revealed a severely depleted Olfm4
expression in Brg1 deﬁcient intestinal epithelium. Scale bars represent 100 µm.
In order to obtain a more direct measure of stem cell depletion in response to Brg1
loss, a Cre recombinase expressed under the control of the Lgr5 promoter was used to
drive recombination of the ﬂoxed Brg1 alleles. Notably, the Lgr5-EGFP-IRES-creERT2
knock-in allele (further abbreviated as Lgr5CreER) provided extra functionality by driv-
ing enhanced green ﬂuorescent protein (EGFP, further referred to as GFP) expression
under the Lgr5 locus control, thus permitting visualisation of the Lgr5 expressing stem
cell compartment (Barker et al., 2007). A cohort of Lgr5CreER+Brgfl/fl mice was in-
duced along with Lgr5CreER+Brg+/+ controls by four daily intraperitoneal tamoxifen
injections. Animals were dissected at day 4 PI and small intestine tissue samples were
collected. Immunohistochemical analysis of GFP expression revealed positively stained
CBC cells at the crypt base of control and experimental animals (Figure 3.19a), consistent
with the Lgr5 expression pattern (Barker et al., 2007). Quantitative analysis of the fre-
quency of GFP expressing crypts revealed signiﬁcantly reduced numbers of GFP positive
crypts in the intestinal epithelium of Lgr5CreER+Brgfl/fl compared to control animals
(0.16±0.05 and 0.42±0.09 respectively, p=0.001, n=4, Figure 3.19b). It should be noted,
1In situ hybridisation with anti-Olfm4 probe was carried out by Maddy Young on intestinal sections
provided by me.
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however, that both experimental and control animals expressed the transgene at very low
frequency. In order to take into account possible ﬂuctuations in the transgene expression
frequency, an average number of GFP positive cells per GFP expressing crypt was cal-
culated. In line with the score obtained for the frequency of GFP expressing crypts, the
intestinal epithelium of Lgr5CreER+Brgfl/fl mice displayed signiﬁcantly reduced num-
ber of GFP positive cells per crypt compared to control mice (2.03±0.13 and 2.68±0.27
respectively, p=0.003, n=4, Figure 3.19c).
Figure 3.19: Stem cell-speciﬁc Brg1 loss abrogates Lgr5 expression and induces terminal diﬀerentiation.
(a) Immunohistochemical analysis of GFP expression in the small intestinal epithelium of Lgr5CreER+-
Brgfl/fl mice and Lgr5CreER+Brg+/+ controls revealed positive staining of CBC cells at the crypt
base. The frequency of staining was highly variable across the section in both cohorts. (b) Quantitative
analysis of the number of GFP positive crypts per total number of crypts revealed a signiﬁcant decrease
in the number of GFP positive crypts in Lgr5CreER+Brgfl/fl (grey bar) small intestine compared to
control animals (white bar, p=0.001, n=4). (c) Quantitative analysis of the number of GFP positive
cells per crypt revealed a signiﬁcantly reduced number of GFP positive cells in Lgr5CreER+Brgfl/fl
mice compared to control animals (p=0.003, n=4). (d) Immunostaining of serial sections with the
antibodies against GFP and Brg1 revealed a non-overlapping pattern of Brg1 loss (black arrowheads)
and GFP expression (white arrowheads) at the crypt base. Additionally, clusters of Brg1 deﬁcient cells
were observed mid-crypt (black arrowheads). Scale bars represent 50 µm.
This observation conﬁrmed that Brg1 loss resulted in depletion of the intestinal stem
cell population. In order to assess Brg1 status of the GFP expressing cells that remained
present upon induction of Brg1 loss, serial sections of the small intestine were stained
with Brg1 and GFP antibodies (Figure 3.19d). Immunohistochemical analysis of Brg1
and GFP expression demonstrated that the remaining GFP positive cells retained Brg1
expression (Figure 3.19d, white arrowheads), indicating that functional Brg1 was essential
for expression of the small intestinal stem cell marker Lgr5. Notably, immunohistochemi-
cal analysis of Brg1 expression detected clusters of Brg1 deﬁcient cells in GFP expressing
crypts (Figure 3.19d , black arrowheads). However, careful examination of such crypts
failed to detect Brg1 deﬁcient cells that retained GFP expression (Figure 3.19d).
These observations, along with the severe phenotype caused by extensive Brg1 loss and
gradual elimination of Brg1 deﬁcient cells upon partial Brg1 deletion, strongly support
an in vivo role for Brg1 in maintaining the intestinal stem cell population.
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3.2.16 Brg1 haploinsuﬃciency impairs clonogenic repopulation
of the small intestine
High radiosensitivity of the intestinal stem cells results in stem cell ablation upon exposure
to ionising radiation. Subsequent regeneration of the intestinal epithelium from post-
irradiation damage is driven by surviving clonogenic stem cells and can serve as a readout
of intestinal stem cell function (Potten, 1998). The number of surviving clonogens that
drive regeneration reﬂects the number of clonogenic cells in the whole of the intestinal
epithelium and therefore can act as a quantitative measure of the stem cell population
size. I therefore aimed to assess the eﬀects of Brg1 loss on the regenerative capacity
of the intestinal stem cell population. Rapid crypt ablation in response to homozygous
loss of Brg1 made it unfeasible to conduct the clonogenic survival assay in V illinCre+-
Brgfl/fl mice. It has been reported that heterozygous loss of Brg1 impairs the self-renewal
capacity of the embryonic stem cells (Ho et al., 2009). It is therefore possible that Brg1
haploinsuﬃciency may result in a suboptimal regenerative capacity of the intestinal stem
cell population under the stress conditions of DNA damage.
Figure 3.20: Brg1 haploinsuﬃciency impairs clonogenic repopulation of the small intestine.
V illinCre+Brg+/fl mice and V illinCre−Brg+/fl controls induced with high-dose protocol were ex-
posed to gamma irradiation at day 4 PI. Mice were allowed to recover for 72 hours, at which point
small intestinal samples were collected. Histological analysis of H&E stained small intestinal sections
from V illinCre+Brg+/fl and control mice displayed numerous clonogens driving epithelial regeneration
((a), black arrowheads). Scale bars represent 100 µm. (b) Quantitative analysis of epithelial clonogenic
capacity revealed signiﬁcantly reduced number of clonogens per circumference in V illinCre+Brg+/fl
mice (grey bar) compared to control (white bar) animals (p=0.03, n≥3). Error bars represent standard
deviation.
In order to investigate this possibility, V illinCre+Brg+/fl mice along with V illinCre−-
Brg+/fl controls were induced with four daily injections of 80 mg/kg tamoxifen. At day
4 PI all mice were subjected to a single dose of 15 Gy of gamma irradiation from a cae-
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sium source. Irradiated mice were left for 72 hours for intestinal regeneration to take
place. Mice were then sacriﬁced and small intestinal tissue was harvested. The num-
ber of surviving clonogens was scored as the average number of regenerating crypts per
radial circumference of the intestine on H&E stained sections (Figure 3.20a, black arrow-
heads). The average number of surviving clonogens (± standard deviation) in control
versus V illinCre+Brg+/fl mice was found to be 118±6.25 and 83.2±19.3 respectively
(p=0.03, n≥3, Figure 3.20b). The reduced number of clonogens in the mice with het-
erozygous loss of Brg1 shows that Brg1 haploinsuﬃciency reduces the number of viable
clonogens under stress conditions.
3.3 Discussion
Brg1 loss has been extensively reported in cancer cell lines and primary tumours (Becker
et al., 2009; Reisman et al., 2003; Wong et al., 2000). Re-expression of Brg1 in Brg1
deﬁcient cancer cell lines has also been reported to induce cell cycle arrest (Hendricks et
al., 2004, Wong et al., 2000). It appears, therefore, that Brg1 acts as a tumour suppressor
in a range of cancers. However, since these observations were made in late stage cancers,
they can not conclusively demonstrate whether Brg1 loss per se has an initiating onco-
genic eﬀect. Interestingly, insights from the transgenic animal models have suggested that
Brg1 haploinsuﬃciency confers susceptibility to neoplasia at least in mammary and lung
epithelial tissues (Bultman et al., 2007, Glaros et al., 2008). At the same time, complete
Brg1 loss in lung epithelium was able to facilitate development of existing tumours, but
not de novo tumourigenesis (Glaros et al., 2008). These observations therefore suggest
that, while Brg1 haploinsuﬃciency may facilitate tumourigenesis in certain tissues, bial-
lelic Brg1 loss seen in human cancers is likely to be acquired at later stages of tumour
progression. However, the role of Brg1 in the small intestinal epithelium has not yet been
explored. Although not reported to be directly involved in intestinal homeostasis, Brg1
has been implicated as an important factor for the trans-activation of Wnt target genes
(Barker et al., 2001). Another indirect link connecting Brg1 to intestinal homeostasis is
the tumour suppressor LKB1. LKB1 has been shown to interact with BRG1 and mediate
BRG1 induced cell cycle arrest (Marignani et al., 2001). Notably, Lkb1 loss in murine
small intestinal epithelium has been found to alter diﬀerentiation of Goblet and Paneth
cells via increased expression of the Notch pathway target gene Hes5 as well as suppres-
sion of Delta ligand Dll1 in these cell types. Altered Notch signalling upon loss of Lkb1
has been found to result in increased size and perturbed morphology of mucin-secreting
cells (Shorning et al., 2009). Given the observed interaction between Brg1 and Lkb1, one
could speculate that Brg1 deﬁciency might recapitulate the small intestinal manifestations
of Lkb1 loss.
Bearing in mind the pivotal role of the Wnt and Notch pathways in intestinal home-
ostasis and intestinal stem cell maintenance, as well as the proposed tumour suppressor
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role of Brg1 in other tissues, I aimed to investigate the eﬀects of Brg1 loss and haploin-
suﬃciency in the normal small intestinal epithelium.
In order to dissect the role of Brg1 in normal intestinal homeostasis I attempted to
achieve the complete loss of Brg1 in the small intestinal epithelium. I ﬁrst employed
AhCre recombinase (Ireland et al., 2004) to speciﬁcally inactivate Brg1 in the stem and
progenitor cell compartments of the crypt. Unfortunately, oﬀ-target expression of the
AhCre recombinase resulted in embryonic lethality of the animals bearing ﬂoxed Brg1
alleles and therefore prevented any further exploitation of this model for analysis of Brg1
deﬁciency. Instead, it was used to analyse consequences of Brg1 haploinsuﬃciency.
I then employed the AhCreER recombinase transgene (Kemp et al., 2004) to exert
a higher degree of control over the recombinase expression and overcome the embryonic
lethality. Although the use of AhCreER recombinase proved successful in this aspect,
induction of Brg1 deletion occurred at a frequency deemed too low to readily observe any
subtle eﬀects or permit the use of whole tissue approaches, such as qRT-PCR or Western
blotting.
Finally, I employed the VillinCre recombinase transgene (el Marjou et al., 2004), which
is ubiquitously expressed in the small and large intestinal epithelium. High-dose induction
of VillinCre recombinase resulted in complete loss of Brg1 in the epithelial compartment of
the small intestinal epithelium at 4 days PI, which was conﬁrmed by immunohistochemical
staining with anti-Brg1 antibody. Low-dose induction of VillinCre recombinase resulted in
mosaic loss of Brg1 in a pattern comparable to that driven by activation of the AhCreER
recombinase.
3.3.1 Partial Brg1 loss results in gradual repopulation with wild
type cells
Although the frequency of Brg1 inactivation driven by AhCreER recombinase was deemed
too low for quantitative characterisation, I aimed to investigate the long-term fate of Brg1
deﬁcient cells. Multiple time point analysis of the frequency of crypts containing Brg1
deﬁcient cells revealed their gradual decline and near complete elimination within 15 days
PI. Even though no quantitative analysis of apoptosis levels in Brg1 deﬁcient crypts was
performed, no gross signs of increased cell death were apparent. Instead, Brg1 deﬁcient
cells were observed to migrate onto the villus and eventually shed into the lumen, while
the crypts were repopulated with wild type cells. The small intestinal epithelium of
V illinCre+Brgfl/fl mice induced with a low-dose protocol displayed a similar pattern.
Mosaic loss of Brg1 was detected in cells across the crypt-villus axis at 5 days PI. How-
ever, 30 days later the intestinal epithelium was found to be fully repopulated with wild
type cells. The slightly higher recombination frequency observed in low-dose induced
V illinCre+Brgfl/fl mice allowed me to indirectly conﬁrm elimination of Brg1 deﬁcient
cells. Cre recombinase-mediated induction of the LacZ reporter gene in control and Brg1
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deﬁcient epithelium demonstrated substantially reduced retention rate of LacZ expressing
crypts in the latter. Taken together, these data highlight the selective pressure against
long-term retention of Brg1 deﬁcient cells in the small intestinal epithelium. However, due
to the low frequency of recombination events, these observations provided no explanation
of the mechanism behind the repopulation of Brg1 deﬁcient cells.
3.3.2 Complete Brg1 loss has mild immediate eﬀects on intesti-
nal homeostasis
Having established that high-dose induction of VillinCreER recombinase drives complete
loss of Brg1 in the intestinal epithelium, I set out to examine the eﬀects of Brg1 deﬁciency
on small intestinal homeostasis.
Histological inspection of the small intestinal mucosa 4 days after high-dose induction
revealed no abnormalities in the general crypt-villus architecture despite complete loss of
Brg1 from the epithelial cells. However, quantitative analysis revealed a number of subtle
alterations to epithelial homeostasis.
Firstly, Brg1 deﬁcient epithelium displayed slightly elevated levels of apoptosis based
on morphological appearance. This observation, however was not replicated based of
cleaved Caspase-3 staining. Interestingly, although morphology based scoring is able to
detect a wider range of apoptosis stages than Caspase-3 staining, both methods produced
not only comparable fold change, but also very close average numbers of apoptotic cells.
The lack of signiﬁcant diﬀerence in Caspase-3 staining is therefore likely to be attributed
to high variation and lower sample size. It should be noted, however, that whilst apop-
tosis levels in Brg1 deﬁcient epithelium was nearly three times higher than that observed
in normal intestine, it still equated to less than one apoptotic cell per crypt. This is
considerably less than the elevation in apoptosis levels observed upon loss of proteins
involved in cell cycle progression and cell-to-cell adhesion Chk1, Brca2 and E-cadherin
(Greenow et al., 2009; Hay et al., 2005, Schneider et al., 2010). Similarly, ablation of Wnt
signalling in the intestinal epithelium via deletion of β-catenin or expression of the Wnt
antagonist Dickkopf-1 failed to induce signiﬁcant increase in apoptosis suggesting that
Wnt signal abrogation has no pro-apoptotic eﬀect on the intestinal epithelium (Fevr et
al., 2007, Kuhnert et al., 2007).
Examination of the proliferative compartment by quantiﬁcation of mitotic ﬁgures and
Ki67 positive cells revealed no diﬀerence in the number of proliferating cells between Brg1
deﬁcient and control epithelium suggesting that Brg1 is dispensable for the proliferative
activity of the majority of crypt cells. In contrast to this observation, conditional loss of
β-catenin has been found to result in ablation of the proliferative compartment as early
as 2 days after β-catenin deletion (Fevr et al., 2007). Despite this ﬁnding, Brg1 deﬁcient
intestines displayed a signiﬁcant increase in the number of BrdU positive cells 2 hours
post labelling. The discrepancy between the lack of detectable changes in mitosis levels
Chapter 3. The eﬀects of Brg1 loss in the small intestinal epithelium 110
on one hand and increased BrdU incorporation on the other, implies a post-S phase cell
cycle arrest. Cell cycle arrest at this stage could be an early indicator of the subsequent
signiﬁcant reduction in mitosis levels observed at day ﬁve PI. Of interest, while Brg1 loss
in normal lung epithelium has been reported to result in increased apoptosis (Glaros et
al., 2008), there are no reports to date linking Brg1 loss to the induction of cell cycle
arrest in vivo. On contrary, numerous reports have demonstrated that Brg1 is required
for Rb-mediated cell cycle arrest (Strobeck et al., 2000; Strober et al., 1996; Zhang et al.,
2000). As discussed later in this chapter, Brg1 deﬁciency-induced cell cycle arrest and
the subsequent decrease in proliferation may potentially be caused by the exhaustion of
the proliferative pool due to the lack of replenishment from the stem cell population.
Analysis of the BrdU positive cell distribution 24 hours post labelling revealed a signif-
icantly impaired migration in Brg1 deﬁcient intestine. It should be noted, however, that
this observation was based on cell migration over the period spanning the 24 hours between
day four and ﬁve PI. Importantly, several changes occurred in the biology of the Brg1
deﬁcient epithelium during this time period. While Brg1 deﬁcient intestine at day four
PI displayed no changes in mitosis levels compared to control epithelium, a signiﬁcantly
lower proliferation rate was observed in Brg1 deﬁcient crypts at day ﬁve PI (discussed
later in this chapter). It is therefore diﬃcult to ascertain whether impaired migration
apparent at day ﬁve PI is a secondary eﬀect of the reduced cell proliferation or a primary
eﬀect of Brg1 loss. However, an equivalent experiment tracing migration of BrdU labelled
cells over the period between three and four days PI detected a similar reduction in cell
migration in Brg1 deﬁcient epithelium. Although complete Brg1 loss might not have been
achieved over this time period, this observation provided some support in favour of the
hypothesis that impaired migration was a primary eﬀect of Brg1 deletion. Interestingly,
a signiﬁcant decrease in villus length was detected in Brg1 deﬁcient epithelium at day
four PI. Considering the lack of changes in cell proliferation at this stage, decreased villus
length could be attributed to impaired migration due to the lack of positive upward force
generated by epithelial cells migration along the underlying stroma (Heath, 1996).
In addition to decreased villus length and elevated levels of both apoptosis and BrdU
incorporation, Brg1 deﬁcient epithelium at day four PI displayed mild alterations in dif-
ferentiation of certain cell types. Remarkably, the two cell types whose diﬀerentiation was
aﬀected by Brg1 loss belonged to diﬀerent lineages, namely enteroendocrine cells from the
secretory and enterocytes from the absorptive lineages respectively. Wnt signalling has
been previously reported to play a crucial role in diﬀerentiation of small intestinal secre-
tory cell types in a dose-dependent manner. Conditional deletion of the Wnt pathway co-
activator Tcf4 has been shown to abrogate cell proliferation and diﬀerentiation of Paneth
and Enteroendocrine cells, but not enterocytes or Goblet cells in developing gut (Korinek
et al., 1998; van Es et al., 2005a). Overexpression of the Wnt pathway inhibitor Dkk1 has
been found to result in a more severe phenotype as it not only inhibited cell proliferation,
but also completely abrogated diﬀerentiation of all secretory cell lineages without aﬀect-
Chapter 3. The eﬀects of Brg1 loss in the small intestinal epithelium 111
ing enterocyte diﬀerentiation (Pinto et al., 2003). In the current study short-term Brg1
loss was found to suppress enteroendocrine cell diﬀerentiation without aﬀecting other se-
cretory cell lineages or cell proliferation. It can be hypothesised, therefore, that Brg1 loss
attenuates Wnt signalling to a level suﬃcient to impair enteroendocrine cell diﬀerentia-
tion, but not cell proliferation or Goblet and Paneth cell diﬀerentiation. Notably, loss of
the tumour suppressor Lkb1 in the murine small intestine has been reported to perturb
normal Goblet and Paneth cell maturation via increased expression of the Notch pathway
target gene Hes5 (Shorning et al., 2009). Resultant Lkb1 deﬁcient Goblet and Paneth
cells have been found to display an appearance characteristic of immature Intermediate
cells, considered to represent a transitional step between undiﬀerentiated and mature se-
cretory cells (Troughton and Trier, 1969). Despite the observed interaction between Brg1
and Lkb1 (Marignani et al., 2001), no changes (neither quantitative nor morphological)
were registered in these cell types upon Brg1 deletion. This observation thus suggests a
lack of functional interaction between Lkb1 and Brg1 in the small intestinal epithelium.
Although Brg1 loss did not block diﬀerentiation along the absorptive lineage com-
pletely, enterocytes in the Brg1 deﬁcient epithelium displayed a very thin brush border
compared to control epithelium. Notably, enterocyte diﬀerentiation has been found to be
driven by Notch signalling, as constitutive activation of the Notch pathway suppressed
diﬀerentiation of secretory cell lineages and induced diﬀerentiation of post-mitotic cells
into enterocytes (Fre et al., 2005). Conversely, treatment with Notch inhibitors has been
shown to result in expansion of secretory lineages at the expense of enterocytes (Milano
et al., 2004). The fact that Brg1 loss perturbed the development of the brush border
without increasing diﬀerentiation along secretory lineages, suggests that Brg1 loss does
not block enterocyte diﬀerentiation, but rather decreases expression of the brush border
components. Expression analysis of other enterocyte markers, such as Villin might be
required to ascertain whether Brg1 loss impairs enterocyte diﬀerentiation. Since entero-
cyte diﬀerentiation relies on Notch signalling, expression analysis of Notch pathway target
genes could provide an insight into the eﬀects of Brg1 deﬁciency on Notch signalling in
the small intestinal epithelium. Notably, β-catenin deletion in the small intestinal epithe-
lium has been found to rapidly induce loss of the crypt progenitor cell marker CD44 and
activation of alkaline phosphatase expression in the intervillus region indicating an early
terminal diﬀerentiation of the intestinal progenitor cells (Fevr et al., 2007). Contrary to
this observation, no alkaline phosphatase expression was detected in the crypt region of
Brg1 deﬁcient intestine, suggesting that Brg1 deﬁcient transit amplifying cells retained
the progenitor phenotype at least for some time.
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3.3.3 Brg1 loss compromises the function of the small intestinal
stem cell
In drastic contrast to the mild immediate eﬀects of Brg1 loss observed at four days PI,
Brg1 deﬁcient epithelium displayed a marked disruption of intestinal architecture and
homeostasis as early as ﬁve days PI. Simple visual inspection of the tissue sections from
Brg1 deﬁcient epithelium at this stage revealed loss of normal architecture characterised
by shortened villi and the disappearance of clear crypt villus junctions. Disruption of the
intestinal architecture was accompanied by reduced cell proliferation as determined by
quantiﬁcation of Ki67 positive cells. Interestingly, Wnt signalling suppression in the small
intestinal epithelium via conditional loss of β-catenin or Dickkopf-1 expression has been
found to result in immediate and complete abrogation of cell proliferation and terminal
diﬀerentiation of crypt progenitor cells (Fevr et al., 2007; Kuhnert et al., 2004). In
contrast to these ﬁndings, loss of Brg1 resulted in gradual contraction of the intestinal
proliferative compartment. This observation suggested that the proliferative compartment
in Brg1 deﬁcient epithelium was exhausted eventually with cells at the top of the crypt
losing their proliferative capacity ﬁrst.
The further attempt to age mice with Brg1 deﬁcient intestinal epithelium resulted in
rapidly deteriorating health and animal morbidity at around 7-8 days PI. Histological
analysis of the small intestinal epithelium from sick animals revealed severe disruption
of intestinal architecture with complete loss of normal crypt-villus organisation. At the
same time, immunohistochemical analysis of Brg1 expression detected rare crypts that
retained Brg1 expression. These crypts had an enlarged appearance and a number of
these crypts were found to be undergoing the process of crypt ﬁssion. Crypt ﬁssion is a
powerful mechanism of intestinal regeneration following damage caused, for instance, by
ionising radiation (Cairnie and Millen, 1975). Interestingly, a similar increase in crypt
ﬁssion was observed upon the loss of the intestinal stem cell marker and regulator Ascl2
in murine intestine (van der Flier et al., 2009).
Taken together, the very mild immediate consequences of Brg1 deﬁciency and the
severe crypt loss shortly afterwards led me to hypothesise that Brg1 may aﬀect intestinal
stem cell function. In order to investigate the eﬀect of Brg1 inactivation on the stem
cell population I performed a series of experiments aimed to assess the state of the stem
cell population. Quantitative RT-PCR analysis of stem cell markers Lgr5 and Ascl2
revealed a signiﬁcant decrease in expression of these genes. Notably, both Lgr5 and
Ascl2 have been found to be target genes of the Wnt pathway (Barker et al., 2007; Jubb
et al., 2006). Decreased expression of Lgr5 and Ascl2 can therefore be attributed to
attenuated Wnt signalling rather than depletion of the stem cell population. In order
to overcome this shortcoming of Lgr5 and Ascl2 as stem cell markers, I used in situ
hybridisation analysis of Olfm4, a Wnt-independent stem cell marker, to assess the state
of the stem cell population (van der Flier et al., 2009). Similar to the other two stem cell
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markers, Olfm4 expression was substantially decreased in the Brg1 deﬁcient epithelium.
Coincidentally depletion of the stem cell population induced by conditional deletion of
Ascl2 has been reported to be accompanied by a similar loss of Olfm4 expression (van der
Flier et al., 2009). It should be noted that reduced expression of the stem cell markers was
detected at day 4 PI, i.e. prior to any changes in cell proliferation, suggesting strongly
that depletion in the stem cell population is a direct eﬀect of Brg1 deﬁciency. Stem cell
loss and subsequent exhaustion of the proliferative pool could result in the cell cycle arrest
of transit amplifying cells consistent with increase in BrdU labelling prior to any visible
changes to cell proliferation. These observations further supported the notion that Brg1
is essential for the small intestinal stem cell maintenance. Coincidentally, Brg1 has been
previously reported to be involved in maintenance and diﬀerentiation of several somatic
stem cells including neural (Matsumoto et al., 2006) and mesenchymal (Alessio et al.,
2010; Napolitano et al., 2007) stem cells.
While providing strong evidence in favour of the notion that pan-epithelial Brg1 loss
results in compromised stem cell function, the data presented so far do not show directly
that intestinal stem cells require functional Brg1 to maintain their activity. Indeed, Brg1
may be essential for the function of some auxiliary cell type, which, in turn, is indispens-
able for the stem cell maintenance. An obvious candidate for such a cell type would be
the Paneth cells (Sato et al., 2010). Equally important is the question of stem cell fate
upon Brg1 inactivation. A limited increase in apoptosis, which was not entirely conﬁned
to the crypt bottom favours the notion that Brg1 loss does not cause stem cell death, but
rather impairs its function.
To answer these questions I attempted to speciﬁcally delete Brg1 in the small intestinal
stem cell compartment using the Lgr5-EGFP-CreER transgene (Barker et al., 2007).
This experimental system uses the Lgr5 promoter to drive stem cell speciﬁc expression
of an inducible Cre recombinase. GFP expression from the same construct provides an
additional beneﬁt of permitting visualisation of stem cells within the crypt. Stem cell-
speciﬁc Brg1 loss was induced by tamoxifen administration. Analysis of GFP expression
in the small intestinal epithelium at day 5 PI detected positive GFP staining of narrow
cells intercalated between Paneth cells, that correspond to CBC cells. Quantiﬁcation of
GFP expression revealed an extremely low frequency of crypts expressing the transgene in
both, animals carrying wild type and loxP targeted Brg1 alleles. The Lgr5-EGFP-CreER
construct has been found to be expressed only in a fraction of small intestinal crypts. It
has been suggested that low expression of the transgene is caused by epigenetic silencing
of the transgene during gut development (Sansom, personal communication). However,
the level observed in animals used in the present study appears to be exceptionally low,
possibly due to diﬀerent genetic backgrounds of the animals used. Quantitative analysis
of GFP expression detected a signiﬁcantly lower frequency of crypts with detectable GFP
expression in mice harbouring targeted Brg1 alleles compared to control animals. This
parameter, however, is likely to be strongly inﬂuenced by any variation in epigenetic
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silencing of the transgene. In an attempt to eliminate variability introduced by epigenetic
silencing I calculated the average number of GFP positive cells present in GFP expressing
crypts. The rationale behind this mode of analysis lies in the monoclonality of small
intestinal crypts. Crypts in the small intestine of adult mice have been shown to undergo
monoclonal conversion, so that all cells populating the same crypt represent progeny of
a single ‘ancestor’ stem cell (Winton et al., 1988). It can therefore be assumed with a
certain degree of conﬁdence that all stem cells in a GFP expressing crypt originate from
the same GFP positive progenitor cell and also express GFP. Since the average number
of stem cell per crypt is fairly consistent between comparable sections of the gut, any
detrimental eﬀects of Brg1 loss on stem cell maintenance are likely to be manifest in a
reduced number of GFP positive cells per crypt. Indeed, GFP expressing crypts in mice
with targeted Brg1 alleles contained signiﬁcantly lower number of GFP positive cells per
crypt.
Although likely to be unreliable due to the low level of the transgene expression, these
observations provide extra support in favour of the notion that stem cell depletion is
likely to be a direct consequence of Brg1 deﬁciency, rather than a secondary eﬀect of a
compromised function of some auxiliary cell type.
Brg1 deﬁciency-mediated depletion of GFP positive cells still did not clarify the intesti-
nal stem cell fate upon Brg1 inactivation. In order to trace the progeny of Brg1 deﬁcient
stem cells I performed immunohistochemical analysis of Brg1 expression. Crypts con-
taining clusters of Brg1 deﬁcient cells were detected in the small intestinal epithelium of
Lgr5CreER+Brgfl/fl mice at a frequency comparable to that of GFP positive crypts.
Staining of serial sections with antibodies against GFP and Brg1 detected GFP expres-
sion in crypts containing Brg1 deﬁcient cells. However, careful examination of the staining
pattern failed to detect GFP expression in Brg1 deﬁcient cells. The GFP positive cells
present in these crypts were therefore likely to be represented by stem cells escaping Brg1
deletion or early progenitors de-diﬀerentiating into stem cells. The absence of Brg1 de-
ﬁcient cells expressing GFP further suggests that loss of Brg1 is incompatible with stem
cell functionality, as assessed by GFP expression. On the other hand, the presence of
Brg1 deﬁcient cell clusters indicated that stem cells retain their proliferative ability at
least for a limited period of time.
Taken together, these data suggest that Brg1 loss induces stem cell commitment to
terminal diﬀerentiation rather than cell death. This notion is consistent with the very
small increase in apoptosis levels seen upon Brg1 deletion in V illinCre+Brgfl/fl mice.
Instead, stem cells appear to lose expression of stem cell markers and their ability to self-
renew and turn into committed progenitor cells, retaining a limited ability to proliferate
and diﬀerentiate. Coincidentally, conditional deletion of β-catenin has been found to
result in terminal stem cell diﬀerentiation and loss of putative stem cell markers Sox4 and
Diap3 suggesting that Brg1 loss might exert its phenotype by suppressing Wnt signalling
within the stem cell population (Fevr et al., 2007). It should be noted, however, that
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unlike Brg1 deﬁciency, β-catenin loss induced a more severe phenotype causing terminal
diﬀerentiation not only in the stem cell, but also in the progenitor cell compartment.
Considering delayed loss of cell proliferation and virtually no eﬀect on diﬀerentiation
of the secretory lineages upon Brg1 deletion, it appears that Brg1 deﬁciency has a very
mild eﬀect on Wnt signalling in the crypt progenitor cells. The drastic eﬀect of Brg1
loss on the stem cell homeostasis could, therefore, be explained by two mechanisms.
The ﬁrst mechanism implies that the small intestinal stem cell require higher levels of
Wnt signalling compared to progenitor cells. In this case, subtle attenuation of Wnt
signalling by Brg1 loss would compromise functionality of the stem cell population, but
leave progenitor cells unaﬀected. This mechanism is consistent with existence of the Wnt
ligands gradient, which peaks around the crypt base (Gregorieﬀ et al., 2005). Additionally,
expression levels of the Wnt target genes, such as EphB2, have been found to display
positive correlation with stem cell properties (Merlos-Sua´rez et al., 2011). An alternative
mechanism proposes that other signalling pathways essential for the small intestinal stem
cell maintenance (for example Notch) may rely on Brg1 for their proper function. The
intestinal stem cell population has been found to exist in a steady state of symmetric
divisions giving either two new stem cells (self-renewal) or two committed progenitor cells
(diﬀerentiation) (Lopez-Garcia et al., 2010; Snippert et al., 2010). Given the Paneth cell
role in creating the stem cell niche (Sato et al., 2010) the choice between self-renewal and
diﬀerentiation appears to be determined by the proximity of the stem cell to the Paneth
cell. It is plausible, therefore, that Brg1 is involved in mediation of the signalling pathways
activated within stem cells by proximity to Paneth cells. Notably, Brg1 has been reported
to regulate expression of genes involved in self-renewal and pluripotency in ES cells (Ho et
al., 2009; Kidder et al., 2009). These include, but are not limited to Oct4, Sox2, Nanog,
Stat3, Sall4 and others. It would be insightful, therefore, to ascertain whether Brg1 loss
compromises the intestinal stem cell self-renewal by disrupting expression of these genes.
The marked diﬀerence between phenotypes seen upon partial versus complete loss of
Brg1 could be explained in the context of the stem cell niche provided by Paneth cells
(Figure 3.21). In both cases loss of Brg1 within the intestinal stem cell compartment
induces stem cell commitment to terminal diﬀerentiation. Due to the expression pattern
of AhCreER recombinase, this transgene only drives Brg1 loss in a limited populations of
stem and early progenitor cells (Kemp et al., 2004). As a result, crypts that undergo Brg1
loss under control of AhCreER recombinase retain a substantial number of wild type cells
(Figure 3.21a). In accordance with the steady state dynamics of crypt homeostasis, any
stem cells that escaped Brg1 inactivation would be able to expand and repopulate the
whole crypt (Snippert et al., 2010). Alternatively, in crypts, where AhCreER recombinase
was successful in driving Brg1 loss in every stem cell, commitment to terminal diﬀerentia-
tion and subsequent migration out of the crypt base would create points of access around
existing Paneth cells. Undiﬀerentiated progenitor cells retaining Brg1 expression could
then gain access to the stem cell niche, undergo de-diﬀerentiation, assume the role of
Chapter 3. The eﬀects of Brg1 loss in the small intestinal epithelium 116
stem cells and drive epithelial repopulation with Brg1 positive cells (Figure 3.21a). A
similar situation is observed upon post-irradiation damage repair. The small intestinal
epithelium has been found to contain a tiered system of stem and progenitor cells with
gradually increasing resistance to ionising radiation. In this system low dose irradiation
causes stem cells and lower tiers of progenitor cells to undergo apoptosis, while higher
tiers of progenitor cells are capable of driving regeneration of the epithelium by assuming
the role of stem cells (Potten, 1998). Intriguingly, a recent report by Montgomery et al.
(2011) has provided convincing evidence of a predominantly quiescent stem cell popula-
tion resistant to ionising radiation. It is plausible that the proposed system of progenitor
cells may instead be comprised of such cells capable of driving epithelial regeneration upon
radiation damage. Notably, the pattern of AhCreER recombinase expression in regard
of the proposed quiescent stem cells remains to be established. A possibility, therefore,
exists that lack of AhCreER expression in the quiescent stem cells could result in Brg1
retention and such sells could then contribute to repopulation of the intestinal epithelium
with wild type cells.
Conversely, induction of Brg1 loss using VillinCre recombinase leads to ubiquitous
Brg1 loss creating a dearth of wild type progenitor and/or reserve stem cells that would
be capable of functionally replacing active stem cells (Figure 3.21b). Upon pan-epithelial
loss of Brg1, epithelial homeostasis is maintained for a limited period of time due to the
activity of transit amplifying cells. However, eventual depletion of the proliferative pool
due to the lack of replenishment from the stem cell compartment sequentially results in
cell cycle arrest and disruption of epithelial architecture.
3.3.4 Brg1 haploinsuﬃciency does not induce intestinal tumouri-
genesis, but impairs the stem cell clonogenic capacity
Biallelic loss of Brg1 has been widely reported in cancer cell lines and primary tumours
(Becker et al., 2009; Reisman et al., 2003; Wong et al., 2000). In contrast, a number of
animal studies showed no increase in tumour incidence upon complete Brg1 loss (Glaros
et al., 2008; Wang et al., 2009). Conversely, animals with heterozygous Brg1 loss have
been found to be prone to tumourigenesis in a range of tissues (Bultman et al., 2007;
Glaros et al., 2008). Importantly, tumours developing in Brg1 heterozygous animals have
been found to retain a functional copy of Brg1. This observation suggested that at least
in some tissues, Brg1 haploinsuﬃciency rather than loss of heterozygousity contributed to
tumourigenesis. In this study I induced heterozygous loss of Brg1 in the small intestinal
epithelium using AhCre recombinase. Survival analysis of Brg1 haploinsuﬃcient mice
revealed no signiﬁcant decrease in survival compared to wild type controls. Furthermore,
macroscopic and histological analysis of the small intestinal epithelium of animals aged
for as long as 643 days PI revealed no signs of intestinal neoplasia. It appears, therefore,
that Brg1 haploinsuﬃciency has no oncogenic eﬀect in the context of the small intestinal
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Figure 3.21: Scenarios of Brg1 loss in the small intestinal epithelium. (a) Depletion of the stem cell
compartment upon partial loss of Brg1 can be rescued by non-recombined stem or progenitor cells that
are able to repopulate the intestinal epithelium with wild type cells. (b) The lack of Brg1 proﬁcient
stem/progenitor cells upon complete Brg1 deletion results in gradual depletion of the proliferative pool
and crypt ablation.
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epithelium. This conclusion is consistent with the observation that tumourigenesis in
mice constitutively heterozygous for Brg1 is limited to mammary epithelium (Bultman et
al., 2007).
Rapid repopulation of Brg1 deﬁcient cells with wild type counterparts suggested a
strong selective pressure against Brg1 deﬁcient cells in the small intestinal epithelium. In
order to investigate whether heterozygous loss of Brg1 confers a similar selective disad-
vantage I analysed retention of the recombined Brg1 allele. DNA samples were extracted
from the small intestinal epithelium of AhCre+Brg+/fl mice as late as 643 days PI and
subjected to recombined PCR analysis. The signal corresponding to the recombined al-
lele was detected in all AhCre+Brg+/fl animals analysed. This observation demonstrated
that Brg1 haploinsuﬃcient cells were successfully retained in the small intestinal epithe-
lium over an extensive period of time. Long-term retention of cells heterozygous for Brg1
suggests that under normal conditions Brg1 haploinsuﬃciency is unlikely to have any
detrimental eﬀect on the stem cell long-term maintenance. In order to assess the eﬀect
of Brg1 haploinsuﬃciency on small intestinal stem cell function under stress conditions,
I carried out an analysis of clonogenic repopulation upon exposure to ionising radiation.
The small intestinal epithelium of V illinCre+Brg+/fl mice demonstrated a signiﬁcantly
reduced number of clonogenic units compared to control animals. Since the number of
clonogenic units reﬂects the abundance of stem cells within the crypt, one could hypoth-
esise that Brg1 haploinsuﬃcient crypts contained a lower number of stem cells. This
would imply, however, that heterozygous Brg1 loss somehow negatively aﬀected stem cell
homeostasis, which is unlikely in view of the long-term retention of Brg1 haploinsuﬃcient
cells in the small intestine. It is more likely, therefore, that the detrimental eﬀect of
Brg1 haploinsuﬃciency on stem cell physiology only manifests under stress conditions of
ionising radiation, potentially due to higher susceptibility to the DNA damage.
To conclude, the ﬁndings presented here suggest that Brg1 heterozygousity has no
detrimental eﬀect on the normal small intestinal homeostasis under physiological condi-
tions, but impairs regeneration upon radiation damage.
3.3.5 Future directions
Requirement of functional Brg1 for maintenance of the small intestinal stem cells provides
a potentially useful tool to further our understanding of intestinal homeostasis. Analysis of
the alterations to expression patterns upon Brg1 loss could unveil transcriptional networks
involved in the regulation of intestinal stem cell physiology. To this end we are planning
to carry out genome-wide expression analysis of Brg1 deﬁcient small intestinal epithelium.
This type of analysis, however, is likely to register transcriptional eﬀects of Brg1 loss in the
whole of the intestinal epithelium, which might obscure stem cell speciﬁc changes. The
Lgr5-EGFP-Cre transgene could prove useful in enriching for the stem cell population
in order to increase signal to noise ratio. However, rapid loss of GFP expression upon
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Brg1 deletion creates a substantial obstacle in the isolation of Brg1 deﬁcient stem cells.
In order to overcome this limitation we are planning to use wild type mice harbouring
Lgr5-EGFP-Cre transgene for Brg1 chromatin immunoprecipitation (ChIP) analysis of
the stem cell enriched population of epithelial cells, in order to investigate locus-speciﬁc
recruitment of Brg1. This could be followed by genome-wide analysis (ChIP-on-Chip) to
determine stem cell-speciﬁc targets of Brg1-mediated expression.
Finally, in order to conﬁrm that Brg1 loss directly targets stem cells, we are planning
to conduct an in vitro experiment making use of organoid culture system published previ-
ously by Sato et al. (2009). Single cell suspension from Lgr5CreER+BrgHomfl/fl small
intestine will be enriched for GFP expressing cells and grown in media with or without
tamoxifen supplementation. Preliminary results, however, demonstrated remarkably low
yield of organoids from animals carrying Lgr5-EGFP-Cre transgene regardless of their
Brg1 status.
Chapter 4
Investigating the multiple tissue
phenotypes of Brg1 loss
4.1 Introduction
The data presented in the previous chapter described a range of responses observed in
the small intestinal epithelium as a result of Brg1 loss, which I interpret to be due to
compromised function of the small intestinal stem cell. A number of previous reports
have implicated Brg1 in the development and maintenance of a wide range of tissues
(Bultman et al,. 2005; Chi et al., 2003; De et al., 2011; Griﬃn et al., 2008; Hang et al.,
2010; Inayoshi et al., 2006; Indra et al., 2005; Matsumoto et al., 2006; Ohkawa et al,. 2006;
Stankunas et al., 2008; Xu et al., 2006). In particular, adult mesenchymal stem cells have
been reported to require tightly regulated Brg1 levels for their maintenance (Alessio et al.,
2010; Napolitano et al., 2007). Furthermore, in a subset of tissues, heterozygous Brg1 loss
has been demonstrated to induce or facilitate tumourigenesis (Bultman et al., 2007; Glaros
et al., 2008), suggesting that in these tissues Brg1 acts as a bona ﬁde tumour suppressor.
Because of the oﬀ-target-tissue expression proﬁle of the AhCreER recombinase I was able
to analyse Brg1 loss in a range of tissues outside of the small intestine. Additionally, pan-
intestinal expression of VillinCre recombinase enabled me to investigate the consequences
of Brg1 deletion in the large intestinal epithelium. This chapter describes the eﬀects of
Brg1 deﬁciency in forestomach, glandular stomach, large intestine and bladder epithelial
tissues1.
1Some of the animals involved in the long-term ageing experiments using AhCreER recombinase were
induced and dissected by Dr Boris Shorning. The subsequent analysis of the tissue sections was carried
out by me.
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4.2 Results
4.2.1 Brg1 haploinsuﬃciency does not induce tumourigenesis in
multiple tissues expressing AhCre recombinase
Brg1 mutations have been detected in cancer cell lines and primary tumours from a range
of tissues (Becker et al., 2009; Reisman et al., 2003; Wong et al., 2000). More speciﬁcally,
Brg1 haploinsuﬃciency has been reported to contribute to tumourigenesis in the mam-
mary gland and lung epithelium Bultman et al., 2007, Glaros et al., 2008). In order to
further explore the role of Brg1 as a tumour suppressor, I aimed to assess the tumouri-
genic eﬀect of Brg1 haploinsuﬃciency in multiple tissues expressing AhCre recombinase,
including large intestine, forestomach and glandular stomach epithelium, bladder urothe-
lium and liver. To this end AhCre+Brg+/fl mice were induced by four intraperitoneal
injections of 80 mg/kg β-naphthoﬂavone and aged along with AhCre+Brg+/+ controls
(for survival analysis see section 3.2.3). The organs reported to express AhCre recombi-
nase were harvested at the end of the ageing experiment or earlier, if the animal developed
signs of ill health. Tissue samples were ﬁxed and processed for histology and genomic DNA
was extracted from the paraﬃn embedded sections. Recombined PCR analysis detected
a strong signal for the recombined Brg1 allele in the liver, the glandular and forestomach,
the small and large intestine of AhCre+Brg+/fl animals (Figure 3.3) indicating successful
retention of cells with heterozygous Brg1 loss. The signal for recombinant allele in the
bladder urothelium was not detected. This, however, could be attributed to a smaller
amount of tissue available for the analysis.
As described in section 3.2.3, analysis of survival probability revealed no signiﬁcant
diﬀerence between AhCre+Brg+/fl and AhCre+Brg+/+ mice (Figure 3.2). Macroscopic
analysis of internal organs from AhCre+Brg+/fl mice at the time of dissection revealed no
consistent causes of ill health. Among the most commonly observed symptoms of ill health
were uterus and sebaceous gland inﬂammation in female and male animals respectively.
Additionally, tumour-like formations in the liver were occasionally observed, which were
identiﬁed as lymphomas and were encountered in both experimental and control animals.
Histological analysis of the tissues with known AhCre expression revealed no signs of
neoplastic transformation. As an example, H&E stained sections of the glandular and
forestomach epithelium from AhCre+Brg+/fl and control animals are presented in Figure
4.1.
4.2.2 Brg1 loss drives benign hyperplasia in the forestomach
epithelium
Unlike the human stomach, the murine stomach is divided into two compartments: non-
glandular forestomach and glandular stomach separated by the limiting ridge (Figure 4.2).
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Figure 4.1: Brg1 haploinsuﬃciency does not induce oncogenic transformation in the tissues of the
murine stomach. Histological analysis of H&E stained sections of the murine stomach from AhCre+-
Brg+/fl mice and AhCre+Brg+/+ controls revealed no signs of tumourigenesis in any of the stomach
tissues over an observation period of 600 days. Scale bars represent 100 µm.
The forestomach is lined with soft keratinised stratiﬁed squamous epithelium, which it
shares with oesophageal mucosa (Figure 4.2b). Proliferation in the forestomach epithelium
is limited to the basal layer of cells, which diﬀerentiate and undergo keratinisation as they
migrate towards the lumen (Karam, 1999).
4.2.2.1 Brg1 deﬁcient cells are retained in the forestomach epithelium
Having established that no obvious oncogenic eﬀect of Brg1 haploinsuﬃciency was ob-
served in the murine forestomach epithelium, I aimed to examine the consequence of Brg1
deﬁciency in this tissue. To this end, AhCreER+Brgfl/fl mice as well as AhCreER−
controls were induced with ﬁve intraperitoneal injections of 80 mg/kg β-naphthoﬂavone
and tamoxifen. Animals were dissected at day 35 PI and whole stomachs were harvested,
processed and subjected to histological analysis. Immunohistochemical analysis of Brg1
expression in the forestomach epithelium of AhCreER+Brgfl/fl mice at day 35 PI de-
tected occasional Brg1 deﬁcient cells intermingled with Brg1 positive cells (Figure 4.3).
In contrast, all epithelial cells of wild type forestomach displayed high levels of Brg1 ex-
pression. Analysis of H&E stained sections, however, detected no marked diﬀerences in
the histology of AhCreER+Brgfl/fl and control forestomach (Figure 4.3).
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Figure 4.2: General anatomical structure of the murine stomach with representative H&E stained
sections of the respective regions (a-c) and histological organisation of gastric glands (d). See main text
for detailed description. Adapted from (Green, 1966).
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Figure 4.3: Brg1 deﬁcient cells are retained in the forestomach epithelium of AhCreER+Brgfl/fl
mice. (a) Histological analysis of H&E stained sections of the forestomach epithelium from AhCreER+-
Brgfl/fl mice and Cre− controls at day 35 PI revealed no gross diﬀerences in tissue morphology between
the groups. (b) Immunohistochemical analysis of Brg1 expression in the forestomach epithelium of
AhCreER+Brgfl/fl mice at day 35 PI detected occasional Brg1 deﬁcient cells distributed throughout
the epithelium. No Brg1 deﬁcient cells were detected in the forestomach epithelium of AhCreER− mice.
Scale bars represent 50 µm.
4.2.2.2 Brg1 loss in the forestomach epithelium induces formation of squa-
mous cell papillomas
In order to examine the long-term consequences of Brg1 loss in the forestomach epithe-
lium, AhCreER+Brgfl/fl mice were induced along with AhCre− controls as described
above, aged and dissected at 80, 490 and 700 days PI (a minimum of 3 animals per time
point). Histological analysis of H&E stained sections detected multiple lesions in the
forestomach epithelium of AhCreER+Brgfl/fl mice as early as day 80 PI (Figure 4.4a).
Histopathological examination of the lesions identiﬁed them as squamous cell papillo-
mas2. Histopathological analysis of the lesions at later time points revealed a substantial
increase in the size of papillomas. However all lesions observed retained benign, highly
diﬀerentiated histology with well deﬁned borders and displayed no sign of dysplasia or
invasive disease even at the latest time point (Figure 4.4). No lesions of any pathological
nature were detected in the forestomach epithelium of AhCre− mice at any time point
(n≥3 for all time points).
Immunohistochemical analysis of Brg1 expression in the forestomach epithelium of
AhCreER+Brgfl/fl mice revealed that papillomas were composed of Brg1 deﬁcient cells
(Figure 4.4a, bottom panels). Interestingly, Brg1 positive tissue that surrounded Brg1
2Histopathological description of forestomach lesions was provided by Prof Geraint T. Williams, De-
partment of Pathology, University Hospital of Wales, Cardiﬀ University, UK
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Figure 4.4: Brg1 loss in the forestomach epithelium induces formation of squamous cell papillomas. (a)
Histological analysis of H&E stained sections of the forestomach epithelium from AhCreER+Brgfl/fl
mice at day 80, 490 and 700 PI revealed squamous cell papillomas. Although papillomas varied in size, no
signs of invasive disease were detected. Immunohistochemical analysis of Brg1 expression in forestomach
papillomas revealed that they were predominantly composed of Brg1 deﬁcient cells with Brg1 expression
status marking a clear border between hyperplastic and normal epithelium. (b) Immunohistochemical
analysis of control Cre− control mice revealed Ki67 staining in the basal layer of squamous epithelium.
Immunostaining of serial sections ofAhCreER+Brgfl/fl forestomach at day 80 PI with antibodies against
Brg1 and Ki67 revealed an expansion of Ki67 positive cells beyond the basal layer in Brg1 deﬁcient
epithelium. Note that despite aberrant appearance of some sections of Brg1 positive epithelium, Ki67
expression in these sections remained conﬁned to the basal layer of cells. Scale bars represent 200 µm.
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deﬁcient papillomas occasionally had abnormal appearance (Figure 4.4a, bottom panels).
This phenomenon could potentially be attributed to distortion of the architecture of the
surrounding tissue by growing papilloma, which could result in abnormal appearance of
tissue sections. Alternatively, Brg1 deﬁcient cells could be secreting growth stimulating
factors that would induce a proliferative response in the surrounding wild type tissue.
In order to distinguish between these two possibilities I stained the forestomach sections
with the proliferation marker Ki67 (Figure 4.4b). Immunohistochemical analysis of Ki67
expression revealed that proliferation in the forestomach epithelium of the control animal
was largely limited to a single layer of basal cells (Figure 4.4b). Expression analysis of
serial sections of Brg1 deﬁcient forestomach epithelium stained with Brg1 and Ki67 re-
vealed a substantially expanded proliferative compartment within Brg1 deﬁcient lesions
(Figure 4.4b). However, adjacent lesion-like Brg1 positive structures displayed the expres-
sion pattern of Ki67 comparable to that observed in control animals. This observation
suggested that lesion-like appearance of Brg1 positive epithelium of AhCreER+Brgfl/fl
forestomach was most likely caused by a disturbed tissue architecture.
4.2.2.3 Brg1 deﬁcient papillomas in the forestomach are not driven by acti-
vation of PI3K/AKT pathway, but by attenuated p21/pRb signalling
In order to investigate potential mechanisms leading to the formation of squamous cell
papillomas in Brg1 deﬁcient forestomach epithelium I assessed the status of a number of
signalling pathways potentially involved in forestomach neoplasia.
Coordinated activation of the MEK/ERK and the PI3K/AKT pathways via simulta-
neous expression of activated form of Kras and loss of Pten has been reported to drive
development of diﬀuse papillomatous hyperplasia of the forestomach epithelium (Marsh, in
preparation). In order to investigate whether Brg1 loss induced papillomas in the murine
forestomach epithelium by activating PI3K/AKT signalling, I analysed phosphorylation
status of the PI3K/AKT pathway eﬀector ribosome subunit S6. Immunohistochemical
analysis of S6 phosphorylation in the forestomach epithelium of AhCreER+Brgfl/fl and
control mice revealed no diﬀerence in the levels of S6 phosphorylation between Brg1
deﬁcient and wild type epithelium (Figure 4.5a). This suggests that activation of the
PI3K/AKT pathway is unlikely to drive development of Brg1 deﬁcient papillomas in the
forestomach epithelium.
Brg1 has been reported to facilitate pRB-mediated cell cycle control via positive reg-
ulation of p21 expression, which in turn induces pRB hypophosphorylation and imposes
cell growth arrest (Hendricks et al., 2004; Kang et al., 2004). In order to assess the ef-
fects of Brg1 loss on p21 expression I carried out immunohistochemical analysis of p21
expression in the forestomach epithelium of AhCreER+Brgfl/fl and control mice. p21
expression analysis detected a substantially reduced staining levels in squamous cell pa-
pillomas compared to the epithelium of control mice (Figure 4.5b). Furthermore, regions
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Figure 4.5: Brg1 deﬁcient forestomach papillomas show no alterations in S6 phosphorylation, but
exhibit p21 suppression. (a) Immunohistochemical analysis of expression of phosphorylated S6 ribosomal
subunit in the forestomach epithelium of AhCreER+Brgfl/fl and control mice at day 80 PI revealed
no diﬀerence in S6 phosphorylation levels between hyperplastic and normal squamous epithelium. (b)
Analysis of p21 expression in the forestomach epithelium of AhCreER+Brgfl/fl and control mice at day
80 PI revealed a substantially reduced p21 expression in the forestomach papillomas compared to both
adjacent normal epithelium and epithelium of control mice. Scale bars represent 100 µm.
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of Brg1 proﬁcient epithelium in the forestomach of AhCreER+Brgfl/fl animals displayed
levels of p21 expression compared to that observed in the forestomach of control mice
(Figure 4.5, black arrowhead). These observations propose a model, where Brg1 loss
induces the development of squamous cell papillomas in the forestomach epithelium via
attenuation of p21 expression and inhibition of pRb-mediated control over the cell cycle.
4.2.3 The eﬀects of Brg1 loss in the glandular stomach epithe-
lium
The mucosa of the glandular stomach is composed of a simple columnar epithelium that
forms tube-like invaginations into the lamina propria, structures termed gastric glands.
Gastric gland morphology varies depending on their location within the stomach. Cardiac
glands are the least abundant and are located in cardiac antrum, where the oesophagus
enters the stomach. Pyloric glands are conﬁned to the pylorus region of the stomach,
just before it joins the small intestine (4.2a), while the most abundant fundic glands
line the stomach body (corpus)(4.2c) (Seeley et al., 2002). All glands share a common
organisation in that they are divided in three structurally distinct parts: gastric pit,
isthmus and proper gland. One or more proper glands enter the isthmus where they join
with the gastric pit, which then opens into the stomach lumen. Fundic and pyloric glands
diﬀer from each other in the respective size of their compartments and cell composition
(Lee, 1985). The pyloric gland is occupied by a relatively long gastric pit followed by
short isthmus and gland, all of which are lined by mucous cells and infrequently scattered
G cells that secrete gastrin (4.2d). Fundic glands are more structurally complex and
consist of a short pit and isthmus followed by long gland. The gland itself is further
subdivided into neck, body and base. The pit, isthmus and neck of fundic glands are
lined with mucous producing Neck cells. The neck of the gland also contains eosinophilic
Parietal (Oxyntic) cells secreting gastric acid and intrinsic factor. The body and the base
of the fundic gland is mainly occupied by basophilic Chief (Zymogenic) cells secreting
pepsinogen and a variety of Enteroendocrine cells producing hormones such as gastrin, its
antagonist somatostatin, histamine, endorphins, serotonin, and cholecystokinin (Seeley et
al., 2002). All gastric cell lineages originate from the isthmal stem cell residing in the
isthmus region of the gastric gland. Depending on the lineage some precursor cells retain a
limited proliferative potential as they undergo terminal diﬀerentiation and migrate either
towards the lumen of the gland base (Karam, 1999).
4.2.3.1 Brg1 deﬁcient cells are retained in the glandular stomach epithelium
Having established that Brg1 haploinsuﬃciency has no obvious oncogenic eﬀect in the
glandular stomach epithelium, I set out to analyse the outcome of complete Brg1 loss in
this tissue. To this end, AhCreER+Brgfl/fl mice along with AhCreER− controls were
induced by ﬁve intraperitoneal injections of 80 mg/kg β-naphthoﬂavone and tamoxifen.
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The mice were then dissected 35 days PI, at which point whole stomachs were harvested
and processed for histological analysis. Immunohistochemical analysis of Brg1 expression
in the glandular stomach epithelium revealed occasional gastric glands composed of Brg1
deﬁcient cells (Figure 4.6). Gastric glands containing Brg1 deﬁcient cells were detected
in the epithelium of both fundic (corpus) and pyloric regions of the glandular stomach
(Figure 4.6). Analysis of H&E stained sections of the gastric epithelium revealed no
abnormalities in the morphology of Brg1 deﬁcient glands in either region of the gandular
stomach (Figure 4.6)
Figure 4.6: Brg1 deﬁcient cells are retained in the pyloric and fundic epithelium of AhCreER+Brgfl/fl
mice. Immunohistochemical analysis of Brg1 expression in the pyloric (a) and fundic (b) epithelium of
AhCreER+Brgfl/fl mice at day 35 PI revealed occasional gastric glands largely populated by Brg1
deﬁcient cells. While histological analysis of H&E stained sections of the pyloric stomach of AhCreER+-
Brgfl/fl mice revealed no morphological abnormalities (a), Brg1 deﬁcient fundic glands at day 35 PI
displayed a moderate expansion of the mucinous neck cells in the gastric pit (b). Scale bars represent 50
µm.
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4.2.3.2 Brg1 loss in glandular stomach epithelium results in fundic gland
polyposis
In order to assess the long-term eﬀects of Brg1 loss in the gastric epithelium, AhCreER+-
Brgfl/fl mice were aged along with AhCreER− controls and whole stomachs were har-
vested at day 80, 490 and 700 PI (a minimum of 3 mice per time point). Histological
analysis of the H&E stained sections of fundic stomach epithelium detected regions of
hyperplastic growth in AhCreER+Brgfl/fl mice as early as day 80 post induction (Fig-
ure 4.7a). Histopathological analysis of these hyperplastic malformations identiﬁed them
as fundic gland polyps (FGPs) with characteristic superﬁcial and deep cysts lined with
mucous neck, parietal and chief cells3. Analysis of the glandular stomach epithelium at
later time points (490 and 700 days PI) revealed that FGPs substantially increased in size
and occasionally displayed low grade dysplasia. However, all the observed FGPs retained
a high degree of diﬀerentiation and displayed no sign of invasive disease even at the latest
time point analysed (Figure 4.7a). No signs of hyperplastic transformation was detected
in the glandular stomach of AhCreER− mice at any time point.
Immunohistochemical analysis of Brg1 expression in AhCreER+Brgfl/fl glandular
stomach revealed that the polyps were largely composed of Brg1 deﬁcient cells (Figure
4.6a, bottom panels). Histological analysis of the early Brg1 deﬁcient lesions demonstrated
that they were formed by expansion of mucous neck cells of the gastric pit and isthmus
of the fundic gland (Figure 4.7a). This ﬁnding is consistent with the location of the
gastric epithelium proliferative and stem cell compartments. In order to compare the
proliferative activity of wild type and Brg1 deﬁcient epithelium, sections of the glandular
stomach were immunostained with an antibody against the proliferation marker Ki67
(Figure 4.7c). Analysis of Ki67 staining conﬁrmed that proliferation in wild type fundic
stomach was largely conﬁned to a short region around the isthmus of the gastric gland.
Conversely, in the fundic epithelium of AhCreER+Brgfl/fl mice, Ki67 staining was found
to be substantially expanded and distributed throughout the epithelium (Figure 4.7c).
Of note, all hyperplastic lesions observed in the glandular stomach epithelium were
found to be located in the body of the stomach. Whilst Brg1 deﬁcient pyloric glands were
detected at all time points, they displayed no signs of hyperplasia (Figures 4.6a and 4.7b).
Taken together, these observations suggest that long-term Brg1 loss is tolerated in the
whole of the glandular stomach epithelium, but induces benign fundic gland polyposis.
Brg1 thus appears to act as a tumour suppressor in the fundic, but not pyloric stomach
epithelium.
3Histopathological description of glandular stomach hyperplasia was provided by Prof Geraint T.
Williams, Department of Pathology, University Hospital of Wales, Cardiﬀ University, UK
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Figure 4.7: Brg1 loss induces gastric gland polyposis in the fundic, but not pyloric stomach. (a)
Histological analysis of H&E stained sections of AhCreER+Brgfl/fl fundic stomach epithelium revealed
hyperplastic fundic gland polyps (FGPs) as early as day 80 PI. Analysis of the fundic stomach histology at
later time points revealed an increase in polyp size, but no signs of invasive disease. Immunohistochemical
analysis of Brg1 expression in AhCreER+Brgfl/fl fundic stomach revealed a substantial Brg1 deﬁcient
component in FGPs. (b) Immunostaining with an antibody against Ki67 revealed an expansion of Ki67
positive cells in the fundic stomach of AhCreER+Brgfl/fl mice compared to control fundic epithelium,
where Ki67 expression was conﬁned to the isthmus region of the gland. (c) Immunohistochemical analysis
of Brg1 expression in the pyloric stomach of AhCreER+Brgfl/fl mice revealed occasional Brg1 deﬁcient
glands at all inspected time points. No aberrations in morphology of Brg1 deﬁcient pyloric glands were
observed at any time point. Scale bars represent 200 µm.
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4.2.3.3 Fundic gland polyposis in Brg1 deﬁcient glandular stomach is not
driven by the Wnt/β-catenin, PI3K/AKT, AMPK or p21/Rb path-
ways
In order to dissect the potential mechanisms leading to polyp formation in Brg1 deﬁcient
gastric epithelium, a number of signalling cascades implicated in gastrointestinal polyposis
were analysed.
Tumours of a histopathological nature similar to that of Brg1 deﬁcient fundic gland
polyps are commonly detected in patients with Familial Adenomatous Polyposis (FAP)
and attenuated FAP (AFAP), which are caused by a range of mutations in the APC gene
(Abraham et al., 2000). Furthermore, sporadic FGPs are frequently found to arise due
to activating mutations in β-catenin (Abraham et al., 2001). These observations strongly
implicate activation of the Wnt pathway in fundic gland polyposis. Considering the pre-
viously reported requirement of functional BRG1 for trans-activation of Wnt pathway
target genes (Barker et al., 2001) and the fact that FGPs are commonly driven by ac-
tivation of the Wnt pathway, makes the observation that Brg1 deﬁciency induces FGPs
highly unexpected. I, therefore, aimed to investigate the state of Wnt signalling in Brg1
deﬁcient FGPs. To this end, sections of glandular stomach from AhCreER+Brgfl/fl mice
containing Brg1 deﬁcient FGPs were stained with an antibody against β-catenin (Figure
4.8a). Analysis of β-catenin intracellular distribution in Brg1 deﬁcient FGPs revealed its
strong cell membrane localisation in the majority of cells within the lesion (Figure 4.8a,
white arrowhead), but with occasional cells exhibiting high levels of cytoplasmic β-catenin
(Figure 4.8a, black arrowhead). No cells with distinct nuclear localisation of β-catenin
were detected. This pattern of β-catenin distribution suggested that polyp formation was
unlikely to be driven by Wnt pathway activation.
Having established that FGPs in the Brg1 deﬁcient stomach epithelium did not dis-
play signs of Wnt pathway activation, I attempted to assess the state of other pathways
involved in known intestinal polyposis conditions. Loss of the PTEN and LKB1 tu-
mour suppressors have been found to be the genetic lesion underlying Cowden’s and
Peutz-Jeghers (PJS) syndromes respectively (Jenne et al., 1998; Liaw et al., 1997). Both
syndromes have been linked to intestinal polyposis including polyps in gastric epithe-
lium (reviewed in Bronner, 2003). These polyps, however, are histologically distinct from
FGPs and are characterised by a more pronounced presence of stromal components. Loss
of PTEN and LKB1 results in activation of the PI3K/AKT and AMPK pathways re-
spectively and both pathways have been shown to converge on the mammalian target of
rapamycin (mTOR) pathway that controls cell growth and is frequently deregulated in
cancers (reviewed in Shackelford and Shaw, 2009). In order to investigate possible acti-
vation of the PI3K/AKT and AMPK pathways I assessed phosphorylation status of an
mTOR downstream target, ribosomal subunit S6 (Figure 4.8b). Analysis of Brg1 deﬁcient
FGPs revealed strong phospho-S6 staining, indicating activation of the mTOR pathway
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Figure 4.8: Brg1 deﬁcient FGPs display no nuclear accumulation of β-catenin or changes in S6 phos-
phorylation and p21 expression. (a) Immunostaining of serial sections of Brg1 deﬁcient FGPs at day
490 PI with antibodies against Brg1 and β-catenin revealed widespread membrane-associated β-catenin
staining (white arrowhead) and occasional cells with elevated cytoplasmic β-catenin (black arrowhead).
However, no distinct nuclear localisation of β-catenin was observed. (b,c) Immunohistochemical analy-
sis of S6 phosphorylation (b) and p21 expression (c) in the fundic stomach at day 80 PI revealed no
diﬀerences between control and AhCreER+Brgfl/fl epithelium. Scale bars represent 100 µm.
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in Brg1 deﬁcient epithelium. However, a comparable intensity of phospho-S6 staining was
observed in the proliferative compartment of wild type gastric glands (Figure 4.8b). It ap-
pears unlikely, therefore, that activation of PI3K/AKT or AMPK pathways is responsible
for development of FGPs in the gastric epithelium of AhCreER+Brgfl/fl mice.
Finally, Brg1 has been reported to participate in regulation of cell proliferation via
control of p21 expression and subsequent Rb-mediated G1 checkpoint (Hendricks et al.,
2004; Kang et al., 2004). In order to assess any potential role of the p21/Rb pathway in
polyp formation, I analysed expression of p21 in wild type glandular stomach and Brg1
deﬁcient FGPs. Immunohistochemical analysis of p21 expression demonstrated that both
normal epithelium and FGPs displayed comparable levels of p21 expression (Figure 4.8c).
Together, these observations suggested that development of Brg1 deﬁcient FGPs in the
glandular stomach epithelium of AhCreER+Brgfl/fl mice was unlikely to be mediated
by aberrant activation of the Wnt/β-catenin, PI3K/AKT, AMPK or p21/Rb pathways.
4.2.4 Long-term Brg1 loss is tolerated in the large intestinal
epithelium and has no oncogenic eﬀect
Having detected no tumourigenic eﬀect of Brg1 haploinsuﬃciency in the large intestinal
epithelium, I aimed to analyse the outcome of complete Brg1 loss in this tissue. This was
achieved by conditional deletion of Brg1 using either AhCreER or VillinCre recombinase
and subsequent analysis of Brg1 deﬁcient crypts4
4.2.4.1 Brg1 deﬁcient cells are retained in the large intestine
In order to analyse the long-term consequences of Brg1 loss in the large intestinal ep-
ithelium, mice bearing loxP targeted Brg1 alleles and AhCreER transgene were induced
with 5 intraperitoneal injections of 80 mg/kg β-naphthoﬂavone and tamoxifen along with
AhCreER− controls. Mice from both cohorts were then aged and harvested at 35, 80
and 490 days PI, at which point whole large intestines were harvested and processed for
histological analysis.
Macroscopic analysis of the large intestinal epithelium at the time of dissection did
not reveal any signs of large intestinal tumourigenesis at any of the time points. Im-
munohistochemical analysis of Brg1 expression in the large intestine of control animals
revealed ubiquitous Brg1 expression throughout the epithelium (Figure 4.9). Conversely,
analysis of Brg1 expression in the large intestinal epithelium of AhCreER+Brgfl/fl mice
at all time points revealed the presence of occasional crypts fully populated by Brg1 de-
ﬁcient cells (Figure 4.9). All Brg1 deﬁcient crypts were indistinguishable from adjacent
Brg1 proﬁcient epithelium. They retained normal appearance and displayed no signs of
4The results presented in this section were obtained with the assistance of Joanna Krzystyniak. Breed-
ing, induction and dissection of experimental animals were conducted by me. Histological and immuno-
histochemical analysis of tissue sections were conducted by Joanna under my direction and supervision.
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Figure 4.9: Brg1 deﬁcient crypts are retained in the large intestinal epithelium. Immunohistochemical
analysis of Brg1 expression in the large intestinal epithelium of AhCreER+Brgfl/fl mice at day 35, 80
and 490 PI revealed occasional Brg1 deﬁcient crypts. No gross morphological diﬀerences were observed
between Brg1 deﬁcient and adjacent Brg1 positive crypts. No Brg1 deﬁcient crypts were detected in the
large intestinal epithelium of control mice at any time point. Scale bars represent 200 µm.
tumourigenesis even at the latest time point. These observations suggested that Brg1 de-
ﬁciency has no oncogenic eﬀect in the context of the large intestinal epithelium, at least
within the time period observed here.
4.2.4.2 Brg1 deﬁcient large intestinal crypts retain normal levels of Wnt
signalling
The long-term retention of Brg1 deﬁcient crypts in the large intestinal epithelium sug-
gested that Brg1 function is dispensable for large intestinal homeostasis. This observation
is in apparent contradiction with the established role of Wnt signalling in large intesti-
nal homeostasis (reviewed in Gregorieﬀ and Clevers, 2005) and the proposed requirement
of Brg1 for trans-activation of Wnt pathway target genes (Barker et al., 2001). In or-
der to investigate potential eﬀects of Brg1 loss on Wnt signalling in the context of the
large intestine, I aimed to analyse expression levels of Wnt target genes in Brg1 deﬁcient
crypts. Since AhCreER recombinase induced Brg1 loss with a limited eﬃciency, I used
the VillinCre recombinase transgene to increase the frequency of Brg1 deﬁcient crypts. In-
duction of V illinCre+Brgfl/fl animals with a single intraperitoneal injection of 40 mg/kg
tamoxifen was suﬃcient to generate large intestinal Brg1 deﬁcient crypts at a frequency
exceeding that observed in AhCreER+Brgfl/fl mice.
Large intestinal samples from V illinCre+Brgfl/fl mice were harvested at day 30 PI
and subjected to immunohistochemical analysis of the Wnt target genes c-Myc and CD44.
Analysis of serial sections stained with antibodies against Brg1, c-Myc and CD44 detected
no discernible diﬀerences in Wnt target gene expression between Brg1 deﬁcient and pro-
ﬁcient crypts (Figure 4.10a, black and white arrowheads respectively).
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Figure 4.10: Brg1 loss in the large intestinal epithelium is compensated by Brm overexpression. (a) Im-
munohistochemical analysis of expression of the Wnt target genes c-Myc and CD44 in the large intestinal
epithelium of V illinCre+Brgfl/fl mice at day 30 PI revealed no diﬀerences in the Wnt target genes ex-
pression between Brg1 deﬁcient (black arrowheads) and adjacent Brg1 positive (white arrowhead) crypts.
(b) Immunohistochemical analysis of Brm expression revealed a substantial increase in Brm levels in
Brg1 deﬁcient crypts (black arrowheads) compared to adjacent Brg1 positive tissue (white arrowheads).
While occasional cells with prominent nuclear Brm localisation were detected (red arrow), Brm staining
was predominantly conﬁned to mucus containing compartment of Goblet cells (green arrows). (c) Quan-
titative analysis of Alcian blue stained sections of the large intestinal epithelium of V illinCre+Brgfl/fl
mice at day 30 PI revealed a signiﬁcant increase in number of mucus secreting cells in Brg1 deﬁcient
crypts compared to adjacent Brg1 positive epithelium (One-Way ANOVA, p=0.017, n=3). Scale bars
represent 100 µm. Error bars represent standard deviation.
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4.2.4.3 Brg1 deﬁciency in large intestinal epithelium is compensated by Brm
overexpression
The observation that Brg1 loss had no tangible eﬀect on Wnt target gene expression in
the large intestinal epithelium could be potentially attributed to a compensatory mech-
anism that ensured long-term retention of Brg1 deﬁcient crypts. The Brg1 paralogue
Brahma (Brm) represents a likely mechanism for such compensation. In order to investi-
gate potential alterations to Brm expression in response to Brg1 deﬁciency, immunohis-
tochemical analysis of Brm expression was carried out in the large intestinal epithelium
of V illinCre+Brgfl/fl mice. Moderate levels of Brm staining were detected throughout
the large intestinal epithelium (Figure 4.10b). However, occasional crypts were found to
display substantially elevated levels of Brm expression. Analysis of serial sections stained
with antibodies against Brg1 and Brm revealed a consistent overlap between Brg1 de-
ﬁcient crypts and crypts with elevated Brm expression (Figure 4.10b, black and white
arrowheads respectively). This observation suggested that loss of Brg1 function in the
large intestine is likely to be compensated for by elevated levels of Brm expression, which
in turn could explain the lack of any detrimental eﬀects of Brg1 deﬁciency on large intesti-
nal homeostasis and tumourigenesis. Curiously, whilst rare cells with prominent nuclear
Brm staining were detected in the lower half of some Brg1 deﬁcient crypts (Figure 4.10b,
red arrowhead), elevated Brm staining was most prominent in what appeared to be mu-
cus containing vacuoles of the Goblet cells (Figure 4.10b, green arrowheads). Although
some goblet cells in the small intestine exhibited this staining pattern, no excessive Brm
staining was detected in Brg1 positive large intestinal Goblet cells.
4.2.4.4 Brg1 loss in the large intestine promotes cell diﬀerentiation along
mucus producing cells lineages
Having established that Brg1 loss does not compromise long-term crypt survival I set out
to analyse more subtle parameters of epithelial homeostasis, namely cell diﬀerentiation.
The large intestinal epithelium is comprised of three major cell lineages: vacuolated-
columnar, Goblet and deep crypt secretory (DCS) cells (Karam, 1999). Of these, Goblet
and DCS cells are characterised by mucus secretion and thus can be easily identiﬁed by
staining with a mucus-aﬃne dye, such as Alcian blue. In order to investigate cellular
diﬀerentiation along these two lineages, large intestinal tissue sections were stained with
Brg1 antibody and counter-stained with Alcian blue dye (Figure 4.10a, leftmost panel).
The average number of Alcian blue positive cells per half-crypt was scored in Brg1 deﬁcient
and adjacent Brg1 positive crypt (10 pairs per mouse). This analysis was repeated in 3
mice and the overall average was calculated. The average number of Alcian positive cells
(± standard deviation) was found to be 14.07±1.39 and 17.53±0.651 in Brg1 positive and
negative crypts respectively (Figure 4.10c). This diﬀerence was found to be statistically
signiﬁcant (One-way ANOVA, p=0.017, n=3). This observation suggested that Brg1
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deﬁciency stimulated cell diﬀerentiation along the mucus secreting lineages of the large
intestinal epithelium.
4.2.5 Long-term Brg1 loss is tolerated in the bladder urothelium
and has no oncogenic eﬀect
Bladder, as well as the rest of the genitourinary tract, including renal pelvis, ureter
and prostatic urethra is lined with urothelium (traditionally also termed as transitional
epithelium), a tissue unique for the urinary tract. Murine urothelium consists of three
cellular levels: basal, intermediate and superﬁcial (umbrella) of which only ﬁrst two main-
tain direct contact with the basal membrane.The distinctive feature of the transitional
epithelium is a substantial elasticity enabling it to accommodate signiﬁcant changes in
surface area (Wu et al,. 2009). Oﬀ-target-tissue expression of AhCreER recombinase in
the bladder urothelium enabled me to investigate the eﬀects of Brg1 loss in this tissue.
4.2.5.1 Brg1 deﬁcient cells are retained in the bladder urothelium over a long
period of time
In order to explore the potential consequences of Brg1 deﬁciency in the bladder urothe-
lium, AhCreER+Brgfl/fl mice along with AhCreER− controls were induced by intraperi-
toneal injection of 80 mg/kg β-naphthoﬂavone and tamoxifen. Mice from both cohorts
were sacriﬁced at various time points and whole bladders were harvested and processed
for histological analysis. Immunohistochemical analysis of Brg1 expression at day 10
PI revealed ubiquitous Brg1 expression in the bladder urothelium of control mice (Fig-
ure 4.11). Conversely, the bladder urothelium of AhCreER+Brgfl/fl mice displayed a
substantial loss of Brg1 expression (Figure 4.11). In order to investigate the long-term
retention of Brg1 deﬁcient cells in the bladder urothelium, bladder tissue was collected
from AhCreER+Brgfl/fl and control mice at day 100 and 490 PI. Immunohistochemical
analysis of Brg1 expression revealed eﬃcient retention of Brg1 deﬁcient cells in the blad-
der urothelium of AhCreER+Brgfl/fl mice even at the latest time point analysed (Figure
4.11). Histological analysis of H&E stained sections of the bladder urothelium revealed
no discernible morphological diﬀerences between Brg1 deﬁcient and wild type urothelium.
No signs of tumourigenesis were detected in either Brg1 deﬁcient or wild type urothelium
at any of the time points analysed.
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Figure 4.11: Brg1 deﬁcient cells are retained in the bladder urothelium. Immunohistochemical analysis
of Brg1 expression in the bladder urothelium of AhCreER+Brgfl/fl mice at day 10, 100 and 490 PI
detected a substantial number of Brg1 deﬁcient cells distributed throughout the urothelium at all time
points. Occasional Brg1 deﬁcient cells were also detected in the urothelium of control mice albeit at a
very low frequency. Scale bars represent 100 µm.
4.3 Discussion
4.3.1 Brg1 haploinsuﬃciency has no overt oncogenic eﬀect in a
subset of tissues expressing AhCre recombinase
A number of studies have suggested that Brg1 haploinsuﬃciency promotes tumourigen-
esis in mammary and lung epithelial tissue (Bultman et al., 2007; Glaros et al., 2007).
Oﬀ-target-tissue expression of AhCre recombinase allowed me to investigate whether Brg1
loss induces tumourigenesis in a subset of epithelial tissues outside of the small intestinal
epithelium. In contrast to the aforementioned ﬁndings, Brg1 haploinsuﬃciency failed to
induce tumourigenesis in any of the analysed tissues, namely in the forestomach, glan-
dular stomach, large intestine and bladder epithelia over a long period of observation.
This observation is not entirely unexpected, since tumourigenesis induced by constitutive
heterozygous loss of Brg1 has been found to be limited to the mammary gland epithelium
(Bultman et al., 2007). Together with the previously published data, ﬁndings presented
in this chapter highlight the tissue-dependent ability of Brg1 haploinsuﬃciency to induce
tumourigenesis.
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4.3.2 Brg1 loss induces the development of benign tumours in
epithelial tissues of the murine stomach
AhCreER recombinase expression in the epithelium of murine glandular and forestomach
enabled me to investigate the eﬀects of Brg1 loss in these tissues. The data presented in
this chapter suggest that Brg1 loss results in early onset hyperplasia of murine stomach
epithelium. Rather surprisingly, Brg1 loss induced formation of benign lesions in both
parts of the stomach, despite their lining being represented by considerably distinct types
of epithelium: simple columnar and keratinised stratiﬁed squamous epithelium in glandu-
lar and forestomach respectively (Karam, 1999). According to their respective tissues of
origin, Brg1 deﬁcient lesions were identiﬁed as squamous cell papillomas in the forestom-
ach and fundic gland polyps in the glandular stomach epithelium. Interestingly, while
Brg1 haploinsuﬃciency has been implicated in mammary tumourigenesis (Bultman et al.,
2007) and numerous studies have reported the presence of Brg1 mutations in cancer cell
lines and primary tumours (Becker et al., 2009; Reisman et al., 2003; Wong et al., 2000),
no reports have demonstrated tumourigenesis as a direct consequence of Brg1 loss. More-
over, some reports have indicated that Brg1 loss in physiologically sound tissue may have
an adverse eﬀect on cancer initiation by inducing apoptosis (Glaros et al., 2008, Wang
et al., 2009). Results presented in this chapter provide the ﬁrst evidence that Brg1 loss
directly induces tumourigenesis in the epithelial tissues of the murine stomach.
Despite the distinct tissues of origin and histopathological appearance of the tumours,
Brg1 deﬁcient lesions from both sections of the murine stomach shared a number of com-
mon characteristics. Brg1 deﬁcient lesions appeared in both tissues within a similar time
frame (between 35 and 80 days post induction) and tumours from both tissues remained
benign for an extensive period of time (up to 700 days post induction). Although lesions
from the two tissues shared a number of common features, it could not be conclusively
demonstrated whether hyperplasia in both tissues was driven by a common signalling
pathway. While some evidence suggested that the hyperproliferative response in either
tissue was unlikely to rely on activation of Wnt, PI3K/AKT or AMPK signalling cas-
cades, some data indicated that forestomach, but not glandular stomach hyperplasia was
likely to be driven by reduced levels of p21, a negative cell cycle regulator.
It is worth noting that aberrant activation of a range of rather distinct signalling
pathways have been implicated in similar hyperproliferative responses in glandular and
forestomach epithelia. Simultaneous deletion of Pten and knock-in of an activated form of
K-Ras (further referred to as Pten/K-Ras) oncogene results in development of squamous
cell papillomas in the forestomach epithelium (Marsh et al., in preparation). Notably,
despite Pten loss and K-Ras activation having been widely implicated in the aberrant ac-
tivation of PI3K/AKT and MEK/ERK pathways respectively (reviewed in McCubrey et
al., 2006), forestomach lesions from this model displayed no elevation in phosphorylated
Akt and only a limited increase in MEK phosphorylation. Consistent with this, histo-
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logically similar papillomas from Brg1 deﬁcient forestomach epithelium failed to exhibit
increased phosphorylation of S6 ribosomal subunit, which acts as a downstream target of
PI3K/AKT pathway activation. However, an in depth analysis of MEK/ERK pathway
activation status would be necessary to eliminate the possibility of MEK/ERK driven
tumourigenesis in Brg1 deﬁcient forestomach epithelium. In contrast to Brg1 deﬁcient
and Pten/K-Ras papillomas, the simultaneous inactivation of Pten and the TGFβ/BMP
component Smad4 in murine forestomach has been reported to result in forestomach hy-
perplasia rapidly progressing to invasive squamous cell carcinoma (Teng et al., 2006). In
contrast to Pten/K-Ras deﬁcient forestomach tumours, Pten/Smad4 double knock-out
tumours displayed a drastic increase in the levels of phosphorylated Akt in line with their
more aggressive nature. Interestingly, Pten/Smad4 double knock-out tumours displayed
a substantial decrease in p21 expression levels, not dissimilar to the situation observed in
Brg1 deﬁcient tumours. Brg1 has been shown to mediate cell growth arrest via positive
control of p21 expression and subsequent hypophosphorylation of RB protein (Hendricks
et al., 2004; Kang et al., 2004). It appears, therefore, that Brg1 loss in the forestomach
epithelium partially relaxes proliferative control over the tissue, most likely by compro-
mising p21 expression. It should be noted, however, that expression analysis of pRb/E2F
transcription targets, such as Cyclins A and E2, would be required to conclusively demon-
strate that Brg1 loss induces such a relaxation of cell cycle control. The hyperproliferative
response to Brg1 loss, however, is probably not suﬃcient to drive tumour progression to
advanced stages over a substantial period of observation. Loss of another tumour suppres-
sor, such as Pten or an oncogene activation, such as K-Ras might be required to advance
Brg1-deﬁciency-induced tumourigenesis to aggressive disease.
Since non-keratinised squamous epithelium is shared by murine forestomach and oe-
sophagus, the murine forestomach is a potentially attractive model tissue for human
oesophageal neoplasia. However, some diﬀerences exist between the two tissues that need
to be considered when developing mouse cancer models. Despite a lack of direct evidence,
a number of observations indicate that Brg1 might play a diﬀerential tumour suppressor
role in forestomach and oesophageal epithelia. Mouse models that induce tumourigenesis
of the oesophagus are characterised by very short survival, due to early obstruction of
alimentary tract and animal death from starvation (Teng et al,. 2006). An earlier observa-
tion has suggested that AhCreER recombinase is successfully induced in the oesophageal
epithelium by an induction protocol similar to the one used in this work (Meniel, personal
communication). Although no deliberate pathological analysis of oesophagus nor conﬁr-
mation of Brg1 loss in oesophageal epithelium was conducted in this study, a number of
observations indicate that Brg1 loss does not induce tumourigenesis in the oesophageal
epithelium. Firstly, mice with Brg1 loss under control of AhCreER recombinase were
able to survive for an extended period of time with no sign of weight loss. Secondly, no
macroscopic abnormalities of oesophagus were detected at the time of dissection, while
distinguishable overgrowth of epithelium was clearly visible in the forestomach of the same
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mice. Together, these observations suggest that Brg1 loss speciﬁcally induces hyperplasia
of the forestomach, but not in the oesophageal epithelium. This ‘organ-speciﬁcity’ of
Brg1-loss-induced tumourigenesis is in apparent contrast with a number of previous re-
ports that described tumour initiation in both organs upon tissue-speciﬁc loss of tumour
suppressors or oncogene activation (Teng et al., 2006; Vitale-Cross et al., 2004). However,
it may be a consequence of subtle diﬀerences in homeostasis and tumourigenesis between
the two organs sharing the same type of epithelium. Apparent preference for Brg1 loss-
driven tumourigenesis in forestomach, but not oesophagus, therefore, highlights potential
diﬀerences in homeostasis of these tissues, which should be considered, when using murine
stomach as a model tissue for oesophageal cancer.
Fundic gland polyps (FGPs) are hamartomatous lesions that develop in the mucosa
of the body (fundus) of the stomach and are characterised by shortening of the gastric
pits and cystic dilation of the gastric glands (Wu et al., 1998). FGPs are composed of
the cell types normally present in the normal fundic mucosa with cysts mainly lined with
parietal and chief cells. While sporadic FGPs rarely undergo dysplastic transformation,
FGPs in FAP patients frequently display neck cell and surface epithelial dysplasia (Wu
et al., 1998). The FGPs observed in the glandular stomach of AhCreER+Brgfl/fl mice
closely resembled this histopathological description, including dysplastic transformation
of the surface epithelium being detected at late time points. These observations indicate
that activation of Wnt signalling might be involved in the development of Brg1 deﬁcient
FGPs. This notion, however, is highly unexpected in the light of the proposed requirement
of Brg1 for trans-activation of the Wnt target genes. Indeed, analysis of subcellular β-
catenin localisation failed to detect nuclear β-catenin in Brg1 deﬁcient FGPs. It is unlikely,
therefore, that Wnt signalling activation is involved in the development of FGPs in the
Brg1 deﬁcient glandular stomach.
Whilst FGPs represent the most common gastric lesion type, a number of other in-
herited polyposis syndromes are also characterised by the development of gastric polyps.
The most common of them are Peutz-Jeghers syndrome (PJS), Juvenile Polyposis Syn-
drome (JPS) and Cowden Syndrome (CS). It should be noted, however, that polyps
arising in these conditions substantially diﬀer from the FGPs observed in Brg1 deﬁcient
gastric epithelium. PJS polyps are characterised by frond-like overgrowth of otherwise
normal epithelium and an abundance of smooth muscle tissue, which forms tree-like struc-
tures. Both JPS and CS share a common histological appearance and are characterised
by the presence of inﬂamed stromal tissue (reviewed in Bronner et al., 2003). The ge-
netic aberrations underlying these syndromes were found to be inactivating mutations in
LKB1, SMAD4 or BMPR1A and PTEN in PJS, JPS and CS respectively (Houlston et
al., 1998; Jenne et al,. 1998; Liaw et al., 1997; Zhou et al., 2001). Notably, loss of function
of LKB1 and PTEN has been shown to result in activation of AMPK and PI3K/AKT
pathways respectively. These two pathways have been found to converge on a common
eﬀector – mTOR pathway involved in control of protein synthesis, cell growth and sur-
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vival (reviewed in Shackelford and Shaw, 2009). In order to explore potential activation of
mTOR signalling as a mechanism responsible for the development of Brg1 deﬁcient FGPs
phosphorylation levels of mTOR downstream target ribosomal subunit S6 were analysed.
However, no consistent diﬀerence in S6 phosphorylation was observed between prolifer-
ative isthmal region of wild type gastric epithelium and Brg1 deﬁcient FGPs. Having
said that, positive staining for phosphorylated S6 was more widespread in FGPs in line
with the expanded proliferative compartment. This observation indicates that the mTOR
pathway is active in proliferating cells of Brg1 deﬁcient FGPs, but does not necessarily
suggest that its hyperactivation acts as a driving force behind Brg1 deﬁciency-induced
polyposis.
Finally, Brg1 has been reported to be involved in regulation of pRB-mediated cell
cycle control by facilitating p21 expression. Loss of Brg1 in the gastric epithelium could,
therefore, relax control over the cell cycle by attenuating p21 expression. This notion
is particularly attractive in the light of the observed pattern of Ki67 expression in Brg1
deﬁcient gastric epithelium. Ki67 staining was detected throughout enlarged fundic gland
neck region. Notably, this region in wild type fundic glands is occupied by early progen-
itors of the cell lineages derived from the isthmal stem cell. It is, therefore, tempting
to hypothesise that compromised exit from the cell cycle in this region would result in
expansion of the proliferative compartment. Despite the attractiveness of this hypothesis,
immunohistochemical analysis of p21 expression in Brg1 deﬁcient FGPs found no evidence
of reduced p21 expression compared to gastric epithelium of control mice. Interestingly,
proliferating cells in Brg1 deﬁcient FGPs were found to express p21 at levels comparable
to that of diﬀerentiated cells of the wild type gastric epithelium. It appears, therefore,
that hyper-proliferating Brg1 deﬁcient cells were able to overcome the cell cycle control
constraints imposed by the p21/pRb pathway. A similar overlap between expression of
proliferative markers and p21 expression has been found to be characteristic of human
FGPs displaying dysplasia of the gastric pit and surface epithelia (Wu et al., 1998).
Taken together, the data presented in this chapter show that Brg1 loss drives benign
hyperplasia in the glandular and forestomach epithelium. The oncogenic eﬀect of Brg1
loss in these two tissues is, however, likely to be mediated by diﬀerent mechanisms. While
attenuated p21 expression in the hyperplastic forestomach epithelium implied alleviation
of p21/pRb mediated cell cycle arrest as a potential driving force behind the squamous cell
hyperplasia, no obvious candidate signalling cascade was found in case of the glandular
stomach epithelium.
4.3.3 Long-term Brg1 loss is tolerated in the large intestinal and
bladder epithelial tissue and has no tumourigenic eﬀect
Having established that Brg1 loss induces benign hyperplasia in the epithelial tissues of
the murine stomach I aimed to explore the impact of Brg1 deﬁciency on two more ep-
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ithelial tissues expressing AhCreER recombinase, namely the large intestine and bladder.
Immunohistochemical analysis of Brg1 expression detected retention of Brg1 deﬁcient cells
over a long period of observation.
Retention of Brg1 deﬁcient cells in the bladder urothelium of AhCreER+Brgfl/fl
mice at 100 days PI could be attributed to the extremely slow turnover rate of this tissue
(approximately 200 days) and associated low proliferation rate (Wu et al., 2009). However,
Brg1 deﬁcient cells were still present in the bladder urothelium at day 490 PI, suggesting
that Brg1 is likely to be dispensable for urothelium proliferation. Interestingly, a recent
study have shown that activation of the Wnt pathway stimulates basal cell proliferation
of the bladder epithelium in response to bacterial infection or chemical injury (Shin et al.,
2001). Although it is not clear whether the Wnt pathway drives physiological proliferation
of the bladder epithelium, long-term retention of Brg1 deﬁcient cells suggests that Brg1
is likely to be dispensable for Wnt signalling in the urothelium.
Retention of Brg1 deﬁcient crypts in the large intestinal epithelium also highlights dis-
pensability of Brg1 for large intestinal homeostasis. However, unlike in the urothelium,
Wnt signalling has a long established role in maintaining the proliferative compartment of
both the large intestinal epithelium and colorectal cancer (reviewed in de Santa Barbara
et al., 2003). It can therefore be extrapolated that the Wnt pathway in the large intestine
does not require Brg1 for its physiological activity. Consistent with this notion, expres-
sion levels of the Wnt target genes c-Myc and CD44 were found to be undistinguishable
between Brg1 deﬁcient and proﬁcient crypts. This ﬁnding is in apparent contradiction
with the proposed role of Brg1 in trans-activation of the Wnt target genes even more so
considering that the original observation was made in CRC cells (Barker et al., 2001).
A number of factors could contribute to the discrepancy between the reliance of Wnt
signalling of Brg1 function in cultured CRC cell and the lack of phenotype in Brg1 de-
ﬁcient large intestinal epithelium. The most likely explanation of such discrepancy is
a dose-dependent reliance of Wnt signalling on Brg1 function. Whilst Brg1 is required
to facilitate high levels of Wnt-driven transcription found in CRC cells, its requirement
for physiological levels of Wnt signalling might be less stringent. In support of this hy-
pothesis, Brm expression was found to be up-regulated in Brg1 deﬁcient large intestinal
crypts. It is plausible, therefore, that increased Brm expression is capable of maintaining
physiological levels of Wnt signalling and thus compensate for Brg1 deﬁciency. Notably,
the cell line used by Barker et al. (2001) to demonstrate Brg1 requirement for transcrip-
tional activation of Wnt target genes also has been reported to express Brm at high levels
(Watanabe et al., 2010), suggesting that in the context of constitutively activated Wnt
signalling Brm is unable to compensate for Brg1 loss. Interestingly, constitutive Brm
knock-out mice are viable and fertile, which is thought to be due to compensation by
up-regulated Brg1 (Reyes et al., 1998). This compensation appears to be unidirectional
as constitutive loss of Brg1 results in embryonic lethality (Bultman et al., 2000). Data
presented in this chapter suggest that Brm is capable of compensating for Brg1 loss at
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the tissue level under physiological conditions. Concomitant deletion of Brm and Brg1
in the large intestinal epithelium would be insightful in establishing the overall role of
SWI/SNF-mediated chromatin remodelling in large intestinal homeostasis.
While little evidence exists that would conclusively associate diﬀerentiation of par-
ticular large intestinal cell lineages with speciﬁc signalling cascades, extrapolation of the
data available for the small intestinal epithelium would implicate active Wnt and Notch
signalling in the diﬀerentiation of secretory and absorptive lineages respectively (reviewed
in Crosnier et al., 2006). Following this extrapolation, the increase in the number of se-
cretory cells in Brg1 deﬁcient crypts suggests either increased Wnt or suppressed Notch
signalling. The ﬁrst option, however, appears contradictory to the proposed relationship
between Brg1 and Wnt signalling and the observation of normal expression levels of the
Wnt target genes detected in Brg1 deﬁcient crypts. Although a number of studies have
implicated Brg1 containing complexes in the mediation of Notch signalling, such interac-
tion has not been reported in the intestinal epithelium (Lamba et al., 2008; Takeuchi et
al., 2007). Notably, an earlier study has reported preferential recruitment of Brm, but not
Brg1 to the promoters of the Notch target genes Hes1 and Hes5 in mouse erythroleukemia
cells (Kadam and Emerson, 2003). However the putative Notch pathway suppression in
Brg1 deﬁcient cells with substantially upregulated Brm expression makes such interaction
in the large intestinal epithelium unlikely.
Curiously, one more tissue was found to tolerate long-term Brg1 loss without displaying
any signs of tumourigenesis. Brg1 deﬁcient glands were detected in the pyloric stomach of
AhCreER+Brgfl/fl mice at all the time points observed. These glands appeared indistin-
guishable from their Brg1 positive neighbours and pyloric crypts in the glandular stomach
of control mice. Low frequency of Brg1 deﬁcient pyloric glands, however prevented any
detailed investigation of the eﬀects of Brg1 deﬁciency on pyloric homeostasis.
Taken together, the ﬁndings presented in this and previous chapters highlight a re-
markable tissue-speciﬁcity of Brg1 functions. These range from requirement for the stem
cell maintenance in the small intestine to tumour suppression in glandular and forestom-
ach, to potentially very subtle alterations of tissue homeostasis in the large intestine and
bladder.
4.3.4 Future directions
Remarkably, Brg1 loss was found to induce hyperplasia of both the forestomach squamous
and glandular stomach columnar epithelium. These were the only two tissues expressing
AhCreER recombinase that displayed any signs of tumourigenesis induced by Brg1 de-
ﬁciency. While observation of p21 suppression in Brg1 deﬁcient forestomach papillomas
suggested a putative mechanism for Brg1 loss-driven hyperplasia in this tissue, no such
mechanism was evident in the fundic stomach epithelium. In view of these ﬁndings being
the ﬁrst evidence of direct oncogenic eﬀect of Brg1 deﬁciency it would be insightful to
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further investigate molecular events upon Brg1 loss in these tissues.
Chapter 5
Investigating the eﬀects of small
intestinal Brg1 loss in the context of
activated Wnt signalling
5.1 Introduction
Despite the Wnt pathway being aberrantly activated in more than 90% of CRC cases,
therapeutic approaches targeted against this pathway remain extremely limited (Goss
and Kahn, 2011). A number of reasons are regarded to contribute to the scarcity of
Wnt targeted therapies. Among them are the pathway complexity, redundancy between
its components and its indispensability for maintenance of adult tissue homeostasis (Re-
viewed in Clevers, 2006). Despite the pathway complexity and diversity of its components,
the vast majority of mutations leading to aberrant Wnt signalling activation in CRC in-
volves either components of the destruction complex (e.g. APC and AXIN) or β-catenin
(Paul and Dey, 2008). For this reason therapeutic targets downstream of β-catenin rep-
resent a particular interest. These include both pathway components, such as TCF1 and
TCF4 (van de Wetering et al., 2002), and Wnt target genes, such as c-Myc (Sansom et
al., 2007b). Targeting downstream components and target genes of the pathway may also
impart an additional beneﬁt of reducing toxicity to normal tissues.
The observation that BRG1 interacts with β-catenin and is required for trans-activation
of Wnt target genes in CRC cells (Barker et al., 2001) establishes BRG1 as a potential
therapeutic target in Wnt driven tumourigenesis. The downstream position of Brg1 in
relation to β-catenin makes it a particularly attractive target due to the reasons outlined
above. In this chapter I aim to inspect the feasibility of Brg1 as an anti-Wnt therapeutic
target by investigating the impact of Brg1 deﬁciency on Wnt driven carcinogenesis in the
context of the murine small intestinal epithelium.
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5.2 Results
5.2.1 Placing Brg1 loss in a context of aberrant Wnt signalling
In order to place Brg1 deﬁciency in the context of aberrant Wnt signalling, I aimed to
simultaneously inactivate Apc and Brg1 in the small intestinal epithelium. To this end, I
used the Cre/loxP conditional transgenesis system, employing a range of Cre recombinases
to drive inactivation of the loxP targeted Brg1 and Apc alleles. The eﬀects of conditional
inactivation of Brg1 have been described in Chapter 3. The targeted Apc allele I use
here carries two loxP sites ﬂanking exon 14 (Figure 2.1b). Cre recombinase-mediated
recombination between these loxP sites introduces a frame-shift mutation and results in
the expression of a truncated version of Apc eﬀectively inducing loss of function (Shibata
et al., 1997).
5.2.2 Brg1 haploinsuﬃciency does not accelerate Wnt-driven
tumourigenesis
A number of studies have demonstrated that tumours arising in animals with heterozy-
gous loss of Brg1 retain functional copy of Brg1 (Bultman et al,. 2007; Glaros et al.,
2008). This observation indicates that Brg1 haploinsuﬃciency rather than loss of het-
erozygousity contributes to carcinogenesis in those animals. Heterozygous inactivation
of Brg1 in the small intestinal epithelium described earlier in this work failed to induce
tumourigenesis or indeed any adverse eﬀects on tissue homeostasis. I, therefore, aimed to
examine whether Brg1 haploinsuﬃciency would be able to accelerate Wnt-driven tumouri-
genesis. Heterozygous inactivation of Apc is a well established approach for induction of
Wnt-driven tumourigenesis in the gastrointestinal tract. Spontaneous loss of the second
copy of Apc results in the development of aberrant crypt foci, which then progress to
adenomas. With this in mind, I generated two cohorts of mice expressing AhCre re-
combinase. Mice in the ﬁrst cohort carried one targeted Apc allele, while mice from the
second cohort carried loxP sites within one of the Apc and one of the Brg1 alleles. Both
AhCre+Apc+/flBrg+/+ and AhCre+Apc+/flBrg+/fl mice were viable and fertile.
In order to examine the eﬀects of Brg1 haploinsuﬃciency on the survival of mice with
heterozygous inactivation of Apc, mice from both cohorts along with the AhCre+Apc+/+-
Brg+/+ controls (for all cohorts n≥9) were induced with four intraperitoneal injections
of 80 mg/kg β-naphthoﬂavone at 8 hour intervals and regularly inspected for signs of
intestinal tumourigenesis. Mice were then aged for a maximum of 600 days or until they
developed signs of ill health due to extensive tumour burden and had to be sacriﬁced.
While very few mice from the control cohort displayed signs of ill health within the time
frame of the experiment, both AhCre+Apc+/flBrg+/+ and AhCre+Apc+/flBrg+/fl mice
started developing signs of intestinal neoplasia and becoming ill as early as 245 and 330
days post induction respectively. However, analysis of the overall survival probability re-
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vealed no statistically signiﬁcant diﬀerence between the two experimental cohorts (Figure
5.1, median survival 345 and 371 days for AhCre+Apc+/flBrg+/+ and AhCre+Apc+/fl-
Brg+/fl mice respectively, Log-Rank test p=0.22, n≥9).
Figure 5.1: Brg1 haploinsuﬃciency does not impair survival of mice with heterozygous Apc loss. Co-
horts of AhCre+Apc+/flBrg+/fl and AhCre+Apc+/flBrg+/+ mice were induced with an appropriate
protocol along with AhCre+Apc+/+Brg+/+ control animals (n≥9). Mice were aged for 600 days PI or
until have displayed signs of ill health. Survival data was presented as a Kaplan-Meier plot. Analysis of
survival probability revealed a signiﬁcantly reduced survival of AhCre+Apc+/flBrg+/fl and AhCre+-
Apc+/flBrg+/fl mice compared to control animals (for either cohort p<0.01, n≥9). No signiﬁcant dif-
ference in survival probability was observed between two experimental cohorts (p=0.22, n≥9).
In order to analyse whether Brg1 haploinsuﬃciency aﬀected Wnt-driven tumourigene-
sis in mice with heterozygous loss of Apc, the alimentary tract of AhCre+Apc+/flBrg+/+
and AhCre+Apc+/flBrg+/fl animals was dissected at the time of sacriﬁce and analysed
for parameters such as tumour number, size and position within the small and large
intestines (Figure 5.2). Statistical analysis of these parameters revealed no signiﬁcant
diﬀerence between the two cohorts (Table 5.1).
Histological analysis of H&E stained sections of the tumours arising in the small and
large intestinal epithelium of AhCre+Apc+/flBrg+/+ and AhCre+Apc+/flBrg+/fl ani-
mals identiﬁed them as adenomas and detected no tangible diﬀerences in the tumour
progression between the two cohorts (Figure 5.3, left panel). Immunohistochemical anal-
ysis of β-catenin expression showed that the tumours in both cohorts displayed nuclear
localisation of β-catenin, indicating aberrant activation of Wnt signalling (Figure 5.3,
middle panel). Staining with anti-Brg1 antibody revealed that all analysed tumours re-
tained Brg1 expression (Figure 5.3, right panel) indicating that, at least at this stage in
tumour development, there was no selective pressure favouring loss of the second Brg1
allele. At the same time, recombined PCR analysis of DNA extracted from tumour tissue
detected retention of recombined allele in both small and large intestinal tumours (Fig-
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Table 5.1: Analysis of small and large intestinal tumour burden observed in AhCre+-
Apc+/flBrg+/+ and AhCre+Apc+/flBrg+/fl mice
Parameter Cohort Median Mean SD p Value
Small
intestine
Tumour Number
Apc Het 7.00 9.22 8.23
0.06
Double 4.00 4.00 2.76
Tumour Size (mm2)
Apc Het 12.57 18.58 19.75
0.51
Double 12.57 19.54 17.20
Tumour Position
(cm from stomach)
Apc Het 26.90 24.83 14.41
0.10
Double 12.00 17.64 15.17
Large
intestine
Tumour Number
Apc Het 4.00 4.67 3.61
0.29
Double 2.00 3.55 4.50
Tumour Size (mm2)
Apc Het 12.57 22.67 20.72
0.61
Double 12.57 14.61 10.00
Tumour Position
(cm from rectum)
Apc Het 2.05 2.27 1.13
0.90
Double 2.00 1.97 0.84
AhCre+Apc+/flBrg+/+ (labelled here asApc Het) and AhCre+Apc+/flBrg+/fl (labelled here asDou-
ble) mice were aged for up to 600 days PI or until have dispalyed signs of ill health. The small and large
intestines were dissected and inspected for macroscopic signs of tumourigenesis. Parameters of tumour
burden, such as tumour number, size and position were recorded. p value was calculated by Mann-
Whitney U test for Tumour Number and Mood’s Median Test for Tumour Size and Position. Experi-
mental units are represented by number of individual mice per group for Tumour Number and number
of individual tumours per group for Tumour Size and Position
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Figure 5.2: Brg1 haploinsuﬃciency does not aﬀect intestinal tumourigenesis in mice with heterozygous
Apc loss. Tumour burden was analysed in the small and large intestinal epithelium of AhCre+Apc+/fl-
Brg+/+ and AhCre+Apc+/flBrg+/fl animals at the time of death. Statistical analysis of tumour burden
parameters, such as tumour number, size and position, revealed no signiﬁcant diﬀerences between the
cohorts. Data is presented in the form of a Box Plot. Mean value for tumour number is marked with
an asterisk. Outliers on the graphs with tumour number represent values for individual mice. Outliers
on the graphs with tumour size and positions represent values for individual tumours. Exact values
for each parameter’s mean, median and standard deviation, along with p values (experimental units
are represented by mice for tumour number and individual tumours for tumour size and position) are
provided in Table 5.1.
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ure 5.4). Together with the lack of diﬀerence in survival and tumour progression, these
observations indicated that Brg1 haploinsuﬃciency neither attenuated nor accelerated
Wnt-driven carcinogenesis in the small and large intestinal epithelium.
Figure 5.3: Brg1 haploinsuﬃciency does not aﬀect tumour progression in mice with heterozygous loss
of Apc. Histological analysis of H&E stained sections of small (a) and large (b) intestinal tumours from
AhCre+Apc+/flBrg+/+ and AhCre+Apc+/flBrg+/fl mice dissected at comparable time points revealed
no diﬀerences in tumour progression between the groups. All macroscopic tumours from either group
displayed nuclear localisation of β-catenin and retained Brg1 expression. Scale bars represent 100 µm.
5.2.3 Brg1 loss under the control of AhCreER recombinase is
incompatible with Wnt activation
Since homozygous Brg1 loss under the control of AhCre recombinase caused embryonic
lethality, I induced loss of Apc alone and in conjunction with Brg1 using the AhCreER
transgene. To induce Cre recombinase expression and activation, mice were administered
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Figure 5.4: Brg1 heterozygous cells are retained in the intestinal tumours of AhCre+Apc+/flBrg+/fl
mice. A PCR reaction designed to detect the product of recombination of loxP sites in the targeted Brg1
allele was carried out using DNA extracted from formalin ﬁxed small and large intestinal tumours from
AhCre+Apc+/flBrg+/+ and AhCre+Apc+/flBrg+/fl mice dissected at various time points. Primers
used for routine genotyping were used as a positive control to test for the presence of DNA in the sample
and to conﬁrm the genotype of the animal (407 bp and 500 bp products are ampliﬁed from the wild type
and targeted Brg1 alleles respectively, top section). Recombination-speciﬁc product (484 bp, bottom
panel) was detected in all intestinal tumours from AhCre+Apc+/flBrg+/fl mice. No recombination
product was detected in the tumours from AhCre+Apc+/flBrg+/+.
ﬁve bi-daily doses of 80 mg/kg β-naphthoﬂavone and tamoxifen. Animals were sacriﬁced
10 days post induction and their small intestines were harvested for histological analysis.
Figure 5.5: Brg1 loss is incompatible with Wnt signalling activation in the stem and early progeni-
tor cells in small intestinal epithelium. Immunohistochemical analysis of β-catenin expression revealed
numerous lesions with nuclear localisation of β-catenin in the small intestinal epithelium of AhCreER+-
Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl mice at day 10 PI. Immunostaining of serial sections
with antibodies against Brg1 and β-catenin revealed a non-overlapping pattern of Brg1 loss and lesions
with nuclear accumulation of β-catenin. Scale bars represent 100 µm.
Immunohistochemical analysis of β-catenin expression revealed numerous aberrant
crypt foci (ACF) with nuclear β-catenin in the small intestinal epithelium of AhCreER+-
Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl mice (Figure 5.5, left and middle panels).
Similarly, occasional crypts containing clusters of Brg1 deﬁcient cells were detected upon
staining with anti-Brg1 antibody (Figure 5.5, right panel). However, despite presence
of both Wnt-activated ACFs and Brg1 deﬁcient cell clusters, analysis of serial sections
stained with anti-Brg1 and anti β-catenin antibodies failed to detect any overlap between
these cell populations (Figure 5.5, middle and right panels). While Brg1 deﬁcient Wnt-
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activated cells could have been present at the level of single cells, they would be diﬃcult
to detect on serial sections. It appears therefore, that by the ACF stage all Brg1 deﬁcient
cells with activated Wnt signalling were eliminated and only cells that selectively lost Brg1
or Apc were able to survive for 10 days. This observation suggests that Wnt pathway
activation in the small intestinal epithelium is somehow incompatible with Brg1 loss.
5.2.4 Brg1 loss improves survival in Apc deﬁcient animals
In order to assess the long-term eﬀects of Brg1 loss onWnt-driven neoplasia in the small in-
testinal epithelium, cohorts of AhCreER+Apcfl/flBrg+/+ andAhCreER+Apcfl/flBrgfl/fl
mice were induced as above and aged for up to 100 days along with AhCreER− controls
(for all cohorts n≥8). Mice were aged until they developed signs of ill health, at which
point they were humanely killed and intestinal tissues were harvested. Survival analysis of
the aged cohorts showed that allAhCreER+Apcfl/flBrg+/+ animals became ill and had to
be sacriﬁced within 3 weeks of induction (Figure 5.6, median survival 9 days). Conversely,
AhCreER+Apcfl/flBrgfl/fl mice survived signiﬁcantly longer with some mice surviving
past 100 days (Figure 5.6, median survival 58 days, Log-Rank test p<0.0001). None of
the control mice developed signs of ill health within the time frame of the experiment
(Figure 5.6).
Figure 5.6: Concurrent Brg1 deletion improves survival of mice with intestinal Apc loss. AhCreER+-
Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl mice were induced with an appropriate protocol along
with Cre− controls and aged for 100 days PI or until have developed signs of terminal ill health. Survival
data was presented as Kaplan-Meier plot and revealed reduced survival probability of both experimental
cohorts compared to control animals (for either comparison Log-Rank test p<0.0001, n≥8). Compar-
ison of survival probability between the experimental groups revealed a signiﬁcantly improved survival
of AhCreER+Apcfl/flBrgfl/fl mice compared to AhCreER+Apcfl/flBrg+/+ animals (Log-Rank test
p<0.0001, n≥20).
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5.2.5 Brg1 loss is incompatible with Wnt-driven adenoma for-
mation
Immunohistochemical analysis of β-catenin expression in the small intestinal epithelium of
AhCreER+Apcfl/flBrgfl/fl mice 30 days post induction revealed numerous lesions with
nuclear β-catenin localisation (Figure 5.7), indicating Wnt signalling activation. Notably,
all lesions were found to express Brg1 as assessed by Brg1 immunostaining (Figure 5.7).
Consistent with repopulation of Brg1 deﬁcient cells seen in AhCreER+Brgfl/fl mice (Sec-
tion 3.2.5), no Brg1 deﬁcient cells were detected in the normal epithelium of AhCreER+-
Apcfl/flBrgfl/fl either. A similar situation was observed in AhCreER+Apcfl/flBrgfl/fl
mice that survived up to 100 days post induction (not shown). Namely, all lesions with
nuclear localisation of β-catenin were found to express Brg1. Surprisingly, large adenomas
(Figure 5.7,b) were rarely detected in the small intestine of AhCreER+Apcfl/flBrgfl/fl
mice with the vast majority of Wnt-activated lesions being represented by small micro-
adenomas conﬁned within distended villi (Figure 5.7,a). The lack of large adenomas
combined with Brg1 positive status of all Wnt-activated lesions in the small intestine in-
dicated that Brg1 loss in conjunction with Wnt pathway activation somehow eliminated
lesions with a potential to progress from adenoma to carcinoma.
Figure 5.7: Concurrent Brg1 deletion prevents development of macroscopic adenomas in the small
intestinal epithelium of AhCreER+Apcfl/flBrgfl/fl. Immunohistochemical analysis of β-catenin distri-
bution in the small intestinal epithelium of AhCreER+Apcfl/flBrgfl/fl at day 100 PI detected frequent
microadenomas (a) and rare macroadenomas (b) with nuclear accumulation of β-catenin. Immunohis-
tochemical analysis of Brg1 expression revealed that both types of adenomas retained Brg1 expression.
Scale bars represent 200 µm.
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5.2.6 VillinCre drives combined loss of Brg1 and Apc at high
penetrance in the small intestine
In order to investigate the molecular mechanism behind the absence of Brg1 deﬁcient Wnt
activated lesions and the lack of advanced adenomas in the small intestinal epithelium
of AhCreER+Apcfl/flBrgfl/fl mice, I used VillinCre recombinase to induce high level
recombination of Brg1 and Apc. V illinCre+Apcfl/flBrg+/+ and V illinCre+Apcfl/fl-
Brgfl/fl mice were induced by four daily intraperitoneal injections of Tamoxifen at 80
mg/kg dose. Induced mice were then dissected at day 4 post induction and intestinal
tissues were harvested for histological and gene expression analysis.
Figure 5.8: VillinCre recombinase drives simultaneous deletion of Brg1 and Apc in the small intesti-
nal epithelium. Histological analysis of H&E stained sections of the small intestinal epithelium from
V illinCre+Apcfl/flBrg+/+ and V illinCre+Apcfl/flBrgfl/fl mice at day 4 PI revealed signs of aberrant
Wnt signalling activation, such as elongated crypts and elevated apoptosis, in the small intestine of either
group. Analysis of β-catenin distribution in these animals revealed nuclear accumulation of β-catenin in
the small intestinal epithelium of animals from either group, although not as prominent in V illinCre+-
Apcfl/flBrgfl/fl intestine. Immunohistochemical analysis of Brg1 expression detected near complete loss
of Brg1 in the epithelial cells of V illinCre+Apcfl/flBrgfl/fl small intestine. Scale bars represent 100
µm.
Immunohistochemical analysis of Brg1 expression revealed nearly complete loss of
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Brg1 in the small intestinal epithelium of V illinCre+Apcfl/flBrgfl/fl mice (Figure 5.8).
Similarly, analysis of β-catenin expression showed nuclear localisation of β-catenin in the
majority of the epithelial cells (Figure 5.8) indicating eﬃcient loss of Apc and Wnt sig-
nalling activation. Together, these observations suggested that VillinCre recombinase was
successful in driving combined Brg1 and Apc inactivation with high penetrance. Most
notably, short-term loss of Brg1 under the control of VillinCre recombinase was compat-
ible with Wnt signalling activation. Unfortunately, both V illinCre+Apcfl/flBrg+/+ and
V illinCre+Apcfl/flBrgfl/fl animals became ill around day 5 PI and thus the long-term
fate of double mutant cells could not be explored using this model.
5.2.7 Brg1 loss in the context of activated Wnt signalling atten-
uates some of the manifestations of Wnt pathway activa-
tion
Considering the proposed role of Brg1 as a mediator for trans-activation of Wnt target
genes and the apparent incompatibility of Brg1 loss with Wnt signalling activation ob-
served in the previous section, I investigated whether Brg1 loss attenuated the eﬀects
of aberrant Wnt pathway activation. Histological analysis of small intestinal tissue sec-
tions from V illinCre+Apcfl/flBrg+/+ and V illinCre+Apcfl/flBrgfl/fl mice revealed that
they shared histological features of Wnt activated intestinal epithelium, such as elongated
crypts and high levels of mitosis and apoptosis (Figure 5.8, left panels), as has been pre-
viously reported (Sansom et al., 2004). However, careful quantiﬁcation of histological
parameters (crypt and villus size, apoptosis and mitosis levels as well as BrdU incorpo-
ration) detected substantial diﬀerences between V illinCre+Apcfl/flBrg+/+ and double
knock-out (DKO) animals (Figure 5.9, Table 5.2).
The length of crypts and villi were scored on H&E stained sections as the average
number of cells (± standard deviation) between the crypt base and the crypt-villus junc-
tion and between the crypt-villus junction and the tip of the villus respectively. Crypts in
the intestinal epithelium of V illinCre+Apcfl/flBrg+/+ and DKO mice were found to be
longer compared to control animals (for all comparisons p<0.001). Conversely, animals
from both experimental groups displayed signiﬁcantly longer villi compared to control
mice (for all comparisons p=0.001). Comparison of crypt length between the experimen-
tal cohorts revealed signiﬁcantly longer crypts in Apc deﬁcient epithelium compared to
DKO mice (46.36±4.97 and 41.21±1.85, p=0.049, n≥4, Figure 5.9a). Quantiﬁcation of
the villus length, however, revealed no diﬀerence between the two groups (61.1±4.57 and
59.79±9.71, p=0.465, n≥4, Figure 5.9b).
Apoptosis and mitosis levels were quantiﬁed on H&E stained sections as the aver-
age number (± standard deviation) of apoptotic bodies and mitotic ﬁgures per half-
crypt respectively. Quantiﬁcation of apoptotic bodies within crypts revealed signiﬁcantly
elevated apoptosis in the intestine of the experimental animals compared to controls
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Table 5.2: Quantitative analysis of the impact of Brg1 loss on the histology of Wnt
activated small intestinal epithelium
Parameter Cohort Mean SD
p Value
Control Vs
Apc KO
Control
Vs DKO
Apc KO
Vs DKO
Crypt Length (cells)
Control 27.48 1.86
0.000
0.000Apc KO 46.36 4.97
0.049
DKO 41.21 1.85
Villus Length (cells)
Control 76.11 3.26
0.001
0.001Apc KO 61.10 4.57
0.465
DKO 59.79 9.71
Apoptosis per
half-crypt
Control 0.14 0.09
0.001
0.008Apc KO 6.06 3.68
0.002
DKO 2.67 0.45
Caspase positive
cells per half-crypt
Control 0.11 0.04
0.000
0.011Apc KO 1.76 0.48
0.006
DKO 0.92 0.39
Mitosis per
half-crypt
Control 0.25 0.05
0.002
0.034Apc KO 0.75 0.29
0.278
DKO 0.61 0.15
Ki67 positive cells
per half-crypt
Control 17.28 4.28
0.000
0.001Apc KO 46.18 5.03
0.000
DKO 31.91 3.07
BrdU positive cells
per half-crypt
Control 8.41 0.90
0.000
0.001Apc KO 32.51 6.38
0.010
DKO 23.91 0.99
Small intestinal tissue samples from V illinCreER− (marked here as Control), V illinCreER+Apcfl/fl-
Brg+/+ (marked here as Apc KO) and V illinCreER+Apcfl/flBrgfl/fl (marked here as DKO) mice
were collected at day 4 PI. Histological parameters, such as crypt and villus length, apoptosis, proliferation
and BrdU incorporation were quiantiﬁed and compared between the three cohorts.
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Figure 5.9: Histological analysis of the eﬀects of short-term Brg1 deﬁciency in Wnt activated small
intestinal epithelium. V illinCre+Apcfl/flBrg+/+ and V illinCre+Apcfl/flBrgfl/fl mice were induced
using the high-dose protocol along with Cre− controls. Samples of the small intestinal epithelium were
harvested at day 4 PI. (a-f) Histological parameters such as crypt length (a), villus length (b), apoptosis
(c, left panel) and mitosis (e) were scored on H&E stained sections of the small intestinal epithelium from
control (white bars), V illinCre+Apcfl/flBrg+/+ (grey bars) and V illinCre+Apcfl/flBrgfl/fl (black
bars) mice. The average numbers of BrdU (d), cleaved Caspase3 (c, right panel) and Ki67 (f) positive
cells were scored on respective immunostained sections. Error bars represent standard deviation. Aster-
isks mark histological parameters, which displayed a statistically signiﬁcant diﬀerence (p value <0.05)
between the groups. Exact values, standard deviations and respective p values are provided in Table
5.2; (g) Cumulative frequency analysis of Ki67 positive cells revealed an expansion of the proliferative
compartment in V illinCre+Apcfl/flBrg+/+ and V illinCre+Apcfl/flBrgfl/fl mice compared to control
animals (for either comparison Kolmogorov-Smirnov Z test p<0.0001, n≥4). Comparison of cumulative
frequency of Ki67 positive cells between the experimental groups revealed a signiﬁcantly shorter prolifer-
ative compartment in V illinCre+Apcfl/flBrgfl/fl animals (Kolmogorov-Smirnov Z test p<0.001, n≥4).
(h) Immunohistochemical analysis of Ki67 expression conﬁrmed a shorter proliferative zone in the small
intestinal epithelium of V illinCre+Apcfl/flBrgfl/fl mice. Scale bars represent 100 µm.
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(for all comparisons p<0.01). Notably, signiﬁcantly higher apoptosis levels were de-
tected in V illinCre+Apcfl/flBrg+/+ mice compared to DKO animals (6.06±3.68 and
2.67±0.45, p=0.002, n≥4, Figure 5.9c). Quantiﬁcation of cleaved Caspase-3 positive cells
revealed a similar change in apoptosis levels. V illinCre+Apcfl/flBrg+/+ intestine dis-
played higher levels of Caspase-3 staining compared to DKO animals (1.76±0.48 and
0.92±0.39, p=0.006, n=5, Figure 5.9c).
Figure 5.10: Brg1 loss attenuates BrdU incorporation and further impairs cell migration in Apc deﬁcient
small intestinal epithelium. (a) Cumulative frequency analysis of BrdU immunostaining 2 hours post
labelling revealed a signiﬁcant expansion of BrdU positive cells in the small intestine of V illinCre+-
Apcfl/flBrg+/+ and V illinCre+Apcfl/flBrgfl/fl mice at day 4 PI compared to control animals (for both
comparisons Kolmogorov-Smirnov Z test p<0.0001, n≥4). Comparison of cumulative frequency of BrdU
positive cells between the experimental groups also revealed a signiﬁcantly shorter BrdU labelled zone
in V illinCre+Apcfl/flBrgfl/fl animals (Kolmogorov-Smirnov Z test p<0.0001, n≥4). (b-d) Cumulative
frequency analysis of BrdU staining 24 hours post labelling between two experimental groups detected a
marginally reduced cell migration in V illinCre+Apcfl/flBrgfl/fl intestine (d, median migration distance
4.82 cells) compared to V illinCre+Apcfl/flBrg+/+ (c, median migration distance 6.54 cells) epithelium.
Both groups exhibited a substantially reduced cell migration compared to control animals (b, median
migration distance 30.39 cells).
Whilst both experimental cohorts displayed signiﬁcantly elevated levels of mitosis com-
pared to control animals (for all comparisons p<0.05), quantiﬁcation of mitotic ﬁgures
revealed no diﬀerence in their number between V illinCre+Apcfl/flBrg+/+ and DKO mice
(0.75±0.29 and 0.61±0.15, p=0.278, n≥4, Figure 5.9e). Conversely, quantiﬁcation of Ki67
positive cells detected signiﬁcantly higher number of proliferating cells in V illinCre+-
Apcfl/flBrg+/+ mice compared to DKO animals (46.18±5.03 and 31.91±3.07, p<0.001,
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n≥4, Figure 5.9f,h). Additionally, the positions of Ki67 positive cells were scored in order
to assess distribution of proliferating cells. Distributional analysis of Ki67 positive cell
position revealed signiﬁcant expansion of the proliferative compartment in Apc deﬁcient
epithelium compared to DKO mice (Figure 5.9g, Kolmogorov-Smirnov Z test p<0.001,
n≥4). Finally, the number and position of BrdU positive cells 2 hours post labelling was
scored to analyse quantity and distribution of cells in S-phase of the cell cycle. Quantiﬁ-
cation of BrdU positive cells per half-crypt (± standard deviation) revealed signiﬁcantly
elevated BrdU incorporation in V illinCre+Apcfl/flBrg+/+ epithelium compared to DKO
mice (32.51±6.38 and 23.91±0.99, p=0.01, n≥4, Figure 5.9d). In line with an expanded
proliferative compartment as assessed by Ki67 staining, cumulative distribution analysis
of BrdU positive cells detected a greater expansion of the proliferative compartment in
Apc deﬁcient intestine compared to DKO epithelium (Figure 5.10a, Kolmogorov-Smirnov
Z test p<0.0001, n≥4).
Overall, histological analysis of the small intestinal epithelium from V illinCre+-
Apcfl/flBrg+/+ and V illinCre+Apcfl/flBrgfl/fl demonstrated that Brg1 loss in the con-
text of Apc deletion was able to attenuate the eﬀects of aberrant Wnt pathway activation,
such as increased crypt length, apoptosis and the expansion of the proliferative compart-
ment.
5.2.8 Brg1 loss in the context of Apc deﬁciency further inhibits
cell migration
One of the eﬀects of aberrantly activated Wnt signalling on intestinal homeostasis is im-
paired migration of the epithelial cells along the crypt-villus axis (Sansom et al., 2004).
In order to investigate the eﬀects of Brg1 loss on cell migration in Wnt activated small
intestinal epithelium, mice were treated with BrdU labelling agent 24 hours prior to dis-
section. The positions of BrdU labelled cells 24 hours post labelling were scored and
compared to the positions of BrdU labelled cells at 2 hours post labelling. The average
migration distance over a 22 hour period was determined as the distance between me-
dian positions of BrdU positive cells at 2 and 24 hours post labelling (Figure 5.10b-d).
Cumulative distribution analysis of BrdU positive cells revealed that the average migra-
tion distance in Apc deﬁcient epithelium (Figure 5.10c, median migration distance 6.54
cells) was marginally longer than in DKO animals (5.10d, median migration distance
4.82 cells). Notably, both experimental cohorts displayed markedly impaired epithelial
migration compared to control animals (Figure 5.10b, median migration distance 30.39
cells). This observation suggested that Brg1 loss in the context of Apc deﬁciency further
inhibited cell migration induced by aberrant Wnt pathway activation.
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5.2.9 Brg1 loss modulates cell type-speciﬁc responses to aber-
rant Wnt signalling activation
Cell fate decisions governing diﬀerentiation of various mature cell types in the small
intestinal epithelium are tightly regulated by the interplay between various signalling
pathways, in particular the Wnt and Notch pathways (Fre et al., 2009). Additionally,
aberrant Wnt activation has been found to promote the proliferative program at the
expense of cell diﬀerentiation (Sansom et al., 2004). To investigate the eﬀects of Brg1
loss on cell diﬀerentiation in the context of aberrant Wnt activation I quantiﬁed diﬀerent
mature cell types in the small intestinal epithelium of V illinCre+Apcfl/flBrg+/+ and
V illinCre+Apcfl/flBrgfl/fl mice (Figures 5.11 and 5.12). The results of quantitative
analysis of diﬀerentiated cells in control, Apc deﬁcient and DKO animals are collated in
Table 5.3.
Table 5.3: Quantitative analysis of Brg1 deﬁciency impact on cell diﬀerentiation in the
context of Wnt activated small intestinal epithelium
Parameter Cohort Mean SD
p Value
Control Vs
Apc KO
Control
Vs DKO
Apc KO
Vs DKO
Goblet cells per
half-crypt
Control 4.85 0.85
0.037
0.219Apc KO 3.26 1.08
0.408
DKO 3.73 1.81
Enteroendocrine
cells per half-crypt
Control 0.76 0.09
0.467
0.418Apc KO 0.71 0.21
0.474
DKO 0.68 0.24
Paneth cells per
half-crypt
Control 1.13 0.31
0.003
0.500Apc KO 2.12 0.45
0.004
DKO 1.14 0.49
Small intestinal tissue samples from V illinCreER− (marked here as Control), V illinCreER+Apcfl/fl-
Brg+/+ (marked here as Apc KO) and V illinCreER+Apcfl/flBrgfl/fl (marked here as DKO) mice
were collected at day 4 PI. Cell type-speciﬁc stains were used to detect major cell types of the small in-
testinal epithelium. Frequency of Goblet, Enteroendoctine and Paneth cells was quantiﬁed and compared
between the three cohorts.
Speciﬁc staining for alkaline phosphatase located at the brush border formed by en-
terocytes revealed no diﬀerence between Apc deﬁcient and normal intestinal epithelium
(Figure 5.11a). However, the intestinal epithelium from DKO animals displayed consis-
tently reduced staining for alkaline phosphatase (Figure 5.11a).
Consistent with impaired diﬀerentiation in Wnt activated small intestinal epithelium
(Sansom et al., 2004) staining with Alcian blue (Figure 5.11b) and scoring of positive
cells revealed reduced numbers of Goblet cells per half-crypt-villus structure in the ep-
ithelium of V illinCre+Apcfl/flBrg+/+ mice compared to control animals (3.26±1.08 and
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Figure 5.11: Qualitative analysis of cell diﬀerentiation upon Brg1 loss in Wnt activated small intestinal
epithelium. Small intestinal sections of V illinCre+Apcfl/flBrg+/+ and V illinCre+Apcfl/flBrgfl/fl
mice at day 4 PI were subjected to cell type-speciﬁc stains to visualise Enterocytes (a), Goblet cells
(b), Paneth cells (c) and Enteroendocrine cells (d). Alkaline phosphatase staining revealed a slightly
diminished brush border in the small intestine of V illinCre+Apcfl/flBrgfl/fl mice (a). No apparent
diﬀerences were observed in diﬀerentiation of Goblet and Enteroendocrine cell lineages between the
cohorts (b and d). While lysozyme staining revealed mislocalisation of Paneth cells in V illinCre+-
Apcfl/flBrg+/+ mice, the small intestinal epithelium of V illinCre+Apcfl/flBrgfl/fl animals displayed
normal localisation of Paneth cells at the crypt base (c). Arrows mark positive cells for each staining
method. Scale bars represent 100 µm.
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Figure 5.12: Quantitative analysis of cell diﬀerentiation upon Brg1 loss in Wnt activated small intes-
tine. (a-c) The average number of Goblet (a), Enteroendocrine (b) and Paneth (c) cells per half-crypt
and associated villus was scored in the small intestine of control (white bars) V illinCre+Apcfl/flBrg+/+
(grey bars) and V illinCre+Apcfl/flBrgfl/fl (black bars) mice at day 4 PI. While the number of Goblet
cells was signiﬁcantly reduced in V illinCre+Apcfl/flBrg+/+ mice compared to control animals (p=0.037,
n≥4), no changes between the groups were detected in diﬀerentiation of Enteroendocrine cells. The num-
ber of Paneth cell was found to be signiﬁcantly increased in V illinCre+Apcfl/flBrg+/+ mice compared
to both V illinCre+Apcfl/flBrgfl/fl and control animals (for both comparisons p<0.01, n≥4). Error
bars represent standard deviation. Exact values, standard deviations and respective p values are pro-
vided in Table 5.3. (d) Cumulative frequency analysis of Paneth cell distribution revealed a signiﬁcant
expansion of Paneth cells throughout the crypt in V illinCre+Apcfl/flBrg+/+ small intestine compared
to both V illinCre+Apcfl/flBrgfl/fl and control animals (for either comparison Kolmogorov-Smirnov Z
test p<0.001, n≥4).
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4.85±0.85 respectively, p=0.037, n≥4, Figure 5.12a). Notably, scoring of Alcian blue
stained sections of the small intestine of DKO animals detected an intermediate number
of Goblet cells (3.73±1.81) which did not diﬀer signiﬁcantly from either Apc deﬁcient or
control epithelium (Figure 5.12a, for either comparison p>0.05, n≥4).
Grimelius staining was used to detect Enteroendocrine cells in the intestinal epithe-
lium (Figure 5.11d). Quantiﬁcation of positively stained cells revealed no diﬀerence
in Enteroendocrine cell numbers per half-crypt-villus structure in control (0.76±0.09),
V illinCre+Apcfl/flBrg+/+ (0.71±0.21) and DKO (0.68±0.24) animals (Figure 5.12b, for
all comparisons p>0.05, n≥4).
Finally, immunohistochemical analysis of Lysozyme expression was used to detect
Paneth cells in the small intestinal epithelium (Figure 5.11c). Quantiﬁcation of Lysozyme
positive cells (Figure 5.12c) revealed a signiﬁcant increase in Paneth cell number per
half-crypt in V illinCre+Apcfl/flBrg+/+ mice (2.12±0.45) compared to control animals
(1.13±0.31, p=0.003, n≥4). Notably, scoring of Paneth cells in the intestinal epithelium
of DKO mice detected full reversal to the normal level of Paneth cells, indistinguishable
from control epithelium (1.14±0.49, p=0.500, n=4) and signiﬁcantly lower compared to
V illinCre+Apcfl/flBrg+/+ mice ( p=0.004, n≥4). Since the Wnt pathway is involved
in the regulation of Paneth cell positioning within the crypt, I also scored the positions
of Lysozyme positive cells in control, V illinCre+Apcfl/flBrg+/+ and DKO epithelium.
Cumulative distribution analysis revealed no diﬀerence in Paneth cell positions between
epithelia of control and DKO animals (Figure 5.12d, Kolmogorov-Smirnov Z test p=0.17,
n=4). Conversely, cumulative distribution analysis of Lysozyme positive cells in the ep-
ithelium of V illinCre+Apcfl/flBrg+/+ mice detected a signiﬁcant expansion of the Paneth
cell population compared to either control or DKO epithelium (Figure 5.12d, for either
comparison Kolmogorov-Smirnov Z test p<0.001, n≥4). Visual inspection of Lysozyme
stained sections conﬁrmed conﬁnement of Paneth cells to the crypt base in DKO small
intestine, while epithelium of V illinCre+Apcfl/flBrg+/+ mice exhibited Paneth cell dis-
tribution throughout the crypt (Figure 5.11c).
5.2.10 Brg1 loss does not aﬀect levels of activated β-catenin
Quantitative analysis of apoptosis, cell proliferation and diﬀerentiation in V illinCre+-
Apcfl/flBrg+/+ and DKO mice suggested that Brg1 loss suppressed some components of
the phenotype of aberrant Wnt signalling in the small intestinal epithelium. In order
to dissect the mechanism of Brg1 loss-mediated suppression of aberrant Wnt signalling
I analysed Wnt activation at the level of β-catenin stabilisation. One of the primary
‘tumourigenic’ eﬀects of Apc loss is the disruption of the cytoplasmic destruction complex
and stabilisation of β-catenin due to lack of phosphorylation at Ser37 and Thr41 residues.
Stabilised β-catenin is therefore allowed to accumulate in the cytoplasm and nucleus
resulting in activation of the Wnt transcriptional program (Waterman, 2002). Nuclear
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accumulation of β-catenin is therefore one of the very ﬁrst signs of activated Wnt signalling
upon Apc inactivation. I therefore aimed to assess nuclear accumulation of β-catenin in
the small intestinal epithelium of V illinCre+Apcfl/flBrg+/+ and DKO mice at day 4 post
induction.
As previously mentioned, immunohistochemical analysis of β-catenin localisation in
the intestinal epithelium demonstrated that both V illinCre+Apcfl/flBrg+/+ and DKO
mice exhibited nuclear localisation of β-catenin (Figure 5.8). Closer inspection of the
stained sections revealed substantial variation in β-catenin staining both, within and
between samples of the same and diﬀerent genotypes. Overall, nuclear localisation of β-
catenin appeared to be more common in the intestinal epithelium of V illinCre+Apcfl/fl-
Brg+/+ mice (Figure 5.8). If Brg1 loss negatively aﬀected accumulation of activated
β-catenin, that would explain the attenuated phenotype of Apc inactivation in DKO
mice.
Figure 5.13: Brg1 loss in the context of Apc loss does not aﬀect levels of activated β-catenin. Western
blotting analysis of epithelial-enriched samples from V illinCre+Apcfl/flBrg+/+, V illinCre+Apcfl/fl-
Brgfl/fl and Cre− control animals revealed a substantial increase in the levels of activated β-catenin in
the small intestine of experimental mice compared to control animals. However, no diﬀerence was detected
in the levels of activated β-catenin between V illinCre+Apcfl/flBrg+/+ and V illinCre+Apcfl/flBrgfl/fl
small intestine. β-actin served as a loading control.
In order to investigate this hypothesis I aimed to quantitatively assess levels of ac-
tivated β-catenin in the intestinal epithelium of V illinCre+Apcfl/flBrg+/+ and DKO
animals. Since, immunohistochemistry is a non-quantiﬁable technique, Western blotting
was used to assay the levels of activated β-catenin. Epithelial-enriched cell fractions were
obtained from the small intestine of control, V illinCre+Apcfl/flBrg+/+ and DKO mice
(n=3). These samples were further used for protein extraction and Western blotting anal-
ysis. Quantitative analysis of the protein samples detected substantially higher levels of
activated β-catenin (de-phosphorylated at Ser37 and Thr41 residues) in both groups of
experimental animals compared to controls (Figure 5.13). At the same time, no diﬀerence
was detected in the levels of activated β-catenin between V illinCre+Apcfl/flBrg+/+ and
DKO intestinal samples (Figure 5.13). This observation suggested that the attenuation
of aberrant Wnt signalling caused by Brg1 loss is not mediated at the level of β-catenin
stabilisation and accumulation and is more likely to occur downstream of β-catenin.
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5.2.11 Brg1 deﬁciency attenuates the expression of Wnt target
genes
In the original publication describing the interaction between β-catenin and Brg1, it has
been proposed that Brg1 binds to the TCF/β-catenin complex and facilitates the trans-
activation of Wnt target genes (Barker et al., 2001). In order to investigate if Brg1 loss
suppressed β-catenin mediated activation of the Wnt transcriptional program, quanti-
tative analysis of Wnt target gene expression was performed on intestinal samples from
control, V illinCre+Apcfl/flBrg+/+ and DKO animals (n≥3). Total RNA was extracted
from epithelial enriched samples of the small intestine and subjected to reverse transcrip-
tion and quantitative real-time PCR (qRT-PCR) analysis of expression levels of a subset
of Wnt target genes.
Figure 5.14: Brg1 loss attenuates expression of the Wnt target genes. Quantitative RT-PCR analysis
revealed a signiﬁcant up-regulation of a range of Wnt target genes in the small intestinal epithelium of
V illinCre+Apcfl/flBrg+/+ (grey bars) and V illinCre+Apcfl/flBrgfl/fl (black bars) mice compared to
Cre− controls (white bars) at day 4 PI. Expression levels of c-Myc, CD44, and Cyclin D1, but not Axin2
or β-catenin were signiﬁcantly reduced in V illinCre+Apcfl/flBrgfl/fl mice compared to V illinCre+-
Apcfl/flBrg+/+ animals. Asterisks mark the pair-wise comparisons that were found to be signiﬁcantly
diﬀerent (p<0.05). For all comparisons n≥3.
qRT-PCR analysis of CD44, c-Myc and Cyclin D1 levels detected a signiﬁcantly ele-
vated expression of these genes in V illinCre+Apcfl/flBrg+/+ and DKO animals compared
to control samples (Figure 5.14, for all comparisons p<0.05, n≥3). Notably, however,
up-regulation of these genes was less prominent in DKO mice compared to V illinCre+-
Apcfl/flBrg+/+ samples (Figure 5.14, for all comparisons p=0.0285, n≥3). Conversely,
expression levels of Axin2, a commonly used readout of the Wnt pathway activation,
were elevated in both V illinCre+Apcfl/flBrg+/+ and DKO mice compared to control
animals (Figure 5.14, for both comparisons p<0.05, n≥3), with no diﬀerence being de-
tected in Axin2 expression between the two experimental groups (Figure 5.14, p=0.2,
n≥3). Together these observations suggest that Brg1 deﬁciency is likely to suppress β-
catenin mediated trans-activation of Wnt target genes, and indicate that this interaction
is gene-speciﬁc.
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5.2.12 Brg1 loss attenuates Wnt activation-mediated expansion
of the stem cell population
The hyperproliferative response of Wnt pathway activation is associated with the expan-
sion of the intestinal stem cell population (Jubb et al., 2006; Merlos-Sua´rez et al., 2011).
Considering the devastating eﬀect of Brg1 deﬁciency on the intestinal stem cell home-
ostasis in normal tissue, I aimed to examine if Brg1 loss suppressed the expansion of the
stem cell population in Wnt activated intestinal epithelium. To this end, I analysed the
expression levels of the intestinal stem cell markers Ascl2 and Lgr5 in RNA samples ex-
tracted from small intestinal epithelium of control, V illinCre+Apcfl/flBrg+/+ and DKO
mice.
Figure 5.15: Brg 1 loss attenuates Wnt driven expansion of the small intestinal stem cell compart-
ment. (a) Quantitative RT-PCR expression analysis revealed a signiﬁcant up-regulation of the stem cell
markers Ascl2 and Lgr5 in the small intestinal epithelium of V illinCre+Apcfl/flBrg+/+ (grey bars) and
V illinCre+Apcfl/flBrgfl/fl (black bars) mice compared to Cre− controls (white bars) at day 4 PI (for
all comparisons p<0.05, n≥3). Expression levels of Ascl2, but not Lgr5 were found to be signiﬁcantly
reduced in the small intestine of V illinCre+Apcfl/flBrgfl/fl mice compared to V illinCre+Apcfl/fl-
Brg+/+ intestine. Asterisks mark the pair-wise comparisons that were found to be signiﬁcantly diﬀerent
(p<0.05). For all comparisons n≥3. (b) In situ hybridisation analysis of Olfm4 expression revealed a
substantial expansion of the stem cell compartment in the small intestinal epithelium of V illinCre+-
Apcfl/flBrg+/+ compared to control animals. While the signs of expanded stem cell population were
detected in the small intestine of V illinCre+Apcfl/flBrgfl/fl mice, the expression levels of Olfm4, ap-
peared to be substantially lower compared to V illinCre+Apcfl/flBrg+/+ small intestine. Scale bars
represent 100 µm.
Expression levels of Ascl2 and Lgr5 were signiﬁcantly elevated in V illinCre+Apcfl/fl-
Brg+/+ and DKO mice compared to control animals (Figure 5.15a, for all comparisons
p<0.05, n≥3), indicating an expanded stem cell population in both experimental groups.
However, Ascl2 expression levels were signiﬁcantly lower in DKO mice compared to
V illinCre+Apcfl/flBrg+/+ animals (Figure 5.15a, p=0.015, n≥3). Conversely, no sig-
niﬁcant diﬀerence was detected in Lgr5 expression between V illinCre+Apcfl/flBrg+/+
and DKO mice, although DKO epithelium displayed a tendency to attenuated Lgr5 ex-
pression (Figure 5.15a, p=0.115, n≥3).
Since both Ascl2 and Lgr5 have been shown to be Wnt target genes, their use as
markers for the intestinal stem cell in this particular experimental system may be com-
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promised. In order to assess the state of the stem cell population in a Wnt-independent
manner, I resorted to in situ hybridisation analysis of Olfm4 expression. Small intestinal
samples from control, V illinCre+Apcfl/flBrg+/+ and DKO animals harvested at day 4
PI were stained using an anti-Olfm4 riboprobe (Figure 5.15b)1. Analysis of Olfm4 ex-
pression in control epithelium detected positive staining in the region of the crypt base
(Figure 5.15b). Conversely, the small intestinal epithelium of V illinCre+Apcfl/flBrg+/+
mice displayed Olfm4 staining throughout the crypt length, indicating an expansion of
the stem cell compartment (Figure 5.15b). Meanwhile, Olfm4 staining of the DKO ep-
ithelium failed to detect a similar expansion of the stem cell population (Figure 5.15b).
Notably, loss of Brg1 in context of Apc deﬁciency did not restore normal stem cell locali-
sation at the crypt bottom. Instead, Olfm4 expression in DKO small intestine was found
to be substantially lower compared to Apc deﬁcient mice.
Taken together, these observations suggest that Brg1 deﬁciency in the context of
activated Wnt signalling suppresses Wnt-driven expansion of the stem cell compartment.
5.3 Discussion
I have previously analysed the eﬀects of Brg1 deﬁciency in the small intestinal epithelium.
Despite numerous reports linking Brg1 loss to enhanced tumourigenesis in other tissues,
neither heterozygous, nor homozygous Brg1 loss in the small intestinal epithelium was
able to induce tumour formation over an extensive period of observation. Furthermore,
induction of partial Brg1 loss resulted in the repopulation of Brg1 deﬁcient cells with wild
type counterparts, while induction of complete Brg1 loss led to rapid crypt abrogation
due to compromised stem cell function. Taken together, these observations suggested that
Brg1 deﬁciency or haploinsuﬃciency alone was not suﬃcient to induce carcinogenesis in
the small intestinal epithelium. The reported interaction of Brg1 with β-catenin and
the resulting requirement of Brg1 for trans-activation of Wnt target genes (Barker et
al., 2001) implicated Brg1 as a potential therapeutic target in Wnt-driven neoplasia.
This contradicts with the recognised Brg1 role as a tumour suppressor in other tissues
(Becker et al., 2009; Reisman et al., 2003; Wong et al., 2000). Investigation of the Brg1
interaction with the Wnt pathway, and the eﬀects of Brg1 deﬁciency and haploinsuﬃciency
on aberrant Wnt signalling in vivo is therefore, of importance for the validation of Brg1
as a potential therapeutic target.
In this chapter I pursued two aims. First, to test whether Brg1 haploinsuﬃciency
enhanced Wnt-driven intestinal tumourigenesis. Second, to study modulation of aberrant
Wnt pathway activation by homozygous Brg1 loss. To this end, I exploited Cre recombi-
nase constructs expressed in the intestinal epithelium to inactivate one or two Brg1 alleles
in the context of activated Wnt signalling. The latter was achieved by introducing an
1Olfm4 in situ hybridisation was carried out by Maddy Young on the small intestinal sections provided
by me.
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Apc allele targeted with loxP sites in transgenic mice also bearing a targeted Brg1 allele
and various Cre recombinase constructs. Data presented in this chapter show that Brg1
haploinsuﬃciency does not accelerate or in any other way enhance Wnt mediated car-
cinogenesis, while Brg1 deﬁciency inhibits Wnt-driven tumour formation via suppression
of Wnt target genes and elimination of Wnt activated stem cells.
5.3.1 Brg1 haploinsuﬃciency does not accelerate Wnt driven
intestinal tumourigenesis
Having established that heterozygous inactivation of Brg1 does not induce tumourige-
nesis in normal intestinal tissue, I aimed to test whether Brg1 haploinsuﬃciency would
enhance tumour formation in mice with heterozygous deletion of Apc. However, analysis
of tumour burden and survival probability failed to detect diﬀerences in tumour incidence
and progression between Apc heterozygous mice with or without Brg1 haploinsuﬃciency.
The observation that Brg1 haploinsuﬃciency is unable to induce tumourigenesis alone
or accelerate Wnt-driven tumour formation in the small intestine is in contrast to the
ﬁndings that Brg1 haploinsuﬃciency promotes tumourigenesis in both the mammary and
lung epithelium (Bultman et al,. 2007; Glaros et al., 2008). This discrepancy indicates the
tissue-speciﬁc nature of Brg1’1 role as a tumour suppressor and highlights the importance
tissue-speciﬁc protein interactions in potential therapeutic target validation.
Loss of both Brg1 alleles is a commonplace event in lung tumourigenesis (Fukoka et
al., 2004; Reisman et al., 2003). I, however failed to observe any instances of Brg1 loss
of heterozygousity (LOH) in the tumours from AhCre+Apc+/flBrg+/fl mice. Retention
of the functional Brg1 allele is all more remarkable considering the high chromosomal
instability of Apc deﬁcient tumours (Fodde et al., 2001). Taken together, this ﬁnding
indicates that Brg1 deﬁciency provides no selective advantage to Wnt driven intestinal
tumours. On the other hand, the presence of the recombined Brg1 allele in tumour
tissue suggested retention of Brg1 haploinsuﬃcient cells and thus the lack of selective
pressure against Brg1 haploinsuﬃciency. It should be noted, however, that the recombined
signal detected in tumours could be derived from normal Brg1 heterozygous tissue present
within the tumour and genotyping of microdissected tumour tissue would be required to
conclusively establish retention of recombined Brg1 allele in tumour cells.
Combined with the data from Chapter 3, these results suggest that in the context of
the normal small intestine, and Wnt-driven neoplasia, Brg1 haploinsuﬃciency is likely to
act as a neutral factor, neither enhancing, nor impairing tumour formation or progression.
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5.3.2 Brg1 deﬁciency attenuates the eﬀects of aberrant Wnt
activation by suppressing Wnt-driven gene expression
Given the proposed role of Brg1 as a Wnt signalling mediator (Barker et al., 2001), I aimed
to investigate the functional interaction between Brg1 and Wnt signalling in the murine
small intestinal epithelium. To this end, I activated Wnt signalling by conditionally
deleting Apc in the context of Brg1 deﬁciency using VillinCre recombinase.
The overall eﬀect of Brg1 deﬁciency in Wnt activated small intestinal epithelium was
the attenuation of responses driven by activated Wnt signalling. Quantitative measure-
ments of histological parameters, such as crypt length, apoptosis and proliferation were
all elevated in Wnt activated epithelium in both Brg1 deﬁcient and proﬁcient tissue com-
pared to control mice, consistent with previous reports of conditional Apc deletion in the
small intestine (Sansom et al., 2004). However, the epithelium of double knock-out (DKO)
mice displayed a signiﬁcantly reduced degree of Wnt-mediated responses compared to Apc
deﬁcient mice with functional Brg1.
Consistent with an increase in crypt length and number of proliferating cells, posi-
tional analysis of Ki67 and BrdU positive cells at 2 hours post labelling detected spatial
expansion of the proliferative compartment, which was nonetheless signiﬁcantly less pro-
nounced in DKO mice. Of note, the proliferative compartment’s size or distribution
was not aﬀected upon Brg1 loss in otherwise normal epithelium at the comparable time
point (Section 3.2.9), indicating that Brg1 might be speciﬁcally required for the Wnt
activation-driven increase in proliferation. Expansion of the stem cell population in Wnt
activated intestinal epithelium is postulated to contribute to the Wnt mediated prolifera-
tive response (Jubb et al., 2006; Merlos-Sua´rez et al., 2011). Interestingly, the attenuated
increase in proliferation in DKO mice coincided with depletion of the stem cell compart-
ment in the small intestine of these mice compared to Apc deﬁcient animals. Notably,
despite restoring normal localisation of Paneth cells, Brg1 loss in the context of activated
Wnt signalling did not seem to restore stem cell localisation to the crypt bottom as as-
sessed by Olfm4 expression. Instead, DKO mice displayed attenuated expression of Olfm4
throughout the crypt compartment.
One of the Wnt mediated responses not attenuated by Brg1 deﬁciency was abrogation
of cellular migration. In contrast, migration of epithelial cells in the small intestine of
DKO mice was marginally further impaired in comparison with Apc deﬁcient epithelium.
While this response seemed unexpected in the context of overall attenuated manifesta-
tions of activated Wnt signalling, it could be accounted for by the reduced proliferative
activity of DKO intestinal epithelium. While Wnt pathway activation strongly impairs
cell migration, active cell proliferation ensures some residual level of cell migration. It is
possible therefore, that the attenuated cell proliferation seen in DKO mice would reduce
this residual cell migration thus further impairing apparent migration. It should be noted
however, that Brg1 deﬁciency in the otherwise normal small intestine impaired epithelial
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cell migration at very early stages (Section 3.2.10). Further inhibition of cell migration
in the context of aberrant Wnt signalling could thus indicate a cumulative eﬀect of Brg1
deﬁciency and Wnt pathway activation on migration of the intestinal epithelium.
Brg1 loss was found to modulate a number of cell diﬀerentiation responses mediated by
aberrant Wnt signalling. Most notable of these was the restoration of Paneth cell number
and position to a state comparable with that of the normal intestine. Paneth cells are the
only terminally diﬀerentiated intestinal cell type that exhibit high levels of Wnt signalling.
The Paneth cell’s transcriptional program governed by activated Wnt pathway drives
EphB3 receptor expression, which combined with the Ephrin ligand gradient in normal
intestine ensures the Paneth cell’s strict conﬁnement to the crypt base (Batlle et al., 2002).
Aberrant activation of the Wnt pathway has been found to disrupt control over Paneth
cell diﬀerentiation and position. As a result, Wnt activated intestinal epithelium has
been shown to exhibit an increased number of Paneth cells and their presence throughout
the crypt as opposed to crypt-base conﬁnement in normal epithelium (Sansom et al,.
2004). Brg1 deﬁciency in the context of aberrant Wnt signalling was found to reverse
both Paneth cell number and positioning to the normal state. Notably, Brg1 loss was not
suﬃcient to repress other Wnt mediated responses, such as apoptosis, cell proliferation
and migration, to physiological levels. Taken together, these data suggest that Brg1
might be preferentially involved in trans-activation of particular Wnt target genes, rather
than homogeneously regulating the entire Wnt transcriptional program. This notion is
consistent with the observation that Brg1 knock-down in the HEK293T cancer cell line
down-regulates less than 70% of the genes induced by Wnt pathway activation the same
cells (Mahmoudi et al., 2010). Although to a lesser extent, Brg1 was found to modulate
diﬀerentiation of Goblet cells. While Goblet cells were signiﬁcantly under-represented in
Apc deﬁcient mice compared to normal intestine, combined Brg1-Apc loss resulted in an
intermediate phenotype, neither signiﬁcantly diﬀerent from Apc deﬁcient mice, nor from
wild type controls. Quantiﬁcation of enteroendocrine cells found that their frequency was
unaltered between control, Apc deﬁcient and DKO mice. This observation is in contrast
with the previous study of Apc deletion in the small intestine (Sansom et al., 2004),
which reported a decrease in enteroendocrine cell number in Wnt activated epithelium.
Several diﬀerences in experimental design, however, could contribute to this discrepancy.
Sansom et al., studied the eﬀects of Apc loss at day 5 post induction (as opposed to
day 4 in this study), which allowed more time for Wnt mediated responses to develop.
Additionally, the reported decrease in enteroendocrine cell number was observed within
the transformed crypt compartment, whilst in this study enteroendocrine cells were scored
throughout the crypt-villus axis. Similarly, while Apc deﬁcient intestine was reported to
display diminished expression of alkaline phosphatase (Sansom et al., 2004), no apparent
decrease in alkaline phosphatase expression was detected in Apc deﬁcient mice in this
study. This, again, could be attributed to an earlier time point used in the present
experiment. Surprisingly, however, the small intestinal epithelium of DKO mice was
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consistently found to exhibit reduced alkaline phosphatase staining. This observation is
consistent with impaired alkaline phosphatase expression in Brg1 deﬁcient mice (Section
3.2.11) and suggests that Brg1 might play a role in enterocyte maturation independent
of Wnt signalling.
In summary, Brg1 deﬁciency attenuated a range of responses mediated by aberrant
Wnt signalling, in particular apoptosis, proliferation and diﬀerentiation of Goblet and
Paneth cells, while not aﬀecting cell migration and enteroendocrine cell diﬀerentiation.
At the same time, the impaired enterocyte maturation caused by Brg1 deﬁciency appears
to be independent of Wnt activation.
In order to investigate the mechanism behind the attenuated phenotype of Apc loss
in Brg1 deﬁcient epithelium, I explored a number of possibilities. At least one study
suggested that Brg1 may be involved in modulation of the Wnt pathway at two lev-
els, expression of Wnt receptors and trans-activation of Wnt target genes (Griﬃn et al.,
2011). The former option implies that Brg1 deﬁciency might attenuate Wnt signalling
by suppressing expression of Wnt receptors and thus causing a suboptimal level of Wnt
activation. In this case, one can expect to observe a reduced level of β-catenin activation
in response to Brg1 loss. β-catenin activation in the small intestinal epithelium can be
assessed qualitatively by examining its nuclear accumulation or quantitatively by assess-
ing levels of active β-catenin, which is not phosphorylated at residues Ser37 and Thr41.
Immunohistochemical analysis of β-catenin localisation proved to be variable between and
within samples, potentially due to ﬁxation/staining artefacts. However, the overall trend
suggested that cells with nuclear β-catenin were more common in Apc deﬁcient epithelium
than the epithelium of DKO mice, indicating a reduced level of β-catenin activation in
DKO animals. However, quantitative Western-blotting analysis of active β-catenin levels
revealed no diﬀerences between Apc deﬁcient and DKO small intestinal epithelium, indi-
cating that Brg1 loss did not aﬀect the stabilisation and accumulation of active β-catenin.
Interestingly, the reported physical interaction between Brg1 and β-catenin (Barker et al.,
2001) may facilitate nuclear retention of β-catenin and thus account for reduced nuclear
β-catenin accumulation in the epithelium of DKO mice. Overall, these observations sug-
gest that while Brg1 loss is unlikely to aﬀect β-catenin stabilisation and accumulation, it
might impair nuclear retention of β-catenin, which could contribute to the attenuation of
Wnt mediated responses.
In order to examine the second possibility, namely Brg1 mediated modulation of Wnt
signalling by trans-activation of Wnt target genes, I assessed the expression levels of a
number of genes known to be a part of Wnt signalling transcriptional program. Indeed
a subset of Wnt target genes (CD44, c-Myc, Cyclin D1, Lgr5 ) was found to be down-
regulated in the small intestinal epithelium of DKO mice compared to Apc deﬁcient
epithelium. Notably, at least some Wnt target genes (Axin2 ) were found to escape this
down-regulation. This observation raises two possibilities. The ﬁrst is that there is dif-
ferential Brg1 involvement in the trans-activation of diﬀerent Wnt targets. The second is
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consistent with reduced accumulation of nuclear β-catenin in the epithelial cells of DKO
mice and implies a dose-dependent trans-activation of Wnt target genes. If the dose of
Wnt signal (in the form of nuclear β-catenin) required for a gene to be expressed is dif-
ferent for diﬀerent genes, partial inhibition of nuclear accumulation of β-catenin would
result in impaired expression of ‘high-dose’ genes (c-Myc, etc), while ‘low dose’ genes
(Axin2 ) would receive suﬃcient signal to be transcribed to a ‘fully activated’ state. An
elegant study by Kielman et al. (2002) used ES cells expressing truncated versions of Apc
protein of various severity to generate teratomas. Kielman et al. observed an increase
in tissue diﬀerentiation defects along with increasing severity of Apc mutations and de-
gree of nuclear accumulation of β-catenin. Expression proﬁling of teratomas with various
doses of Wnt/β-catenin signal revealed a substantial number of diﬀerentially expressed
genes. Although not stressed by authors, a subset of these genes displayed a substantial
increase or decrease in expression when compared between teratomas with the highest
and intermediate levels of Wnt activation. These genes require a high level of Wnt signal
in order to be fully transcribed and thus represent the ‘high-dose’ group. Conversely,
another subset of genes was found to be up- or down-regulated in Apc deﬁcient teratomas
compared to wild type conterparts, while their expression levels were indistinguishable be-
tween teratomas with the highest and intermediate degree of Wnt activation (Kielman et
al., 2002). Unfortunately, none of the genes examined in the present work was reported as
diﬀerentially expressed in the study by Kielman et al., which prevents direct comparison.
To summarise, the results presented in this chapter suggest that the immediate eﬀect
of Brg1 loss in the context of aberrant Wnt signalling activation is impaired expression
of a number of Wnt target genes (notably those involved in proliferative response). This
suppression is likely to be caused by either suboptimal ability of the β-catenin/TCF
complex to trans-activate its target genes in the absence of Brg1 or by impaired nuclear
retention of β-catenin and, as a result, reduced likelihood of the complex formation.
Diminished levels of Wnt target gene expression then can lead to attenuated cellular
responses to Wnt pathway activation, such as aberrant cell proliferation, diﬀerentiation
and apoptosis.
5.3.3 Brg1 loss suppresses Wnt-driven tumourigenesis in the
small intestinal epithelium
In order to test the long-term eﬀects of Brg1 loss in the context of activated Wnt sig-
nalling, targeted Brg1 and Apc alleles were deleted using the AhCreER recombinase.
Experimental cohorts of DKO and AhCreER+Apcfl/flBrg+/+ mice were aged along with
AhCreER− controls. A proportion of animals were sacriﬁced at early time-points (day
7–10 PI) to analyse early Brg1 deﬁcient lesions with aberrant Wnt signalling. Surpris-
ingly, no DKO lesions were detected despite presence of apparently normal Brg1 deﬁ-
cient cell clusters and Wnt activated lesions, which retained Brg1 expression. The lack
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of DKO lesions was unexpected, when compared to DKO mice expressing VillinCre re-
combinase, which displayed combined Brg1 and Apc loss in nearly 100% of epithelial
cells. The diﬀerence in the expression pattern of AhCreER and VillinCre recombinases
should, however, be considered, when comparing results from these two models (see Fig-
ure 3.1b,c). VillinCre recombinase is expressed in the entirety of the small intestinal
epithelium and thus is able to induce simultaneous loss of the targeted alleles in all ep-
ithelial cells. AhCreER, in contrast, is expressed in a limited cell population, mainly
conﬁned to the intestinal stem cells and their early progenitors. In the latter model, for
the cells with induced loss of the targeted alleles to become detectable it is necessary to
undergo several rounds of cell division. In the case of Apc loss, although smaller lesions
with nuclear β-catenin can be detected at early time points, it is at the aberrant crypt
focus (ACF) stage that they can be reliably identiﬁed, before which an induced cell would
have undergone numerous divisions. It appears, therefore, that even if DKO cells arise
in the small intestine of AhCreER+Apcfl/flBrgf/f mice, they are eliminated before they
can reach the ACF stage and the only surviving mutant cells are those that incidentally
underwent complete loss of only one of the two targeted genes. Of these, Brg1 deﬁcient
cells are gradually repopulated leaving Brg1 positive Wnt activated lesions as the only
mutant cells. Together, these observations suggest that Brg1 loss is incompatible with
long-term activation of the Wnt pathway, most likely due to attenuation of Wnt signalling,
although this can be tolerated for a short period of time. A more intriguing explanation
of the apparent lack of DKO lesions in the small intestine of AhCreER+Apcfl/flBrgf/f
mice can be derived from the diﬀerences in spatial expression pattern of VillinCre and
AhCreER recombinases. As previously discussed, VillinCre recombinase drives deletion
of the targeted alleles in all intestinal cell populations, including transit amplifying and
diﬀerentiated cells. Conversely AhCreER activity is largely conﬁned to the stem cell
population. The lack of DKO lesions in AhCreER+Apcfl/flBrgf/f mice may, therefore,
signal the stem cell-speciﬁc incompatibility of Brg1 deﬁciency and aberrant Wnt activa-
tion. This notion is consistent with the attenuated expansion of the stem cell population
observed in V illinCre+Apcfl/flBrgf/f mice.
Survival analysis of the experimental cohorts revealed a signiﬁcant survival advantage
of DKO mice compared to Apc deﬁcient animals. Whilst all AhCreER+Apcfl/flBrg+/+
mice became ill and had to be sacriﬁced within 3 weeks of Cre recombinbase induction,
a substantial proportion of DKO mice survived signiﬁcantly longer, with some DKO
mice surviving past 100 days PI. This increase in survival is consistent with long-term
incompatibility of Brg1 loss with aberrant Wnt activation. Due to limited eﬃciency of
Cre recombinase, three distinct subpopulations of mutant cells in the intestinal epithelium
of DKO mice would be represented by Apc deﬁcient cells (Apc−), Brg1 deﬁcient cells
(Brg1−) and double mutant cells (Brg−/Apc−) (Figure 5.16a). Elimination of all the
double mutant cells would result in an overall decrease in numbers of Apc deﬁcient cells
resulting in lower tumour burden and improved animal survival (Figure 5.16b). This
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Figure 5.16: Brg1 deﬁciency in the context of small intestinal Wnt-driven tumourigenesis improves
animal survival by reducing tumour burden. See the main text for detailed explanation.
model is supported by retention of Brg1 expression in all adenomas in the small intestine
of AhCreER+Apcfl/flBrgfl/fl mice (Figure 5.16c). Interestingly, a similar relationship
between Brg1 loss and the tumour suppressor Snf5/Ini1 was observed in another mouse
cancer model. Simultaneous deletion of Snf5 and Brg1 using T-cell lineage speciﬁc Lck-Cre
recombinase resulted in reduced tumour incidence and slower onset of disease. Similar
to our observations, all the tumours detected in that model retained Brg1 expression,
indicating their origin from a sub-population of mutant cells that had lost only Snf5 (Wang
et al., 2009). An additional mechanism that might have contributed to the improved
animal survival derives from the notion that the intestinal stem cell acts as the cell of
origin of cancer. It has been observed that aberrant activation of the Wnt pathway
within the intestinal stem cell population leads to the development of rapidly growing
adenomas, whilst transit-amplifying cells with activated Wnt signalling give rise to micro-
adenomas with restricted growth (Barker et al., 2009, Figure 5.17). Notably, numerous
micro-adenomas were detected in the small intestinal epithelium of long-surviving DKO
mice, while large adenomas were infrequently observed in these mice. This mechanism is
further supported by the notion that Brg1 loss is incompatible with long-term survival of
the Wnt activated small intestinal stem cells discussed earlier in this section. Together,
these observations suggest that small intestinal Brg1 loss in the context of aberrant Wnt
signalling improves animal survival not only by reducing the tumour burden, but also by
eliminating stem cell-derived Wnt-driven tumours with a higher potential to progress to
advanced cancer.
5.3.4 Future directions
In summary, the ﬁndings presented in this chapter suggest that Brg1 is required for
optimal activation of the Wnt transcriptional program and Wnt-driven tumourigenesis in
the murine small intestinal epithelium.
It has been recently reported that in HEK293T cancer cell line BRG1 is involved in the
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Figure 5.17: Brg1 deﬁciency in the context of small intestinal Wnt-driven tumourigenesis improves
animal survival via speciﬁc elimination of stem cell-derived adenomas with high tumourigenic potential.
See the main text for detailed explanation.
regulation of a diverse transcriptional program of which Wnt target genes constitute only
20% (Mahmoudi et al., 2010). It therefore would be interesting to explore the genome-wide
eﬀects of Brg1 loss on the Wnt pathway activation in vivo. To this end, we are planning to
carry out genome-wide expression analysis of the Wnt activated small intestinal epithelium
with and without Brg1 loss using an Illumina microarray. Additionally, Brg1 chromatin
immunoprecipitation (ChIP) analysis of the Wnt activated small intestinal epithelium will
be carried out in order to verify whether Brg1 occupies promoters of Wnt target genes in
vivo.
An intriguing concept stemming from the data presented in this chapter is that tar-
geting intestinal stem cells with aberrant Wnt signalling may have therapeutic beneﬁts,
for instance in patients with FAP, where elimination of Wnt activated stem cells would
prevent development of adenomas with the higher potential for malignant transformation.
We are planning to explore the suitability of Brg1 as a therapeutic target using two types
of mouse cancer models. The ﬁrst aims to verify whether stem-cell speciﬁc loss of Brg1
in the context of the Wnt pathway activation is able to improve animal survival by pre-
venting the development of advanced adenomas. To this end, targeted Brg1 and/or Apc
alleles are to be deleted in the intestinal stem cells using Lgr5CreER recombinase (Barker
et al., 2007). In this scenario mice carrying only the targeted Apc allele are expected to
rapidly develop macro-adenomas, which would be absent in the small intestine of DKO
mice. The second model will aim to assess the ability of Brg1 loss to act as a therapeutic
factor in a pre-formed tumour. To this end animals harbouring targeted Brg1 alleles and
Lgr5CreER recombinase are to be interbred with mice carrying the ApcMIN allele. As
previously mentioned, ApcMIN mice develop multiple intestinal tumours within 6 months
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of age. These adenomas are to be treated by the induction of Lgr5CreER recombinase ac-
tivity thus facilitating Brg1 deletion in normal and cancer stem cell populations. Tumour
burden is then to be analysed in animals with and without induction of Brg1 loss.
Chapter 6
Investigating the multiple tissue
phenotypes of combined Apc and
Brg1 loss
6.1 Introduction
Mutations of the core components of the Wnt pathway that ultimately result in the path-
way’s aberrant activation have been found in cancers with diverse tissues of origin. These
include, but are not limited to, cancers of the gastrointestinal tract, breast, liver, ovarian,
endometrial and pancreatic cancers as well as melanoma (reviewed extensively in Giles et
al., 2003). Of these, colorectal cancer and the role of Wnt signalling in its pathogenesis are
arguably the most studied, presumably due to its high clinical signiﬁcance, the well de-
ﬁned mechanisms of tumour initiation and progression and the availability of established
animal models (reviewed in Schneikert and Behrens, 2007). However, the involvement of
aberrant Wnt signalling in the tumourigenesis of other organs implies that the develop-
ment of therapies targeted against Wnt signalling could prove beneﬁcial in various types
of cancer (reviewed in Ewan and Dale, 2008).
With this in mind I set about to examine the consequences of Wnt activation via
conditional deletion of a loxP targeted Apc allele in multiple tissues expressing AhCreER
recombinase. Additionally, I aimed to investigate modulation of the Apc loss-induced
phenotype in these tissues by concurrent loss of Brg1. Importantly, any attempt to
study Apc deﬁciency using AhCreER recombinase is likely to be hampered by the severe
intestinal phenotype of Wnt activation and limited animal survival (Ahmad et al., 2011;
Marsh et al., 2008). To circumvent this diﬃculty I relied on the extended life span of
Apc/Brg1 double knock-out animals described in the previous chapter, which enabled me
to study relatively long-term consequences of AhCreER recombinase-induced Apc loss.
This chapter describes the consequences of Apc deﬁciency in forestomach, fundic,
pyloric, large intestinal and bladder epithelia, as well as the impact of Brg1 loss on Wnt-
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driven tumourigenesis in these tissues. Additionally, I investigated tumour initiation
in non-intestinal AhCre recombinase expressing tissues via examination of the eﬀects of
heterozygous deletion of Apc and modulation of this phenotype by Brg1 haploinsuﬃciency.
6.2 Results
6.2.1 Combined Brg1 and Apc heterozygous loss has no ap-
parent oncogenic eﬀect in tissues outside of the intestinal
epithelium
The results presented in Chapter 4 suggested that Brg1 haploinsuﬃciency alone does not
induce tumour formation in tissues expressing AhCre recombinase within the observed
time frame. At the same time, the data presented in the previous chapter demonstrated
that Brg1 haploinsuﬃciency did not modulate Wnt driven tumourigenesis in the small
or large intestinal epithelium of mice with heterozygous loss of Apc allele. To study the
consequences of combined Apc and Brg1 loss in AhCre recombinase expressing tissues
outside of the intestinal epithelium I analysed a range of tissues harvested from AhCre+-
Apc+/flBrg+/fl and AhCre+Apc+/flBrg+/+ mice. Mice in these cohorts were induced by
5 intraperitoneal injections of 80 mg/kg β-naphthoﬂavone. Mice from each cohort were
then aged for up to 600 days post induction or until they developed signs of terminal
ill health. Tissues from sacriﬁced animals were harvested and processed for histological
analysis.
Histological analysis of H&E stained sections of forestomach, glandular stomach and
bladder epithelium of either AhCre+Apc+/flBrg+/+ or AhCre+Apc+/flBrg+/fl revealed
no signs of tumourigenesis in any of the tissues analysed at any time point. Occasional
mice displayed tumour-like formations in the liver, which were identiﬁed as lymphomas.
6.2.2 Brg1 loss is permissive of Wnt-driven tumourigenesis in
the pyloric, but not fundic or forestomach epithelium
The extended survival of AhCreER+Apcfl/flBrgfl/fl mice allowed me to analyse the
long-term eﬀects of Brg1 deﬁciency on Wnt driven tumourigenesis in tissues with delayed
tumour development, such as the glandular and forestomach epithelium. AhCreER+-
Apcfl/flBrg+/+ andAhCreER+Apcfl/flBrgfl/fl mice were induced along withAhCreER−
controls by ﬁve intraperitoneal injections of 80 mg/kg β-naphthoﬂavone and tamoxifen.
Mice were sacriﬁced at deﬁned time points or upon displaying signs of ill health, at which
point they were dissected and whole stomachs were harvested and processed for histolog-
ical analysis.
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6.2.2.1 AhCreER+Apcfl/flBrgfl/fl mice develop Wnt-driven adenomas in the
pyloric stomach
Immunohistochemical analysis of β-catenin expression in the glandular stomach ofAhCreER+-
Apcfl/flBrgfl/fl mice revealed small lesions in the pyloric stomach that exhibited nuclear
localisation of β-catenin as early as day 19 PI (n=3, Figure 6.1a, leftmost panel). These
lesions were characterised by an abnormal glandular architecture and increased nucleus-
to-cytoplasm ratio and were identiﬁed as gastric adenomas. Analysis of Brg1 expression
revealed positive Brg1 staining in the vast majority of these lesions (Figure 6.1a, mid-
dle panel). In fact, no Brg1 deﬁcient lesions with nuclear β-catenin were observed in the
pyloric stomach of AhCreER+Apcfl/flBrgfl/fl mice at this time point. Rare AhCreER+-
Apcfl/flBrg+/+ mice that survived until day 19 PI displayed Wnt activated pyloric lesions
of comparable size (n=2, Figure 6.1a, rightmost panel). Immunohistochemical analysis
of Brg1 and β-catenin expression in the pyloric epithelium of AhCreER+Apcfl/flBrgfl/fl
mice at 30 days PI revealed a similar pattern of Brg1 expression and nuclear accumulation
of β-catenin (n=6, not shown). Analysis of Brg1 expression in pyloric stomach at day 60
PI, however, detected occasional lesions with nuclear β-catenin that displayed loss of Brg1
expression (n=6, Figure 6.1b). While most of the Wnt activated lesions in the pyloric
stomach remained relatively small and sessile, a single macroscopic lesions was observed in
the pyloric junction of an AhCreER+Apcfl/flBrgfl/fl mouse that survived past 100 days
PI (n=6, Figure 6.1c). This tumour exhibited nuclear localisation of β-catenin and was
identiﬁed as a well diﬀerentiated gastric adenoma with low-grade dysplasia1. Immunohis-
tochemical analysis of Brg1 expression in the gastric adenoma revealed occasional Brg1
deﬁcient clusters within the predominantly Brg1 positive tumour (Figure 6.1c, rightmost
panel).
Comparative analysis of β-catenin localisation in Brg1 positive and negative pyloric
lesions revealed a reduction in the levels of nuclear β-catenin in Brg1 deﬁcient lesions
(Figure 6.1d). β-catenin staining of Brg1 deﬁcient lesions was substantially stronger than
that of surrounding normal tissue. However, nuclear localisation of β-catenin was found to
be less prominent than that observed in Brg1 positive lesions. This pattern of β-catenin
distribution in Brg1 deﬁcient pyloric lesions was consistently observed at all the time
points analysed irrespective of the lesion size.
6.2.2.2 Brg1 loss suppresses some Wnt targets in the Wnt-driven pyloric
lesions
The presence of Brg1 deﬁcient lesions with increased levels of β-catenin suggested that
Brg1 may be dispensable for Wnt-driven tumourigenesis in the pyloric stomach epithelium.
On the other hand, the late onset of Brg1 deﬁcient lesions, their low number and the lack
1Histopathological description was provided by Prof Geraint T. Williams, Department of Pathology,
University Hospital of Wales, Cardiﬀ University, UK
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Figure 6.1: Brg1 loss in the pyloric stomach is permissive of Wnt-driven tumourigenesis. (a) Lesions
with nuclear accumulation of β-catenin were revealed in the pyloric stomach of AhCreER+Apcfl/fl-
Brg+/+ and AhCreER+Apcfl/flBrgfl/fl mice at day 19 PI. No loss of Brg1 expression was observed
in pyloric lesions of AhCreER+Apcfl/flBrgfl/fl mice at this time point. (b) Loss of Brg1 expression
was revealed in occasional Wnt activated lesions in the pyloric stomach of AhCreER+Apcfl/flBrgfl/fl
mice as early as day 60 PI. (c) A single macroadenoma that developed in the pyloric epithelium of a
AhCreER+Apcfl/flBrgfl/fl mouse displayed nuclear accumulation of β-catenin and rare clusters of Brg1
deﬁcient cells. (d) Analysis of β-catenin distribution revealed frequent attenuation of nuclear β-catenin
accumulation in Brg1 deﬁcient pyloric lesions. Scale bars represent 100 µm (a,b), 500 µm (c) and 50 µm
(d).
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of nuclear β-catenin staining all signalled that Brg1 loss in the context of Wnt activated
pyloric epithelium could result in suboptimal levels of Wnt signalling. I, therefore, aimed
to assess the eﬀects of Brg1 loss on downstream Wnt target gene expression. To this
end, immunohistochemical analysis of CD44 and c-Myc expression was performed on
pyloric stomach sections containing both Brg1 positive and negative lesions. Comparative
analysis of c-Myc expression revealed its frequent down-regulation in Brg1 deﬁcient lesions
compared to adjacent lesions retaining Brg1 expression (Figure 6.2). In contrast to this
observation, no consistent correlation between the levels of CD44 expression and Brg1
status of the lesion was observed (Figure 6.2).
Figure 6.2: Brg1 loss in Wnt-driven pyloric adenomas suppressed c-Myc, but not CD44 expression.
Immunohistochemical analysis of c-Myc and CD44 expression was carried out on serial sections of pyloric
adenomas from AhCreER+Apcfl/flBrgfl/fl mice at day 105 PI. Comparative analysis of Brg1 positive
(white arrowhead) and negative (black arrowhead) adenomas revealed attenuation of c-Myc expression
in Brg1 deﬁcient adenomas. No changes in CD44 expression were detected between Brg1 positive and
negative adenomas. Scale bars represent 200 µm.
6.2.2.3 Wnt pathway activation does not induce tumourigenesis in the fundic
or forestomach epithelium
Immunohistochemical analysis of β-catenin expression detected no lesions with nuclear
β-catenin in the fundic portion of the stomach epithelium neither in AhCreER+Apcfl/fl-
Brg+/+, nor in AhCreER+Apcfl/flBrgfl/fl animals, indicating that activation of the Wnt
pathway via Apc loss alone is not suﬃcient to drive tumourigenesis in this tissue.
Similarly, no signs of Wnt-driven tumourigenesis were observed in the forestomach ep-
ithelium of AhCreER+Apcfl/flBrgfl/fl mice. While very small (4-6 cells in cross section)
lesions with prominent nuclear localisation of β-catenin were detected in the basal layer
of the forestomach epithelium of AhCreER+Apcfl/flBrg+/+ and AhCreER+Apcfl/fl-
Brgfl/fl animals at day 10 PI (n=3, Figure 6.3a), no similar lesions were observed at
later time points. Surprisingly, occasional regions of the forestomach epithelium from
AhCreER+Apcfl/flBrgfl/fl mice were found to display loss of Brg1 (Figure 6.3b, right-
most panel). These regions appeared indistinguishable from adjacent Brg1 positive ep-
ithelium and showed no sign of nuclear accumulation of β-catenin (Figure 6.3b, left and
middle panels). These regions, thus, were likely to be represented by cells that have un-
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dergone Brg1 deletion, but escaped loss of Apc. Additionally, rare lesions that resembled
Brg1 deﬁcient squamous papillomas found in AhCreER+Brgfl/fl mice were detected in
the forestomach of AhCreER+Apcfl/flBrgfl/fl animals (Figure 6.3c). In contrast to the
papillomas from AhCreER+Brgfl/fl forestomach epithelium, Brg1 deﬁcient lesions in the
forestomach of AhCreER+Apcfl/flBrgfl/fl animals remained very small in size as late as
160 days PI. These lesions exhibited loss of Brg1 expression and a moderate increase in β-
catenin staining (Figure 6.3c). However, a similar pattern of β-catenin staining (an overall
increase in intracellular β-catenin levels without any marked increase in nuclear localisa-
tion) was occasionally observed in the wild type forestomach epithelium. It is, therefore,
diﬃcult to ascertain whether increased β-catenin levels in the Brg1 deﬁcient forestomach
lesions of AhCreER+Apcfl/flBrgfl/fl epithelium were a consequence of activated Wnt
signalling and if, indeed, Apc was lost in these lesions.
6.2.3 Brg1 deﬁciency is permissive for Wnt-driven tumourigen-
esis in the large intestinal epithelium
Having established that Brg1 loss has no detrimental eﬀect on the long-term mainte-
nance of the large intestinal epithelium (see section 4.2.4), I aimed to ascertain whether
loss of Brg1 would manifest a phenotype in the context of aberrant Wnt signalling.
To this end, AhCreER+Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl mice were in-
duced along with AhCreER− controls by ﬁve intraperitoneal injections of 80 mg/kg
β-naphthoﬂavone and tamoxifen. Mice were sacriﬁced at deﬁned time points or upon
displaying signs of ill health, at which point samples of the large intestine were collected
and processed for histological analysis.
6.2.3.1 Brg1 deﬁciency is permissive of Wnt-driven adenoma formation in
the large intestinal epithelium
Immunohistochemical analysis of β-catenin expression in the large intestinal epithelium of
AhCreER+Apcfl/flBrgfl/fl mice detected small lesions that displayed nuclear localisation
of β-catenin as early as day 19 PI (n=3, Figure 6.4a, left panel). These lesions were repre-
sented by individual abnormal crypts that displayed signs of low-grade dysplasia. Analysis
of Brg1 expression in the large intestine of AhCreER+Apcfl/flBrgfl/fl mice revealed that
the majority of the Wnt activated lesions retained Brg1 expression. However, occasional
Brg1 deﬁcient lesions with nuclear β-catenin were detected as early as day 19 PI (Figure
6.4a, middle panel). Interestingly, rare Brg1 deﬁcient crypts were detected in the large
intestinal epithelium of AhCreER+Apcfl/flBrgfl/fl mice that displayed no signs of dys-
plasia or nuclear β-catenin accumulation (Figure 6.4b, black arrowheads). These crypts
most likely originated from cells that had lost Brg1 but escaped Apc deletion. The large
intestine of AhCreER+Apcfl/flBrgfl/fl mice thus contained all three cellular populations
resulting from suboptimal Cre recombinase activity, namely Brg1 deﬁcient, Apc deﬁcient
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Figure 6.3: Activation of Wnt signalling in the forestomach epithelium fails to induce tumourigen-
esis. (a) Immunostaining with β-catenin antibody revealed small lesions with nuclear accumulation of
β-catenin in the forestomach epithelium of AhCreER+Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl
mice as early as day 10 PI. (b) No lesions with nuclear accumulation of β-catenin were detected in the
forestomach epithelium of AhCreER+Apcfl/flBrgfl/fl mice as late as day 160 PI. However, immuno-
histochemical analysis of Brg1 expression revealed occasional forestomach regions of Brg1 loss in these
mice (marked by black arrowheads). These regions were indistinguishable from normal epithelium on
H&E stained sections and displayed no sign of nuclear accumulation of β-catenin. (c) Rare Brg1 deﬁ-
cient malformations were detected in the forestomach epithelium of AhCreER+Apcfl/flBrgfl/fl mice.
Despite increased levels of β-catenin expression in these structures, no prominent nuclear accumulation
of β-catenin was observed. Scale bars represent 100 µm
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and double knock-out cells. The large intestine of occasional AhCreER+Apcfl/flBrg+/+
mice that survived until day 19 PI was found to contain Wnt activated lesions compa-
rable in size to those observed in AhCreER+Apcfl/flBrgfl/fl animals (Figure 6.4a, right
panel).
Macroscopic analysis of the large intestinal epithelium fromAhCreER+Apcfl/flBrgfl/fl
mice revealed occasional macroscopic tumours as early as day 60 PI (n=6, Figure 6.4d
and e). Histological analysis of these tumours identiﬁed them as intestinal adenomas of
characteristic pedunculated appearance. Adenomas were predominantly composed of ep-
ithelial cells, which displayed strong nuclear β-catenin staining and low-grade dysplasia
(Figure 6.4d and e). Immunohistochemical analysis of Brg1 expression within the polyps
revealed a mosaic pattern of Brg1 staining. The majority of the polyps contained both
Brg1 positive and negative cells. These cells were organised into distinct substructures
within the polyp, so that each substructure was completely composed of either Brg1 posi-
tive or negative cells rather that containing a mixture of both (Figure 6.4d). Notably, Brg1
deﬁcient substructures displayed a pattern of β-catenin staining similar to that observed
in Brg1 deﬁcient fundic lesions. Whilst general level of β-catenin in these substructures
was substantially higher compared to normal tissue, its nuclear accumulation was less
prominent than in Brg1 positive substructures (Figure 6.4d). Additionally, adenomas
containing only Brg1 positive substructures were also frequently observed (Figure 6.4e).
Conversely, whilst individual Brg1 deﬁcient lesions (similar to those present at day 19 PI)
were occasionally observed (Figure 6.4c), no macroadenomas composed entirely of Brg1
deﬁcient substructures were detected.
Macroscopic analysis of AhCreER+Apcfl/flBrgfl/fl mice that survived past 100 days
PI revealed multiple macroscopic tumours of adenoma appearance (n=6). Histological
and immunohistochemical analysis of these tumours found them to be indistinguishable
from the large adenomas observed at day 60 PI (Figure 6.4f). No signs of progression
towards adenocarcinoma were detected in the large intestinal adenomas of AhCreER+-
Apcfl/flBrgfl/fl mice at any stage.
6.2.3.2 Large intestinal Brg1 loss does not alter the phenotype of aberrant
Wnt signalling
2 The presence of Brg1 deﬁcient lesions with nuclear β-catenin in the large intestinal ep-
ithelium of AhCreER+Apcfl/flBrgfl/fl mice suggested dispensability of functional Brg1
for Wnt driven tumourigenesis in this tissue. Conversely, the low frequency occurrence
of Brg1 deﬁcient Wnt activated substructures compared to Brg1 positive counterparts
and the absence of Brg1 deﬁcient large adenomas indicated suboptimal eﬃciency of
Wnt-driven tumourigenesis in the context of Brg1 deﬁciency. In order to investigate
whether Brg1 loss impaired Wnt-driven tumourigenesis in the large intestinal epithelium
2Quantitative analysis of cell proliferation and apoptosis in Brg1 positive and negative substructures
was carried out by Joanna Krzystyniak under my direction and supervision.
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Figure 6.4: Brg1 deﬁciency is permissive of Wnt-driven tumourigenesis in the large intestinal epithe-
lium. (a) Numerous lesions with nuclear accumulation of β-catenin were detected in the large intestinal
epithelium of AhCreER+Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl mice as early as day 19 PI.
Occasional large intestinal lesions of AhCreER+Apcfl/flBrgfl/fl mice displayed Brg1 loss. (b) Rare
Brg1 deﬁcient crypts with normal appearance and no sign of nuclear β-catenin were detected in the
large intestine of AhCreER+Apcfl/flBrgfl/fl mice at various time points. (c) Individual Brg1 deﬁ-
cient lesions with nuclear β-catenin were detected at various time points. (d, e) Large intestines of
AhCreER+Apcfl/flBrgfl/fl mice were found to develop macroscopic adenomas as early as day 60 PI.
These adenomas displayed nuclear accumulation of β-catenin and either mosaic loss of Brg1 (d) or no
Brg1 loss at all (e). (f) AhCreER+Apcfl/flBrgfl/fl that survived past 100 days PI developed large
benign adenomas with mosaic pattern of Brg1 loss and nuclear accumulation of β-catenin. Scale bars
represent 100 µm (a-e) and 500 µm (f).
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of AhCreER+Apcfl/flBrgfl/fl mice, I aimed to analyse certain phenotype manifestations
of Wnt pathway activation in Brg1 deﬁcient and proﬁcient lesions.
To assess the impact of Brg1 deﬁciency on the expression levels of downstream Wnt
target genes, large intestinal samples containing tumours with mosaic Brg1 loss were
immunostained with antibodies against c-Myc and CD44 (Figure 6.5a). Comparative
analysis of c-Myc and CD44 expression in Brg1 positive and negative portions of mosaic
adenomas, however, failed to detect any consistent correlation between the expression
levels and Brg1 status of the substructure (Figure 6.5a).
Figure 6.5: Brg1 loss in Wnt-driven large intestinal adenomas does not suppress Wnt target gene
expression. (a) Immunohistochemical analysis of c-Myc and CD44 expression was carried out on serial
sections of large intestinal mosaic adenomas from AhCreER+Apcfl/flBrgfl/fl mice at day 105 PI. Com-
parative analysis of Brg1 positive and negative substructures revealed no consistent correlation between
expression of Wnt target genes and Brg1 status of the lesion. (b,c) Quantitative analysis of Ki67 stained
mosaic adenomas (c) revealed a signiﬁcant increase in the number of proliferating cells in Brg1 deﬁcient
substructures (b, p=0.036, n≥9). (d, e) Quantitative analysis of Cleaved Caspase3 stained mosaic ade-
nomas (e) revealed no signiﬁcant diﬀerence in the number of apoptotic cells in between Brg1 negative
(grey bars) and positive (white bars) substructures (d, p=0.135, n≥15). Error bars represent standard
deviation. Scale bars represent 100 µm.
In order to investigate whether Brg1 loss in the context of activated Wnt signalling af-
fected proliferative activity of the tumour cells, large intestinal sections from AhCreER+-
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Apcfl/flBrgfl/fl mice containing adenomas with mosaic Brg1 deletion were immunos-
tained with nuclear proliferation marker Ki67 and the number of positively stained cells
was scored as a percentage (± standard deviation) of all cells in the substructure (Figure
6.5b and c). Rather counter intuitively, quantitative analysis of the Ki67 stained sections
revealed a signiﬁcantly lower number of Ki67 positive cells in Brg1 positive substructures
compared to their Brg1 negative counterparts (41.05±14.19 and 56±15.28, p=0.036). A
minimum of 9 substructures were scored per group (Figure 6.5b).
Finally, in order to assess the eﬀects of Brg1 loss on cell death in the context of
aberrant Wnt signalling, large intestinal sections containing adenomas with Brg1 positive
and negative substructures were stained with an antibody against cleaved Caspase 3 and
the number of positively stained cells was scored as a percentage (± standard deviation)
of all cells in the substructure (Figure 6.5d and e). Quantiﬁcation of Caspase 3 positive
cells did not reveal any signiﬁcant diﬀerence in apoptosis levels between Brg1 proﬁcient
and deﬁcient substructures (1.85±0.93 and 2.45±1.29, p=0.135). 15 substructures were
scored per group (Figure 6.5d).
Taken together, these observations suggest that Brg1 deﬁciency is permissive for Wnt
driven tumourigenesis in the context of the large intestinal epithelium. Brg1 deﬁciency in
Wnt activated tissue has no eﬀect on the expression levels of Wnt target genes or upon
the levels of cell death. Brg1 loss, however, appears to increase cell proliferation in Wnt
driven large intestinal tumours.
6.2.4 Brg1 deﬁciency weakly modiﬁes the Wnt pathway activa-
tion in the context of the bladder urothelium
Having established that Brg1 haploinsuﬃciency does not induce urothelial carcinogenesis
alone or in combination with heterozygous Apc loss, I aimed to investigate the conse-
quences of urothelial Brg1 loss in the context of aberrant Wnt signalling. To achieve this,
AhCreER+Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl mice along with AhCreER−
controls were induced with ﬁve intraperitoneal injections of 80 mg/kg β-naphthoﬂavone
and tamoxifen. The mice were dissected at deﬁned time points, and whole bladders were
harvested and processed for histological analysis.
6.2.4.1 Aberrant Wnt signalling in the bladder induces the development of
short-lived lesions with nuclear β-catenin
Histological analysis of H&E stained sections of the bladder urothelium from AhCreER+-
Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl mice at day 10 PI revealed numerous
compact lesions (n=6, Figure 6.6, left panel). These lesions were characterised by a
well deﬁned border and an increased nucleus-to-cytoplasm ratio. Immunohistochemi-
cal analysis of β-catenin expression revealed nuclear localisation of β-catenin in both
AhCreER+Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl lesions (Figure 6.6, middle
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panel). Immunostaining with an antibody against Brg1 revealed strong Brg1 immunore-
activity in AhCreER+Apcfl/flBrg+/+ lesions, while AhCreER+Apcfl/flBrgfl/fl lesions
displayed complete loss of Brg1 expression (Figure 6.6, right panel). No abnormalities in
the urothelium morphology of AhCreER- control mice were observed at any time point.
Figure 6.6: Brg1 deﬁciency is permissive of Wnt-driven tumourigenesis in the bladder urothelium.
Histological analysis of H&E stained sections of the bladder urothelium from AhCreER+Apcfl/flBrg+/+
and AhCreER+Apcfl/flBrgfl/fl mice at day 10 PI revealed numerous compact lesions. Analysis of β-
catenin distribution revealed nuclear accumulation of β-catenin in these lesions. Immunohistochemical
analysis of Brg1 expression revealed complete loss of Brg1 expression in AhCreER+Apcfl/flBrgfl/fl
bladder lesions. Scale bars represent 100 µm.
Despite their abundance in the bladder epithelium at day 10 PI, histological analysis of
AhCreER+Apcfl/flBrgfl/fl mice at day 30 PI failed to detect any urothelial lesions (not
shown). This observation suggested that Wnt activated lesions in the bladder urothelium
had a very short lifespan. In order to analyse the fate of the Wnt-driven urothelial
lesions, mice were induced as described above and dissected at day 7, 10, 14 and 19 PI
(n≥3 per time point). Immunostaining with an antibody against β-catenin allowed clear
visualisation of the lesion size (Figure 6.7a). Visual analysis of the lesion size indicated
initial growth, which stalled around day 14 PI. Analysis of AhCreER+Apcfl/flBrg+/+
and AhCreER+Apcfl/flBrgfl/fl bladder urothelium at day 19 PI stained with a β-catenin
antibody detected infrequent small lesions with nuclear β-catenin and large lacunae ﬁlled
with dead cells, which appeared to be the remnants of the earlier resolved lesions (Figure
6.7a, black arrowheads).
In order to obtain a more quantitative measure of lesion fate I scored the number of cells
per lesion in the AhCreER+Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl bladders at
7, 10 and 14 days PI (a minimum of 50 lesions was scored per cohort at each time
point). Quantitative analysis of the lesion size revealed an initial increase in median
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Figure 6.7: Brg1 facilitates Wnt-driven bladder tumourigenesis, but is unable to overcome lesions’
regression. (a) Visual inspection of β-catenin stained urothelial lesions over the time course from day 7
to day 19 PI revealed an initial increase in the lesion size, which stalled around day 10 PI and regression
of lesions around day 19. While lesions in the bladder of AhCreER+Apcfl/flBrgfl/fl mice appeared
larger than AhCreER+Apcfl/flBrg+/+ lesions at the same time point, they also were found to disappear
around day 19. (b) Quantiﬁcation of the lesion size conﬁrmed that Brg1 deﬁcient (grey bars) lesions
were signiﬁcantly larger than AhCreER+Apcfl/flBrg+/+ (white bars) lesions at the same time point (at
each time point p<0.001, a minimum of 50 lesions was analysed per time point per genotype). The data
were presented as a box plot. Filled dimond shape marks the mean value. (c) Immunohistochemical
analysis of BrdU incorporation 3 hours post labelling and Ki67 expression, both revealed a substantial
increase in the number of proliferating cells in Brg1 deﬁcient lesions compared to bladder lesions from
AhCreER+Apcfl/flBrg+/+ mice. Scale bars represent 100 µm. (d) Quantitative RT-PCR analysis
of bladder urothelium at day 10 PI revealed no diﬀerence in expression levels of Wnt target genes be-
tween AhCreER+Apcfl/flBrg+/+ (grey bars) and AhCreER+Apcfl/flBrgfl/fl (black bars) urothelium.
While all Wnt target genes were up-regulated in AhCreER+Apcfl/flBrg+/+ epithelium compared to
control Cre− (white bars) mice, only CD44 and Axin2 were found to be up-regulated in AhCreER+-
Apcfl/flBrg+/+ mice in comparison to control urothelium. Asterisks mark pairwise comparisons that
showed a signiﬁcant diﬀerence (p<0.05, n≥4).
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lesion size between day 7 and 10 PI followed by the reduction in size between day 10 and
14 PI. This pattern was observed in both AhCreER+Apcfl/flBrg+/+ and AhCreER+-
Apcfl/flBrgfl/fl urothelium (Figure 6.7b). Although Brg1 deﬁcient and proﬁcient lesions
displayed the same progression pattern and were largely eliminated by day 19 PI, at any
time point Brg1 deﬁcient lesions were larger in size based on the quantitative information
(Figure 6.7a and b). Statistical comparison of the median lesion size between AhCreER+-
Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl urothelium at each time point revealed
a signiﬁcant diﬀerence between the cohorts (Mood median test p<0.001 for each time
point). Consistent with this observation, Brg1 deﬁcient lesions from AhCreER+Apcfl/fl-
Brgfl/fl urothelium displayed increased expression of the proliferation marker Ki67 and
elevated levels of BrdU incorporation at 3 hours post labelling compared to AhCreER+-
Apcfl/flBrg+/+ urothelium (Figure 6.7c).
Taken together, these observations demonstrate that aberrant activation of the Wnt
pathway in the context of the bladder urothelium results in the development of short lived
lesions. Both Brg1 positive and negative lesions are largely eliminated from Wnt activated
bladder urothelium by day 19 PI. However, within the short life span of bladder Wnt-
driven tumourigenesis, Brg1 deﬁcient lesions display increased cell proliferation compared
to Brg1 positive lesions. It appears therefore that Brg1 deﬁciency is favourable in a
context of Wnt-driven bladder tumourigenesis, even though it is unable to avoid early
regression of urothelial lesions.
6.2.4.2 Brg1 loss does not aﬀect the expression levels of Wnt target genes in
the Wnt activated bladder urothelium
In order to analyse the potential impact of Brg1 deﬁciency on Wnt signalling activation,
I aimed to assess expression levels of the Wnt target genes in AhCreER+Apcfl/flBrg+/+
and AhCreER+Apcfl/flBrgfl/fl bladder urothelium. To this end, AhCreER+Apcfl/fl-
Brg+/+ and AhCreER+Apcfl/flBrgfl/fl mice were induced as described above along with
AhCreER- controls. Mice were sacriﬁced at day 10 PI and the whole bladders were col-
lected. The bladder urothelium was then separated from the muscular wall and subjected
to RNA extraction and quantitative RT-PCR analysis.
Expression analysis of the Wnt target genes c-Myc, CD44, Cyclin D1 and Axin2 re-
vealed a signiﬁcant increase in their expression in the bladder urothelium of AhCreER+-
Apcfl/flBrg+/+ mice compared to control animals (Figure 6.7d, for all genes p<0.05).
However, no signiﬁcant diﬀerence was detected in the Wnt target gene expression levels
between AhCreER+Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl urothelium (Figure
6.7d, for all genes p>0.05). Furthermore, only a proportion of the Wnt target genes anal-
ysed were found to be signiﬁcantly up-regulated in AhCreER+Apcfl/flBrgfl/fl urothe-
lium compared to control animals (Figure 6.7d, for CD44 and Axin2 p<0.05, for Cyclin
D1 and c-Myc p>0.05). It should be noted that, with the exception of Axin2, all the
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Wnt target genes analysed displayed only a very moderate up-regulation in AhCreER+-
Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl urothelium compared to control mice
(Figure 6.7d).
6.3 Discussion
Despite numerous reports of Wnt pathway activating mutations in a diverse range of
cancer types, these studies are often associative and do not provide clear evidence of the
causative role of activated Wnt signalling in pathogenesis of these cancers (Giles et al.,
2003). In this chapter I investigated the ability of conditional Apc deletion to induce
tumourigenesis in forestomach, fundic, pyloric, large intestinal and bladder epithelium.
Additionally, I examined the ability of Brg1 loss to modulate Wnt-driven tumourigenesis
in these tissues.
In summary, aberrant activation of Wnt signalling via Apc deletion failed to induce
tumour formation in the forestomach and fundic epithelium and only produced short-lived
lesions in the bladder urothelium. While Brg1 loss appeared to increase the proliferation
rate of the Wnt-driven bladder lesions, it was unable to rescue the short life span of
the lesions. Conversely, Apc loss was found to induce adenoma formation in the pyloric
and large intestinal epithelium. While Brg1 loss appeared to impair the development of
gastric adenomas, no detrimental eﬀect of Brg1 deﬁciency on Wnt-driven large intestinal
tumourigenesis was observed. Additionally, heterozygous loss of Apc failed to induce
tumourigenesis in any of these tissues apart from the large intestine, as described in the
previous chapter.
6.3.1 Heterozygous loss of Apc does not induce overt tumouri-
genesis in AhCre expressing non-intestinal tissues
Germline mutations in Apc gene have been linked to familial adenomatous polyposis
(FAP), an inherited condition characterised by development of numerous gastrointestinal
polyps (Groden et al., 1991). In addition to numerous colonic polyps FAP patients are also
prone to tumourigenesis of the upper gastrointestinal tract, including fundic gland polyps
(Abraham et al., 2000) and gastric adenocarcinoma (Park et al., 2011). This observation
was reproduced in animal models as mice with heterozygous truncation of Apc protein
were found to develop gastric adenomas in addition to intestinal polyps (Pollard et al.,
2009; Tomita et al., 2007). In the previous chapter I demonstrated that heterozygous loss
of Apc under control of the AhCre recombinase was successful in driving tumourigenesis
in the small and large intestines and was not aﬀected by Brg1 haploinsuﬃciency. In
this chapter I aimed to investigate Wnt-driven tumourigenesis and its modulation by
Brg1 haploinsuﬃciency in the murine stomach tissues as well as the bladder urothelium.
To this end, one copy of loxP targeted Apc allele was deleted under control of AhCre
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recombinase with or without concurrent heterozygous loss of Brg1.
In contrast to previous murine models of heterozygous Apc loss (Pollard et al., 2009;
Tomita et al., 2007) no malformations were observed in epithelial tissues of the stomach
irrespective of Brg1 status. This discrepancy is even more remarkable considering sub-
stantially longer life span of AhCre+Apc+/flBrg+/+ and AhCre+Apc+/flBrg+/fl mice
compared to either Apc1322T or ApcMIN animals and, thus, a wider window of opportunity
for tumour development. This discrepancy, however, may be attributed to a substantial
variation of Apc deﬁciency phenotypes, depending on particular Apc mutations involved
(Pollard et al., 2009). As an example Apc1322T mice display a substantially shortened
life span and accelerated tumourigenesis compared to ApcMIN animals (Pollard et al.,
2009). Notably, while no gastric adenomas were observed in the pylorus of AhCre+-
Apc+/flBrg+/+ or AhCre+Apc+/flBrg+/fl, these lesions can be diﬃcult to distinguish
from duodenal adenomas in cases, where the tumour develops at the pyloric junction.
Such adenomas were analysed as a part of the small intestinal phenotype of Apc loss
(section 5.2.2).
Similarly, no bladder lesions were detected in mice with heterozygous loss of Apc at
any time point irrespective of Brg1 status. This observation is consistent with a limited
presence of Wnt activating mutations in urothelial carcinomas (Stoehr et al., 2002) as well
as a recent report indicating that Wnt activation alone has a restricted ability to induce
tumourigenesis in the urothelium (Ahmad et al., 2011).
The results presented in this chapter, therefore, indicate that among those tissues
expressing AhCre recombinase, the ability of heterozygous Apc loss to induce tumour
development is limited to the intestinal epithelium.
6.3.2 Brg1 loss partially attenuates aberrant Wnt signalling in
the pyloric stomach, but is permissive for Wnt driven tu-
mourigenesis
Gastric cancer is the fourth most common cancer and the second leading cause of cancer
related death in the world (Hamilton and Meltzer, 2006). Although its role in gastric
cancer is not as well established as in CRC, activation of the Wnt pathway has been im-
plicated in the gastric neoplasia by numerous reports. Nuclear accumulation of β-catenin
in gastric adenocarcinomas has been found to vary from 17% to 54% among diﬀerent
studies (Clements et al., 2002; Oshima et al., 2006; Woo et al., 2001). The evidence for
APC and β-catenin mutations in gastric cancer is as variable between diﬀerent studies
and has been reported to reach up to 60% for APC and 27% for β-catenin (Clements et
al., 2002; Ebert et al., 2002; Lee et al., 2002; Woo et al., 2001). Furthermore, a number of
transgenic mouse models with Apc gene truncations have been reported to develop gastric
neoplasia (Pollard et al., 2009; Tomita et al., 2007).
Consistent with these observations, conditional deletion of Apc using AhCreER re-
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combinase was found to induce adenomatous lesions in the pyloric stomach epithelium of
AhCreER+Apcfl/flBrg+/+ mice as early as 19 days PI. These lesions displayed strong
nuclear accumulation of β-catenin and were histologically similar to those reported in
the stomach of ApcMIN mice (Tomita et al., 2007). Unfortunately, the short life span
of AhCreER+Apcfl/flBrg+/+ mice due to small intestinal tumourigenesis prevented the
long-term study of pyloric lesions in these mice. Conversely, the extended life span of
AhCreER+Apcfl/flBrgfl/fl enabled an investigation of the relatively long-term gastric
adenoma progression. Due to suboptimal levels of Cre recombinase activity, the pyloric
stomach of AhCreER+Apcfl/flBrgfl/fl mice contained both Brg1 deﬁcient and proﬁcient
lesions, all of which displayed nuclear localisation of β-catenin. In fact, whilst Brg1 posi-
tive pyloric adenomas were visible at day 19 PI, Brg1 deﬁcient adenomas were not detected
until approximately day 60 PI and were substantially under-represented compared to Brg1
positive lesions. The late onset and low frequency of Brg1 deﬁcient pyloric adenomas sug-
gested impaired Wnt-driven tumourigenesis in response to Brg1 loss. Consistent with this
notion, Brg1 deﬁcient adenomas were shown to display reduced expression levels of the
Wnt target gene c-Myc, although the same pattern was not observed for another Wnt
target, CD44. Additionally, Brg1 deﬁcient adenomas displayed attenuated levels of nu-
clear β-catenin compared to Brg1 positive lesions. It is, therefore tempting to hypothesise
that Brg1 deﬁciency attenuates expression of some Wnt target genes in the Wnt activated
pyloric epithelium, thus delaying the development of the Brg1 deﬁcient adenomas without
blocking it completely.
The vast majority of gastric adenomas observed in the pylorus of AhCreER+Apcfl/fl-
Brgfl/fl mice remained small and sessile over the whole period of observation (up to 160
days PI) irrespective of their Brg1 status. In fact, only one macroscopic polyp-like ade-
noma was detected amongst six mice that survived past 100 days PI. While predominantly
Brg1 positive, this macroadenoma also contained small clusters of Brg1 deﬁcient cells. All
pyloric adenomas remained benign and displayed no signs of invasive disease. This obser-
vation is consistent with that made in ApcMIN mice (Tomita et al., 2007). Only ApcMIN
mice that were additionally treated with N-methyl-N-nitrosourea (MNU) were reported
to progress to invasive adenocarcinomas, whilst adenomas in the stomach of untreated
ApcMIN mice remained benign (Tomita et al., 2007). Together, these observations sug-
gest that while activation of Wnt signalling via Apc loss in the pyloric epithelium is able
to initiate adenoma formation, additional mutations are required to drive its progression
towards advanced disease.
6.3.3 Aberrant Wnt signalling does not induce tumourigenesis
in the fundic and forestomach epithelium
In contrast to the pyloric stomach, activation of the Wnt pathway failed to induce tu-
mourigenesis in fundic and forestomach epithelium of either AhCreER+Apcfl/flBrgfl/fl
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or AhCreER+Apcfl/flBrg+/+ mice. Whilst small lesions with nuclear β-catenin were ob-
served in the basal cell layer of the forestomach epithelium of both cohorts at day 10 PI,
no Wnt activated lesions were identiﬁed at later time points. Due to the short life span of
AhCreER+Apcfl/flBrg+/+ animals it cannot be established with certainty whether long-
term Wnt activation would be able to induce tumourigenesis in these tissues. It could
therefore, be hypothesised that it was the loss of Brg1 that prevented the development of
Wnt driven lesions in the fundus and forestomach of long surviving AhCreER+Apcfl/fl-
Brgfl/fl mice. However, given the suboptimal eﬃciency of AhCreER recombinase in the
analysed tissues, one could expect to ﬁnd a residual subpopulation of Apc-only deﬁcient
cells. This was not, however, the case as the only mutant cells detected in these two tissues
were occasional Brg1 deﬁcient cells with no sign of nuclear β-catenin in the forestomach
epithelium. Thus, the lack of Wnt-driven tumours in the fundic and forestomach epithe-
lium of AhCreER+Apcfl/flBrgfl/fl mice strongly suggests that Wnt signalling activation
alone is insuﬃcient to induce tumourigenesis in these tissues regardless of Brg1 status.
Interestingly, the inability of Wnt pathway activation to drive tumourigenesis in the
forestomach and fundic epithelium coincides with the lack of Wnt signalling in the nor-
mal homeostasis of these tissues. Morphogenesis and patterning of the oesophagus and
stomach epithelial compartments have been reported to rely on Wnt pathway suppres-
sion. Expression of the homeodomain transcription factor Barx1 in the mesenchymal
tissue underlying prospective oesophagus and stomach has been found to be essential
for developmental speciﬁcation of the stomach (Kim et al., 2005) and oesophageal (Woo
et al., 2011) epithelium by stimulating expression of Wnt antagonists, such as secreted
frizzled-related proteins (sFRPs). Conversely, the lack of Barx1 expression in the intesti-
nal mesenchyme is permissive of Wnt signalling and thus intestinal diﬀerentiation (Kim
et al., 2005).
In contrast to the fundic epithelium, pyloric stomach physiology appears to be closer
to the small intestinal epithelium in terms of reliance on Wnt signalling. First of all,
the pyloric but not fundic stem cells have been found to express the intestinal stem cell
marker Lgr5 (Barker et al., 2007). It should be noted, however, that Lgr5 expression in
the pyloric epithelium has been found to be restricted to the base of the glands, which
contrasts with the conventional position of the stomach stem cell at the gland isthmus
(Karam, 1999). In spite of this controversy, Lgr5 positive cells have been reported to
be able to drive long-term maintenance of the pyloric glands both in vivo and in vitro.
Consistent with these ﬁndings, conditional deletion of the Apc gene in Lgr5 positive cells
has been shown to induce gastric adenoma formation in the pyloric, but not fundic region
of the murine stomach. Similarly, gastric adenomas in mice with constitutive heterozygous
truncation of Apc were found to develop in pyloric, but not fundic epithelium (Pollard
et al., 2009; Tomita et al., 2007). These observations are, however, inconsistent with
common occurrence of genetic aberrations in APC and β-Catenin genes in FAP-related
and sporadic cases of fundic gland polyps respectively (Abraham et al., 2000, Abraham
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et al., 2001). This discrepancy suggests potentially distinct mechanisms of Wnt-driven
fundic gland polyposis in the human and murine stomach epithelium.
While Wnt pathway suppression is required for normal development and homeostasis
of oesophageal epithelium, Wnt signalling activation have been shown to play a limited
role in oesophageal neoplasia. Two major types of cancer can be distinguished in the
oesophageal epithelium: oesophageal squamous cell carcinoma (ESCC) and oesophageal
adenocarcinoma (EAC). Of these, ESCC accounts for nearly 95% of oesophageal cancer
cases (Kuwano et al., 2005). In contrast to ESCCs, which retain squamous epithelium
identity, EACs undergo a metaplastic change and convert from squamous into columnar
epithelium in response to chronic gastro-oesophageal reﬂux, a condition termed Barett’s
oesophagus (Flejou, 2005). Consistent with this intestine-like transformation of the ep-
ithelial identity, activation of the Wnt pathway has been associated with progression
from Barett’s oesophagus to EAC (Bian et al., 2000). However, mutational analysis of
primary components of the Wnt pathway, such as β-Catenin, APC and AXIN revealed
that mutations in these genes are rarely detected (Bian et al., 2000; Koppert et al., 2004;
Gonzalez et al., 1997). Instead, APC and a Wnt signalling inhibitor SFRP1 were found
to be frequently silenced via promoter hypermethylation in Barett’s oesophagus and EAC
(Clement et al., 2006). In the light of the notion that promoter hypermethylation tends
to be a post-initiation event in cancer progression (Jones and Baylin, 2002), these reports
suggest that aberrant activation of Wnt signalling in EAC is likely to occur at later stages
and be involved in cancer progression rather than initiation.
In a similar manner to EAC, analysis of ESCC samples have suggested a limited role
of the Wnt pathway in ESCC development. Expression analyses have detected nuclear
β-catenin in a minority of ESCC samples as well as a more frequent increase in Cyclin
D1 expression (Kudo et al., 2007). Similarly, progression from basal cell hyperplasia to
malignant ESCC has been found to correlate with a decrease in expression of APC and E-
Cadherin as well as an increase in nuclear β-catenin and Cyclin D1 expression (Peng et al.,
2009). Additionally, a number of the Wnt pathway antagonists, such as WNT5A, SFRP1
and WIF1 have been frequently found to be epigenetically silenced in ESCC via promoter
hypermethylation (Chan et al., 2007; Li et al., 2010; Meng et al., 2011). However, despite
these and other reports suggesting correlation of Wnt activation with ESCC progression,
no study has yet implicated Wnt signalling activation in ESCC initiation.
Taken together, the observations presented in this chapter and earlier ﬁndings suggest
that unlike the pyloric epithelium, which harbours Wnt-responsive stem cells, fundic and
forestomach mucosa contain a Wnt-independent stem cell populations. Aberrant activa-
tion of Wnt signalling in these stem cell populations appears insuﬃcient to drive neoplastic
transformation in these tissues, although it might contribute to tumour progression.
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6.3.4 Brg1 loss has no major detrimental eﬀect on Wnt-driven
large intestinal tumourigenesis
The role of aberrant Wnt signalling in colorectal cancer has been well established both
in vitro using human CRC cell lines and in vivo (reviewed in Gregorieﬀ and Clevers,
2005). Consistent with this role and previously reported mouse models of CRC (Sansom
et al., 2004; Shibata et al., 1997; Su et al., 1992), conditional deletion of Apc under
the control of AhCreER recombinase induced rapid tumourigenesis in the large intestinal
epithelium. Dysplastic aberrant crypt foci (ACF) with nuclear β-catenin were detected in
the large intestine of both, AhCreER+Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl
mice as early as day 19 PI. Although the majority of ACFs in the large intestine of
double knock-out (DKO) AhCreER+Apcfl/flBrgfl/fl animals retained Brg1 expression,
a substantial number of lesions displayed Brg1 loss. The extended life span of DKO
animals made it feasible to investigate the eﬀects of Brg1 deﬁciency on long-term Wnt-
driven tumourigenesis in the large intestinal epithelium. Although AhCreER+Apcfl/fl-
Brg+/+ mice became terminally ill by or around day 19 PI, Brg1 positive lesions in the
large intestine of DKO mice could serve as a control for Wnt-driven tumours unaﬀected
by Brg1 loss.
Analysis of the tumour burden in the large intestinal epithelium of DKO mice at day 60
PI and later revealed numerous macroscopic adenomas. Immunohistochemical analysis of
Brg1 expression in these adenomas revealed two types of tumours. While some adenomas
appeared to be fully composed of Brg1 positive cells, others displayed clear areas of
Brg1 loss. Brg1 deﬁcient cells in these tumours were organised in distinct substructures
so that the whole substructure would be either fully Brg1 positive or negative, rather
than comprised of a mixture of cells. The origin of such mosaic substructures implies
two alternatives. The ﬁrst suggests that each macroadenoma originated from a single
Brg1 positive crypt that only lost one copy of Brg1 due to suboptimal eﬃciency of Cre
recombinase. Some substructures of such Brg1 heterozygous adenoma could afterwards
lose the second copy of Brg1 via loss of heterozygousity. This scenario is plausible in
view of the high chromosomal instability of Apc deﬁcient tumours (Alberici and Fodde,
2006). However, it implies that complete Brg1 loss confers a selective advantage over Brg1
positive substructures. In contrast to this notion, no macroadenomas were observed that
would be fully populated by Brg1 deﬁcient cells. Furthermore, such a mechanism would
predict mosaic adenomas in the large intestine of Brg1 haploinsuﬃcient AhCre+Apc+/fl-
Brg+/fl mice (section 5.2.2). However, all adenomas observed in the large intestinal
epithelium of these mice were found to retain Brg1 expression.
An alternative mechanism invokes a polyclonal origin for mosaic adenomas. In this
scenario, outgrowth of several Brg1 positive and negative aberrant crypts generates a
single macroadenoma. Notably, the polyclonal nature of large intestinal adenomas has
been previously demonstrated both in FAP patients with XY/XO mosaicism (Novelli et
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al., 1996; Thirlwell et al., 2010), and in ApcMIN mice (Merritt et al., 1997). In support
of this hypothesis, intermediate stages of polyp formation were detected in the large
intestinal epithelium of AhCreER+Apcfl/flBrgfl/fl mice. These mini-adenomas appeared
as clusters of individual Brg1 negative and/or positive aberrant crypts that had not, or
had only just started to, raise above the epithelial surface. Brg1 mosaicism was, therefore,
detected at very early stages of adenoma formation, which supports a polyclonal origin
for mosaic adenomas.
Interestingly, the mosaic nature of some adenomas enabled visualisation of individual
clones within the adenoma, in a similar manner to the use of ROSA26 marker driving
expression of β-galactosidase in ApcMIN mice (Merritt et al., 1997). Brg1 mosaicism,
however, holds an advantage over the use of X-Gal staining, which was found to have a
limited penetration distance and which impaired the analysis of larger adenomas (Merritt
et al., 1997). The most prominent characteristic of the mosaic adenomas was a substan-
tially increased size of the individual clones within the adenoma compared to individual
aberrant crypts (both Brg1 positive and negative) elsewhere in the large intestinal mucosa.
This ﬁnding suggests that clustering of several individual aberrant crypts may create a
favourable environment for their growth. This notion is consistent with the observation
that colorectal cancers express increased levels of Wnt ligands, such as Wnt2, compared
to normal colonic mucosa (Holcombe et al., 2002) and thus create a positive feedback loop
creating a favourable environment for cancer progression.
Notably, while large adenomas fully comprised of Brg1 positive cells were almost as
frequent as mosaic ones, no fully Brg1 deﬁcient adenomas were detected. This observa-
tion could merely reﬂect a lower frequency of individual Brg1 deﬁcient aberrant crypts
compared to Brg1 positive lesions. A somewhat more interesting conclusion could be
drawn from the observation that aberrant crypt foci (ACFs) grow via crypt ﬁssion of
individual aberrant crypts (Fujimitsu et al., 1996; Paulsen et al., 1994). The lack of large
Brg1 deﬁcient adenomas could, therefore, imply a compromised ability of Brg1 deﬁcient
aberrant crypts to undergo ﬁssion. This notion, however, is undermined by the presence
of a substantial number of individual Brg1 positive aberrant crypts in the large intestine
of AhCreER+Apcfl/flBrgfl/fl mice that survived past 100 days PI.
To investigate whether Brg1 loss impaired Wnt signalling in the large intestinal ade-
nomas, I analysed expression levels of two Wnt target genes, c-Myc and CD44, in Brg1
positive and negative substructures within mosaic adenomas. However, comparative anal-
ysis revealed no consistent diﬀerence in c-Myc and CD44 expression levels between the
substructures. In order to obtain a more quantitative measure of Wnt signalling modu-
lation by Brg1 deﬁciency, I quantiﬁed the levels of proliferation and cell death in Brg1
positive and negative substructures within mosaic adenomas. While no diﬀerence was
detected in apoptosis levels, Brg1 deﬁcient substructures were found to display increased
levels of proliferation as assessed by expression of the proliferative marker Ki67. This
result is unexpected considering the proposed role of Brg1 in mediation of the Wnt sig-
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nalling in human CRC cell lines (Barker et al., 2001). Additionally, this observation is in
contrast to the situation observed in the murine small intestine, where Brg1 loss signiﬁ-
cantly suppressed proliferation in Wnt activated epithelium (section 5.2.7). On the other
hand, increased proliferation in Brg1 deﬁcient substructures is consistent with widely re-
ported role of Brg1 as a tumour suppressor (Becker et al., 2009; Reisman et al., 2003;
Wong et al., 2000) and a mediator of the cell cycle control (Hendricks et al., 2004).
6.3.5 Brg1 deﬁciency does not impair Wnt driven tumourigen-
esis in the bladder urothelium
Urothelial cell carcinoma (UCC) is the seventh most common cancer in the UK (exclud-
ing non-melanoma skin cancer) and is even more common worldwide (Cancer Research
UK, 2011). Somatic mutations of the key components of the Wnt pathway have been
reported in urothelial carcinomas (Miyamoto et al., 1996, Shiina et al., 2002), as well
as frequent upregulation of β-catenin (Zhu et al., 2000). A number of studies have also
demonstrated correlation between Wnt signalling activation in bladder cancer and reduced
survival (Kastritis et al., 2009; Marsit et al., 2005). Signiﬁcantly, conditional activation
of β-catenin and loss of Pten in murine urothelium have been reported to induce the
development of urothelial papillary carcinoma (Ahmad et al., 2011). Notably, while sole
activation of Wnt signalling via expression of an activated form of β-catenin was suﬃcient
to induce the development of hyperplastic lesions in the bladder urothelium, these lesions
remained small and benign for as long an 18 months (Ahmad et al., 2011).
Since activation of Wnt signalling has been shown to induce urothelial hyperplasia
(Ahmad et al., 2011), I aimed to investigate, whether Brg1 loss could modulate the eﬀects
of Wnt activation achieved by conditional loss of Apc. Both AhCreER+Apcfl/flBrg+/+
and AhCreER+Apcfl/flBrgfl/fl mice were found to develop hyperplastic lesions by day 7
PI. These hyperplastic lesions displayed strong nuclear localisation of β-catenin. Notably,
a similar time frame of hyperplasia development was reported by Ahmad et al. using the
same transgenic system. Analysis of Brg1 expression in urothelial lesions of AhCreER+-
Apcfl/flBrgfl/fl mice revealed complete loss of Brg1, while AhCreER+Apcfl/flBrg+/+
animals displayed strong Brg1 staining. In contrast to large intestinal and pyloric Brg1
deﬁcient adenomas, which displayed attenuated nuclear accumulation of β-catenin, no
diﬀerence in nuclear β-catenin staining was detected between AhCreER+Apcfl/flBrg+/+
and AhCreER+Apcfl/flBrgfl/fl lesions. Notably, responsiveness of the bladder urothe-
lium to Wnt activation concurs with a physiological role for the Wnt pathway in this
tissue. Thus, under normal conditions Wnt signalling in the urothelium is dormant in
consonance with the near-quiescent state of the epithelial cells. However it has been
found to be activated in response to epithelial injury and to drive post-injury epithelial
repopulation (Shin et al., 2011).
Analysis of the hyperplastic urothelial lesions at later time points revealed an initial
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increase in the lesion size, which however stalled around day 14 PI. Analysis of the bladder
urothelium from both experimental cohorts revealed the disappearance of lesions with
nuclear β-catenin. Instead, apparently empty lacunae were detected, which appeared to
be ﬁlled with the dead cells. These lacunae most likely represented the remnants of the
lesions and signiﬁed a rapid death of the majority of hyperplastic cells. In contrast to this
observation, urothelial lesions induced by β-catenin stabilisation via loss of both copies of
glycogen synthase kinase 3 under the control of AhCreER recombinase, have been shown
to persist in the bladder urothelium for as long as 4 months PI (Ahmad et al., 2011).
This discrepancy could be attributed to additional functionality of Apc outside of Wnt
signalling suppression, such as regulation of mitotic spindle formation and chromosomal
segregation (reviewed in Aoki and Taketo, 2007).
Ahmad et al. have demonstrated that the restricted growth pattern of Wnt activated
hyperplastic lesions in the bladder urothelium was imposed by Pten overexpression. Ac-
cordingly, concurrent loss of Pten and Apc under the control of AhCreER recombinase
resulted in signiﬁcantly increased cell proliferation and enlarged lesions compared to the
mice with sole loss of Apc (Ahmad et al., 2011). In a similar fashion, Brg1 deﬁcient lesions
in the bladder urothelium of AhCreER+Apcfl/flBrgfl/fl mice displayed signiﬁcantly in-
creased lesion size and elevated proliferation levels as assessed by BrdU incorporation
and expression of the proliferation marker Ki67, when compared to AhCreER+Apcfl/fl-
Brg+/+ urothelium. Increased proliferation of Brg1 deﬁcient lesions suggested a potential
further increase in Wnt signalling activation in the absence of Brg1. To explore this
possibility, I analysed the expression levels of known Wnt target genes in hyperplastic
urothelium of AhCreER+Apcfl/flBrg+/+ and AhCreER+Apcfl/flBrgfl/fl mice at day
10 PI using quantitative RT-PCR. Despite the increased cell proliferation in Brg1 deﬁ-
cient lesions, AhCreER+Apcfl/flBrgfl/fl urothelium displayed no diﬀerence in the expres-
sion levels of Wnt targets compared to Brg1 proﬁcient hyperplastic bladder epithelium.
Moreover, when compared to wild type bladder urothelium, Brg1 deﬁcient lesions showed
no signiﬁcant up-regulation of c-Myc or Cyclin D1, two Wnt targets directly involved
in mediation of the proliferative response of activated Wnt signalling. These observa-
tions suggested that Brg1 deﬁciency accelerated proliferation in hyperplastic lesions via
a mechanism independent of Wnt signalling. Notably, increased cell proliferation of Brg1
deﬁcient hyperplastic bladder coincides with the reported role of Brg1 in p21/pRb path-
way mediated cell cycle control (Kang et al., 2004). Coincidentally, p21 was found to be
substantially upregulated in hyperplastic lesions upon expression of activated β-catenin
(Ahmad et al., 2011). It would be insightful, therefore, to investigate expression levels of
the tumour suppressors p21 and p16 in response to additional Brg1 loss in Wnt activated
urothelial hyperplasia.
Despite accelerated proliferation of Brg1 deﬁcient lesions, Brg1 loss was unable to
rescue an early proliferation block and rapid loss of Wnt activated cells. Conversely,
Pten loss combined with β-catenin activation has been shown to drive progression of
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hyperplastic urothelial lesions towards urothelial cell carcinoma (Ahmad et al., 2011). It
appears, therefore, that activity of other tumour suppressors, most likely Pten and/or
p53 (Wu, 2005), is able to impose cell cycle arrest and induce apoptosis in Wnt activated
urothelial hyperplasia regardless of Brg1 status.
Chapter 7
General discussion
Colorectal cancer (CRC) is one of the most common cancers and the second leading
cause of cancer-related mortality after lung cancer in the UK (Cancer Research UK).
Although aberrant activation of the Wnt signalling is observed in more than 90% of CRC
cases, therapies targeting the Wnt pathway are extremely limited (Goss and Kahn, 2011).
One obstacle to the development of Wnt targeted therapies is a substantial toxicity of
such compounds. Some therapies, which target upstream Wnt pathway components have
shown promising results in certain cancers driven by paracrine expression of Wnt ligands.
However, it is a common consensus that targeting downstream components and target
genes of the Wnt pathway is preferable in order to minimise the potential toxicity of such
therapies (reviewed in Ewan and Dale, 2008). The interaction of Brg1 with β-catenin and
its requirement for trans-activation of Wnt target genes in CRC cells in vitro places Brg1
downstream of the majority of Wnt activating mutations (Barker et al., 2001). Brg1,
therefore, represents a potentially valuable therapeutic target in Wnt-driven neoplasia.
However, the involvement of Brg1 in the mediation of various signalling cascades raises
concerns of potential side eﬀects induced by therapeutic inhibition of Brg1.
With a view to validating Brg1 as a potential therapeutic target in Wnt-driven tu-
mourigenesis, I aimed to investigate the consequences of Brg1 loss in normal tissue home-
ostasis and in the context of aberrant Wnt signalling activation. While this investigation
primarily focused on the small intestinal epithelium as a tissue of choice to model human
colorectal cancer, these questions were also addressed in other epithelial tissues of the
gastrointestinal tract as well as in the bladder urothelium.
The main ﬁndings described in this thesis are:
• Brg1 is essential for the maintenance of stem cell homeostasis in the small intestinal
epithelium;
• Brg1 deﬁciency impedes Wnt-driven small intestinal neoplasia via attenuation of
Wnt signalling and elimination of stem cell derived tumours, which have a higher
tumourigenic potential;
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• Epithelial tissues of the gastrointestinal tract and bladder display a remarkable
diversity in their reliance on Brg1 for tissue homeostasis, tumour suppression and
Wnt-driven tumourigenesis;
In this chapter I will discuss the latter two of these ﬁndings. The role of Brg1 in the
maintenance of small intestinal stem cell homeostasis has been previously discussed in
Chapter 3.
7.1 Brg1 loss highlights a remarkable tissue-speciﬁc
diversity of Brg1 functions
Concordant with its role in the mediation of various signalling pathways (Trotter and
Archer, 2008), Brg1 has been reported to participate in a plethora of developmental
processes. These range from deﬁning the very early stages of embryogenesis (Bultman
et al., 2006; Ho et al., 2009; Kidder et al., 2009; Wang et al., 2010) to diﬀerentiation
and homeostasis of particular tissues (Hang et al., 2010; Indra et al., 2005; Matsumoto
et al., 2006). Consistent with this diverse role, constitutive Brg1 loss was found to result
in pre-implantation abortion of embryonic development (Bultman et al., 2000). Tissue-
speciﬁc loss of Brg1 has been reported to result in abnormal proliferation, diﬀerentiation
and tissue morphogenesis (reviewed in de la Serna et al., 2006). Notably, while the role of
Brg1 in developing tissues is reasonably well described, its functions in adult tissues are
less well-deﬁned. The data presented in this thesis reveal a diversity of Brg1 roles in the
homeostasis of adult tissues of the gastrointestinal tract and bladder under physiological
conditions and in the context of activated Wnt signalling.
Analysis of the eﬀects of Brg1 deﬁciency in epithelial tissues of the gastrointestinal
tract and bladder revealed a gradient of tissue-speciﬁc reliance on Brg1 function (Figure
7.1a). If considered just through the impact of Brg1 on cell proliferation, a subset of
tissues, namely the small intestinal epithelium, appear to require Brg1 for maintenance
of the pluripotent and self-renewing stem cell population. This observation is consis-
tent with an established role of Brg1 in the maintenance of neural (Matsumoto et al.,
2006) and mesenchymal stem cells (Alessio et al., 2010; Napolitano et al., 2007). The
role of Brg1 in the normal small intestinal epithelium can, therefore, be viewed as largely
pro-proliferative. Further down the gradient, another subset of tissues, namely the large
intestinal, pyloric and bladder epithelia, are able to tolerate long-term Brg1 deﬁciency
without displaying signs of perturbed homeostasis. Brg1 function, thus, appears dispens-
able for the maintenance of physiological proliferation in these tissues. Finally, at the
other end of the spectrum tissues such as the forestomach and fundic epithelium require
Brg1 in order to keep cellular proliferation in check, as loss of Brg1 in these tissues results
in a hyperplastic response. Thus the role of Brg1 the forestomach and fundus appears to
be that of an anti-proliferative tumour suppressor.
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These observations reveal a full spectrum of Brg1 impact on cell proliferation, from
maintenance of stem cell self-renewal to cell cycle suppression within a limited set of
tissues. The diversity of roles for Brg1 is even more remarkable given that the majority of
the analysed tissues belong to the same system of organs and share a similar histological
organisation and, to some extent, signalling pathways involved in their homeostasis.
Figure 7.1: Epithelial tissues of the gastrointestinal tract and bladder exhibit a substantial diversity in
Brg1 requirement for normal tissue homeostasis (a), which largely correlates with tissues’ responsiveness
to Wnt activation (b) and Brg1 requirement for the Wnt-driven tumourigenesis (c).
Consistent with the proposed interaction between Brg1 and the Wnt pathway, the gra-
dient of requirement for functional Brg1 appears to reﬂect the gradient of these tissues’
reliance upon active Wnt signalling for their development and homeostasis. Active Wnt
signalling has been extensively reported to play a pivotal role in homeostasis of the small
and large intestinal epithelium as well as the pyloric stomach (de Lau et al., 2007; Mills
and Shivdasani, 2011). Ablation of Wnt signalling in these gastrointestinal tissues by
adenoviral expression of the Wnt inhibitor Dickkopf-1 has been found to result in a rapid
crypt and villus loss in the small intestinal epithelium. The same phenotype, although
delayed, was observed in the large intestine, while pyloric stomach was largely unaﬀected
(Kuhnert et al., 2004). This observation indicates that out of the three tissues, the small
intestine is the most reliant on active Wnt signalling, followed by the large intestine and
pylorus. Accordingly, Brg1 loss was found to cause severe crypt ablation in the small intes-
tine, while the pylorus and large intestine were largely unaﬀected. Similarly, the bladder
urothelium was found to tolerate Brg1 deﬁciency over an extensive period of time. This
observation appears to coincide with the fact that the bladder epithelium is exposed to
negligible levels of Wnt signal in steady-state homeostasis (Shin et al., 2011). Finally,
forestomach (oesophageal) and fundic epithelium rely on Wnt pathway suppression for
their development and homeostasis (Kim et al., 2005; Woo et al., 2011). Curiously, depen-
dence of these tissues on a lack of Wnt signalling coincides with a hyperplastic response
to Brg1 loss. Taken together, these observations suggest a close correlation between a
given tissues reliance on active Wnt signalling and its response to Brg1 deﬁciency.
Rather predictably, dependence of the analysed tissues on Wnt signalling for their
normal homeostasis was found to correlate with responsiveness of these tissues to aberrant
Wnt pathway activation (Figure 7.1b). While Wnt pathway activation fails to drive
tumourigenesis in the forestomach and fundic stomach, all other tissues develop Wnt-
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driven lesions consistent with previous reports (Ahmad et al., 2011; Barker et al., 2010;
Sansom et al., 2004; Shibata et al., 1997). An apparent gradient in the tissue responses to
Wnt activation was observed between the analysed tissues. Consistent with physiological
levels of Wnt signalling in the respective tissues, the strongest response was observed in the
small intestine followed by the large intestine and ﬁnally, pyloric epithelium. Interestingly,
a similar pattern of tumourigenesis has been observed in ApcMIN mice, which develop
numerous small intestinal, less frequent large intestinal and rare pyloric adenomas (Su et
al., 1992; Tomita et al., 2007). Bladder urothelium represents a peculiar case amongst
the Wnt responsive tissues. While lesions with nuclear β-catenin appear soon after Apc
deletion, they appear to undergo an early cell cycle arrest and regression. At least one
report has provided strong evidence that this behaviour is likely to be mediated by up-
regulation of tumour suppressors Pten and p21 (Ahmad et al., 2011).
Notably, analysed tissues diﬀered not only in the intensity of their response to Wnt
activation, but also in the requirement for Brg1 in Wnt-driven tumourigenesis (Figure
7.1c). While small intestinal loss of Brg1 was utterly incompatible with Wnt signalling
activation, other tissues were found to develop Brg1 deﬁcient Wnt-driven tumours, albeit
with altered penetrance. Intriguingly, while Brg1 appears to be dispensable for normal
homeostasis of the pyloric, large intestinal and bladder epithelium, placing Brg1 deﬁ-
ciency in the context of aberrant Wnt signalling reveals slight diﬀerences between these
tissues. Both the large intestinal and pyloric epithelium of the double knock-out (DKO)
mice develop a mixture of Brg1 positive and negative Wnt-driven lesions, suggesting that
Brg1 loss is permissive for Wnt-driven tumourigenesis in these tissues. Additionally, Brg1
deﬁcient lesions appear to be under-represented in both tissues compared to Brg1 posi-
tive tumours. However, in contrast to pyloric epithelium, large intestinal Brg1 deﬁcient
lesions appear much earlier and go on to form a part of large mosaic adenomas. It is
therefore tempting to speculate that Brg1 deﬁciency is less permissive for Wnt-driven
tumourigenesis in the pylorus than it is in the large intestine. This speculation, however,
is likely to be biased due to the fact that pyloric lesions generally develop slower than
colonic tumours, regardless of Brg1 status. In contrast to both the pylorus and large
intestine, all Wnt activated lesions in the bladder epithelium of DKO mice exhibit loss
of Brg1 expression. Furthermore, within a short life span of urothelial hyperplasia, DKO
lesions appear larger in size and display a higher rate of proliferation compared to Brg1
positive lesions. It therefore appears that Brg1 deﬁciency is not only permissive, but is
favourable for Wnt-driven urothelial tumourigenesis. Taken together, the eﬀects of Brg1
deﬁciency in the context of the Wnt-driven tumourigenesis highlight subtle diﬀerences
between tissues that do not appear to require Brg1 for their normal homeostasis. The
small intestine appears at the top of the gradient with absolute incompatibility of Brg1
loss and Wnt activation. It is followed by the pyloric and large intestinal epithelium with
increasing degree of tolerance for Brg1 deﬁciency in Wnt activated lesions. Finally, in
the bladder urothelium Brg1 deﬁciency appears favourable in the context of Wnt-driven
Chapter 7. General discussion 207
tumourigenesis.
Curiously, Wnt signalling activation in the forestomach and fundic epithelium appears
to be able to negate the oncogenic eﬀect of Brg1 loss in these tissues. While Brg1 loss alone
results in a hyperplastic response in the forestomach and fundic epithelium, no lesions
of similar histopathological nature are detected in the respective tissues of DKO mice.
The lack of such lesions suggests that Wnt signalling activation is not only insuﬃcient
to drive tumourigenesis, but it is also likely to confer a survival disadvantage to Brg1
deﬁciency-induced hyperplasia of these tissues. This observation is particularly unusual
considering that fundic gland polyps developing in Brg1 deﬁcient stomach epithelium are
histologically related to gastric polyps commonly linked to Wnt activating mutations in
humans (Abraham et al., 2000; Abraham et al., 2001).
7.2 The tumour suppressor role of Brg1 is tissue- and
dosage-dependent
Brg1 has been widely implicated as a tumour suppressor in a range of cancers due to
the frequent incidence of Brg1 mutations in both cancer cell lines and primary cancers
(Reviewed in de la Serna et al., 2006). Previous attempts to explore the ability of Brg1
loss to induce or promote tumourigenesis in vivo have yielded some unexpected results.
Mice with constitutive heterozygous deletion of Brg1 have been found to be prone to
mammary tumourigenesis. Analysis of the mammary tumours arising in these mice, how-
ever, revealed retention of Brg1 expression, indicating that mammary tumourigenesis was
driven by Brg1 haploinsuﬃciency rather than loss of heterozygousity (Bultman et al.,
2007). Similarly, analysis of chemically induced lung tumourigenesis has demonstrated
that heterozygous, but not homozygous loss of Brg1 is able to facilitate tumour initia-
tion (Glaros et al., 2008). Similar to the mammary epithelium, lung tumours in Brg1
heterozygous mice were found to retain Brg1 expression, which again implicates Brg1
haploinsuﬃciency in tumour initiation. Conversely, biallelic Brg1 deletion in pre-formed
lung tumours has been found to accelerate tumour progression (Glaros et al., 2008). This
observation is consistent with the correlation of Brg1 mutations in lung cancers with poor
prognosis (Fukoka et al., 2004; Reisman et al., 2003). In this thesis I aimed to explore the
tumour suppressor role of Brg1 in the tissues of the gastrointestinal tract and bladder.
To this end, its hetero- and homozygous loss was analysed under physiologically normal
conditions and in the context of activated Wnt signalling.
Although Brg1 haploinsuﬃciency has been reported to confer cancer susceptibility
(Bultman et al., 2007; Glaros et al., 2008), no increase in gastric, intestinal or urothelial
tumourigenesis was detected in mice with heterozygous Brg1 loss in these tissues. The lack
of tumourigenesis in otherwise normal Brg1 deﬁcient tissues is not entirely unexpected,
as tumour formation in mice with constitutive heterozygous Brg1 loss was largely lim-
Chapter 7. General discussion 208
ited to the mammary gland epithelium (Bultman et al., 2007), while lung carcinogenesis
was facilitated by chemical mutagenesis to manifest Brg1-mediated tumour suppression
(Glaros et al., 2008).
Similarly, analysis of Brg1 haploinsuﬃciency in the context of heterozygous loss of
Apc failed to reveal acceleration of Wnt-driven intestinal tumourigenesis as no signiﬁcant
diﬀerence in tumour size, number or distribution was observed between Apc heterozygous
and double heterozygous animals. In addition to this ﬁnding, no signiﬁcant diﬀerence in
survival probability was observed between the cohorts. While these observations diﬀer
from the ones reported in the lung tumourigenesis (Glaros et al., 2008), they underscore
the tissue-speciﬁc nature of Brg1-mediated suppression of cancer progression. Consistent
with this notion, Brg1 mutations appear to be exceptionally frequent in lung cancers,
particularly in non-small cell lung carcinoma indicating a particularly important role
for Brg1 in lung cancer pathogenetics (Medina et al., 2008). Additionally, the lack of
acceleration in tumour progression in the intestinal epithelium of double heterozygous
mice could be related to the requirement of functional Brg1 for Wnt-driven tumourigenesis
in the small intestinal epithelium, as discussed earlier.
While loss of Brg1 failed to induce tumourigenesis in the majority of epithelial tissues
of the gastrointestinal tract and bladder urothelium, two tissues presented an exception to
this rule. Brg1 deﬁciency in the forestomach and fundic epithelium resulted in relatively
rapid development of hyperplastic lesions. The signiﬁcance of this ﬁnding is that, while
Brg1 mutations have been frequently observed in cancer cell lines and primary cancers
(Medina and Sanchez-Cespedes, 2008), this is the ﬁrst report to demonstrate tumouri-
genesis as a direct consequence of Brg1 deﬁciency. Importantly, no lesions of a similar
histopathological nature were observed in the forestomach and fundic epithelium of mice
with heterozygous loss of Brg1. This observation suggests that a single copy of Brg1 is
suﬃcient to suppress tumourigenesis in these tissues.
Taken together, previous ﬁndings and the data presented in this thesis suggest a
dosage-dependent nature of Brg1-mediated tumour suppression across diﬀerent tissues.
Some tissues (the large intestinal, pyloric and bladder epithelium) do not seem to require
Brg1 for tumour suppression. In others (forestomach and fundic epithelium) a single
copy of Brg1 gene appears suﬃcient to maintain eﬀective tumour suppression as only loss
of both copies results in hyperplastic response. Finally, a number of tissues (mammary
and lung epithelium) require both copies of Brg1 to suppress tumour initiation as Brg1
haploinsuﬃciency renders them prone to tumourigenesis (Bultman et al., 2007; Glaros et
al., 2008).
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7.3 Brg1 is a potential therapeutic target in the Wnt-
driven neoplasia
In order to investigate the feasibility of Brg1 as a potential therapeutic target in Wnt-
driven neoplasia in vivo, Brg1 was conditionally deleted in the context of activated Wnt
signalling in the murine gastrointestinal tract. The data described in Chapter 5 of this
thesis demonstrated that Brg1 loss in the context of aberrant activation of Wnt signalling
had a profound therapeutic eﬀect on animal survival by reducing the small intestinal
tumour burden and speciﬁcally eliminating Wnt-driven tumours that arise from the stem
cell population.
The speciﬁc requirement for Brg1 for the stem cell derived Wnt-driven tumours makes
it a potentially attractive target in individuals with FAP syndrome. These individuals
develop multiple benign adenomas in the colonic epithelium, some of which progress to
carcinoma. In order to minimise the likelihood of adenoma-carcinoma transformation FAP
patients have to undergo prophylactic colectomy in order to remove the aﬀected regions
or even the whole colon (Gryfe, 2009). Eﬀective targeting of Wnt activated colonic stem
cells in such patients could provide a valuable non-surgical alternative and substantially
improve patients’ quality of life. The data presented in this thesis serves as an in vivo
proof of concept that such an approach of targeting the Wnt activated stem cell is feasible
and may have a therapeutic advantage. It should be noted, however, that the diversity
of Brg1 requirement for Wnt driven tumourigenesis even between Wnt responsive tissues
suggests that Brg1 is unlikely to be a universal anti-Wnt signalling target and its utility
may be limited to particular types of Wnt-driven neoplasia.
While targeting Brg1 was found to be eﬀective in elimination of stem cell derived Wnt-
driven tumours in the murine small intestine, it remains to be determined whether Brg1
could serve as a therapeutic target in human CRC. Notably, loss of Brg1 was unable to
prevent Wnt-driven tumourigenesis in the murine large intestinal epithelium. This obser-
vation could undermine its signiﬁcance as a therapeutic target in human CRC. However,
a number of observations suggest that the murine small intestine might be a more repre-
sentative tissue for modelling human CRC. A range of mouse models have been found to
respond to heterozygous loss of Apc by developing predominantly small intestinal adeno-
mas, while tumourigenesis driven by Apc loss in humans is largely conﬁned to the colonic
epithelium (Heyer et al., 1999). In the particular case of Brg1, human CRC cell lines were
found to suppress a range of Wnt target genes in response to inhibition of Brg1 function
(Barker et al., 2001). However, the data presented in this thesis show no evidence of
Wnt target gene suppression in Brg1 deﬁcient large intestinal lesions. In order to validate
Brg1 as a potential therapeutic target in Wnt-driven neoplasia, the consequences of its
loss must be studied in human colonic tissue. A research group led by Eduard Batlle
at the Biomedical Research Institute in Barcelona has been successful in developing a
method of culturing normal and malignant human colonic epithelium in vitro in the form
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of spheroid culture (Jung et al., 2011). A potential collaboration could therefore now be
arranged to investigate the eﬀects of BRG1 depletion (e.g. using shRNA against BRG1)
in normal and neoplastic human colonic epithelium.
Extrapolation of the consequences of concurrent deletion of Brg1 and Apc into a
clinical setting has a number of caveats. Simultaneous Brg1 and Apc loss prevents the
development of stem cell derived Wnt-driven adenomas and thus represents a prophylac-
tic treatment. It remains to be seen, whether Brg1 loss in pre-formed adenoma would
be able to stop its further development and/or induce tumour regression. In the context
of the intestinal stem cell niche provided by the Paneth cells (Sato et al., 2010), a pos-
sibility remains that upon loss of Brg1 and subsequent ablation of Wnt activated stem
cells within the adenoma, early cancer progenitor cells would be able to occupy the stem
cell niche and acquire stem cell properties. A similar scenario is observed upon partial
Brg1 loss in the murine small intestine, where either stem or progenitor cells retaining
Brg1 expression are able to drive intestinal repopulation. While this process in Wnt-
driven cancers could be prevented by sustained Brg1 inhibition, this is likely to result in
substantial toxicity to normal intestinal mucosa, as seen upon high-penetrance Brg1 loss
in the mouse small intestine. In order to partially address the ability of cancer progen-
itor cells to de-diﬀerentiate upon cancer stem cell ablation, we are currently generating
ApcMIN mice carrying the Lgr5-CreER transgene and loxP targeted Brg1 alleles. In-
duction of conditional Brg1 loss in normal and neoplastic mucosa of these mice should
be able to create a situation more representative of therapeutic rather than prophylactic
treatment. The use of a Brg1 inhibitor however, would be preferential for this type of
study as alterations in expression patterns within tumour cells could result in suboptimal
Cre recombinase expression. Furthermore, the question of the plasticity of cancer stem
cells and their progenitors and trans-diﬀerentiation between these two populations has
wider implications for the actively developing ﬁeld of cancer stem cell targeted therapies
(de Sousa et al., 2011).
Another likely caveat of using Brg1 as a therapeutic target concerns the potential
side eﬀects due to the role of Brg1 as a transcriptional co-activator in various signalling
pathways (Reviewed in Trotter and Archer, 2008). Analysis of the consequences of Brg1
loss in a limited number of epithelial tissues described in this work reveals a substantial
diversity of responses to Brg1 deﬁciency between tissues. While the majority of analysed
tissues tolerated long-term loss of Brg1 without perturbation of normal homeostasis, Brg1
deﬁciency induced benign cell hyperplasia in forestomach and fundic epithelium. Notably,
the forestomach and fundic phenotype of Brg1 loss is likely to be unrelated to the inter-
action of Brg1 with the Wnt pathway, since Wnt signalling is suppressed in these tissues
under physiological conditions (Kim et al., 2005; Woo et al., 2011). It should therefore
be possible to avoid at least some of the potential side eﬀects by speciﬁcally targeting
Brg1/β-catenin interactions. Interestingly, a similar strategy targeting β-catenin/TCF
interaction with small-molecule compounds has been shown to suppress Wnt signalling
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and induce apoptosis in CRC cells (Leproucelet et al., 2004). Speciﬁc targeting of the
Brg1/β-catenin interaction, would mostly likely lead to tissue disruption if invoked at a
high level in the small intestine. However, the small intestinal epithelium has demon-
strated a sound capacity to regeneration upon partial Brg1 loss and might be successfully
managed with an appropriate dosage and treatment plan.
Overall, although many aspects of targeting Wnt-driven cancers using Brg1-based
therapies remain yet to be investigated, initial results presented in this thesis portray
Brg1 as a promising potential therapeutic target.
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